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GENERAL INTRODUCTION
Stroke is one of the leading causes of disability in the world.1 Worldwide, stroke 
incidence is estimated around 17 million events each year,2 and approximately 50 
million stroke survivors currently live with remaining deficits that limit their daily 
functioning.3 In the Netherlands, stroke affects around 41,000 individuals each 
year,4 and this number increases steadily due to the aging population.5 Though 
the length of hospitalization after stroke decreased in the past years due to better 
acute treatment,6 stroke is responsible for 2.5% of the total health care costs.7 
Currently, more than 240,000 individuals deal with the consequences of stroke 
in daily life.8 Beside motor, sensory, and speech deficits, cognitive deficits and 
neuropsychiatric symptoms like depression and apathy are frequent after stroke, 
occurring in around 30% of stroke survivors.9-11
Neuropsychiatric symptoms are associated with poor prognosis, as these have a 
negative influence on functional recovery12-14 and quality of life after stroke.15,16 
Despite their high frequency, neuropsychiatric symptoms are less salient compared 
with physical, visual, speech, or cognitive dysfunctions. They are therefore 
frequently under-recognized in clinical practice,17 and treatment needs of these 
stroke patients are often unmet.18 Post-stroke depression (PSD) and post-stroke 
apathy (PSA) are two of the most common neuropsychiatric outcomes after stroke, 
and have substantial overlap in symptoms.19 Particularly, the phenomenological 
overlap in the key criterion ‘loss of interest’ makes it difficult to differentiate 
between these two syndromes.20 Several studies found indications for differences 
between PSD and PSA, though there remains discussion whether these support 
the hypothesis that PSD and PSA are two independent syndromes. 
PREVALENCE AND DIAGNOSIS OF PSD
According to a meta-analysis, PSD occurs in approximately 31% of the stroke 
population at any time point after stroke.9 PSD is associated with an increased 
risk for cognitive impairment21 and has a large impact on long-term prognosis, 
as it results in increased mortality22,23 and more disability.20 According to the fifth 
edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), PSD 
is categorized as a mood disorder due to another medical condition, and the 
diagnostic criteria are described in Table 1.24 PSD can develop in the acute period 
after stroke, but also later in the course, i.e. in the sub-acute or chronic stage. 
A major difficulty in diagnosing depression in stroke survivors is to make sure that 
the somatic depression symptoms are related to mood and are not the result of 
the stroke itself, as symptoms like psychomotor retardation, changes in appetite, or 
fatigue are frequent after stroke.25 However, Cumming et al.26 showed that patients 
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with PSD show roughly the same profile of depressive symptoms compared with 
depressed individuals in the general population, although patients with PSD were 
less likely to report anhedonia. Despite their medical condition, patients with PSD 
were thus no more likely than depressed individuals in the general population 
to report somatic symptoms over psychological symptoms.26 Hence, it has been 
suggested that clinicians should not exclude the somatic symptoms in diagnosing 
PSD, but these need to be considered separately, next to psychological and 
neurocognitive symptoms of depression.25,26
Table 1. Diagnostic criteria for depression due to stroke according to the fifth edition of the Diagnostic 
and Statistical Manual of Mental Disorders24
For a diagnosis of depression due to stroke the patient should fulfill the criteria A, B, C and D
A. A prominent and persistent period of lowered mood (2 weeks or longer) or clear loss of interest 
or pleasure in all, or almost all, activities.
B. At least four of the following symptoms: 
Substantial weight loss or gain 
Insomnia or hypersomnia
Psychomotor agitation or retardation
Fatigue or loss of energy
Worthlessness or inappropriate guilt
Diminished concentration, or indecisiveness
C. There should be evidence that the depressive disorder is due to a somatic condition (i.e. stroke), 
and cannot be better explained by another psychic disorder.
D. The depressive disorder is not the result of a delirium, causes clinically significant distress, and 
results in impairments in social, professional, or other important areas of functioning.
ETIOLOGY AND PREDICTORS OF PSD
Previous research on PSD focused mainly on its etiological factors. Several studies 
examined whether certain stroke lesion locations could be identified that are 
associated with a higher prevalence of PSD. Robinson and colleagues were the first 
to find such an association in 1981, by suggesting that patients with left hemispheric 
lesions presented with PSD more frequently than patients with right hemispheric 
lesions, and the severity of depressive symptoms directly correlated with the 
closeness of the lesion to the anterior pole.27 This finding has led to the ‘lesion location 
hypothesis’ of PSD, stating that PSD is associated with left frontal lesions. However, 
this hypothesis has remained controversial ever since, and meta-analyses could not 
support this relationship.28-30 In addition to the left frontal lobe, associations have been 
found with (left) basal ganglia lesions.31-33 Also, lesions in fronto-subcortical regions 
were found to be involved in PSD,34,35 which seems biologically plausible, as these 
brain areas are known to be involved in regulation of mood.36 According to a study 
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in 275 ischemic stroke survivors, PSD is associated with lesions in fronto-subcortical 
circuits37 and is often presented together with vascular cognitive impairment (VCI). 
VCI occurs frequently after stroke and is defined as the establishment of a cognitive 
disorder with vascular disease being the dominant pathology underlying the 
cognitive impairment.38 Executive dysfunction is particularly frequent after stroke and 
co-occurs with PSD.39 This so-called ‘Depression-Executive Dysfunction Syndrome 
(DES)’ might represent a PSD subtype, and has been suggested to be associated 
with worse stroke outcome. In a longitudinal study in 116 first-ever stroke patients,40 
patients with DES showed less recovery from executive dysfunction (ED) and 
depression compared with patients with ED-only or PSD-only, respectively. Also, in a 
12-year follow-up study, PSD was associated with more rapid stroke recurrence41 and 
increased mortality risk,42 and this was further increased in patients with DES. 
Beside stroke lesion location, also large lesion volume43,44 and lesion severity45 
seem to be associated with PSD. In contrast with lesion-related markers, generalized 
markers of vascular brain pathology like white matter hyperintensities (WMH), 
cerebral microbleeds, (silent) old infarcts, as well as degenerative pathology like 
cerebral atrophy are less frequently studied in association with PSD, though there are 
suggestions that they play a role in the development of PSD as well.46-49 Furthermore, 
there are hypotheses that PSD may be related to an increased inflammatory response50 
and also genetic polymorphisms in the serotonin system might be involved.51 
In addition to abovementioned biological factors, psychosocial mechanisms are 
suggested to be involved in the development of PSD.52 Personality traits, mainly 
neuroticism,53 a passive coping style,52 and poor social support54 are psychosocial 
factors shown to be associated with PSD. A meta-analysis of 19 cross-sectional studies 
showed that post-stroke fatigue (PSF) is associated with PSD.55 However, until now it 
remains unclear whether PSD results in PSF, whether PSF results in PSD, or whether 
the relationship between PSD and PSF is bi-directional.56 For this, longitudinal studies 
are needed that study this temporal relationship in both directions.57,58 Another 
possibility may be that both are caused by a third unknown factor.
Taken together, the pathogenesis of PSD is probably a combination of both biological 
and psychosocial mechanisms,54,59-61 which are summarized in Figure 1. It is likely 
that psychosocial factors interact with biological factors, and the latter is probably 
more than lesion location and also includes background vascular and degenerative 
brain pathology. Thus, both psychosocial and biological factors are contributing to 
the development of PSD, with each factor having its major impact at a different time 
point post-stroke.61 PSD itself may also have an effect on some of these biological 
and psychosocial factors in a bi-directional fashion, like the functioning of frontal-
subcortical circuits, cognition, and fatigue, resulting in a complex interplay between 
these processes.
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Figure 1. Biological and psychosocial processes involved in the etiology of post-stroke depression 
PREVALENCE AND DIAGNOSIS OF PSA
PSA is frequently reported after stroke, with an estimated pooled prevalence of 
almost 35%,62 which is approximately equally frequent as PSD.11,62 Nevertheless, 
PSA is often not recognized as a syndrome on its own, both in research and in 
clinical practice. PSA has shown to be negatively associated with rehabilitation 
outcome43 and presents more often in the post-acute and chronic stroke phase. 
Levels of apathy tend to remain relatively stable during the first year post-stroke.63,64 
The DSM-5 does not define diagnostic criteria for apathy. According to Marin,65 
who was the first to define apathy as a distinct syndrome, apathy can be defined 
as a loss of motivation or lack of interest, characterized by reduced goal-directed 
behavior and cognitive activity, and emotional indifference. These criteria were 
adapted by including the criterion that apathy should not be comorbid with 
depression or cognitive impairment,66 and apathetic symptoms should be present 
during the majority of the day for at least four consecutive weeks.20 During a 
consensus meeting in 2008, these criteria were revised and formulated in such a 
way that they can be applied to the occurrence of apathy in various neuropsychiatric 
disorders or conditions (Table 2).67
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Table 2. Diagnostic criteria for apathy from Robert et al. (2009)
For a diagnosis of apathy the patient should fulfill the criteria A, B, C and D
A. 
Loss of or diminished motivation in comparison to the patient’s previous level of functioning 
and which is not consistent with his age or culture. These changes in motivation may be re-
ported by the patient himself or by the observations of others.
B.
Presence of at least one symptom in at least two of the three following domains for a period of 
at least four weeks and present most of the time. 
Domain B1 (Behavior): Loss of, or diminished, goal-directed behavior as evidenced by at least 
one of the following: 
• Loss of self-initiated behavior (for example: starting conversation, doing basic tasks of day-
to-day living, seeking social activities, communicating choices). 
• Loss of environment-stimulated behavior (for example: responding to conversation, par-
ticipating in social activities). 
Domain B2 (Cognition): Loss of, or diminished, goal-directed cognitive activity as evidenced 
by at least one of the following: 
• Loss of spontaneous ideas and curiosity for routine and new events (i.e., challenging tasks, 
recent news, social opportunities, personal/family and social affairs). 
• Loss of environment-stimulated ideas and curiosity for routine and new events (i.e., in the 
persons residence, neighborhood or community). 
Domain B3 (Emotion): Loss of, or diminished, emotion as evidenced by at least one of the 
following: 
• Loss of spontaneous emotion, observed or self-reported (for example, subjective feeling of 
weak or absent emotions, or observation by others of a blunted affect).
• Loss of emotional responsiveness to positive or negative stimuli or events (for example, 
observer-reports of unchanging affect, or of little emotional reaction to exciting events, 
personal loss, serious illness, emotional-laden news).
C.
The symptoms (A-B) cause clinically significant impairment in personal, social, occupational, or 
other important areas of functioning.
D.
The symptoms (A-B) are not exclusively explained or due to physical disabilities (e.g. blindness 
and loss of hearing), to motor disabilities, to diminished level of consciousness, or to the direct 
physiological effects of a substance (e.g. drug of abuse, a medication). 
ETIOLOGY AND PREDICTORS OF PSA
Compared with PSD, the etiology of PSA has received far less attention. With 
regards to biological factors, PSA has been associated with damage to subcortical 
areas, mainly the basal ganglia.11,68 Also, WMHs in the right fronto-subcortical 
circuit have been associated with PSA.69 According to a meta-analysis by Caeiro 
et al.,70 the frequency of PSA was not associated with stroke lesion laterality or 
lesion type. However, PSA was significantly associated with older age, recurrent 
stroke, cognitive impairment, and depression. Also, patients with acute-phase PSA 
showed an almost four-fold risk of having PSA at one-year follow-up,70 suggesting 
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that PSA can be persistent over time. The meta-analysis by van Dalen et al.11 
showed that PSA is associated with cognitive impairment and increased disability. 
Due to the lack of longitudinal studies examining risk factors of PSA, it remains 
unclear how these factors influence the development of PSA over time.
THE RELATIONSHIP BETWEEN PSD AND PSA
Around 40 percent of patients with PSA show comorbid PSD, while in the 
remaining 60 percent PSA occurs as an independent syndrome.11 According 
to the meta-analysis by Caeiro et al.,70 PSA without PSD occurs twice as often 
than PSD without PSA, which supports the idea that PSA frequently occurs as 
an independent clinical entity. A previous study that attempted to disentangle 
the independence of PSD and PSA found ambiguous results. While at three to 
six months post-stroke the two syndromes tended to occur independently,69 at 
12-month follow-up the co-occurrence of PSA and PSD increased significantly.63 
This suggests that the relationship between PSD and PSA is probably dependent 
on the time of measurement. 
Although lack of motivation or interest plays a role in both apathy and depression, 
apathy is considered to be a motivational disorder, whereas depression is 
mainly seen as a disorder of lowered mood.71 Next to an overlap in clinical 
symptomatology, there is also evidence for an overlap in associated risk factors. 
Both PSD and PSA are related to lesions in fronto-subcortical circuits11,37 and with 
increased WMH severity.48,69 In addition, cognitive impairment,11,21 and impaired 
functional outcome,13,21 are also associated with the development of both. However, 
there are also suggestions for differences between these two syndromes. From a 
biological perspective, different neurotransmitter systems may be involved in the 
development of depression and apathy. For instance, the dopaminergic system has 
been found to play an important role in apathy, whereas the serotonergic system 
seems to play an important role in the development of depression.72,73 In addition, 
different stroke lesion locations have been shown to be associated with PSD and 
PSA,35 and diffusion tensor imaging studies have found that white matter tracks 
subserving different networks are damaged in PSD74 and PSA.75 This suggests 
that disconnection of different brain networks are involved in these syndromes. 
As there might be a differential role for neurotransmitter systems underlying these 
syndromes, this may also have consequences for treatment recommendations. 
A meta-analysis showed that PSD seems to respond well to antidepressants, 
which are usually working on the serotonergic system.76 PSA might benefit from 
different treatment like dopaminergic agents or cholinesterase inhibitors,77 
though this has not been confirmed in randomized-controlled trials. Importantly, 
the use of selective serotonin reuptake inhibitors, which are commonly prescribed 
General introduction, thesis aim and outline
1
15
antidepressants, may worsen symptoms of apathy,78 which is an additional reason 
why screening for apathy and recognizing its independence from depression is 
necessary. 
GAPS IN CURRENT KNOWLEDGE
Several studies found indications for differences between PSD and PSA, though 
associations between PSA and specific risk factors have been less frequently 
studied compared with PSD. Beside suggestions for differences, there is also 
evidence for a significant overlap in associated factors of PSD and PSA (e.g. 
cognitive impairment, poor functional outcome, lesions in frontal-subcortical 
areas). However, these findings were largely based on cross-sectional data. It is 
therefore poorly understood if and how both biological and psychosocial factors 
have a differential influence on the development and course of PSD and PSA 
over time. A better understanding of the role of these factors may result in better 
recognition, distinction, and earlier detection of these conditions. This insight may 
also be valuable for providing patient-tailored treatment options for patients with 
PSD and PSA, leading to a better clinical prognosis after stroke. 
THESIS AIM AND OUTLINE
The main aim of this thesis is to examine the association of biological and 
psychosocial risk factors on the development and course of PSD and PSA, and 
whether differences can be found between the associations with these two 
syndromes. The Cognition and Affect after Stroke: a Prospective Evaluation of Risks 
(CASPER) study is a one-year prospective clinical cohort follow-up study designed 
to examine whether stroke-specific, cerebrovascular and neurodegenerative 
markers, and psychosocial factors are associated with cognitive impairment, PSD, 
and PSA, and whether they predict their course over 12 months. The rationale and 
design of the CASPER study is described in Chapter 3 and data from the CASPER 
study were used in Chapters 4 to 8. The research described in the chapters is 
based on the following research questions:
1) Which imaging markers have been associated with PSD and PSA in previous 
studies? 
Chapter 2 provides a systematic literature review, which gives a comprehensive 
and up-to-date evaluation of imaging markers that have been associated 
with PSD and PSA. In addition, meta-analyses were performed to examine 
the association between PSD and PSA and stroke lesion laterality, type, and 
location. Differences and similarities in the brain correlates associated with 
PSD and PSA were examined. 
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2) Is there evidence for a bi-directional relationship between PSF and PSD, and 
PSF and PSA? 
In Chapter 4, the temporal relationships between PSF and PSD, and between 
PSF and PSA are disentangled. The effect of baseline PSF on the course of 
depressive and apathetic symptoms was examined, and also the effect 
of baseline PSD and PSA on the course of fatigue symptoms. In addition, 
we tested whether change in fatigue levels from baseline to follow-up was 
associated with change in levels of depression and apathy during the same 
period. 
3) Are premorbid personality traits predictive for the course of PSD and PSA?
Chapter 5 examines whether premorbid personality traits are a predictive factor 
for the development and course of PSD and PSA by studying the influence of 
neuroticism, extraversion, openness, conscientiousness, and agreeableness 
on depressive and apathetic symptoms over the course of 12 months. 
4) Which lesion-related and generalized vascular and degenerative imaging 
markers are predictive for the development of PSD and PSA?
Chapter 6 studies the association between both lesion-related imaging 
markers and more generalized imaging markers like WMH, presence of old 
infarcts and microbleeds, cerebral small vessel disease burden, and atrophy 
assessed at three months post-stroke and the development of PSD and PSA 
over a period of 12 months follow-up. 
5) What is the influence of vascular cognitive impairment on the course of PSD 
and PSA? 
In Chapter 7, the association between presence of cognitive impairment in 
any cognitive domain (memory, information processing speed, or executive 
function), and degree of VCI (i.e. impairment in single or multiple cognitive 
domains) and the development of PSD and PSA is examined, and also how 
domain-specific VCI influences the course of PSD and PSA over a period of 12 
months. 
6) Do executive dysfunctions denote a distinct PSD subtype based on clinical 
correlates and prognosis?
Chapter 8 studies whether patients with DES, a potential biological subtype 
of depression in which depression is paired with executive dysfunction, show 
differences in demographic and clinical characteristics, and stroke-related 
or generalized vascular and degenerative brain pathology compared with 
patients with only depression, or only executive dysfunction. In addition, 
differences in the course of executive dysfunction, depressive symptoms, and 
other cognitive domains between patients with and without DES are studied. 
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Chapter 9 provides a general discussion, including a summary of the main 
findings of the various chapters, and implications and recommendations for 
future research and clinical practice. 
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ABSTRACT
Several brain imaging markers have been studied in the development of 
post-stroke depression (PSD) and post-stroke apathy (PSA), but inconsistent 
associations have been reported. This systematic review and meta-analysis 
aims to provide a comprehensive and up-to-date evaluation of imaging 
markers associated with PSD and PSA. Databases (Medline, Embase, 
PsycINFO, CINAHL, and Cochrane Database of Systematic Reviews) were 
searched from inception to July 21, 2016. Observational studies describing 
imaging markers of PSD and PSA were included. Pooled odds ratios (OR) and 
95% confidence intervals (CI) were calculated to examine the association 
between PSD or PSA and stroke lesion laterality, type, and location, also 
stratified by study phase (acute, post-acute, chronic). Other imaging 
markers were reviewed qualitatively. The search retrieved 4502 studies, of 
which 149 studies were included in the review and 86 studies in the meta-
analyses. PSD in the post-acute stroke phase was significantly associated 
with frontal (OR 1.72, 95% CI 1.34–2.19) and basal ganglia lesions (OR 2.25, 
95% CI 1.33–3.84). Hemorrhagic stroke related to higher odds for PSA in the 
acute phase (OR 2.58, 95% CI 1.18–5.65), whereas ischemic stroke related 
to higher odds for PSA in the post-acute phase (OR 0.20, 95% CI 0.06–0.69). 
Frequency of PSD and PSA is modestly associated with stroke type and 
location and is dependent on stroke phase. These findings have to be taken 
into consideration for stroke rehabilitation programs, as this could prevent 
stroke patients from developing PSD and PSA, resulting in better clinical 
outcome.
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INTRODUCTION 
Post-stroke depression (PSD) and post-stroke apathy (PSA) are frequent 
neuropsychiatric symptoms after stroke, with estimated prevalence rates between 
30% and 40%, respectively, in the first few months after stroke.1 Depression can be 
defined as a feeling of low mood, loss of interest, and lack of pleasure that persists 
for a time period of at least 2 weeks.2 Apathy is generally defined as a disorder 
of diminished motivation, characterized by loss of interest, diminished emotional 
response, and loss of initiative,3 and can occur independently,4 or in combination 
with symptoms of depression.5
According to a previous meta-analysis, approximately 40% of patients with PSA also 
suffer from PSD.6 Because depression and apathy share several features, mainly 
loss of interest, patients with apathy after stroke are frequently misdiagnosed as 
having PSD.7 However, despite the considerable overlap in symptoms between 
PSD and PSA, there is evidence indicating that the two syndromes seem to develop 
from different anatomical and neurobiological constructs.8-12
Earlier studies have already attempted to disentangle the relationship between PSD 
and PSA, which have shown inconclusive results. The Sydney Stroke Study showed 
evidence for independence of PSA and PSD when measuring 3 to 6 months post-
stroke.13 However, at 1-year follow-up, a significant overlap between apathy and 
depression was found.14 Contrastingly, Caeiro et al.15 did not find an association 
between PSA and PSD at 1-year post-stroke. It is important to disentangle the 
relationship between PSA and PSD, at least from a clinical perspective, since the 
two syndromes seem to benefit from different types of medication.14 Both PSD 
and PSA are known to have a negative influence on clinical outcome16,17 and 
quality of life.18,19 Early treatment and prevention of PSD and PSA might have a 
positive effect on functional outcome, thereby limiting the impact of stroke on 
patients’ daily lives.20 Identification of associated risk factors is thus important for 
early detection and tailoring of rehabilitation programs.
Several brain imaging markers have been studied in the development of PSD. 
Early studies suggested that PSD is frequent in patients with left frontal lesions,9,13 
but this hypothesis could not be supported by later studies.21 Previous systematic 
reviews primarily looked at the relationship with lesion laterality, while other 
potential imaging markers such as lesion location, lesion type, lesion volume, white 
matter hyperintensities (WMH), and atrophy have been ignored.21-23 In addition, 
imaging markers of PSA have been studied less frequently compared with PSD. 
Some studies provided evidence that PSA is associated with right hemispheric and 
subcortical lesions,8,24,25 though two recent systematic reviews on lesion location 
in PSA reported inconclusive results.6,26 Caeiro et al.26 only studied the association 
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with lesion laterality and were not able to find an association, whereas van Dalen 
et al.6 provided a qualitative overview of associations with lesion location and 
laterality, but no meta-analysis, and concluded that no clear association with lesion 
side or location could be found, though associations with the basal ganglia were 
most consistent. 
A systematic review and meta-analysis was performed to evaluate the association 
between different brain imaging markers and PSD and PSA, thereby updating and 
extending previous meta-analyses just focusing on lesion location in association 
with PSD and PSA. The main aim of the present study was to investigate differences 
and similarities in several brain correlates associated with PSD and PSA. 
Post-stroke depression (PSD) and post-stroke apathy (PSA) are frequent 
neuropsychiatric symptoms after stroke, with estimated prevalence rates between 
30% and 40%, respectively, in the first few months after stroke.1 Depression can be 
defined as a feeling of low mood, loss of interest, and lack of pleasure that persists 
for a time period of at least 2 weeks.2 Apathy is generally defined as a disorder 
of diminished motivation, characterized by loss of interest, diminished emotional 
response, and loss of initiative,3 and can occur independently,4 or in combination 
with symptoms of depression.5
According to a previous meta-analysis, approximately 40% of patients with PSA also 
suffer from PSD.6 Because depression and apathy share several features, mainly 
loss of interest, patients with apathy after stroke are frequently misdiagnosed as 
having PSD.7 However, despite the considerable overlap in symptoms between 
PSD and PSA, there is evidence indicating that the two syndromes seem to develop 
from different anatomical and neurobiological constructs.8-12
Earlier studies have already attempted to disentangle the relationship between PSD 
and PSA, which have shown inconclusive results. The Sydney Stroke Study showed 
evidence for independence of PSA and PSD when measuring 3 to 6 months post-
stroke.13 However, at 1-year follow-up, a significant overlap between apathy and 
depression was found.14 Contrastingly, Caeiro et al.15 did not find an association 
between PSA and PSD at 1-year post-stroke. It is important to disentangle the 
relationship between PSA and PSD, at least from a clinical perspective, since the 
two syndromes seem to benefit from different types of medication.14 Both PSD 
and PSA are known to have a negative influence on clinical outcome16,17 and 
quality of life.18,19 Early treatment and prevention of PSD and PSA might have a 
positive effect on functional outcome, thereby limiting the impact of stroke on 
patients’ daily lives.20 Identification of associated risk factors is thus important for 
early detection and tailoring of rehabilitation programs.
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Several brain imaging markers have been studied in the development of PSD. 
Early studies suggested that PSD is frequent in patients with left frontal lesions,9,13 
but this hypothesis could not be supported by later studies.21 Previous systematic 
reviews primarily looked at the relationship with lesion laterality, while other 
potential imaging markers such as lesion location, lesion type, lesion volume, white 
matter hyperintensities (WMH), and atrophy have been ignored.21-23 In addition, 
imaging markers of PSA have been studied less frequently compared with PSD. 
Some studies provided evidence that PSA is associated with right hemispheric and 
subcortical lesions,8,24,25 though two recent systematic reviews on lesion location 
in PSA reported inconclusive results.6,26 Caeiro et al.26 only studied the association 
with lesion laterality and were not able to find an association, whereas van Dalen 
et al.6 provided a qualitative overview of associations with lesion location and 
laterality, but no meta-analysis, and concluded that no clear association with lesion 
side or location could be found, though associations with the basal ganglia were 
most consistent. 
A systematic review and meta-analysis was performed to evaluate the association 
between different brain imaging markers and PSD and PSA, thereby updating and 
extending previous meta-analyses just focusing on lesion location in association 
with PSD and PSA. The main aim of the present study was to investigate differences 
and similarities in several brain correlates associated with PSD and PSA. 
METHODS
SEARCH STRATEGY AND SELECTION CRITERIA
This systematic review and meta-analysis was conducted according to the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
statement27 and by use of a predefined research protocol. Databases (Medline, 
Embase, PsycINFO, CINAHL, and Cochrane Database of Systematic Reviews) were 
searched from inception to December 2015 and updated to July 21, 2016. A full 
description of the search strategy is presented in supplementary Online Resource 
1. To be eligible for inclusion, studies had to a) include patients with ischemic or 
hemorrhagic stroke, b) assess the presence of depressive or apathetic symptoms, 
c) examine the association between these symptoms and an imaging marker, d) 
the population had to be human adults, e) sample size had to be larger than 25 
to avoid inclusion of spurious associations from underpowered studies, and f) 
language had to be English, German, Dutch, or French. Studies were excluded 
if (a) the study population was other than stroke or a combined population was 
studied without separate results available for stroke, (b) the population consisted 
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of only patients with cognitive impairment or dementia in which vascular damage 
(infarcts, WMH, atrophy) was studied, or (c) no imaging data or lesion-related data 
(e.g. lesion location, type, laterality, WMH) were described. Records of research 
protocols, reviews, and abstracts from scientific meetings were excluded. If studies 
presented results from the same cohort on a certain outcome measure, data from 
the study that used the largest group of patients were used, or if they used an 
equal number of patients, data from the earliest publication were used. 
Two reviewers (E.D. and P.A.) independently screened titles and abstracts manually 
for potential eligibility. Doubtful records were discussed (E.D. and P.A.) and an 
independent third reviewer (S.K.) decided if doubtful cases were included or not 
for full-text scrutiny. For completeness, reference lists were screened for additional 
articles. One reviewer (E.D.) assessed eligibility for inclusion based on full-text 
screening. 
DATA COLLECTION AND EXTRACTION
Data extraction was performed on selected articles for which full texts were 
obtained. Two independent reviewers (E.D. and M.R.) extracted data from each 
study according to a predefined data extraction form. The following information 
was extracted for each study included in the review: (1) first author and year 
of publication, (2) demographic characteristics, (3) in- and exclusion criteria if 
specified, (4) imaging method and imaging markers, (5) questionnaires and criteria 
used to define PSD or PSA, (6) time of measurement after stroke, (7) statistical 
methods used and results needed for the meta-analysis, (8) main conclusion and 
limitations. 
STATISTICAL ANALYSES AND STUDY QUALITY 
Statistical analyses were performed using STATA 13.1 (StataCorp, TX, USA). 
Statistical significance was defined by p < .05 in two-sided tests. Pooled odds 
ratios (ORs) with corresponding 95% confidence intervals (CIs) were calculated 
to examine the association between PSD or PSA and stroke lesion laterality, type, 
and location, also stratified by study phase (acute, post-acute, chronic), using a 
DerSimonian-Laird random-effects model to account for within- and between-
study variance.28 A full description of the observations used in the meta-analyses 
is presented in supplementary Online Resource 2. Studies were stratified 
according to phase in which they measured depression or apathy after stroke: 
acute (< 15 days from stroke onset), post-acute (15 days - 6 months), and chronic 
phase (> 6 months). This stratification was based on the meta-analysis by Caeiro et 
al.26 and was chosen because the acute stroke phase corresponds with the period 
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of hospitalization and acute care29 and in this period the risk of complications 
and recurrent stroke is highest.30 After this period of acute care, patients usually 
start with rehabilitation and most recovery will take place in the first six months.31 
Therefore, we defined this period as the post-acute period, and > 6 months as the 
chronic stroke phase.
To identify possible sources of heterogeneity, random-effect meta-regression 
models were conducted including the following covariates: study phase, mean 
age, PSD/PSA prevalence, percentage of females, imaging method (CT/MRI vs. 
MRI), patient source, and first-ever stroke (yes/no).
The study quality was assessed by a single investigator (E.D.) with the Newcastle-
Ottowa Scale (NOS) for case-control and cohort studies, and a modified NOS was 
applied for cross-sectional studies.32 A maximum score of 9 can be obtained and 
studies with a score < 5 were not included in the meta-analyses (see supplementary 
Online Resource 3). Visual inspection of asymmetry in funnel plots, in which the 
relation between sample size and effect size is assessed, was used to test for 
possible publication bias. Egger’s regression tests were performed to test for 
significant asymmetry of funnel plots as a test for small-study effects.33
RESULTS
Of 4502 identified articles, 167 articles were selected for full-text screening (see 
Figure 1). Nine articles could not be retrieved from authors after several contact 
requests. Based on full-text evaluation of the remaining articles, 135 articles met 
inclusion criteria. Reasons for exclusion were: conference abstract,34 research 
protocol,35 review article,36,37 small sample size,38-45 other outcome than depression 
or apathy,46-48 study population other than stroke or no separate results available 
for stroke subpopulation,49-55 and no evaluation of imaging markers.56 Fourteen 
additional studies found in reference lists and fulfilling eligibility criteria were 
included, resulting in a total of 149 studies. 
CHARACTERISTICS OF INCLUDED STUDIES
A detailed overview of study characteristics for PSD studies (n = 132) and PSA 
studies (n = 23) is presented in supplementary Online Resource 4 and 5. Of 
all PSD studies, 51 (39%) studies included only first-ever strokes. Thirty-nine 
cohorts (30%) were followed prospectively. Some studies used semi-structured 
psychiatric interviews like the Mini International Neuropsychiatric Interview,57 or 
the Structured Clinical Interview for DSM disorders,58 based on Diagnostic and 
Statistical Manual of Mental Disorders (DSM) version III59 or IV,60 whereas others 
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used clinician-rated or self-rated questionnaires (e.g. the Hamilton Depression 
Rating Scale,61 Montgomery-Åsberg Depression Rating Scale,62 or the Geriatric 
Depression Scale63 to evaluate the presence of PSD, and different cut-offs were 
applied. 
Based on 107 (81%) studies that reported on PSD prevalence within the first year, 
a median prevalence of 30.4% was found (IQR 20.1–40.0). Of all PSA studies, nine 
(39%) studies included first-ever stroke patients. Four (17%) cohorts were studied 
prospectively. Most studies used the Apathy Scale64 or Apathy Evaluation Scale65 
to evaluate the presence of PSA, and different cut-offs were applied. Based on 
20 (87%) studies that reported on PSA prevalence within the first year, a median 
prevalence of 37.3% was found (IQR 22.1–42.5).
4502 records identified 
through database 
searching
3673 records screened
167 articles selected for 
full-text screening
158 articles assessed for 
eligibility
23 articles excluded
2 review articles
1 research protocol
1 conference abstract
19 Did not fulfil inclusion criteria
3 other outcome
8 sample size < n = 25
7 other population than stroke
1 no imaging marker
149 studies included in qualitative 
analysis
126 on PSD
17 on PSA
6 on PSD and PSA
86 studies included in quantitative 
meta-analysis
74 on PSD
12 on PSA
3506 records excluded
14 articles from 
references
9 articles unavailable
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flowchart of 
study selection and review
Abbreviations: PSA, post-stroke apathy; PSD, post-stroke depression
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LESION LATERALITY
Sixty (45%) studies presented data on PSD and lesion laterality. In the pooled 
analyses, no significant overall association between PSD and lesion side was 
found (Table 1). A subgroup analysis stratified by study phase showed a 26% 
higher odds of PSD after left-sided stroke in the acute phase, but this effect was 
not statistically significant (OR 1.26, 95% CI 0.95–1.67, I2 = 60.1%, see Figure 2). 
Neither in the post-acute stroke phase (OR 1.00, 95% CI 0.83 – 1.20, I2 = 50.4%), 
nor in the chronic stroke phase (OR 1.12, CI 0.87–1.45, I2 = 0.0%) a significant 
association was found with lesion side (see Figure 3). 
Nine (39%) studies presented data on PSA and lesion laterality. In the pooled 
analyses, the overall odds of PSA were a bit higher after left-sided stroke (Table 1). 
A subgroup analysis stratified by study phase showed higher odds after left-sided 
stroke in the post-acute phase, although this effect was not statistically significant 
(OR 1.90, 95% CI 0.88–4.09, I2 = 0.0%, see Figure 4A). No significant association 
was found in the acute stroke phase (OR 0.95, 95% CI 0.42–2.16, I2 = 72.0%, see 
Figure 4A) and no studies reported on the association in the chronic phase.
Table 1. Overall effect sizes and Egger’s bias coefficients
Effect size Heterogeneity Publication bias
Marker
Number of  
studies 
included
Odd’s 
ratio
95% CI I2 (%) p-value
Egger’s bias  
coefficient
p-value
PSD
Laterality 601 1.07 0.93 – 1.23 49.6 < .001 0.14 .743
Type 142 0.94 0.65 – 1.36 33.3 .102 -0.06 .943
Frontal lesions 303 1.54 1.27 – 1.88 43.4 .004 0.92 .132
Subcortical lesions 104 1.06 0.81 – 1.38 0.0 .601 1.00 .186
Basal ganglia lesions 125 1.78 1.20 – 2.66 65.3  .001 0.24 .884
PSA
Laterality 9 1.16 0.62 – 2.18 63.5 .005 1.69 .262
Type 4 0.82 0.19 – 3.53 75.2 .007 -3.92 .273
Frontal lesions 5 0.84 0.44 – 1.59 0.0 .635 2.71 .055
Subcortical lesions 2 1.03 0.38 – 2.80 0.0 .686           Not enough data
Basal ganglia lesions 4 1.32 0.79 – 2.21 0.0 .891 -0.42 .536
Abbreviations: CI, confidence interval; PSA, post-stroke apathy; PSD, post-stroke depression.
Note: 1 Six of the 60 studies provided data on more than one time point. 2 One of the 14 studies 
provided data on more than one time point. 3 Five of the 30 studies provided data on more than one 
time point. 4 Two of the 10 studies provided data on more than one time point. 5 One of the 12 studies 
provided data on more than one time point. 
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Figure 2. Forest plot of the relationship between post-stroke depression and lesion laterality 
Note: Subanalyses on acute stroke phase are presented. 
Abbreviations: CI, confidence interval; OR, odds ratio.
LESION TYPE
Fourteen (11%) studies reported outcomes on lesion type associated with PSD. 
Overall, no significant association between PSD and lesion type was observed 
(Table 1). A subgroup analysis by study phase showed no significant association 
between lesion type and PSD in the acute (OR 0.95, 95% CI 0.59–1.53, I2 = 14.0%), 
post-acute (OR 0.94, 95% CI 0.47–1.87, I2 = 59.9%), or chronic stroke phase (OR 
0.76, 95% CI 0.22–2.65, I2 = 0.0%, see Figure 5). 
Four (17%) studies reported outcomes on lesion type associated with PSA. Overall, 
the odds of PSA after hemorrhagic stroke was not higher than after ischemic 
stroke (Table 1). A subgroup analysis by study phase showed higher odds after 
hemorrhagic stroke in the acute phase (OR 2.58, 95% CI 1.18–5.65, I2 = 0.0%, see 
Figure 4B), whereas higher odds after ischemic stroke were found in the post-
acute phase (OR 0.20, 95% CI 0.06–0.69, I2 = 0.0%, see Figure 4B). Only two studies 
were included per phase.
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Figure 3. Forest plot of the relationship between post-stroke depression and lesion laterality
Note: Subanalyses on post-acute stroke phase (upper panels) and chronic stroke phase (lower panels) 
are presented. 
Abbreviations: CI, confidence interval; OR, odds ratio.
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Figure 4. Forest plot of the relationship between post-stroke apathy and lesion laterality/type 
Note: In panel A, the results of the meta-analysis on lesion laterality are presented. In panel B, the results 
of the meta-analysis on lesion type are presented. Apart from the overall analysis, the subanalyses on 
acute stroke phase (upper panels) and post-acute stroke phase (lower panels) are presented.
Abbreviations: CI, confidence interval; OR, odds ratio.
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Figure 5. Forest plot of the relationship between post-stroke depression and lesion type
Note: Apart from the overall analysis, the subanalyses on acute stroke phase (upper panels), post-acute 
stroke phase (middle panels), and chronic stroke phase (lower panels) are presented. 
Abbreviations: CI, confidence interval; OR, odds ratio.
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LESION LOCATION
In Table 2, an overview is provided of lesion locations that were significantly 
associated with PSD. As frontal/anterior, subcortical, and basal ganglia lesions were 
frequently associated with PSD, meta-analyses were performed on these locations. 
Thirty (23%) studies reported outcomes on frontal lesion location associated with 
PSD. Overall, a 54% higher odds of PSD after frontal stroke was found (Table 1). 
Subgroup analysis suggested this association was limited to PSD in the post-acute 
stroke phase (OR 1.72, 95% CI 1.34–2.19, I2 = 47.2%), as no significant association 
was found in the acute stroke phase (OR 1.21, 95% CI 0.90–1.63, I2 = 21.1%), see 
Figure 6.
Ten (8%) studies reported outcomes on subcortical lesion location associated with 
PSD. Pooled odds for PSD were not significantly higher after subcortical lesions 
(Table 1). A subgroup analysis by study phase showed no significant associations 
between subcortical lesions and PSD in the acute (OR 1.04, 95% CI 0.64–1.70), 
post-acute (OR 0.93, 95% CI 0.65–1.32), or chronic stroke phase (OR 1.88, 95% CI 
0.92–3.84), see Figure 7A, but the latter association consisted only of two studies. 
No significant heterogeneity was observed (each phase, I2 = 0.0%). Twelve (9%) 
studies reported outcomes on basal ganglia lesion location associated with 
PSD. Overall, basal ganglia lesions were significantly associated with PSD (Table 
1). A subgroup analysis by study phase showed that basal ganglia lesions were 
significantly associated with PSD in the post-acute phase (OR 2.25, 95% CI 1.33–
3.84, I2 = 71.2%), but not in the acute stroke phase (OR 1.26, 95% CI 0.74–2.14, I2 
= 41.4%), see Figure 7B.
Five (22%) studies provided data on the association between PSA and frontal 
lesions. Overall, no significant association between PSA and frontal lesions was 
found (Table 1). Subgroup analyses showed different albeit no significant results 
per phase, with stronger associations with frontal lesions in the acute phase (OR 
1.68, 95% CI 0.52–5.45, I2 = 0.0%), and an inverse relation in the post-acute phase 
(OR 0.63, 95% CI 0.29–1.34, I2 = 0.0%), see Figure 8A. No significant association 
between PSA and subcortical lesions was found (Table 1), but this was only 
evaluated in two (9%) studies (OR 1.03, 95% CI 0.38–2.80, I2 = 0.0%), see Figure 
8B. Four (17%) studies provided data on the association between PSA and basal 
ganglia lesions. Overall, no significant association between PSA and basal ganglia 
lesions was found (Table 1). Stratification by study phase showed similar results, 
with no significant heterogeneity (acute phase: OR 1.45, 95% CI 0.42–4.95, post-
acute phase: OR 1.29, 95% CI 0.73–2.29), see Figure 8C.
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Figure 6. Forest plot of the relationship between post-stroke depression and frontal/anterior lesions
Note: Apart from the overall analysis, the subanalyses on acute stroke phase (upper panels) and post-
acute stroke phase (lower panels) are presented. 
Abbreviations: CI, confidence interval; OR, odds ratio
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Figure 7. Forest plot of the relationship between post-stroke depression and subcortical/basal ganglia 
lesions
Note: In panel A, the results of the meta-analysis on subcortical lesion location are presented. Apart 
from the overall analysis, the subanalyses on acute stroke phase (upper panels), post-acute stroke phase 
(middle panels), and chronic stroke phase (lower panels) are presented. In panel B, the results of the 
meta-analysis on basal ganglia lesions are presented. Apart from the overall analysis, the subanalyses 
on acute stroke phase (upper panels) and post-acute stroke phase (lower panels) are presented. 
Abbreviations: CI, confidence interval; OR, odds ratio.
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Figure 8. Forest plot of the relationship between post-stroke apathy and lesion location 
Note: In panel A, the results of the meta-analysis on frontal lesion location are presented. In panel B, the 
results of the meta-analysis on subcortical lesion location are presented. In panel C, the results of the 
meta-analysis on basal ganglia lesions are presented. Apart from the overall analysis, the subanalyses 
on acute stroke phase (upper panels) and post-acute stroke phase (lower panels) are presented. 
Abbreviations: CI, confidence interval; OR, odds ratio.
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Table 3. Imaging markers associated with post-stroke depression and post-stroke apathy
Imaging marker
Studies
Acute phase Post-acute phase Chronic phase
PSD
Degree of WMH -
Deep WMH: Kim et al. (2011);117 Tang et al. (2010)81
Left frontal WMH: Mok et al. (2010)118 
Overall, BG, frontal WMC: Chatterjee 
et al. (2010);89 
Overall, deep, periventricular WMH: 
Pavlovic et al. (2016)119
Cerebral microbleeds Choi-Kwon et al. (2012)120 Tang et al. (2011a, 2011b, 2014a, 2014b)121-124 -
Large lesion volume
Shimoda and Robinson (1999);68 Ku et al. (2013);125 
Nys et al. (2005)126
Hama et al. (2007);9 MacHale et al. (1998);106 
Morris et al. (1992);72 Schwartz et al. (1993);87 Shimoda and 
Robinson (1999);68 Zhang et al. (2012)83
Sharpe et al. (1990, 1994);127,128 
Shimoda and Robinson (1999)68
Large number of lesions -
Bendsen et al. (1997);129 Jiang et al. (2014);98 Tang et al. 
(2014);124 Zhang et al. (2012)83
Chatterjee et al. (2010);89 Lacunar 
lesions: Pavlovic et al. (2016)119
Metabolism
Huang et al. (2010);130 
Xu et al. (2008)131
Glodzik-Sobanska et al. (2006);132 Wang et al. (2012);133 
Xu et al. (2008)131
-
Atrophy - Left IFG: Fu et al. (2010)134 FL: Tang et al. (2013)135
Subcortical: Astrom et al. (1993);66 
Starkstein et al. (1988)136
Regional cerebral blood flow - Left hemisphere: Wichowicz et al. (2006)137 -
Functional connectivity / fractional anisotropy 
Altered FC in left orbital part of IFG: 
Zhang et al. (2014)138
Frontal WM integrity: Williamson et al. (2010).139 
Increased ratio FA values in bilateral anterior limbs of IC: 
Yasuno et al. (2014)140
-
PSA
Degree of WMH -
RH WMH, right fronto-subcortical circuit WMH: Brodaty et al. 
(2005);13
Periventricular WMH: Tang et al. (2013)115
-
Large lesion volume - Hama et al. (2007)9 -
Large number of lesions - Tang et al. (2013)115 -
Metabolism Glodzik-Sobanska et al. (2005)141 - -
Regional cerebral blood flow Bilateral BG: Onoda et al. (2011)111 -
Right dlF and lFT: Okada et al. 
(1997)142
Fractional anisotropy -
Reduced FA in Genu of CC, left anterior corona radiata, 
splenium of CC, and WM in the right IFG: Yang et al. (2015).143 
Reduced median FA, reduction in WM integrity in anterior 
cingulum, fornix and uncinate fasciculus: Hollocks et al. 
(2015)11
-
Atrophy - Frontal cortical atrophy: Mihalov et al. (2016)112 -
Abbreviations: ATR, atrophy; BG, basal ganglia; CC, corpus collosum; CMB, cerebral microbleeds; dlF, 
dorsolateral frontal; FA, fractional anisotropy; FC, functional connectivity; FL, frontal lobe; IFG, inferior 
frontal gyrus; lFT, left frontotemporal; RH, right hemisphere; WM, white matter; WMC, white matter 
changes; WMH, white matter hyperintensities, PSA, post-stroke apathy; PSD, post-stroke depression.
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Table 3. Imaging markers associated with post-stroke depression and post-stroke apathy
Imaging marker
Studies
Acute phase Post-acute phase Chronic phase
PSD
Degree of WMH -
Deep WMH: Kim et al. (2011);117 Tang et al. (2010)81
Left frontal WMH: Mok et al. (2010)118 
Overall, BG, frontal WMC: Chatterjee 
et al. (2010);89 
Overall, deep, periventricular WMH: 
Pavlovic et al. (2016)119
Cerebral microbleeds Choi-Kwon et al. (2012)120 Tang et al. (2011a, 2011b, 2014a, 2014b)121-124 -
Large lesion volume
Shimoda and Robinson (1999);68 Ku et al. (2013);125 
Nys et al. (2005)126
Hama et al. (2007);9 MacHale et al. (1998);106 
Morris et al. (1992);72 Schwartz et al. (1993);87 Shimoda and 
Robinson (1999);68 Zhang et al. (2012)83
Sharpe et al. (1990, 1994);127,128 
Shimoda and Robinson (1999)68
Large number of lesions -
Bendsen et al. (1997);129 Jiang et al. (2014);98 Tang et al. 
(2014);124 Zhang et al. (2012)83
Chatterjee et al. (2010);89 Lacunar 
lesions: Pavlovic et al. (2016)119
Metabolism
Huang et al. (2010);130 
Xu et al. (2008)131
Glodzik-Sobanska et al. (2006);132 Wang et al. (2012);133 
Xu et al. (2008)131
-
Atrophy - Left IFG: Fu et al. (2010)134 FL: Tang et al. (2013)135
Subcortical: Astrom et al. (1993);66 
Starkstein et al. (1988)136
Regional cerebral blood flow - Left hemisphere: Wichowicz et al. (2006)137 -
Functional connectivity / fractional anisotropy 
Altered FC in left orbital part of IFG: 
Zhang et al. (2014)138
Frontal WM integrity: Williamson et al. (2010).139 
Increased ratio FA values in bilateral anterior limbs of IC: 
Yasuno et al. (2014)140
-
PSA
Degree of WMH -
RH WMH, right fronto-subcortical circuit WMH: Brodaty et al. 
(2005);13
Periventricular WMH: Tang et al. (2013)115
-
Large lesion volume - Hama et al. (2007)9 -
Large number of lesions - Tang et al. (2013)115 -
Metabolism Glodzik-Sobanska et al. (2005)141 - -
Regional cerebral blood flow Bilateral BG: Onoda et al. (2011)111 -
Right dlF and lFT: Okada et al. 
(1997)142
Fractional anisotropy -
Reduced FA in Genu of CC, left anterior corona radiata, 
splenium of CC, and WM in the right IFG: Yang et al. (2015).143 
Reduced median FA, reduction in WM integrity in anterior 
cingulum, fornix and uncinate fasciculus: Hollocks et al. 
(2015)11
-
Atrophy - Frontal cortical atrophy: Mihalov et al. (2016)112 -
Abbreviations: ATR, atrophy; BG, basal ganglia; CC, corpus collosum; CMB, cerebral microbleeds; dlF, 
dorsolateral frontal; FA, fractional anisotropy; FC, functional connectivity; FL, frontal lobe; IFG, inferior 
frontal gyrus; lFT, left frontotemporal; RH, right hemisphere; WM, white matter; WMC, white matter 
changes; WMH, white matter hyperintensities, PSA, post-stroke apathy; PSD, post-stroke depression.
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OTHER IMAGING MARKERS
Several studies examined imaging markers other than lesion location and type in 
association with PSD. These markers could not be evaluated in a meta-analysis. 
Therefore, the most important imaging markers are described qualitatively 
(see Table 3). PSD was associated with total,89,119 deep,119 frontal,89,118 and 
periventricular WMH.119 Also, cerebral microbleeds are associated with PSD,121-124 
and several studies showed that PSD is more prevalent in patients with a large 
lesion volume,9,68,72,83,87,106,125-128 or large number of lesions.83,89,98,119,124,129
More recently, advanced diffusion tensor imaging (DTI) techniques have been used 
to investigate the association between microstructural abnormalities in white matter 
(WM) and PSD. Yasuno et al.140 showed that a reduction in fractional anisotropy 
(FA) in the bilateral anterior limbs of the internal capsule was associated with an 
increased risk of PSD and Williamson et al.139 showed that decreased WM integrity in 
the frontal lobes was associated with mood deficits. This indicates that WM damage 
in certain brain regions is associated with the development of PSD. A resting-state 
functional MRI (fMRI) study showed that altered functional connectivity in regions 
involved in affect was associated with higher levels of depression.138 Atrophy also 
seems to be an important predictor of PSD, as significant associations were found 
with frontal lobe atrophy,135 subcortical atrophy,66,136 and left inferior frontal gyrus 
atrophy.134 Interestingly, none of these studies reported on hippocampal atrophy. 
Recently, Chen et al.144 looked at medial temporal lobe atrophy, but found no 
association with PSD in the acute or post-acute stroke phase. According to proton 
magnetic resonance spectroscopy (1H-MRS) studies, biochemical changes in 
metabolite levels in frontal lobe,131-133 hippocampus,130 and left thalamus130 seem 
to accompany the development of PSD. 
Compared with PSD studies, only few studies evaluated imaging markers related 
to PSA (see Table 3). PSA was significantly associated with degree of right-
hemisphere,13 right fronto-subcortical circuit,13 and periventricular WMH.135 In 
addition, large lesion volume,9 and large number of lesions115 were associated with 
PSA. A recent study by Mihalov et al.112 showed that frontal cortical atrophy was 
a strong predictor of PSA, and this relation increased with higher age. In two DTI 
studies reductions in FA in several brain areas were associated with an increased 
level of apathy.143,145 In addition, PSA was associated with reductions in regional 
cerebral blood flow in the bilateral basal ganglia,111 right dorsolateral frontal 
cortex, and left frontotemporal cortex142 measured with single-photon emission 
computed tomography. An H1-MRS study suggested that lower N-acetylaspartate/
creatine ratio in the right frontal lobe was related to PSA.141
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META-REGRESSION ANALYSES
Egger’s regression tests showed no evidence for statistically significant small-
study effects in above meta-analyses (see Table 1), although it was not possible to 
calculate Egger’s regression coefficients for the association with subcortical lesions 
in PSA as the pooled sample size was too small. Visual inspection of the shape of 
the funnel plots also did not reveal convincing evidence of obvious asymmetry 
(see supplementary Online Resource 6). However, some plots, especially for the 
PSA studies, only consisted of few studies. 
Meta-regression analyses were performed to assess potential sources of 
heterogeneity between PSD studies reporting on lesion laterality (n = 60). None 
of the included variables appeared to be a significant cause of heterogeneity. In 
addition, meta-regression analyses were performed on PSD studies reporting on 
frontal (n = 30) and basal ganglia lesions (n = 12). Only study phase appeared to 
be a significant cause of heterogeneity in both analyses (frontal: p = 0.041, residual 
I2 = 58.9%, Adj. R2 = 25.7%; basal ganglia: p = 0.044, residual I2 = 55.4%, Adj. R2 = 
50.7%). To assess potential sources of heterogeneity among PSA studies reporting 
on lesion laterality (n = 9), meta-regression analyses were performed showing that 
only imaging method appeared to be an important cause of heterogeneity (p = 
0.052, residual I2 = 31.2%, Adj. R2 = 64.6%). 
Table 4. Circuits associated with post-stroke depression and post-stroke apathy
Studies Phase Circuits – network
PSD
Terroni et al. (2011)146 Acute
Disruption of limbic-cortical-striatal-pallidal-thalamic circuit,  
Medial PFC dysfunction
Yang et al. (2015)90 Acute
Frontal lobe, insula, limbic system, parietal lobe, basal ganglia, 
temporal lobe
Vataja et al. (2001)147 Post-acute
Higher number and lesion volume in (left) prefronto-subcortical 
circuit
Tang et al. (2011)148 Post-acute Lesions in frontal subcortical circuits
PSA
Yang et al. (2015)145 Acute
Limbic system, basal ganglia, insula, frontal, temporal, parietal, 
occipital lobe
Abbreviations: PFC, prefrontal cortex; PSA, post-stroke apathy; PSD, post-stroke depression.
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DISCUSSION
This systematic review and meta-analysis summarizes the most up-to-date 
information on a range of imaging markers associated with PSD and PSA during 
the acute, post-acute, and chronic stroke phase. Meta-analyses indicated that PSD 
in the post-acute phase was significantly more frequent in patients with frontal 
or basal ganglia lesions. No significant association was found between PSD and 
lesion laterality in the post-acute and chronic stroke phase. Nevertheless, it is of 
interest to mention that left-sided stroke occurred more often in the PSD group in 
the acute phase. This result became insignificant after the inclusion of four recent 
large studies,73,144,149,150 which differed from the other studies in that they reported 
a relatively low PSD prevalence (median 18.6%, IQR 17.4–30.2). Frequency of PSD 
was equal for ischemic and hemorrhagic stroke in all stroke phases, but PSA was 
more frequent after hemorrhagic stroke in the acute phase, whereas it was more 
frequent after ischemic stroke in the post-acute phase. Since only four PSA studies 
were available, this finding should be interpreted with caution. Also, PSA did not 
depend on lesion laterality or location, but again the amount of available PSA 
studies was small in general.
Our meta-analysis updates and extends previous studies. The meta-analysis by 
Wei et al.23 on lesion laterality and PSD found a significant association between 
right hemispheric lesions and risk of PSD in the post-acute stroke phase (1-6 
months). In contrast to Wei et al.,23 we defined the post-acute period as 15 days to 
6 months, which could explain the difference in results. In agreement with Caeiro 
et al.26 the prevalence of PSA was not associated with lesion laterality. Both meta-
analyses did not study associations with markers other than lesion laterality and 
lesion type, while the review of van Dalen et al.6 evaluated associations between 
PSA and lesion location only qualitatively and concluded that no clear association 
could be found.
The present findings suggest that lesion location is an important risk factor for 
PSD in the post-acute stroke phase. However, in the past few years the hypothesis 
of PSD and PSA being associated with damage to specific lesion locations has 
been shifted to the idea that damage to a neuronal network involved in affect 
is underlying the development of PSD and PSA,146-148 with different sub-circuits 
involved in PSD90 and PSA,145 see Table 4. DTI is a promising tool to identify more 
accurately how these brain networks are affected after stroke. The qualitative 
overview of imaging markers associated with PSD and PSA showed that not 
only direct stroke-related features, such as lesion location, lesion volume, and 
number of lesions, but also other neurovascular, non-directly stroke-related but 
often co-occurring features, such as degree of WMH, cerebral microbleeds, and 
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atrophy, were frequently associated with PSD. With respect to PSA, associations 
with degree of WMH, lesion volume, and number of lesions were found in some 
extent. Co-occurring vascular lesions may make a stroke patient more vulnerable 
for developing PSD and PSA. Therefore, future studies should focus on a broader 
range of imaging markers, including lesion volume, atrophy, WMH, and cerebral 
microbleeds, and also how lesion-related markers may interact with co-occuring 
indirect vascular markers. Besides, advanced imaging techniques (e.g. DTI, 
fMRI) are needed to evaluate how microstructural abnormalities and changes in 
functional connectivity contribute to the development of PSD and PSA. 
Our study has the following strengths. A large amount of publications on PSD 
were identified, resulting in a rich pooled cohort of studies that were not included 
in earlier meta-analyses.73,82,84,95,98,144,149-152 Furthermore, beside information on 
lesion laterality, also data on other imaging markers was retrieved for quantitative 
and qualitative analysis. Therefore, the present review provides an up-to-date and 
extended overview of findings on the association between imaging markers and 
risk of PSD and PSA. 
One limitation of the present study was the small amount of studies on PSA, 
which made it difficult to perform subanalyses. Therefore, future studies are 
needed on imaging markers of PSA, covering a broad range of imaging markers. 
Nevertheless, as heterogeneity was small between PSA studies, we believe that 
the results are still of importance, but should be interpreted with caution as the 
generalizability and validity is compromised in comparison with meta-analyses 
including a larger amount of studies. In addition, moderate to high (unexplained) 
heterogeneity between studies in some meta-analyses indicated large differences 
in methodology between studies. Particularly the use of different scales and cut-offs 
to define the presence of depression and apathy and different imaging methods 
(CT vs. MRI) are of influence on the comparability of findings. Also, differences 
in eligibility criteria (e.g. exclusion of patients with aphasia, differences in age 
range) can create heterogeneity among studies. Meta-regression analyses were 
performed to identify potential sources of heterogeneity, and only study phase for 
PSD studies and imaging method for PSA studies could be identified. However, 
in addition to the included variables, also other potential variables (e.g. years of 
education, cognitive status), that could not be included in the analyses due to the 
large variability in the methods and availability of data between studies, might 
explain some of the between-study difference in effect estimates. Therefore, we 
performed random-effects meta-analyses, which take the heterogeneity between 
studies into account.
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CONCLUSION
The present study suggests that lesion location rather than lesion laterality or type 
may be an important risk factor for PSD in the post-acute stroke phase. In contrast, 
lesion type rather than lesion laterality or location might be an important factor 
in determining who is at risk to develop PSA in the acute and post-acute phase, 
though additional studies are needed to confirm this, as the sample size was small. 
Therefore, large multicenter cohort studies using advanced imaging techniques 
and focusing on both PSD and PSA from the acute to the chronic stroke phase are 
strongly needed. 
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SUPPLEMENTAL DATA
Supplementary Table 1. Search terms used in five databases
M
ed
lin
e
Platform OvidSP
Database MEDLINE® In-Process & Other Non-Indexed Citations 
Limits Human subjects, adult subjects, language (German, Dutch, English, French)
Search
(ischem* OR ischaem* OR stroke OR infarct* OR hemorrhag* OR haemorrhag* OR
lesion).ti,kf,hw 
AND 
(apath* OR depress* OR mood OR motivation OR neuropsychia* OR emotion OR 
abulia).ti,kf,hw 
AND 
(MRI OR (magnetic AND resonance) OR imaging OR SPECT OR (Single-photon 
AND Emission AND Positron AND Computed AND Tomography) OR fMRI OR 
(functional AND MRI) OR PET OR (Positron AND Emission AND Tomography) 
OR CT OR (Computed AND tomography) OR DTI OR (diffusion AND tensor) OR 
connectivity).mp
E
m
b
as
e
Platform OvidSP
Database Embase 1980-present
Limits Human subjects, adult subjects, language (German, Dutch, English, French)
Search
(ischem* OR ischaem* OR stroke OR infarct* OR hemorrhag* OR haemorrhag* OR 
lesion).ti,kw,hw 
AND 
(apath* OR depress* OR mood OR motivation OR neuropsychia* OR emotion OR 
abulia).ti,kw,hw 
AND  
(MRI OR (magnetic AND resonance) OR imaging OR SPECT OR (Single-photon 
AND Emission AND Positron AND Computed AND Tomography) OR fMRI OR 
(functional AND MRI) OR PET OR (Positron AND Emission AND Tomography) 
OR CT OR (Computed AND tomography) OR DTI OR (diffusion AND tensor) OR 
connectivity).mp
Ps
yc
IN
FO
Platform EBSCOhost
Database PsycINFO 1806 – present
Limits Human subjects, adult subjects, language (German, Dutch, English, French)
Search
(ischem* OR ischaem* OR stroke OR infarct* OR haemorrhag* OR hemorrhage* or 
lesion)SU
AND 
(apath* OR depress* OR mood OR motivation OR neuropsychia* OR emotion OR 
abulia)SU 
AND  
(MRI OR magnetic OR resonance OR imaging OR computed OR CT)TX
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C
IN
A
H
L
Platform EBSCOhost
Database CINAHL 1981 – present
Limits Human subjects, adult subjects, language (German, Dutch, English, French)
Search
(ischem* OR ischaem* OR stroke OR infarct* OR hemorrhage* OR haemorrhag* 
OR lesion)SU
AND 
(apath* OR depress* OR mood OR motivation OR neuropsychia* OR emotion OR 
abulia)SU 
AND  
(MRI OR magnetic OR resonance OR imaging OR computed OR CT)TX
C
o
ch
ra
ne
Platform Cochrane
Database Wiley Online Library
Limits Human subjects, adult subjects, language (German, Dutch, English, French)
Search
(ischem* OR ischaem* OR stroke OR infarct* OR haemorrhag*  OR hemorrhage* 
OR lesion) 
AND 
(apath* OR depress* OR mood OR motivation OR neuropsychia* OR emotion OR 
abulia) 
AND
(MRI OR (magnetic AND resonance) OR imaging OR CT OR (Computed 
AND tomography) OR DTI OR (diffusion AND tensor) OR connectivity) TITLE/
ABSTRACT/KEYWORDS
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Supplementary Table 2. Contingency table data of meta-analyses separate for post-stroke depression 
and post-stroke apathy studies
PSD studies
Authors
Laterality Lesion type Frontal lesion
Subcortical 
lesion
Basal ganglia 
lesion
P
SD
N
o
-P
SD
P
SD
N
o
-P
SD
P
SD
N
o
-P
SD
P
SD
N
o
-P
SD
P
SD
N
o
-P
SD
Le
ft
R
ig
ht
Le
ft
R
ig
ht
H
em
Is
ch
H
em
Is
ch
Fr N
Fr
Fr N
Fr
Su
b
c
N
Su
b
c
Su
b
c
N
su
b
c
B
G
nB
G
B
G
nB
G
Acute stroke phase
Robinson et al. (1984a) 11 2 7 10 - - - - - - - - - - - - - - - -
Starkstein et al. (1989) - - - - 2 14 3 22 7 10 5 20 - - - - 3 14 6 19
Starkstein et al. (1991) 18 8 14 16 - - - - - - - - - - - - - - - -
Astrom et al. (1993)* 14 2 7 21 - - - - 12 2 2 5 - - - - - - - -
Morris et al. (1996a) 21 26 56 90 - - - - - - - - - - - - - - - -
Huwel et al. (1998) 12 18 14 11 - - - - - - - - - - - - 3 27 5 20
Gainotti et al. (1999) - - - - - - - - 4 11 12 26 - - - - - - - -
Paradiso et al. (1999) 32 22 31 53 8 46 22 62 37 17 63 21 26 28 38 46 - - - -
Berg et al. (2001) 11 6 21 31 - - - - - - - - - - - - - - - -
Hsieh and Kao (2005) 32 39 54 82 - - - - - - - - - - - - - - - -
Nys et al. (2005) 25 41 28 32 10 56 5 55 - - - - - - - - - - - -
Glodzik-Sob. et al. (2006)* 4 4 11 7 - - - - - - - - 8 0 14 4 - - - -
Caeiro et al. (2006) 21 26 22 29 25 57 32 64 5 7 8 10 17 65 22 74 - - - -
Wongwandee (2012) 8 3 13 15 - - - - 0 11 1 27 - - - - 9 2 12 16
Choi-Kwon et al. (2012)* 29 41 203 235 - - - - 16 54 71 367 - - - - - - - -
Chen et al. (2013) 13 18 29 42 - - - - - - - - - - - - - - - -
Zhang et al. (2013) 9 16 26 40 1 24 6 60 - - - - - - - - - - - -
Shi et al. (2014) - - - - - - - - 36 267 73 691 - - - - - - - -
Terroni et al. (2015) 6 1 15 14 - - - - - - - - - - - - - - - -
Saxena & Suman (2015) 42 19 19 27 10 51 4 42 - - - - - - - - - - - -
Metoki et al. (2016) 59 85 220 248 - - - - 7 64 14 336 - - - - 10 61 25 325
Chen et al. (2016)* 29 33 46 34 - - - - 13 72 19 103 - - - - 18 67 21 101
Wei et al. (2016)* 33 38 133 164 - - - - 15 56 71 226 - - - - - - - -
Zhang et al. (2016) 19 26 109 97 - - - - 2 43 13 193 - - - - 21 24 103 103
Post-acute stroke phase
Eastwood et al. (1989) 14 33 12 20 - - - - - - - - - - - - - - - -
Morris et al. (1990) 18 16 24 30 0 14 7 14 - - - - - - - - - - - -
House et al. (1990)* 4 7 29 23 - - - - 5 2 16 40 - - - - - - - -
Morris et al. (1992) - - - - - - - - - - - - - - - - - - - -
Schwartz et al. (1993) 7 29 21 34 - - - - - - - - - - - - - - - -
Astrom et al. (1993)* 11 8 11 14 - - - - - - - - - - - - - - - -
González. et al. (1995) 23 25 36 46 - - - - - - - - - - - - - - - -
Chapter 2 Imaging markers of PSD and PSA: a systematic review and meta-analysis
2
60
PSD studies
Authors
Laterality Lesion type Frontal lesion
Subcortical 
lesion
Basal ganglia 
lesion
P
SD
N
o
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SD
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o
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SD
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N
o
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SD
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N
o
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o
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Fr N
Fr
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Su
b
c
N
su
b
c
B
G
nB
G
B
G
nB
G
Herrmann et al. (1995) 12 5 20 10 - - - - - - - - - - - - - - - -
Andersen et al. (1995) 15 22 84 71 - - - - 12 16 24 67 21 7 66 25 - - - -
Ng et al. (1995) 4 25 8 15 13 16 2 21 - - - - - - - - - - - -
Bendsen et al. (1997) 13 7 49 59 - - - - - - - - - - - - - - - -
Gainotti et al. (1997) - - - - - - - - 16 34 24 52 - - - - - - - -
MacHale et al. (1998) 3 10 27 15 - - - - 7 6 15 27 - - - - - - - -
Kase et al. (1998) 10 11 12 11 - - - - - - - - - - - - - - - -
Pohjasvaara et al. (1998) 65 46 86 80 - - - - - - - - - - - - - - - -
Paolucci et al. (1999) 51 75 161 178 - - - - 41 85 124 215 - - - - - - - -
Gainotti et al. (1999) - - - - - - - - 5 7 8 26 - - - - - - - -
Singh et al. (2000) 5 24 25 27 - - - - 10 19 4 48 - - - - - - - -
Kim et al. (2000) 11 16 69 52 2 25 20 101 24 3 52 69 - - - - - - - -
Gainotti et al. (2001) - - - - - - - - - - - - - - - - - - - -
Spalletta et al. (2002) - - - - 16 72 20 45 21 51 14 31 32 40 16 29 - - - -
Desmond et al. (2003) 17 30 124 250 - - - - 10 37 81 293 - - - - - - - -
Verdelho et al. (2004)* - - - - 6 40 7 55 - - - - 25 21 40 22 - - - -
Spalletta et al. (2005) 43 69 34 54 - - - - - - - - - - - - - - - -
Tang et al. (2005) - - - - - - - - 17 10 71 83 - - - - - - - -
Wichowicz et al. (2006) 16 7 24 13 - - - - 9 14 11 26 - - - - 11 12 9 28
Glodzik-Sob. et al. (2006)* 7 2 8 9 - - - - - - - - 8 1 14 3 - - - -
Brodaty et al. (2007) 17 20 47 51 - - - - - - - - - - - - - - - -
Fuentes et al. (2009) 5 12 23 19 - - - - - - - - - - - - - - - -
Oladiji et al. (2009) 3 10 17 21 - - - - - - - - - - - - - - - -
Snaphaan et al. (2009) 21 21 99 142 - - - - - - - - 16 26 115 126 0 42 36 205
Sienkiewicz et al. (2010) 61 21 121 39 8 74 16 144 - - - - - - - - - - - -
Nishiyama et al. (2010) 33 30 56 64 - - - - 9 37 15 73 9 37 15 73 12 34 11 77
Bour et al. (2010) 11 15 51 61 - - - - - - - - - - - - - - - -
Tang et al. (2010) 20 58 16 62 - - - - - - - - - - - - - - - -
Effat et al. (2011) - - - - - - - - 21 39 8 52 4 56 5 55 - - - -
Terroni et al. (2011) 13 8 28 19 - - - - - - - - - - - - - - - -
Tang et al. (2011a) - - - - - - - - 9 66 44 472 - - - - 25 50 145 371
Tennen et al. (2011) 21 17 36 28 - - - - - - - - - - - - - - - -
Choi-Kwon et al. (2012)* 35 48 182 204 - - - - 14 69 67 319 - - - - - - - -
Altieri et al. (2012) 22 21 35 27 - - - - - - - - - - - - - - - -
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PSD studies
Authors
Laterality Lesion type Frontal lesion
Subcortical 
lesion
Basal ganglia 
lesion
P
SD
N
o
-P
SD
P
SD
N
o
-P
SD
P
SD
N
o
-P
SD
P
SD
N
o
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SD
P
SD
N
o
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SD
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N
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G
nB
G
Zhang et al. (2012) 17 22 43 81 - - - - 14 25 24 100 - - - - - - - -
Rajashekaran et al. (2013) 19 9 8 26 - - - - - - - - - - - - - - - -
Gozzi et al. (2014) 7 8 20 20 - - - - 8 7 24 16 - - - - - - - -
Jiang et al. (2014) 50 48 60 171 11 87 20 211 22 76 19 212 - - - - 86 12 116 115
Shi et al. (2014) - - - - - - - - 33 187 76 771 - - - - - - - -
Gu et al. (2015) - - - - - - - - 9 47 21 119 - - - - 17 39 32 108
Wichowicz et al. (2015) 21 8 42 30 - - - - 18 11 23 49 - - - - 15 14 19 53
Chen et al. (2016)* 26 26 42 37 - - - - 9 64 20 100 - - - - 15 58 21 99
Wei et al. (2016)* 40 47 126 155 - - - - 24 63 62 219 - - - - - - - -
Chronic stroke phase
House et al. (1990)* 1 4 30 23 - - - - - - - - - - - - - - - -
Sharpe et al. (1990) 6 5 25 24 - - - - - - - - - - - - - - - -
Astrom et al. (1993)* 5 4 16 15 - - - - - - - - - - - - - - - -
Verdelho et al. (2004)* - - - - 1 12 8 52 - - - - 9 4 40 20 - - - -
Provinciali et al. (2008) 144 120 234 233 - - - - - - - - - - - - - - - -
Chatterjee et al. (2010) 12 28 20 67 - - - - - - - - 16 17 20 50 - - - -
Nidhinandana et al. (2010) 17 30 22 32 - - - - - - - - - - - - - - - -
Srivastava et al. (2010) 8 10 16 17 3 15 6 27 - - - - - - - - - - - -
PSA studies
Authors
Laterality Lesion type Frontal lesion
Subcortical 
lesion
Basal ganglia 
lesion
P
SA
N
o
-P
SA
P
SA
N
o
-P
SA
P
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N
o
-P
SA
P
SA
N
o
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P
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Le
ft
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Fr N
Fr
Fr N
Fr
Su
b
c
N
Su
b
c
Su
b
c
N
su
b
c
B
G
nB
G
B
G
nB
G
Acute stroke phase
Starkstein et al. (1993) 6 8 10 34 5 9 10 34 3 11 7 37 - - - - 6 8 15 29
Piamarta et al. (2004) 3 2 16 12 - - - - - - - - - - - - - - - -
Carota et al. (2005) 44 53 78 54 - - - - - - - - - - - - - - - -
Glodzik-Sob. et al. (2005) 6 7 10 8 - - - - - - - - 8 5 10 8 - - - -
Kang and Kim (2008) 28 9 27 27 - - - - - - - - - - - - - - - -
Caeiro et al. (2012) 7 20 24 17 13 23 9 49 4 5 3 8 9 9 17 11 - - - -
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PSA studies
Authors
Laterality Lesion type Frontal lesion
Subcortical 
lesion
Basal ganglia 
lesion
P
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N
o
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o
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o
-P
SA
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G
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G
B
G
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G
Post-acute stroke phase
Yamagata et al. (2004) 7 9 4 9 - - - - - - - - - - - - - - - -
Brodaty et al. (2005) 4 13 10 50 - - - - - - - - - - - - - - - -
Santa et al. (2008) 8 6 19 34 3 11 29 24 5 41 30 123 - - - - 21 25 61 92
Mikami et al. (2013) - - - - 0 23 5 28 - - - - - - - - - - - -
Tang et al. (2013a) - - - - - - - - 2 18 22 143 - - - - 4 16 22 143
Cosin et al. (2015) - - - - - - - - 2 8 7 29 - - - - 0 10 3 33
*Studies that provided data on more than one time point. 
Note: Data represent number of patients. 
Abbreviations: BG, basal ganglia lesion; Fr, frontal lesion; Hem, hemorrhage; Isch, ischemic stroke; 
nBG, non basal ganglia lesion; NFr, non-frontal lesion; NSubc, non-subcortical lesion; PSA, post-stroke 
apathy; PSD, post-stroke depression; Subc, subcortical lesion. 
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Supplementary Table 3. Newcastle-Ottowa Quality Assessment Scale
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S1 S2 S3 S4 C1 C2 O1 O2 O3
Cohort studies (PSD)
Robinson et al. (1984b);  
Robinson et al. (1985b)
* * * / * * * * / 7
Parikh et al. (1988) * * * / / / * * / 5
House et al. (1990) * * * / * * * * * 8
Morris et al. (1990) * * * / * * * * / 7
Astrom et al. (1993) * * * / * * * * * 8
Andersen et al. (1995) * * * * * * * * * 9
Herrmann et al. (1998) * / * / * * * * / 6
Huwel et al. (1998) * * * / * * * * * 8
Shimoda et al. (1999) * * * / * * * * * 8
Singh et al. (2000) * * * * / / * * / 6
Berg et al. (2003) * * * * * * * * * 9
Cassidy et al. (2004) * / * / / * * * * 6
Verdelho et al. (2004) * / * / * * * * * 7
Paolucci et al. (2006);  
Provinciali et al. (2008)
* * * / / * * * * 7
Aben et al. (2006); Leentjens et al. 
(2006); Bour et al. (2010)
* * * / * * * * * 8
Fuentes et al. (2009) * * * / * * * * * 8
Iranmanesh et al. (2009) * / * * * * * * / 7
Terroni et al. (2011) * * * * * * * * * 9
Kim et al. (2011) * * * * * * / * * 8
Castellanos-Pinedo et al. (2011) * * * / * * * * / 7
Altieri et al. (2012) * * * * * * * * * 9
Choi-Kwon et al. (2012) * * * * / / * * * 7
Ku et al. (2013) * * * * * * * * / 8
Zhang et al. (2013) * * * / * * * * / 7
Shi et al. (2014) * * * * * * * * * 9
De Ryck et al. (2014) * * * / * * * * * 8
Gozzi et al. (2014) * / * / / * * * * 6
Tang et al. (2014a) * * * * * * / * / 7
Wichowicz et al. (2015) * * * / * * * * * 8
Wei et al. (2016) * * * * * * * * * 9
Chen et al. (2016) * * * * * * * * * 9
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Case-control studies (PSD)
Eastwood et al. (1989) / * / * * / * * * 6
Dam et al. (1989) * * / * / / * * * 6
Kase et al. (1998) * * * * * * * * * 9
Rao et al. (2001) * / / * * * * * * 7
Desmond et al. (2003) * * * / * * * * * 8
Nys et al. (2005) * * * * * * * * * 9
Glodzik-Sobanska et al. (2006) * * * * * * * * * 9
Caeiro et al. (2006) * * / / * * * * * 7
Brodaty et al. (2007);  
Withall et al. (2011)
* * * * * * * * * 9
Xu et al. (2008) * * * / * / * * * 7
Huang et al. (2010) * * * * * * / / * 7
Wang et al. (2012) * * * * * * * * * 9
Yasuno et al. (2014) * * * * * * * * * 9
Zhang et al. (2014) * * * * * * * * * 9
Brookes et al. (2014) * * * * * * / * * 8
Hollocks et al. (2015) * * * * * * / * * 8
Study
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Cross-sectional studies (PSD)
Robinson et al. (1983) 
Robinson et al. (1984a)
Robinson et al. (1985a)
* * * / * * ** * 8
Starkstein et al. (1988) * / * * * * ** * 8
Starkstein et al. (1989) * / * / * * ** * 7
Sharpe et al. (1990)
Sharpe et al. (1994)
* * * / * * ** * 8
Starkstein et al. (1991) * * * / * * ** * 8
Stern et al. (1991) * / * * / / ** * 6
Morris et al. (1992)
Morris et al. (1996b)
* * * / * * ** * 8
Schwartz et al. (1993) * * * / * * ** * 8
Herrmann et al. (1993) * / * * * * ** / 7
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Herrmann et al. (1995) * / * * * * ** * 8
Ng et al. (1996) * * / / * * ** * 7
Gonzalez-Torrecillas et al. (1995) * * * / * * ** * 8
Morris et al. (1996a) * * * / * * ** * 8
Angeleri et al. (1997) * / * / / / ** * 5
Bendsen et al. (1997) * / / * / * ** * 6
Gainotti et al. (1997) * / * * / / ** / 5
Pohjasvaara et al. (1998); 
Vataja et al. (2001);  
Vataja et al. (2004)
* * * / / / ** * 6
MacHale et al. (1998) * * / / * / ** * 6
Paolucci et al. (1999) * * * * * * ** * 9
Paradiso et al. (1999) * * * / * * ** * 8
Gainotti et al. (1999); 
Gainotti et al. (2001)
* / * * * * ** * 8
Kim et al. (2000) * / * * * * / * 7
Hosking et al. (2000) * * * * * * / * 7
Berg et al. (2001) * * * * * * ** * 9
Spalletta et al. (2002)
Spalletta et al. (2005)
*
* * / / / ** * 6
Piamarta et al. (2004) * / * * * / ** / 6
Kadojić et al. (2005) * / * * / * / / 4
Aybek et al. (2005) * / * / / * ** / 5
Hsieh et al. (2005) * / * * * * ** * 8
Tang et al. (2005) * * * / / * ** * 7
Wichowicz et al. (2006) * / * * / / ** / 5
Barker-Collo et al. (2007) * * * / * * / * 6
Hama et al. (2007) * * * * / / / * 5
Oladiji et al. (2009) * * * / * * / * 6
Snaphaan et al. (2009) * * * / * * / * 6
Chen et al. (2009) * * * * * * / * 7
Nishiyama et al. (2010) * * * * * * / * 7
Chau et al. (2010) * / * / * * / * 5
Mok et al. (2010)
Fu et al. (2010)
*
*
/
/
*
*
*
*
*
*
*
*
**
/
*
*
8
6
Sienkiewicz-Jarosz et al. (2010) * / * / * * / * 5
Williamson et al. (2010) * * * / * * / * 6
Nidhinandana et al. (2010) * * / * * * / * 6
Srivastava et al. (2010) * * / / * * ** * 7
Chatterjee et al. (2010) * * * / * * ** * 8
Tang et al. (2010); Tang et al. (2011b); 
Tang et al. (2011c);  
Tang et al. (2013b)
* / * * * * ** * 8
Tang et al. (2011a) * / * * * * / * 6
Chapter 2 Imaging markers of PSD and PSA: a systematic review and meta-analysis
2
66
Effat et al. (2011) * / * * * * ** * 8
Tennen et al. (2011) * * * / * * / * 6
Marasco et al. (2011) * * * / * * ** * 8
Zhang et al. (2012) * * * * * * ** * 9
Wongwandee et al. (2012) * / * * * * ** * 8
Chen et al. (2013) * / * / * * ** * 7
Rajashekaran et al. (2013) * * * / * * ** * 8
Taylor-Pillae et al. (2013) * / * / * * / * 5
Rashid et al. (2013) * / * / / * ** * 6
Hosking et al. (2013) * * * * * * / * 7
Murakami et al. (2013) * * * * * * / * 7
Jiang et al. (2014) * / * * * * ** * 8
Tang et al. (2014b) * * * * * * / * 7
Stojanovic et al. (2015) * / / * / * ** * 6
Yang et al. (2015b) * * * * * * ** * 9
Terroni et al. (2015) * * * * * * ** * 9
Saxena et al. (2015) * / * * * * ** / 7
Gu et al. (2015) * / * * * * ** * 8
Koivunen et al. (2015) * * * / * * / * 7
Metoki et al. (2016) * / * * * * ** * 8
Pavlovic et al. (2016) * * * * * * ** * 9
Zhang et al. (2016) * / * * * * ** * 8
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Cohort studies (PSA)
Carota et al. (2005) * * / / * * / * * 6
Castellanos-Pinedo et al. (2011) * * * / * * * * / 7
Mikami et al. (2013) * / * * * * * * * 8
Study
Se
le
ct
io
n 
(m
ax
. 4
)
C
o
m
p
ar
ab
ili
ty
 
(m
ax
. 2
)
O
ut
co
m
e
(m
ax
. 3
)
O
ve
ra
ll
Su
m
 s
co
re
S1 S2 S3 S4 C1 C2 O1 O2 O3
Case-control studies (PSA)
Glodzik-Sobanska et al. (2005) * * * * / / * * * 7
Brodaty et al. (2005)
Withall  et al. (2011)
* * * * * * * * * 9
Caeiro et al. (2012) * * / * / / * * * 6
Hollocks et al. (2015) * * * * * * / * * 8
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S1 S2 S3 S4 C1 C2 O1 O2
Cross-sectional studies (PSA)
Starkstein et al. (1993) * * / / * * ** * 7
Okada et al. (1997) * / / / * * ** * 6
Yamagata et al. (2004) * / * * * * / * 6
Piamarta et al. (2004) * / * * * / ** / 6
Hama et al. (2007) * * * * / / ** * 7
Santa et al. (2008) * / * / * * ** * 7
Kang et al. (2008) * * * / / * / * 5
Onoda et al. (2011) * / * * * * ** * 8
Murakami et al. (2013) * * * * * * ** * 9
Tang et al. (2013a) * * * * * * ** * 9
Rochat et al. (2013) * / * / * / ** * 6
Yang et al. (2015c) * / * * * / ** * 7
Yang et al. (2015a) * / * * * * ** * 8
Cosin et al. (2015) * * * * * * ** * 9
Mihalov et al. (2016) * / * / * * ** * 7
Abbreviations: PSA, post-stroke apathy; PSD, post-stroke depression
Chapter 2 Imaging markers of PSD and PSA: a systematic review and meta-analysis
2
68
Supplementary Table 4. Characteristics of post-stroke depression studies
Authors
N,  
% Fem
Mean 
age 
% PSD* Phase Scale, criteria First-ever
Design, 
PT source
Imaging 
method
Imaging markers
LAT LOC TP LV Other
Robinson et al. (1983)
Robinson et al. (1984a) 
Robinson et al. (1984b) 
Robinson et al. (1985a) 
Robinson et al. (1985b)
103, 38.8
36, 38.9
30, 50.0
103, 43.7
61, 44.4
59.0
59.0 
59.4
59.0
59.9
46.6
44.4
36.7
NS
NS
A
A
PA 
A, PA
PA
HRSD, PSE, SDS 
HRSD, PSE, SDS 
HRSD, PSE, SDS
HRSD, PSE, SDS
HRSD, PSE, SDS
Y
Y
Y
Y
Y
CS, H/R
CS, H/R
P, H/R 
CS, H/R
P, H/R
CT
CT 
CT
CT
CT
X
X
X
X
X
X
X
X
X
X
- 
- 
- 
- 
-
X
X
X
X
X
DIST FP
DIST FP 
DIST FP
DIST FP
DIST FP
Starkstein et al. (1988) 26, 26.9 58.0 NS PA, C HRSD, PSE, SDS Y CC, H/R CT - - - - ATR
Parikh et al. (1988) 85, 40.0 63.0 NS A, PA, C HRSD, PSE, SDS N P, H CT X - X - DIST FP
Eastwood et al. (1989) 87, 36.8 63.3 54.0 PA HRSD, GDS, SDS, SADS, RDC N CC, R CT X - - X DIST FP
Dam et al. (1989) 92, 37.0 52.5 30.4 PA HRSD, BDI, RDC N CS, H CT X X - X -
Starkstein et al. (1989) 93, 38.7 62.2 30.1 A DSM-III, SDS, HDRS, PSE N CS, H CT - X X X DIST FP
Sharpe et al. (1990) 60, 38.3 71.0 18.3 C SCID, HADS Y CS, C CT X - X X DIST FP
House et al. (1990) 128, 54.7 71.2 10.4 PA, C DSM-III, PSE, BDI ≥ 13 Y P, C CT X X - X DIST FP
Starkstein et al. (1991) 56, 41.1 59.0 46.4 A DSM-III, PSE, HDRS N P, H CT X X - - DIST FP
Stern and Bachman (1991) 52, 0.0 65.8 NS C VAMS, HRSD, DAC Y CS, R CT X X - - -
Morris et al. (1990)
Morris et al. (1992)
99, 48.5
35, 54.0
70.8
68.4
32.3
40.0
PA, C
PA
CIDI (DSM-III)
DSM-III, MADRS
NS
Y
P, H
CS, H
CT
CT
X
X
- 
-
-
X
-
X
-
DIST FP
Astrom et al. (1993) 76, 38.8 72.0 25.0 A, PA, C DSM-III N P, H CT - X - X DIST FP, ATR
Schwartz et al. (1993) 91, 0.0 66.0 39.6 PA DSM-III, HDRS ≥ 18 N CS, R CT X X - X ATR
Herrmann et al. (1993) 42, 38.1 62.0 NS A CDS, RDC N CS, C CT - X - X DIST FP
Sharpe et al. (1994) 60, 38.3 NS 18.3 C SCID Y CS, C CT - - - X -
Andersen et al. (1995) 285, 46.0 69.0 10.9 PA BDI, HDRS ≥ 13 N P, H CT X X - - -
Herrmann et al. (1995) 47, 34.0 62.0 36.2 PA DSM-III-R, MADRS, CDS Y CS, H CT X X - X DIST FP, ATR
Ng et al. (1995) 52, 44.2 60.0 55.8 PA DSM-III-R, HDRS N CS, R CT X - X - -
González et al. (1995) 130, 53.8 67.6 36.9 PA RDC, HAM-D, MADRS, BDI NS CS, R CT X X - - -
Morris et al. (1996b) 41, 56.1 70.0 36.6 PA DSM-III-R, MADRS, CIDI Y CS, H CT X X X X -
Morris et al. (1996a) 193, 51.8 61.9 24.4 A CES-D ≥ 16 Y CS, H CT X X - X DIST FP
Angeleri et al. (1997) 180, 35.0 63.3 50.0 C ICD-10, BDI ≥ 10 N CS, H CT X - - - -
Bendsen et al. (1997) 128, NS NS 15.6 PA SCID, HAM-D N CS, R CT X - - - NUM, ATR
Gainotti et al. (1997) 126, NS NS 39.7 PA DSM-III, HDRS > 18, PSDRS N CS, H/R CT X X - - -
Herrmann et al. (1998) 150, 50.9 74.9 27.3 PA, C MADRS ≥ 7, SDS ≥ 50 N P, H CT X - - X -
Kase et al. (1998) 74, 54.1 78.7 37.9 PA CES-D ≥ 16 NS CC, C CT X X - - -
Huwel et al. (1998) 102, NS 69.8 54.9 A, PA MADRS ≥ 7, SDS Y P, H CT, NMR X X - - -
Pohjasvaara et al. (1998)
Vataja et al. (2001)
Vataja et al. (2004)
277, NS
275, 48.7
70, 50.0
NS
70.7 
70.3
40.1
39.6
37.1
PA
PA
PA
PSE, MADRS ≥ 6
PSE, MADRS
DSM-III-R, ICD-10
N
N
N
CS, H
CS, H
CS, H
MRI
MRI
MRI
X
X 
X
X
X
X
- 
- 
-
-
X
X
-
NUM, WMH, ATR
NUM, WMH, ATR
MacHale et al. (1998) 55, 48.0 60.0 29.1 PA SADS, DSM-IV, HADS N CS, H CT X X - X DIST FP
Gainotti et al. (1999)
Gainotti et al. (2001)
58, 41.4
64, 43.8
61.9
61.9
29.3
NS
A, PA
PA
DSM-III, HAM-D > 17, PSDRS
DSM-III, HDRS
Y
Y
CS, H/R
CS, H/R
CT, MRI
CT
X 
X
X 
-
- 
-
- 
-
- 
-
Paolucci et al. (1999) 470, 51.9 NS 27.4 PA HDRS ≥ 18, VADS Y CS, H/R CT, MRI X X - - -
Paradiso et al. (1999) 141, 40.4 59.2 38.3 A DSM-IV, HAM-D, PSE N CS, H CT X X X X DIST FP
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Supplementary Table 4. Characteristics of post-stroke depression studies
Authors
N,  
% Fem
Mean 
age 
% PSD* Phase Scale, criteria First-ever
Design, 
PT source
Imaging 
method
Imaging markers
LAT LOC TP LV Other
Robinson et al. (1983)
Robinson et al. (1984a) 
Robinson et al. (1984b) 
Robinson et al. (1985a) 
Robinson et al. (1985b)
103, 38.8
36, 38.9
30, 50.0
103, 43.7
61, 44.4
59.0
59.0 
59.4
59.0
59.9
46.6
44.4
36.7
NS
NS
A
A
PA 
A, PA
PA
HRSD, PSE, SDS 
HRSD, PSE, SDS 
HRSD, PSE, SDS
HRSD, PSE, SDS
HRSD, PSE, SDS
Y
Y
Y
Y
Y
CS, H/R
CS, H/R
P, H/R 
CS, H/R
P, H/R
CT
CT 
CT
CT
CT
X
X
X
X
X
X
X
X
X
X
- 
- 
- 
- 
-
X
X
X
X
X
DIST FP
DIST FP 
DIST FP
DIST FP
DIST FP
Starkstein et al. (1988) 26, 26.9 58.0 NS PA, C HRSD, PSE, SDS Y CC, H/R CT - - - - ATR
Parikh et al. (1988) 85, 40.0 63.0 NS A, PA, C HRSD, PSE, SDS N P, H CT X - X - DIST FP
Eastwood et al. (1989) 87, 36.8 63.3 54.0 PA HRSD, GDS, SDS, SADS, RDC N CC, R CT X - - X DIST FP
Dam et al. (1989) 92, 37.0 52.5 30.4 PA HRSD, BDI, RDC N CS, H CT X X - X -
Starkstein et al. (1989) 93, 38.7 62.2 30.1 A DSM-III, SDS, HDRS, PSE N CS, H CT - X X X DIST FP
Sharpe et al. (1990) 60, 38.3 71.0 18.3 C SCID, HADS Y CS, C CT X - X X DIST FP
House et al. (1990) 128, 54.7 71.2 10.4 PA, C DSM-III, PSE, BDI ≥ 13 Y P, C CT X X - X DIST FP
Starkstein et al. (1991) 56, 41.1 59.0 46.4 A DSM-III, PSE, HDRS N P, H CT X X - - DIST FP
Stern and Bachman (1991) 52, 0.0 65.8 NS C VAMS, HRSD, DAC Y CS, R CT X X - - -
Morris et al. (1990)
Morris et al. (1992)
99, 48.5
35, 54.0
70.8
68.4
32.3
40.0
PA, C
PA
CIDI (DSM-III)
DSM-III, MADRS
NS
Y
P, H
CS, H
CT
CT
X
X
- 
-
-
X
-
X
-
DIST FP
Astrom et al. (1993) 76, 38.8 72.0 25.0 A, PA, C DSM-III N P, H CT - X - X DIST FP, ATR
Schwartz et al. (1993) 91, 0.0 66.0 39.6 PA DSM-III, HDRS ≥ 18 N CS, R CT X X - X ATR
Herrmann et al. (1993) 42, 38.1 62.0 NS A CDS, RDC N CS, C CT - X - X DIST FP
Sharpe et al. (1994) 60, 38.3 NS 18.3 C SCID Y CS, C CT - - - X -
Andersen et al. (1995) 285, 46.0 69.0 10.9 PA BDI, HDRS ≥ 13 N P, H CT X X - - -
Herrmann et al. (1995) 47, 34.0 62.0 36.2 PA DSM-III-R, MADRS, CDS Y CS, H CT X X - X DIST FP, ATR
Ng et al. (1995) 52, 44.2 60.0 55.8 PA DSM-III-R, HDRS N CS, R CT X - X - -
González et al. (1995) 130, 53.8 67.6 36.9 PA RDC, HAM-D, MADRS, BDI NS CS, R CT X X - - -
Morris et al. (1996b) 41, 56.1 70.0 36.6 PA DSM-III-R, MADRS, CIDI Y CS, H CT X X X X -
Morris et al. (1996a) 193, 51.8 61.9 24.4 A CES-D ≥ 16 Y CS, H CT X X - X DIST FP
Angeleri et al. (1997) 180, 35.0 63.3 50.0 C ICD-10, BDI ≥ 10 N CS, H CT X - - - -
Bendsen et al. (1997) 128, NS NS 15.6 PA SCID, HAM-D N CS, R CT X - - - NUM, ATR
Gainotti et al. (1997) 126, NS NS 39.7 PA DSM-III, HDRS > 18, PSDRS N CS, H/R CT X X - - -
Herrmann et al. (1998) 150, 50.9 74.9 27.3 PA, C MADRS ≥ 7, SDS ≥ 50 N P, H CT X - - X -
Kase et al. (1998) 74, 54.1 78.7 37.9 PA CES-D ≥ 16 NS CC, C CT X X - - -
Huwel et al. (1998) 102, NS 69.8 54.9 A, PA MADRS ≥ 7, SDS Y P, H CT, NMR X X - - -
Pohjasvaara et al. (1998)
Vataja et al. (2001)
Vataja et al. (2004)
277, NS
275, 48.7
70, 50.0
NS
70.7 
70.3
40.1
39.6
37.1
PA
PA
PA
PSE, MADRS ≥ 6
PSE, MADRS
DSM-III-R, ICD-10
N
N
N
CS, H
CS, H
CS, H
MRI
MRI
MRI
X
X 
X
X
X
X
- 
- 
-
-
X
X
-
NUM, WMH, ATR
NUM, WMH, ATR
MacHale et al. (1998) 55, 48.0 60.0 29.1 PA SADS, DSM-IV, HADS N CS, H CT X X - X DIST FP
Gainotti et al. (1999)
Gainotti et al. (2001)
58, 41.4
64, 43.8
61.9
61.9
29.3
NS
A, PA
PA
DSM-III, HAM-D > 17, PSDRS
DSM-III, HDRS
Y
Y
CS, H/R
CS, H/R
CT, MRI
CT
X 
X
X 
-
- 
-
- 
-
- 
-
Paolucci et al. (1999) 470, 51.9 NS 27.4 PA HDRS ≥ 18, VADS Y CS, H/R CT, MRI X X - - -
Paradiso et al. (1999) 141, 40.4 59.2 38.3 A DSM-IV, HAM-D, PSE N CS, H CT X X X X DIST FP
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Authors
N,  
% Fem
Mean 
age 
% PSD* Phase Scale, criteria First-ever
Design, 
PT source
Imaging 
method
Imaging markers
LAT LOC TP LV Other
Shimoda et al. (1999) 60, 43.4 59.1 51.7 A DSM-IV, HDRS, PSE Y P, H CT X X - X DIST FP
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Williamson et al. (2010) 108, 49.1 65.0 NS PA CMDI, FrSBe N CS, H MRI, DTI - - - - FA values
Nidhinandana et al. (2010) 101, 31.7 60.7 46.5 C GDS (Thai) > 12 N CS, H CT, MRI X - - - -
Srivastava et al. (2010) 51, 19.6 46.1 35.3 C HDRS, ICD-10 Y CS, R NS X - X - -
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Tang et al. (2011c)
Tang et al. (2013b)
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Tang et al. (2011a) 235, 39.2 66.3 35.7 PA GDS ≥ 7 N CS, H MRI - X - X LACI, WMH, CMB
Terroni et al. (2011) 55, 47.1 51.0 11.8 A, PA SCID, HAM-D Y P, H MRI X X - X WMH
Kim et al. (2011) 133, 46.6 64.7 47.4 A, PA HADS-D > 7 N P, H MRI - X - - WMH, CMB
Effat et al. (2011) 120, 53.3 56.7 NS PA MINI, HAM-D N CS, H CT, MRI - X - - -
Tennen et al. (2011) 102, 49.0 70.8 37.3 PA CES-D ≥ 16 N CS, H/R CT, MRI X - - - -
Castellanos et al. (2011) 89, 48.3 X 42.7 PA HAM-D > 7, NPI N P, H CT, MRI X X - - -
Marasco et al. (2011) 54, 27.8 65.3 40.7 A PSDRS ≥ 9 Y CS, H CT X X - - -
Altieri et al. (2012) 105, 34.3 64.4 21.9 PA BDI-SF, SCID N P, H NS X X - - WMH, ATR
Zhang et al. (2012) 163, NS X 23.9 PA DSM-IV, NPI, WHO-CIDI N CS, H MRI X X - X WMH
Choi-Kwon et al. (2012) 508, 38.8 62.1 13.7 A, PA DSM-IV, BDI > 13 N P, H MRI X X - - WMC, CMB
Wang et al. (2012) 51, 41.2 61.1 21.6 PA HAM-D ≥ 14, SCID Y CS/CC, H MRI, MRS - - - - METAB
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Hollocks et al. (2015) 118, 34.7 68.9 NS PA GDS (24-item) Y CS, H MRI, DTI - - - - FA, WM networks
Saxena and Suman (2015) 107, 43.9 59.1 57.0 A MADRS > 6 N CS, H CT, MRI X X X X -
Gu et al. (2015) 196, 33.7 61.2 28.6 PA DSM-IV, HAM-D N CS, H CT, MRI - X - - -
Wichowicz et al. (2015) 116, 36.2 61.4 22.9 A, PA, C ICD-10, HRSD Y P, H CT, MRI X X - - -
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*Percentage of participants with PSD at baseline measurement.
Note: Studies presented within the same row represent studies of the same cohort.
Abbreviations: A, acute; ATR, atrophy; C, chronic (phase); BDI, Beck Depression Inventory; BDI-II, Beck 
Depression Inventory Second Edition; BDI-SF, Beck Depression Inventory Short Form; C, community 
(patient source); CAMDEX, Cambridge Mental Disorders of the Elderly Examination; CC, case-control; 
CCEI, Crown-Crips Experiential Index; CDS, CSD Cornell Scale for Depression; CES-D, Center for 
Epidemiologic Studies Depression Scale; CIDI, Composite International Diagnostic Interview; CMB, 
cerebral microbleeds; CMDI, Chicago Multiscale Depression Inventory; CS, cross-sectional; CT, 
computed tomography; DAC, Depression Adjective Checklist; DASS-21, Depression Anxiety Stress 
Scale 21-item version; DIST FP, distance to frontal pole; DSM-III, Diagnostic and Statistical Manual 
of Mental Disorders Third Edition; DSM-III-R, Diagnostic and Statistical Manual of Mental Disorders 
Third Edition revised; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders Fourth Edition; 
DTI, diffusion tensor imaging; EBI, Emotional Behavior Index; FA, fractional anisotropy; Fem, female; 
fMRI, functional magnetic resonance imaging; FrSBe, Frontal Systems Behavior Scale; GDS, Geriatric 
Depression Scale; H, hospital; HADS, Hospital Anxiety and Depression Scale; HRSD, HDRS, HAM-D, 
Hamilton Rating Scale for depression; ICD-10, International Statistical Classification of Diseases and 
Related Health Problems 10th Revision; JSS-D, Japan Stroke Scale Depression Scale; LACI, lacunar 
infarcts; LAT, laterality; LOC, location; LV, lesion volume; MADRS, Montgomery-Åsberg Depression 
Rating Scale; METAB, metabolism; MINI, Mini International Neuropsychiatric Interview; MRI, magnetic 
resonance imaging, MRS, proton magnetic resonance spectroscopy; N, number of participants; N, no; 
NMR, nuclear magnetic resonance; NPI, Neuropsychiatric Inventory; NS, not specified; NUM, number 
of lesions; P, prospective; PA, post-acute; PSD, post-stroke depression; PSDRS, Post-Stroke Depression 
Rating Scale; PSE, Present State Examination; PT, patient; R, rehabilitation center; rCBF, regional 
cerebral blood flow; RDC, Research Diagnostic Criteria; ROIs, regions of interest; SADS, Schedule for 
Affective Disorders and Schizophrenia; SCID, Structured Clinical Interview for DSM Disorders; SCID-P, 
Structured Clinical Interview for DSM Disorders Patient Edition; SDS, Zung Self-rating Depression 
Scale; SI, silent infarcts; SIGH-D, Structured Interview Guide for the HDRS; SPECT, single-photon 
emission computed tomography; TP, type of stroke; VAMS, Visual Analogue Mood Scale; WHO-CIDI, 
World Health Organization Composite International Diagnostic Interview; WM, white matter; WMC, 
white matter changes; WMH, white matter hyperintensities; Y, yes.
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Authors
N,  
% Fem
Mean 
age 
% PSD* Phase Scale, criteria First-ever
Design, 
PT source
Imaging 
method
Imaging markers
LAT LOC TP LV Other
Hollocks et al. (2015) 118, 34.7 68.9 NS PA GDS (24-item) Y CS, H MRI, DTI - - - - FA, WM networks
Saxena and Suman (2015) 107, 43.9 59.1 57.0 A MADRS > 6 N CS, H CT, MRI X X X X -
Gu et al. (2015) 196, 33.7 61.2 28.6 PA DSM-IV, HAM-D N CS, H CT, MRI - X - - -
Wichowicz et al. (2015) 116, 36.2 61.4 22.9 A, PA, C ICD-10, HRSD Y P, H CT, MRI X X - - -
Koivunen et al. (2015) 130, 51.5 41.5 23.1 C BDI > 13, HADS Y CS, H CT, MRI - X - X NUM
Wei et al. (2016) 368, 29.1 61.5 19.3 A, PA DSM-IV, BDI > 13 N P, H CT, MRI X X - - WMH
Chen et al. (2016) 207, 27.5 60.8 41.1 A, PA HDRS ≥ 8 N P, H MRI X X - X NUM, WMH, ATR
Metoki et al. (2016) 421, 37.3 72.1 16.9 A JSS-D ≥ 2.4 NS CS, H MRI X X - - -
Pavlovic et al. (2016) 294, 46.3 62.3 39.8 C DSM-IV, HDRS Y CS, H MRI - - - - LACI, WMH
Zhang et al. (2016) 251, 27.9 66.0 17.9 A HAM-D ≥ 7 N CS, H CT, MRI X X - - -
*Percentage of participants with PSD at baseline measurement.
Note: Studies presented within the same row represent studies of the same cohort.
Abbreviations: A, acute; ATR, atrophy; C, chronic (phase); BDI, Beck Depression Inventory; BDI-II, Beck 
Depression Inventory Second Edition; BDI-SF, Beck Depression Inventory Short Form; C, community 
(patient source); CAMDEX, Cambridge Mental Disorders of the Elderly Examination; CC, case-control; 
CCEI, Crown-Crips Experiential Index; CDS, CSD Cornell Scale for Depression; CES-D, Center for 
Epidemiologic Studies Depression Scale; CIDI, Composite International Diagnostic Interview; CMB, 
cerebral microbleeds; CMDI, Chicago Multiscale Depression Inventory; CS, cross-sectional; CT, 
computed tomography; DAC, Depression Adjective Checklist; DASS-21, Depression Anxiety Stress 
Scale 21-item version; DIST FP, distance to frontal pole; DSM-III, Diagnostic and Statistical Manual 
of Mental Disorders Third Edition; DSM-III-R, Diagnostic and Statistical Manual of Mental Disorders 
Third Edition revised; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders Fourth Edition; 
DTI, diffusion tensor imaging; EBI, Emotional Behavior Index; FA, fractional anisotropy; Fem, female; 
fMRI, functional magnetic resonance imaging; FrSBe, Frontal Systems Behavior Scale; GDS, Geriatric 
Depression Scale; H, hospital; HADS, Hospital Anxiety and Depression Scale; HRSD, HDRS, HAM-D, 
Hamilton Rating Scale for depression; ICD-10, International Statistical Classification of Diseases and 
Related Health Problems 10th Revision; JSS-D, Japan Stroke Scale Depression Scale; LACI, lacunar 
infarcts; LAT, laterality; LOC, location; LV, lesion volume; MADRS, Montgomery-Åsberg Depression 
Rating Scale; METAB, metabolism; MINI, Mini International Neuropsychiatric Interview; MRI, magnetic 
resonance imaging, MRS, proton magnetic resonance spectroscopy; N, number of participants; N, no; 
NMR, nuclear magnetic resonance; NPI, Neuropsychiatric Inventory; NS, not specified; NUM, number 
of lesions; P, prospective; PA, post-acute; PSD, post-stroke depression; PSDRS, Post-Stroke Depression 
Rating Scale; PSE, Present State Examination; PT, patient; R, rehabilitation center; rCBF, regional 
cerebral blood flow; RDC, Research Diagnostic Criteria; ROIs, regions of interest; SADS, Schedule for 
Affective Disorders and Schizophrenia; SCID, Structured Clinical Interview for DSM Disorders; SCID-P, 
Structured Clinical Interview for DSM Disorders Patient Edition; SDS, Zung Self-rating Depression 
Scale; SI, silent infarcts; SIGH-D, Structured Interview Guide for the HDRS; SPECT, single-photon 
emission computed tomography; TP, type of stroke; VAMS, Visual Analogue Mood Scale; WHO-CIDI, 
World Health Organization Composite International Diagnostic Interview; WM, white matter; WMC, 
white matter changes; WMH, white matter hyperintensities; Y, yes.
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Supplementary Table 5. Characteristics of post-stroke apathy studies
Study Year N, % Fem
Mean 
age 
% PSA* Phase Scale
First-
ever 
Design, 
PT source
Imaging 
method
Imaging markers
LAT LOC TP LV Other
Starkstein et al. (1993) 1993 80, 46.3 59.5 22.5 A AS ≥ 14 Y CS, H CT X X X X -
Okada et al. (1997) 1997 40, 42.5 71.4 50.0 C AS ≥ 16 N CS, H CT, MRI - X - - rCBF
Yamagata et al. (2004) 2004 29, 72.4 71.7 55.2 PA AS ≥ 16 N CS, H MRI X X - X NUM
Piamarta et al. (2004) 2004 33, 39.4 71.6 15.2 A PSDRS expanded > 4 Y CS, H CT, MRI X X - - -
Carota et al. (2005) 2005 273, 46.9 64.4 47.6 A EBIF ≥ 0.5 Y P, H CT, MRI X X - - -
Glodzik et al. (2005) 2005 31, 48.4 62.9 41.9 A AS > 16 Y CC, H CT, MRI, MRS X X - - METAB
Brodaty et al. (2005) 
Withall et al. (2011)
2005
2011
135, 39.3
106, 39.6
72.2 
72.1
26.7
25.5
PA
PA
AES ≥ 37
AES ≥ 37
Y 
Y
CC, H
P, H
CT, MRI 
CT, MRI
X 
-
- 
-
- 
-
X 
-
NUM, ATR, WMH 
ATR, WMH
Hama et al. (2007) 2007 243, 33.3 65.2 40.3 PA AS ≥ 16 N CS, H CT - X - X -
Santa et al. (2008) 2008 67, 43.3 65.4 20.9 PA AS > 15 Y CS, R MRI X X X - -
Kang and Kim (2008) 2008 100, 42.0 65.1 43.0 A Clinical observation N CS, H MRI, MRA X X - - -
Onoda et al. (2011) 2011 102, 44.1 73.0 36.3 A, PA AS ≥ 16 N CS, H MRI, SPECT - X - - rCBF
Castellanos et al. (2011) 2011 89, 48.3 70.0 13.5 PA NPI N P, H CT, MRI X X - - -
Caeiro et al. (2012) 2012 94, 35.1 55.7 38.3 A AES-10 ≥ 18 N CC, H CT, MRI X X X - -
Murakami et al. (2013) 2013 149, 34.9 66.8 44.3 PA AS ≥ 16 N CS, H MRI - X - - -
Mikami et al. (2013) 2013 56, 35.7 63.9 41.1 PA, C AS, criteria Robert N P, H/C NS - - X - -
Tang et al. (2013a) 2013 185, 37.3 65.2 10.8 PA AES ≥ 37 N CS, H MRI - X - X NUM, WMH
Rochat et al. (2013) 2013 55, NS 56.4 NS PA, C AI Y CS, H CT, MRI - X - X -
Yang et al. (2015c) 2015 54, 35.2 67.4 57.4 PA AES, criteria Robert N CS, H MRI, DTI - X - - FA maps
Yang et al. (2015a) 2015 88, 27.3 68.2 38.6 A, PA AES, criteria Robert N CS, H MRI, DTI - - - X
WM integrity, 
WM networks
Cosin et al. (2015) 2015 46, 17.4 58.0 21.7 PA AI > 2, LARS > 21 N CS, H MRI - X - - LACI, WMH, CMB
Hollocks et al. (2015) 2015 118, 34.7 68.9 NS PA GDS (6-items) Y CS, H MRI, DTI - - - - FA,WM networks
Mihalov et al. (2016) 2016 47, 36.2 67.7 23.4 PA AS ≥ 14 N CS, H CT, MRI - - - - ATR
Note: *Percentage of participants with PSA at baseline measurement. 
Abbreviations: A, acute; AES, Apathy Evaluation Scale; AES-10, Apathy Evaluation Scale 10-item; AS, 
Apathy Scale; ATR, atrophy; C, chronic (phase); C, community (patient source); CC, case-control; CMB, 
cerebral microbleeds; CS, cross-sectional; CT, computed tomography; DTI, diffusion tensor imaging; 
EBIF, Emotion Behavior Index Form; FA, fractional anisotropy; Fem, female; H, hospital; LACI, lacunar 
infarcts; LARS, Lille Apathy Rating Scale; LAT, laterality; LOC, location; LV, lesion volume; METAB, 
metabolism; MRA, magnetic resonance angiography; MRI, magnetic resonance imaging; MRS, proton 
magnetic resonance spectroscopy; N, number of participants; N, no; NPI, Neuropsychiatric Inventory; 
NS, not specified; NUM, number of lesions; P, prospective; PA, post-acute; PSA, post-stroke apathy; 
PSDRS, Post-Stroke Depression Rating Scale; PT, patient; R, rehabilitation center; rCBF, regional 
cerebral blood flow; SPECT, single-photon emission computed tomography; TP, type of stroke; WM, 
white matter; WMH, white matter hyperintensities; Y, yes.
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Supplementary Table 5. Characteristics of post-stroke apathy studies
Study Year N, % Fem
Mean 
age 
% PSA* Phase Scale
First-
ever 
Design, 
PT source
Imaging 
method
Imaging markers
LAT LOC TP LV Other
Starkstein et al. (1993) 1993 80, 46.3 59.5 22.5 A AS ≥ 14 Y CS, H CT X X X X -
Okada et al. (1997) 1997 40, 42.5 71.4 50.0 C AS ≥ 16 N CS, H CT, MRI - X - - rCBF
Yamagata et al. (2004) 2004 29, 72.4 71.7 55.2 PA AS ≥ 16 N CS, H MRI X X - X NUM
Piamarta et al. (2004) 2004 33, 39.4 71.6 15.2 A PSDRS expanded > 4 Y CS, H CT, MRI X X - - -
Carota et al. (2005) 2005 273, 46.9 64.4 47.6 A EBIF ≥ 0.5 Y P, H CT, MRI X X - - -
Glodzik et al. (2005) 2005 31, 48.4 62.9 41.9 A AS > 16 Y CC, H CT, MRI, MRS X X - - METAB
Brodaty et al. (2005) 
Withall et al. (2011)
2005
2011
135, 39.3
106, 39.6
72.2 
72.1
26.7
25.5
PA
PA
AES ≥ 37
AES ≥ 37
Y 
Y
CC, H
P, H
CT, MRI 
CT, MRI
X 
-
- 
-
- 
-
X 
-
NUM, ATR, WMH 
ATR, WMH
Hama et al. (2007) 2007 243, 33.3 65.2 40.3 PA AS ≥ 16 N CS, H CT - X - X -
Santa et al. (2008) 2008 67, 43.3 65.4 20.9 PA AS > 15 Y CS, R MRI X X X - -
Kang and Kim (2008) 2008 100, 42.0 65.1 43.0 A Clinical observation N CS, H MRI, MRA X X - - -
Onoda et al. (2011) 2011 102, 44.1 73.0 36.3 A, PA AS ≥ 16 N CS, H MRI, SPECT - X - - rCBF
Castellanos et al. (2011) 2011 89, 48.3 70.0 13.5 PA NPI N P, H CT, MRI X X - - -
Caeiro et al. (2012) 2012 94, 35.1 55.7 38.3 A AES-10 ≥ 18 N CC, H CT, MRI X X X - -
Murakami et al. (2013) 2013 149, 34.9 66.8 44.3 PA AS ≥ 16 N CS, H MRI - X - - -
Mikami et al. (2013) 2013 56, 35.7 63.9 41.1 PA, C AS, criteria Robert N P, H/C NS - - X - -
Tang et al. (2013a) 2013 185, 37.3 65.2 10.8 PA AES ≥ 37 N CS, H MRI - X - X NUM, WMH
Rochat et al. (2013) 2013 55, NS 56.4 NS PA, C AI Y CS, H CT, MRI - X - X -
Yang et al. (2015c) 2015 54, 35.2 67.4 57.4 PA AES, criteria Robert N CS, H MRI, DTI - X - - FA maps
Yang et al. (2015a) 2015 88, 27.3 68.2 38.6 A, PA AES, criteria Robert N CS, H MRI, DTI - - - X
WM integrity, 
WM networks
Cosin et al. (2015) 2015 46, 17.4 58.0 21.7 PA AI > 2, LARS > 21 N CS, H MRI - X - - LACI, WMH, CMB
Hollocks et al. (2015) 2015 118, 34.7 68.9 NS PA GDS (6-items) Y CS, H MRI, DTI - - - - FA,WM networks
Mihalov et al. (2016) 2016 47, 36.2 67.7 23.4 PA AS ≥ 14 N CS, H CT, MRI - - - - ATR
Note: *Percentage of participants with PSA at baseline measurement. 
Abbreviations: A, acute; AES, Apathy Evaluation Scale; AES-10, Apathy Evaluation Scale 10-item; AS, 
Apathy Scale; ATR, atrophy; C, chronic (phase); C, community (patient source); CC, case-control; CMB, 
cerebral microbleeds; CS, cross-sectional; CT, computed tomography; DTI, diffusion tensor imaging; 
EBIF, Emotion Behavior Index Form; FA, fractional anisotropy; Fem, female; H, hospital; LACI, lacunar 
infarcts; LARS, Lille Apathy Rating Scale; LAT, laterality; LOC, location; LV, lesion volume; METAB, 
metabolism; MRA, magnetic resonance angiography; MRI, magnetic resonance imaging; MRS, proton 
magnetic resonance spectroscopy; N, number of participants; N, no; NPI, Neuropsychiatric Inventory; 
NS, not specified; NUM, number of lesions; P, prospective; PA, post-acute; PSA, post-stroke apathy; 
PSDRS, Post-Stroke Depression Rating Scale; PT, patient; R, rehabilitation center; rCBF, regional 
cerebral blood flow; SPECT, single-photon emission computed tomography; TP, type of stroke; WM, 
white matter; WMH, white matter hyperintensities; Y, yes.
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ABSTRACT
Background: Cognitive impairment and neuropsychiatric syndromes, like 
depression and apathy, are frequent residual consequences of stroke. These 
have a large impact on quality of life and long-term prognosis. Several factors 
are involved in the development of these residual syndromes, although their 
exact role and their interrelationships remain still rather unclear. The Cognition 
and Affect after Stroke: a Prospective Evaluation of Risks (CASPER) study has 
been primarily designed to examine whether stroke-specific (e.g. lesion 
location, volume, type, severity), cerebrovascular and neurodegenerative 
(e.g. white matter changes, atrophy, microbleeds, perivascular spaces), 
inflammatory, endothelial, and (epi)genetic markers are associated with 
cognitive impairment, post-stroke depression, and post-stroke apathy, and 
whether they predict their course over 12 months. The secondary aims are 
to investigate how the above-mentioned markers interact with each other, 
and to determine if patients with apathy and depression after stroke differ in 
pathogenesis, course, and outcome (e.g. functional outcome, neurocognitive 
performance, quality of life). 
Methods/design: CASPER is a 1-year prospective clinical cohort follow-up 
study in 250 stroke patients recruited at the neurological in- and outpatient 
services at Maastricht University Medical Center (MUMC+, Maastricht, the 
Netherlands), and Zuyderland Medical Center (Sittard and Heerlen, the 
Netherlands). At baseline (3 months post-stroke), a neuropsychological 
assessment, neuropsychiatric interview, blood sample, and brain magnetic 
resonance imaging (MRI) scan are conducted. Assessment of neuropsychiatric 
and neurocognitive status are repeated 6 and 12 months later. 
Discussion: The CASPER study investigates stroke-specific, vascular, neuro-
degenerative, inflammatory, and genetic markers of the development of 
vascular cognitive impairment, depression, and apathy after stroke. This 
creates the possibility to study not only the contribution of these individual 
markers but also their joint contribution, which differentiates this study from 
earlier stroke cohorts who lacked long-term follow-up data, a large sample 
size, an extensive MRI protocol, and markers from the blood. The knowledge 
we derive from this study might help in identifying markers that are associated 
with, or can predict the onset, maintenance, and progression of vascular 
cognitive impairment, depression, and apathy after stroke, and could provide 
new insights into possibilities for treatment and rehabilitation that result in 
better functional outcome after stroke.
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BACKGROUND
Stroke is one of the leading causes of disability in the Western world. According 
to the Global Burden of Disease Study in 2010 the stroke incidence worldwide 
was around 17 million persons per year, with 33 million people being still alive 
after stroke, and about 70 % of all stroke patients staying with residual symptoms.1 
Stroke is the second most frequent cause of death, after coronary artery disease.2 
As a result of the aging population, this number will probably increase steadily 
in the next decades.3 At the same time, case fatality rates are declining due to 
better acute treatment. Therefore, more and more individuals will need to learn 
how to deal with the residual disabilities and handicaps.1 Frequent impairments 
after stroke are cognitive impairments and neuropsychiatric syndromes, including 
depression and apathy,4,5 which have an impact on long-term prognosis (higher 
mortality and more disability), and quality of life (QoL) of stroke survivors.6,7
VASCULAR COGNITIVE IMPAIRMENT
Vascular cognitive impairment (VCI) describes the full spectrum from mild to 
severe cognitive impairment in people with cerebrovascular disease, including 
vascular mild cognitive impairment and vascular (or post-stroke) dementia (VaD).8 
Risk factors of VCI after stroke include event-related factors such as infarct severity, 
lesion volume, age, low education, history of diabetes or atrial fibrillation, and 
number of recurrent strokes.9 The risk for post-stroke dementia is known to be 
highest within the first year, with an estimated incidence rate of 20-30 %, which is 
nine-times the general population’s risk.9
It has been suggested that both vascular and neurodegenerative pathologies 
contribute to post-stroke VCI.10 Cognitive impairments can be the result of strategic 
infarcts, but (pre-existing) white matter hyperintensities (WMH) and atrophy of 
the medial temporal lobes can contribute too, and they probably interact with 
each other, though the nature of these interactions is not well understood.11 In 
addition, a higher risk for VCI has been reported in carriers of the Apolipoprotein 
E (ApoE) ε4 allele, which is the major genetic risk factor for Alzheimer’s disease 
(AD) dementia.12 Indeed, evidence accumulates that AD and VaD should not be 
regarded as mutually exclusive diagnoses, but rather as a continuum with pure 
AD and VaD at its extremes, and most people showing mixtures of both type of 
pathologies.13 While the dominating view is that vascular changes work as a catalyst 
of primary neurodegenerative changes in AD it is largely unknown whether the 
opposite is true for VCI, i.e. whether AD-related changes work as a catalyst for 
post-stroke dementia.
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Next to neurodegeneration, neuro- and vascular inflammation might contribute 
to VCI by partly mediating the pathophysiology underlying VCI as part of a 
final common pathway.14 Following stroke, increased auto-immune activity is a 
common response, and it has been shown that up-regulated inflammation markers 
like C-reactive protein (CRP), as a consequence of a prolonged auto-immune 
response, relate to poor prognosis. This includes a higher risk of additional future 
strokes and mortality, but also more severe VCI.15,16 Other enzymes, molecules, 
and ligands (myeloperoxidase, soluble intercellular adhesion molecule, soluble 
vascular cell adhesion molecule-1, soluble E selectin, soluble P selectin and 
CD40 ligand) are involved in vascular inflammation as part of an inflammatory 
response to stroke, and have also been found to be increased in AD.17-20 Also, up-
regulation of proinflammatory cytokines (interleukin-6 and tumor necrosis factor 
alpha) and proteins (high sensitivity CRP) are risk factors for both dementia21,22 and 
cardiovascular disease.23 It is unknown whether similar inflammation mechanisms 
are involved in cognitive deterioration in VCI, and therefore, research is needed 
to investigate whether inflammation contributes to VCI independently or in joint 
action with other (e.g. neuro-degenerative) factors. 
Finally, genetic factors are also suggested to play a role in the pathogenesis of 
VCI, but in contrast to AD, evidence is still scarce. A genome-wide association 
study in VaD identified a novel genetic locus near the androgyn receptor, and this 
finding was replicated in two independent validation datasets.24 Polymorphisms 
and mutations on the genes coding for angiotensin-converting enzyme and 
methylenetetrahydrofolate reductase are risk factors for cardiovascular diseases 
and might be related to the development of VaD, although this relationship is still 
controversial.25 For AD, several genetic risk loci are already identified next to ApoE, 
including clusterin (CLU), phosphatidylinositol binding clathrin assembly protein 
(PICALM), and encoding complement component [3b/4b] receptor 1 (CR1),26 
but their effects are generally small (see http://www.alzgene.org). Whether they 
contribute to post-stroke dementia is not known.
POST-STROKE DEPRESSION
Depression is a common neuropsychiatric syndrome following stroke. According 
to a recent systematic review by Hackett et al.,27 around one-third of the stroke 
survivors experiences depression in the first three months post-stroke, and studies 
with long-term follow-up have shown that it is often a chronic disorder, with a 
remitting-relapsing pattern.28 Patients with post-stroke depression (PSD) have 
worse functional recovery,29 a higher risk for cognitive impairment,7 and higher 
mortality risk.30,31
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Early studies implied that PSD is mainly associated with anterior lesions in the 
left hemisphere, however, a major systematic review and meta-analysis found no 
support for this ‘lesions location hypothesis’.32 Vataja et al.33 suggested that lesions 
in fronto-subcortical regions in general are involved in developing PSD, often 
accompanied by impairments in executive functioning, leading to what has been 
called the ‘depression-executive dysfunction syndrome’. Other factors that have 
been associated with the development of PSD are cognitive impairment, stroke 
severity, physicial disability, and pre-stroke depression and anxiety.7 Diminished 
QoL and also low social support can both contribute independently to the 
severity of depression.34 A study by van Mierlo et al.35 investigated the association 
between a broad range of psychological factors and PSD with a multivariable 
logistic regression analysis. They showed that more passive coping and more 
helplessness, less acceptance and less perceived benefits were all significantly and 
independently associated with symptoms of post-stroke depression. Furthermore, 
fatigue after stroke has been associated with PSD, although not all patients with 
fatigue develop symptoms of depression and vice versa.28 
Neuroinflammation might also play a role in the underlying mechanisms of PSD. 
Levels of CRP, soluble E selectin, CD40 ligand, interleukin-6, tumor necrosis factor 
alpha, and high sensitivity CRP are deregulated in patients diagnosed with major 
depressive disorder.14,18,22,23,36-38 In addition, high plasma levels of neopterin are 
found in people with depression, and might predict the development of PSD.39 
Markers of endothelial function might be important as well, since increased 
expression of soluble intercellular adhesion molecule and soluble vascular 
cell adhesion molecule-1 are associated with depression.40-43 Although several 
inflammation markers have been related to symptoms of depression, studies 
examining these associations in PSD specifically are relatively scarce. Some studies 
found an elevation in interleukin-6 and tumor necrosis factor alpha in PSD.44 
Recently, a study by Tang et al.39 showed an association between elevated serum 
levels of neopterin in the acute phase after stroke and PSD at 6-month follow-up.
High plasma levels of homocysteine are known to increase the risk for 
cerebrovascular disease, but have also been associated with depressive 
disorders. Increased levels of homocysteine result in cerebrovascular disease and 
a deficiency in monoamine neurotransmitters, which might lead to a depressed 
mood.45 Homocysteine, folate and vitamin B12 are all involved in methylation 
reactions that are necessary for monoamine neurotransmitter production, but 
also the production of phospholipids and nucleotides. A deficiency in folate and 
vitamin B12 has also been associated with depressive disorders.46
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POST-STROKE APATHY
Apathy has been defined as a disorder of diminished motivation, characterized 
by lowered initiative, restricted engagement in social interactions and activities, 
diminished cognitive activities, and lack of emotional response.47 It was traditionally 
seen as a symptom of other syndromes (e.g. depression and dementia), but 
mounting evidence suggests that it might be an independent syndrome with a 
different etiology.48-50 Post-stroke apathy (PSA) is as frequent as PSD, with a mean 
prevalence rate of 34.6 % at 4 months post-stroke.5 However, PSA gained relatively 
less attention in research in comparison with PSD, and most research focuses on 
the difference between the two.
While PSD is suggested to be associated with left anterior lesions,51,52 PSA has 
been associated with right hemispheric subcortical lesions, particularly in the 
basal ganglia and in the anterior cingulate circuit which is involved in motivational 
processes.53-55 Other factors associated with PSA are older age, lower education, 
and severity of VCI.4,5,51,56 Furthermore, both PSD and PSA have been associated 
with poor functional recovery and low QoL.5,29 Overall, lack of longitudinal studies, 
differences between time of measurement after stroke (acute phase/chronic 
phase), and lack of studies with a sufficient sample size make it difficult to interpret 
study results.
In conclusion, several factors play a role in the development of VCI, PSD, and 
PSA. However, most studies investigated the underlying mechanisms in isolation 
and did not take into account how several factors interact with each other. The 
Cognition and Affect after Stroke, a Prospective Evaluation of Risks (CASPER) study 
incorporates a broad range of psychosocial, blood and neuroimaging markers to 
be able to study their role alone and in combination with each other to predict 
individual differences in the onset and course of the cognitive and neuropsychiatric 
consequences of stroke.
STUDY AIMS
The primary aim of CASPER is to identify stroke-related, cerebrovascular, 
neurodegenerative, (epi)genetic, endothelial and inflammation markers that 
are associated with VCI, PSD, and PSA in patients with ischemic or hemorrhagic 
stroke. The secondary aims are to investigate how the above-mentioned markers 
interact with each other, and to determine if patients with apathy and depression 
after stroke differ in pathogenesis, course, and outcome (e.g. functional outcome, 
neurocognitive performance, quality of life). 
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The main research questions are: 
1. Are stroke-specific, additional vascular, neurodegenerative, inflammatory 
or genetic markers a) associated with VCI at 3 months after stroke and b) 
predictive for its course over 12 months?
2. Are stroke-specific, additional vascular, neurodegenerative, inflammatory or 
genetic markers a) associated with PSD and PSA at 3 months after stroke and 
b) predictive for their course over 12 months?
3. Do the above-mentioned markers interact on VCI, PSD, and PSA outcome? 
4. Which psychosocial factors are associated with the development of VCI, PSD, 
and PSA?
5. Do PSA and PSD differ in their pathogenesis, cognitive profile, course, and 
outcome? 
METHODS
STUDY DESIGN
CASPER is a prospective clinical cohort study into cognitive impairments and 
neuropsychiatric syndromes after stroke with a follow-up of 1 year. Baseline 
measurements take place in the post-acute phase after stroke (i.e. 10 to 12 
weeks post-stroke) to assess presence and severity of VCI, PSD, and PSA. Serial 
assessments take place at 6 and 12 months after baseline. The total duration of 
the study will be approximately 3.5 years, from June 2013 (first in) until November 
2016 (last out).
PATIENTS 
In total, 250 consecutive patients with either ischemic or hemorrhagic stroke are 
included. Patients who are admitted to the Stroke Unit of the Maastricht University 
Medical Center+ (MUMC+), Maastricht, the Netherlands, the Stroke Unit of 
Zuyderland Medical Center in Sittard-Geleen and Heerlen, the Netherlands, or 
those who visit the Transient Ischemic Attack clinic of MUMC+ for a non-fatal 
ischemic or intracerebral hemorrhagic stroke and fulfill the in- and exclusion 
criteria are asked to participate. Stroke is defined as a clinical stroke syndrome 
(sudden neurological dysfunction lasting >24 h, with no apparent cause other 
than that of vascular origin). The stroke can be a first-ever event or a recurrent 
supra- or infratentorial stroke in a patient who recovered from a previous event 
without obvious residual symptoms. Ischemic strokes might be cortical or lacunar, 
and could be included with or without evidence of ischemia on clinical brain 
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scan. Hemorrhagic strokes are non-traumatic deep, lobar, cerebellar, or brainstem 
hemorrhages as evidenced by a clinical brain scan. Eligibility criteria are chosen 
to make sure that the sample will represent the current clinical situation (Table 
1). Participation of an informant who knows the patient well enough to answer 
questions about his/her functioning over the last ± 10 years is desirable but not 
required. 
Table 1. In- and exclusion criteria
Inclusion criteria Exclusion criteria
- Ischemic or hemorrhagic stroke
- Subarachnoidal hemorrhage, traumatic hemorrhage, 
primary intraventricular hemorrhage and transient 
ischemic attack
- MMSE score ≥ 15 
(to ensure valid testing)
- Age younger than 40 years (to exclude atypical strokes)
- Written informed consent
- Severe aphasia (as it interferes with performance 
on and understanding of the instructions of the 
neuropsychological tests)
- Sufficient knowledge of the Dutch 
language
- Evidence for pre-stroke dementia (based on clinical 
diagnosis or IQ-CODE) in the 5 years prior to the stroke
- Other existing psychiatric and neurological diagnoses 
that are known to affect cognition (Parkinson’s disease, 
bipolar disorder, epilepsy, schizophrenia, or substance 
abuse)1
Note: 1 Lifetime history of depression is not considered as a reason for exclusion as it might be a 
risk factor for post-stroke depression. Abbreviations: IQ-CODE, Informant-Questionnaire on Cognitive 
Decline in the Elderly; MMSE, Mini Mental State Examination.
ASSESSMENTS
The baseline measurement (T0) is scheduled 3 months post-stroke to avoid 
confounding effects by the acute event, including acute inflammatory responses. 
At T0, patients undergo a venipuncture, brain magnetic resonance imaging 
(MRI) scan, neuropsychological assessment and neuropsychiatric interview. 
They fill in several questionnaires to assess the presence and severity of PSD 
and PSA, and to evaluate other factors as functional ability, fatigue, personality, 
and QoL. A semi-structured interview with an informant is performed to provide 
additional information about functional outcome of the patient and presence of 
neuropsychiatric syndromes. Six (T1) and 12 months (T2) after T0, the neuropsycho-
logical assessment and questionnaires are repeated. The venipuncture, MRI scan, 
neuropsychological assessment, and neuropsychiatric interview all take place 
in the academic hospital in Maastricht and are performed by specially trained 
nurses (venipuncture), radiology assistants (MRI scan) and trained research (neuro)
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psychologists (neuropsychological assessment and neuropsychiatric interview). If 
a patient is not able to visit the hospital due to reduced mobility, the patients are 
visited at their current place of residence. 
Patients who suffer from a recurrent stroke during the 12-month follow-up period 
will be followed-up normally, if the health status of the patient allows this, and 
if the patient does not suffer from severe aphasia after the recurrent stroke. 
Information about the type, location, and severity of the lesion of the recurrent 
stroke is collected, which also allows us to study the potential impact of recurrent 
strokes on our outcome measures. Recurrent strokes are taken into account in our 
analyses with longitudinal data to avoid confounding effects. 
CLINICAL DATA 
In a standardized case record form, data on demographics (e.g. age, gender, 
educational level, ethnicity, marital status), medical history (e.g. personal and 
family history of cardiovascular, neurological or psychiatric disorders), medication 
use, physical examination (e.g. weight, height, blood pressure, cholesterol), and 
lifestyle (smoking behavior, alcohol consumption, drug use, physical activity) are 
collected.
NEUROPSYCHOLOGICAL ASSESSMENT AND COGNITIVE ENDPOINTS
The neuropsychological assessment consists of a standardized battery of 
cognitive tests measuring specific cognitive domains: global cognition, episodic 
memory, working memory, information processing speed, executive functioning, 
visuoconstruction, neglect, premorbid IQ, and language (dysphasia). An overview 
of all test instruments and their cognitive domains is presented in Table 2. The 
neuropsychological tests are administered according to a standardized test 
protocol by trained research (neuro)psychologists.
VCI is defined as a score ≤ 1.5 standard deviations below the general population 
mean in one or more cognitive domains, based on available norm scores for age, 
gender, and level of education for the Dutch general population. In addition, there 
should not be any interference in daily activities and no diagnosis of dementia 
according to DSM-5 criteria.57 The impairments have to represent a significant 
decline from premorbid levels of functioning. The diagnosis and type of dementia 
is made by an experienced neuropsychiatrist or neuropsychologist based on 
DSM-5 criteria.57 A consensus meeting is arranged when there is a discrepancy in 
diagnosis, and if no consensus can be reached, the patient will be considered not 
demented. The diagnosis of AD is made according to the standardized clinical 
criteria for AD based on the National Institute for Neurological and Communicative 
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Disorders and Stroke-Alzheimers Disease and Related Disorders Association 
(NINCDS-ADRDA) criteria.58 The diagnosis of VaD is made according to the 
criteria proposed by the National Institute of Neurological Disorders and Strokes – 
Association Internationale pour la Recherche et l’Enseignement en Neurosciences 
(NINDS-AIREN).59 
The Informant Questionnaire on Cognitive Decline in the Elderly (IQ-CODE; 
short form) is used to detect possible dementia prior to the index stroke, and 
is rated retrospectively (past 5 years prior to the index stroke),60 in combination 
with information from medical records. A cut-off score ≥ 3.60 is used to indicate 
possible dementia prior to the stroke, as has been used in a previous study with 
stroke patients.61
NEUROPSYCHIATRIC ASSESSMENT
Depression
The symptoms of a major depressive disorder according to DSM-IV and DSM-5 
are assessed with the Mini International Neuropsychiatric Interview (M.I.N.I.).71 The 
MINI is a semi-structured interview administered to the patient and consists of three 
different parts, which aim to determine whether the patient can be diagnosed with 
a current major depressive disorder, a depressive episode lifetime, and a current 
dysthymic disorder. The clinician-rated Montgomery-Åsberg Depression Rating 
Scale (MADRS) is used to assess the severity of symptoms of depression.72 This 
rating scale consists of 10 items to evaluate the severity of depressive symptoms 
and is filled out by the clinician.72 In addition, the Hospital Anxiety and Depression 
Scale (HADS), a 14-item self-report scale, is used to identify clinically significant 
levels of anxiety and depression.73 According to a study by Kang et al.,81 the HADS 
and MADRS are especially valid as screening instrument for PSD (in both the 
acute and chronic phase), since these scales focus less on the presence of somatic 
symptoms, resulting in less misclassification. 
Apathy
The Apathy Evaluation Scale (AES) is an 18-item scale used to evaluate the 
presence and severity of apathy.75 Three different versions of the AES are available, 
a clinician-rated (administered to the patient), informant-rated, and a patient-rated 
version. The AES has been rated as the most favorable instrument for assessing 
apathy, with the clinician-rated version being most valid of the three different 
versions.82 Both the informant-rated and clinician-rated version (administered to 
the patient) of the AES are used in the CASPER study. 
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Generic
The Neuropsychiatric Inventory (NPI) is administered as a semi-structured 
interview to the informant of the patient.74 The NPI is originally developed to 
evaluate neuropsychiatric symptoms in dementia, but is also frequently used 
in the stroke population.28 It evaluates the presence and severity of 12 different 
neuropsychiatric symptoms (delusions, hallucinations, agitation, depression, 
anxiety, euphoria, apathy, disinhibition, irritability, aberrant motor behavior, sleep, 
and appetite).83 The validity and reliability of the NPI, including the Dutch version, 
has been well established.84,85
Table 2. Neuropsychological measures and neuropsychiatric questionnaires
Instrument T0a T1a T2a
Global cognition MMSE62 X X X
Episodic Memory 15-Word Verbal Learning Test63 X X X
Working memory Digit-span of the WAIS-III64 X X X
Information processing 
speed
Digit Symbol Substitution Test (DSST)
Trail Making Test (TMT; part A and B)64, 65
X X X
Executive functioning
TMT (interference), BADS Zoo Map & Key Search,  
Verbal Fluency (60 seconds; animals and 
professions)65-67
X X X
Visuo-construction Clock drawing67 X X X
Neglect Star cancellation68 X
Premorbid IQ NLV69 X
Language / aphasia Boston Naming Test70 X
Depression MINI, MADRS, HADS, NPI71-74 X X X
Apathy AES, NPI74, 75 X X X
Premorbid dementia IQ CODE60 X
Functional ability Barthel Index, Lawton76, 77 X X X
Quality of life SS-QoL78 X X X
Fatigue FSS79 X X X
Personality NEO-FFI80 X
aT0: baseline measurement, T1: 6-month follow-up, T2: 12-month follow-up. 
Abbreviations: AES, Apathy Evaluation Scale; BADS, Behavioral Assessment of the Dysexecutive 
Syndrome; FSS, Fatigue Severity Scale; HADS, Hospital Anxiety and Depression Scale; IQ-CODE, 
Informant-Questionnaire on Cognitive Decline in the Elderly; MADRS, Montgomery-Åsberg 
Depression Rating Scale; MINI, Mini International Neuropsychiatric Interview; MMSE, Mini-Mental 
State Examination; NEO-FFI, NEO Five Factory Inventory; NLV, Nederlandse leestest voor volwassenen 
(Dutch version of the National Adult Reading Test); NPI, Neuropsychiatric Inventory; SS-Qol, Stroke 
Specific Quality of Life; WAIS; Wechsler Adult Intelligence Scale. 
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ADDITIONAL INTERVIEWS
Fatigue after stroke is assessed with the Fatigue Severity Scale (FSS).79 This 
9-item self-rating scale can be answered on a 7-point scale, with higher scores 
representing more fatigue. The Barthel Index77 is used to evaluate impairments in 
activities of daily living (ADL), and the Lawton Scale76 is used to assess impairment 
in instrumental ADL. Furthermore, the Stroke Specific Quality of Life Scale (SS-
QoL) is used to evaluate health-related QoL, which is defined as the physical, 
psychological, and social aspects of life that can be influenced by a change in 
health status.78 The NEO Five Factor Inventory (NEO-FFI) is used to assess the big-
five dimensions of personality, which are extraversion, neuroticism, openness to 
new experiences, agreeableness, and conscientiousness.80
NEUROIMAGING
A standardized brain MRI protocol is used as described in Table 3. The MRI 
scans are all performed on the same 3.0 Tesla head-only scanner equipped 
with an 8-channel head coil (Philips Achieva, Philips Medical Systems, Best, the 
Netherlands), using the same standardized scanning protocol for every patient. 
This protocol has been optimized for stroke and WMH segmentation, as well as 
segmentation of the hippocampus.86 One scanning session takes approximately 
30 min. After acquisition of the MR images, an anonymisation procedure is 
performed, to make sure that all imaging data are pseudonymised.
Table 3. Brain MRI protocol
Sequence name / 
Acquisition method
Field 
of View 
(mm)
Matrix Slices
Inter-slice
Gap (mm)
Thickness 
(mm)
Voxel 
(mm)
TR /TE/TI (ms)
Coronal 3D  
T1-weighted (TFE)
240x240 240x240 160 0 1 1x1x1 8.2/3.8
2D Axial  
T2-weigthed (FSE)
230x185 328x225 48 0 3 0.7x0.8x3 3000/80
3D fluid-attenuation 
inversion recovery
250x250 228x226 283 0 1.1 0.6x1.1x1.1 8000/332/2400
T2* diffusion 
weighted imaging 
gradient echo EPI
240x240 128x128 28 0 5 1.85x1.85x5 10000/72/2400
SWI 220x180 220x180 260 0 0.5 1x1x0.5 16/22
Abbreviations: TR, repetition time; TE, echo time; TI, inversion time; TFE, turbo field echo; FSE, fast spin 
echo; EPI, echo planar imaging; SWI, susceptibility weighted imaging. 
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MRI MARKERS
Several stroke characteristics are visually scored by an experienced vascular 
neurologist and consist of: presence and type of symptomatic stroke lesion 
(ischemic/hemorrhage), location of the lesion, number, type, and location of old 
infarcts and old hemorrhages, number and location of microbleeds, and degree 
of perivascular spaces in basal ganglia and centrum semiovale. The Fazekas visual 
rating scale is used to score deep and periventricular WMH.87 In addition, a semi-
automatic brain tissue segmentation program, based on the program used in 
the Rotterdam scan study,88 is used to measure WMH volumes and to calculate 
the volume of global brain atrophy, corrected for total intracranial volume. The 
accuracy of this semi-automated method appeared to be within the range of 
the inter-observer variability of fully manual segmentations but is less time-
consuming while still requiring some manual correcting. The medial temporal 
lobe atrophy (MTA) visual rating scale89 is used to indicate the level of atrophy in 
the medial temporal lobes (ranging from 0 to 4), separately for the left and the 
right hemisphere. Furthermore, hippocampal volume is measured based on atlas 
registration with high accuracy using the robust and validated method of learning 
embeddings for atlas propagation (LEAP).90,91
BLOOD MARKERS
At baseline, fasting blood samples are taken. All patients take their morning 
medication after the venipuncture. In total, 35.5 mL of blood are taken and 
directly analyzed or stored. We measure several inflammation markers. In 
addition, standard lab procedures to assess levels of glucose, cholesterol (total, 
high-density lipoprotein cholesterol, low-density lipoprotein cholesterol), and 
triglycerides will be performed directly after the venipuncture.92-94 Biomaterial 
(including deoxyribonucleic acid and ribonucleic acid) is stored anonymously for 
15 years after the end of the study. Table 4 lists the blood markers investigated in 
CASPER. 
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Table 4. Blood sampling procedure
Tubes Blood markers Procedure
EDTA tube
(4x 6.0 mL)
Myeloperoxidase, neopterin, soluble 
intercellular adhesion molecule, 
soluble vascular cell adhesion 
molecule-1, soluble E selectin, soluble 
P selectin, CD40 ligand, interleukin-6, 
tumor necrosis factor alpha, 
Homocysteine
Transported on ice to the Biobank 
Maastricht UMC+ where the 
blood is preprocessed before 
storing. EDTA plasma is 
centrifuged and stored at -80°C 
until analysis.
Natriumfluoride/EDTA 
tube (1x 4.0 mL) 
Coagulation tube
(1x 5.0 mL)
Glucose, total cholesterol
high-density lipoprotein-cholesterol, 
low-density lipoprotein-cholesterol, 
triglyceride, folate, vitamine B12, 
high sensitivity C-reactive protein
Direct analyses of these markers 
are performed at the laboratory 
on the day of sample collection 
after centrifuging.
Buffycoats from the 
4 EDTA tubes for 
DNA extraction
Apoliprotein E, clusterin, 
phosphatidylinositol binding 
clathrin assembly protein, encoding 
complement [3b/4b] receptor 1, 
angiotensin-converting enzyme,
methylenetetrahydrofolate reductase
Buffycoats are taken from four 
EDTA tubes and separately stored 
at the Biobank until analysis.
Epigenetics 1 
PAXgene tube 
(2.5 mL)
RNA
Blood is collected in PAXgene 
tubes to ensure long-term 
stability of ribonucleic acid and 
the tubes are stored at the 
Biobank. RNA extraction and 
subsequent analysis of expression 
of inflammatory and stroke-related 
genes at the mRNA level will be 
done.
Abbreviations: mL, milliliter; EDTA, ethylenediaminetetraacetic acid; DNA, deoxyribonucleic acid; 
RNA, ribonucleic acid; mRNA, messenger ribonucleic acid.
ETHICS, CONSENT AND PERMISSIONS
The study protocol has been approved by the Medical Ethics Committee of MUMC+. 
The research is performed according to the principles of the Declaration of Helsinki 
59th WMA General Assembly, Seoul, (October 2008) and in accordance with the 
Dutch Medical Research Involving Human Subjects Act (WMO). All eligible patients 
are informed about the aim of the study and both the patient and informant receive 
an information letter. All patients receive enough time to consider participation and 
if they agree to participate, an appointment is scheduled to sign informed consent. 
There are no risks for the patients participating in this study. All assessments in 
the study consist of routine operations and all patient data are pseudonymised. 
Contraindications for MRI are checked for every patient, and patients with contra-
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indications are excluded for MRI. If a patient decides to withdraw from the study, 
this has no consequences or risks for the patients. Patients who refuse follow-up 
assessment are contacted to determine the reason for refusal. 
POWER CALCULATION AND SAMPLE SIZE
Based on results of the CODAS study,95 a previous study with stroke patients of 
our research group, it is expected that 50 % of the stroke patients will have VCI 
and 10 % will have VaD after one year. Furthermore, it is expected that 35 % of 
the patients will have minor or major depression after one year post-stroke.96 A 
power calculation was performed with the freeware program G*Power version 
3.1 (http://www.gpower.hhu.de) assuming categorical independent variables to 
which 50 % are exposed and 50 % are not exposed (median-split), since no reliable 
estimates are available for our main predictors from literature (MRI, inflammation 
and genetics). Based on a 1-year follow-up, a two-sided alpha level of .05, and an 
expected drop-out rate of 20 % based on the CODAS study (about 10 % due to 
death), a sample size of 250 resulted in a power of 86 % to detect a relative risk of 
2.00, or 80% to detect a relative risk of 1.89 for PSD, and a 96 % power to detect a 
relative risk of 2.00, or 80 % power to detect a relative risk of 1.70 for VCI. 
STATISTICAL ANALYSES
Categorical data will be presented on group level expressed in absolute numbers 
and percentages, whereas continuous data will be presented by their mean, 
confidence interval, and standard deviation. In case of non-normality, continuous 
data will be presented as medians with their corresponding inter-quartile range. 
Differences between groups will be analyzed using t-tests for continuous variables 
or appropriate non-parametric counterparts, and chi-square tests for categorical 
variables. Pearson’s correlation coefficient will be used to assess the association 
between two continuous variables. Random effects models will be used to 
measure cognitive decline from baseline to follow-up, which has the advantage 
over repeated measures ANOVA that it is not restricted to study completers. The 
effect of baseline predictors on PSD, PSA, and VCI will be estimated with Poisson 
and Cox regression, taking into account differences in individual follow-up time. 
Furthermore, multivariate finite mixture modeling will be used to test the existence 
of separate PSD and PSA subtypes, using lesion location, WMH, inflammation 
markers, genetic risk factors, functional impairment, and cognitive functioning as 
subtype indicators. Age, gender, and education will be included as covariates in 
the multivariate models. Based on theory and statistical evaluation to see whether 
a variable might be a probable confounder it will be decided which additional 
covariates will be added on each analysis. 
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DISCUSSION
The CASPER study is a prospective clinical cohort study examining predictors 
of onset and course of VCI, PSD, and PSA using a deep phenotyping approach. 
It is an observational study with minimal risks for the participating patients. The 
longitudinal design creates the possibility to study independent predictors of 
VCI, PSD, and PSA. The CASPER study provides the possibility to study the course 
of these conditions and potential bidirectional relationships between them. A 
relatively large sample size and an MRI protocol that uses state-of-the-art volumetry 
of WMH and hippocampal atrophy make it more likely to find subtle differences 
in the brain’s macrostructure. Therefore, the CASPER study has an additional 
value to earlier stroke cohort studies (e.g. Sydney Stroke Study, The Fogarty-
Mexico Stroke Cohort, CODAS).10,95,97 Furthermore, CASPER includes extensive 
blood-based biomarker data which results in a rich phenotyping approach 
generating both blood-based biomarker data and clinical brain MRI data, creating 
the possibility to study cerebrovascular, neurodegenerative, inflammatory, and 
genetic markers, and their inter-relationships. This is valuable since this gives a 
better account of how these changes occur in patients, namely in combination. 
Hence, the combination of these markers may predict individual differences in 
the development of VCI, PSD, and PSA better than each marker in isolation. Taken 
together, these methodological strengths promise to yield novel insights into the 
underlying mechanisms of the burdensome consequences of stroke. 
However, some limitations of the study protocol have to be acknowledged here. 
Although the extensive in- and exclusion criteria were formulated with caution, 
they can possibly result in a less representative group of patients compared to the 
general stroke population. For instance, patients who are aphasic or who have pre-
existent cognitive disturbances are excluded. No data are collected in the acute 
phase after stroke, which could yield additional information on the association 
between VCI, PSD, PSA and the earlier mentioned investigated markers, but 
a post-acute baseline time point is chosen to avoid confounding effects in the 
acute phase (e.g. generic acute inflammatory response, sickness behavior). MRI 
scans and venipuncture are only performed on T0, since it is not feasible due to 
logistical and financial reasons to repeat them at T1 and T2. However, if these data 
could also have been collected more information on the causes of VCI, PSD, and 
PSA could have been gathered, e.g. by linking longitudinal changes on MRI to 
changes in outcomes. Furthermore, patients with severe stroke are less probable 
to participate in the study, as the assessment is quite extensive. This can result in 
a cohort of patients with relatively mild stroke, which may influence the frequency 
of VCI, PSD, and PSA. Both ischemic and hemorrhagic strokes are included to 
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increase the inclusion rate, however, due to the different etiologies of these strokes, 
it is likely that this limits the generalizability of the results. Therefore, we have to 
correct for stroke type in our analyses to take this into account. It is also likely that 
patients with depression or apathy after stroke are less motivated to participate in 
the study, resulting in an underestimation of the PSD and PSA prevalence in the 
study sample. In addition, the current follow-up period of 1 year allows testing 
predictions in the post-acute to early chronic phase, but is too short to study long-
term consequences. Finally, CASPER allows for in-depth phenotyping and also 
covers a broad spectrum of factors impacting on the consequences of stroke, but 
it is not powered to test for more subtle associations or to use complex genetic 
models or testing of rare variants. Therefore, the study is also designed as to 
allow harmonization with other stroke cohorts in larger meta-studies as part of the 
STROKOG consortium (https://cheba.unsw.edu.au/group/strokog). 
In conclusion, the CASPER study allows to study the role of several markers, 
consisting of cerebrovascular, neurodegenerative, and inflammatory markers, and 
their inter-relationships, in the development of VCI, PSD, and PSA. Furthermore, 
the longitudinal design and sample size provide the possibility to study the course 
of PSA, PSD, and VCI and explore individual differences in their development. 
Better understanding of the role of all of these markers will make it possible to 
provide new treatment techniques or adapt existing treatment techniques, both on 
a biological and psychological level, which can result in better QoL and functional 
outcome of stroke patients.
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ABSTRACT
Background: Post-stroke fatigue (PSF) is a form of pathological fatigue that 
can develop after stroke and has a negative impact on functional outcome. 
PSF is associated with post-stroke depression (PSD), which in turn shows 
similarities with post-stroke apathy (PSA). This study aimed at disentangling 
the temporal associations between PSF and PSD and between PSF and PSA.
Methods: A total of 250 stroke patients were included, of which 243 
completed the Fatigue Severity Scale, Montgomery-Åsberg Depression 
Rating Scale, and Apathy Evaluation Scale at 3 months post-stroke, with 
follow-up measurements at 6 and 12 months after initial testing. Linear 
mixed models and linear regressions were performed to evaluate the 
temporal associations between PSF and PSD, and between PSF and PSA. 
Results: PSF was present in 119 patients (49%), of whom 62 patients also 
had PSD (26%), and 21 patients (9%) also had PSA. At baseline, PSF patients 
showed higher depression levels, which remained stable at follow-up. 
PSD patients had higher fatigue levels compared with no-PSD patients 
at baseline, which remained stable at follow-up. No association between 
apathy and fatigue was found at baseline and no interaction with time 
was found. Change in fatigue from baseline to 12-month follow-up was 
associated with change in depression and with change in apathy.
Conclusions: Bi-directional associations were found between PSF and PSD. 
In treatment and rehabilitation programs, early focus on presence of PSD 
and PSF is important, since these conditions tend to persist. As there are 
currently more treatment options for PSD, attention for PSD is important and 
might also have a beneficial effect on PSF.
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INTRODUCTION
Post-stroke fatigue (PSF) can be defined as a form of pathological fatigue, 
characterized by a continuous feeling of weariness,1 independent of physical 
exertion,2 and can develop early after stroke or in the chronic stroke phase. It is a 
frequent complaint after stroke, with prevalence estimates between 35 and 92%.1 
PSF has a negative impact on daily functioning and rehabilitation,3,4 resulting 
in higher dependency and poor quality of life.5 PSF has been associated with 
both biological and psychological factors,6 and is therefore hypothesized to be 
of multifactorial origin.7 Lack of acknowledgment of fatigue by others, including 
health professionals, due to its ‘invisible nature’, contributes to the difficulty to 
cope with PSF, and can cause irritability and mood changes.8
A meta-analysis of 19 cross-sectional studies showed that PSF is associated with 
post-stroke depression (PSD).9 Longitudinal studies found evidence that early PSD 
was associated with long-term PSF,10,11 and long-term PSD was also associated 
with long-term PSF.7 Early depressive symptoms correlated positively with both 
early fatigue and long-term fatigue, but no long-term depression data were 
available.12 So, less is known about the effect of early PSF on long-term PSD, 
leaving the question whether a direct relationship between PSF and PSD exists, 
and if so, whether it is uni- or bi-directional.13 In addition, there is large overlap in 
the symptoms of apathy and depression after stroke,14 and both often co-occur,15-17 
suggesting they are closely related. Apathy can be defined as a condition of lack 
of interest and motivation, with diminished participation in activities.18 Hence, 
post-stroke apathy (PSA) might also be related to PSF. Therefore, the main aim of 
the present study is to disentangle the temporal relationships between PSF and 
PSD and between PSF and PSA. 
METHODS
STUDY POPULATION
Participants of the present study took part in the Cognition and Affect after Stroke, 
a Prospective Evaluation of Risks (CASPER) study, a prospective clinical cohort 
study, which aims to examine predictors of post-stroke cognitive impairment, 
depression, and apathy, and its design has been described in detail elsewhere.19 
Patients were approached to participate between June 2013 and November 2015; 
all patients have been admitted to the Stroke Unit of Maastricht University Medical 
Center (MUMC+), or Zuyderland Hospital (the Netherlands). The study protocol 
was approved by the Medical Ethics Committee of MUMC+.
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Patients with non-fatal first-ever ischemic stroke were included. Exclusion 
criteria were: hemorrhage (n = 50), pre-stroke dementia, pre-existing cognitive 
impairment, or mental retardation (n = 86), previous stroke (n = 54), age < 40 
years (n = 17), neurological or psychiatric diseases other than depression that are 
known to affect cognition (n = 75), insufficient knowledge of the Dutch language 
(n = 18), too severe aphasia to understand the study procedure (n = 35), Informant 
Questionnaire on Cognitive Decline in the Elderly (IQ-CODE) score20 ≥ 3.60 (n = 
3), Mini-Mental State Examination Score (MMSE) score21 < 15 (n = 1), no written 
informed consent (n = 1), blindness (n = 2), and post-surgery stroke / post-anoxic 
encephalopathy (n = 2). After one year, initial criteria were adapted to increase 
response rate by additionally including patients with hemorrhage (n = 15) and 
patients with a history of stroke ≥ 3 years, but without residual symptoms (n = 
13). Patients with a history of stroke of < 3 years or with residual symptoms from 
previous stroke were excluded (n = 68). Finally, 250 eligible patients gave their 
written informed consent and were enrolled in the present study (Supplementary 
Figure 1). 
PROCEDURE
Baseline measurements were scheduled approximately 3 months post-stroke to 
avoid confounding effects caused by the acute stroke state.22 At baseline (T0), 
socio-demographic information was recorded and all patients underwent a 
neuropsychiatric interview in order to evaluate the presence and severity of fatigue, 
depression, and apathy, which was repeated at 6-month (T1) and 12-month (T2) 
follow-up.
MEASUREMENTS
The Fatigue Severity Scale (FSS), a 9-item self-report questionnaire, was used to 
assess the presence and severity of PSF.23 The FSS has been validated in stroke 
patients,24 and based on previous studies a cut-off score ≥ 4 was applied to 
indicate PSF.5,25
The Apathy Evaluation Scale (AES) was used to assess presence and severity of 
PSA,26,27 which consists of 18 items measured on a 4-point scale, with a higher 
total score representing a higher level of apathy. The clinician-rated AES (AES-C) 
version was used as outcome measure of apathy, and patients with a score ≥ 37 
on either the AES-C or informant-rated AES were classified as having clinically 
relevant apathy.28
The Mini International Neuropsychiatric Interview (MINI), a semi-structured 
interview based on DSM-IV criteria, was used to diagnose major depressive 
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disorder (MDD) and minor depression (MIND).29 The Montgomery-Åsberg 
Depression Rating Scale (MADRS), a 10-item clinician-rated questionnaire, was 
used as outcome measure of depression.30 The MADRS was evaluated as a 
valid instrument for PSD as it focuses less on somatic symptoms and is sensitive 
to change.31 Patients having MDD or MIND according to the MINI, or having a 
MADRS score ≥ 7 were classified as having clinically relevant depression.
The Barthel Index was used to measure impairment in activities of daily living,32 and 
the NEO Five Factor Inventory was used to assess the personality trait neuroticism, 
which was included as potential covariate in the analyses.33
STATISTICAL ANALYSIS
All statistical analyses were performed with Stata version 13.1 for Mac OS X 
(StataCorp, USA). An alpha level of .05 (two-sided) was used for all analyses. 
Baseline differences between PSF groups were tested using χ2 tests for qualitative 
variables and t-tests for quantitative variables. Pearson, point-biserial, phi, and 
Spearman rho correlations were used to assess correlations between variables. 
Variables that correlated significantly with both fatigue and depression, or fatigue 
and apathy were analyzed in a linear regression model. Variables that were 
significantly associated with both fatigue and depression, or fatigue and apathy 
in the linear regression models were included as potential confounders in the 
analyses. 
Linear mixed models were performed to measure the effect of baseline PSF on 
depression and apathy scores at baseline, and to test whether PSF predicts change 
in depression and apathy scores over time from baseline to 12-month follow-up. A 
group (2-levels: no-PSF, PSF) by time (3-levels: T0, T1, T2) interaction was included 
to study differences in the course of depression between the groups. A χ2-test 
test of homogeneity with two degrees of freedom (df) tested the null hypothesis 
of no difference in rate of change over time between the groups by examining 
whether there is a significant group-by-time interaction. The models included a 
random intercept and random slope with an unstructured correlation matrix as this 
resulted in the best fit and the analyses were corrected for relevant confounders. 
Furthermore, we tested whether change in FSS from baseline to T1 or T2 was 
associated with change in PSD or PSA during the same period. For this, a change 
score of the FSS was calculated by regressing FSS scores at follow-up on baseline 
FSS scores, thereby accounting for different FSS baseline levels (autoregression). 
The FSS change score was then used as the independent variable in a linear 
regression in which MADRS or AES-C scores at follow-up were regressed on 
baseline MADRS or AES-C scores. 
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Next, the same analytic approach was adopted with FSS as outcome to measure 
the effect of baseline PSD or PSA on fatigue scores at baseline, and to test 
whether PSD or PSA predicted change in fatigue scores over time from baseline to 
12-month follow-up. We additionally adjusted for the PSA-by-time or PSD-by-time 
interaction to study the independence of these effects. The linear mixed models 
only included a random intercept as this resulted in the best fit. 
RESULTS
Of the 250 participants, 243 completed the FSS, MADRS, and AES-C at T0 
(97.2%), of which 210 patients (86.4%) completed T1 and 215 patients (88.5%) 
completed T2 (Supplementary Figure 1). Patients lost to follow-up at one or 
two time measurements (n = 27) did not differ from patients who completed all 
measurements (n = 216) (Supplementary Table 1). 
Table 1 shows the baseline characteristics of the total sample (n = 243), and also 
separately for PSF group at baseline. PSF was present in 119 patients at T0 (49.0%). 
Patients with PSF were significantly younger compared to the no-PSF group, more 
often reported sleep apnea, and showed higher levels of neuroticism, depression, 
and apathy. PSD was present in 94 patients at T0 (38.7%), of which 13 (5.3%) 
fulfilled criteria for MDD, 15 (6.2%) for MIND, and 66 (27.2%) had a MADRS score 
≥ 7. A significantly higher frequency of PSD and MDD was found in the PSF group 
in comparison with the no-PSF group, and 62 (25.5%) of the patients experienced 
both PSD and PSF. PSA was present in 40 patients at T0 (16.5%). Presence of both 
PSA and PSD at baseline was seen in 26 patients (10.7%), whereas presence of 
both PSA and PSF at baseline was seen in 21 patients (8.6%).
Based on correlation analyses (Supplementary Table 2) and linear regression 
models, only sleep apnea was associated with all outcomes, whereas neuroticism 
and history of depression were significantly associated with fatigue and depression 
scores. As sleep apnea has a direct influence on fatigue level, it was included in the 
primary analyses, together with baseline age, sex, and highest level of education. 
In the secondary analyses, also neuroticism and depression history were included 
to see how they influence the relationship between depression and fatigue, and 
apathy and fatigue. 
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THE COURSE OF DEPRESSION BY PSF GROUP
In the PSF group, a significantly higher MADRS score was found at T0 (χ2 = 10.68; 
df = 1; p = .001), which remained stable at T1 (p = .044) and T2 (p = .008). There 
was no significant interaction between PSF and MADRS score over time (χ2 = 1.37; 
df = 2; p = .504; Figure 1A). Adding neuroticism and history of depression to the 
model did not change the results (Table 2). 
THE COURSE OF APATHY BY PSF GROUP
No significant group effect at T0 (p = .121; Table 2) or interaction by time effect 
(χ2 = 1.37; df = 2; p = .505) was found between PSF and AEC-C score (Figure 
1B). While groups scored similar at T0 or T1 (p = .218), a significant difference in 
apathy score between the PSF and no-PSF group was found at T2 (p = .046). By 
the addition of neuroticism and history of depression to the model, the group 
difference in AES-C score at T2 was not significant anymore (p = .119). 
Table 1. Baseline characteristics 
Variable Overall No PSF PSF 
N (%) 243 (100.0) 124 (51.0) 119 (49.0)
Age (in years) 67.41 (11.76) 69.44 (11.33) 65.30 (11.87)b
Male sex, n (%) 157 (64.6) 83 (66.9) 74 (62.2)
Low education, n (%)
Middle education, n (%)
High education, n (%)
100 (41.3)
85 (35.1)
57 (23.6)
50 (40.3)
38 (30.7)
36 (29.0)
50 (42.4)
47 (39.8)
21 (17.8)
Time since stroke (months) 2.93 (0.43) 2.90 (0.41) 2.96 (0.46)
First-ever stroke, n (%) 227 (93.4) 119 (96.0) 108 (90.8)
Barthel Index 19.44 (1.47) 19.40 (1.74) 19.48 (1.14)
Sleep apnea, n (%) 18 (7.4) 2 (1.6) 16 (13.5)b
High neuroticism, n (%) 115 (48.7) 69 (59.0) 46 (38.7)b
Pre-stroke depression, n (%) 55 (22.6) 23 (18.6) 32 (26.9)
Family history of depression, n (%) 34 (14.1) 15 (12.2) 19 (16.0)
MADRS 6.07 (5.84) 4.24 (4.43) 7.96 (6.49)b
AES-C 26.36 (7.87) 25.26 (6.88) 27.50 (8.66)a
FSS 3.78 (1.59) 2.47 (0.92) 5.14 (0.79)b
MINI minor or major depression, n (%)
MDD
MIND
28 (11.5)
13 (5.4)
15 (6.2)
10 (8.1)
2 (1.6)
8 (6.5)
18 (15.1)
11 (9.2)b
7 (5.9)
PSA, n (%) 40 (16.5) 19 (15.3) 21 (17.7)
PSD, n (%) 94 (38.7) 32 (25.8) 62 (52.1)b
Abbreviations: AES-C, Apathy Evaluation Scale Clinician-rated; FSS, Fatigue Severity Scale; MADRS, 
Montgomery-Åsberg Depression Rating Scale; MDD, major depressive disorder; MIND, minor 
depression; MINI, Mini International Neuropsychiatric Interview; PSA, post-stroke apathy; PSD, post-
stroke depression; PSF, post-stroke fatigue.
Note: Data are mean (SD), unless otherwise specified. 
a p < 0.05, b p < 0.01.
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THE COURSE OF FATIGUE BY PSD GROUP
At T0, a significantly higher FSS score was found in the PSD group (χ2 = 27.25; df = 
1; p < .001; Table 2), which remained stable at T1 (p < .001) and T2 (p < .001). The 
overall interaction between PSD and FSS scores over time was not significant (χ2 = 
2.02; df = 2; p = .365; Figure 1C). 
THE COURSE OF FATIGUE BY PSA GROUP
No significant group difference in FSS score between the PSA and no-PSA group 
was found at T0 (χ2 = 0.20; df = 1; p = .659, Table 2), T1 (p = .571) or T2 (p = .865; 
Figure 1D), and the overall interaction between PSA and FSS scores over time was 
not significant either (χ2 = 0.17; df = 2; p = .921).
Figure 1. Course of apathy and depression by post-stroke fatigue (PSF) group and course of fatigue by 
post-stroke depression (PSD) and post-stroke apathy (PSA) group 
(A) Course of depression scores by PSF group. (B) Course of apathy scores by PSF group. (C) Course 
of fatigue scores by PSD group. (D) Course of fatigue scores by PSA group. Based on random effects 
analyses adjusted for age at baseline, sex, highest level of education, sleep apnea, history of depression, 
and high neuroticism. Predicted mean scores are estimated marginal means of time by group, with all 
covariates fixed at their means. Higher mean scores indicate a higher level of depression, apathy, or 
fatigue, respectively. 
Abbreviations: PSA, post-stroke apathy; PSD, post-stroke depression; PSF, post-stroke fatigue.
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ASSOCIATION BETWEEN CHANGE OF FATIGUE AND CHANGE OF DEPRESSION
Linear regression analyses showed that change in FSS score from T0 to T1 was not 
significantly associated with change in MADRS score from T0 to T1 (B = 0.07, p 
= .820). However, from T0 to T2 change in FSS score was significantly associated 
with change in MADRS score (B = 1.47, p < .001). When neuroticism and history of 
depression were added to this model, change in FSS score remained significant 
(B = 1.35, p < .001).
ASSOCIATION BETWEEN CHANGE OF FATIGUE AND CHANGE OF APATHY
There was no significant association between change in FSS score and change in 
AES-C score from T0 to T1 (B = 0.62, p = .086). However, from T0 to T2 change 
in FSS score was significantly associated with change in AES-C score (B = 1.21, 
p = .004). When neuroticism and history of depression were added to this model, 
change in FSS score remained significant (B = 0.91, p = .027).
Table 2. Mean differences (and 95% confidence intervals) in depression, apathy and fatigue score and 
in rate of change (slopes) from baseline to follow-up 
Parameter
Time
Baseline Change T0 – T1 Change T0 – T2
Difference 95% CI Change 95% CI Change 95% CI
MADRS by PSF
Model 1c 2.75b 1.10, 4.40 -0.99 -2.65, 0.67 -0.44 -2.09, 1.21
Model 2d 2.14b 0.76, 3.52 -0.95 -2.59, 0.69 -0.46 -2.21, 1.29
AES-C by PSF
Model 1c 1.57 -0.42, 3.56 -0.22 -2.07, 1.63 0.91 -1.28, 3.10
Model 2d 0.99 -1.04, 3.03 -0.26 -2.12, 1.59 0.90 -1.25, 3.05
FSS by PSD
Model 1c 1.08b 0.67, 1.49 -0.17 -0.57, 0.23 0.13 -0.27, 0.53
Model 2d 0.83b 0.42, 1.24 -0.19 -0.60, 0.22 0.10 -0.30, 0.51
FSS by PSA
Model 1c -0.12 -0.64, 0.41 -0.04 -0.57, 0.49 0.07 -0.45, 0.59
Model 2d -0.05 -0.56, 0.46 -0.09 -0.62, 0.45 0.04 -0.48, 0.57
Abbreviations: AES-C, Apathy Evaluation Scale Clinician-rated; FSS, Fatigue Severity Scale; MADRS, 
Montgomery-Åsberg Depression Rating Scale; PSA, post-stroke apathy; PSD, post-stroke depression; 
PSF, post-stroke fatigue; T0, 3 months post-stroke; T1, 6-month follow-up; T2, 12-month follow-up.
a p < 0.05.
b p < 0.01.
c Model 1: corrected for age, sex, highest level of education, and sleep apnea. 
d Model 2: corrected for age, sex, highest level of education, sleep apnea, high neuroticism, and history 
of depression. 
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DISCUSSION
This study aimed to disentangle the temporal relationship between PSF and PSD, 
and between PSF and PSA. Patients with PSF at baseline had higher depression 
scores that remained stable throughout time, and patients with PSD at baseline 
had higher fatigue scores that remained stable throughout time as well. No 
association between PSF and the baseline level or course of apathy symptoms was 
found, and neither in the reverse direction, as no association between PSA and 
the baseline level or course of fatigue symptoms was found. Additionally, change 
in fatigue score from baseline to 12-month follow-up was significantly associated 
with change in depression and change in apathy from baseline to 12-month 
follow-up. No associations were found when looking at change from baseline to 
6-month follow-up.
Half of the stroke patients experienced PSF at baseline, which is in agreement 
with a previous meta-analysis that showed a range between 35% and 92%.1 PSD 
at baseline was present in almost 40%,34 which is somewhat higher than the 
estimated prevalence of 31% reported in an earlier meta-analysis and baseline 
PSA was present in less than 20%, which is lower than the reported estimated 
prevalence of 35% in the meta-analysis by van Dalen et al.15 However, this can be 
explained partially by the variability in the time range between the measurements 
and the stroke date, the cut-off scores that were applied, and the use of different 
questionnaires.
The present findings suggest that both PSF and PSD are frequent early after stroke 
and remain relatively stable throughout time. Half of the patients with PSF at 
baseline also had PSD, suggesting a strong bi-directional association between the 
two symptoms. These results are in agreement with the study of Lerdal et al.35 who 
also found an association between early fatigue and early depressive symptoms. 
In addition, baseline depression scores were associated with high fatigue scores 
at follow-up. This is in line with a previous longitudinal study that suggested that 
baseline depression was associated with long-term fatigue.10
With respect to the temporal relationship between PSD and PSF, the results of this 
study indicate that fatigue and depression show a similar course over time and co-
occur in a quarter of the stroke patients 3 months after stroke. Patients with PSD 
had high FSS scores, which remained stable over time, whereas patients with PSF 
had high MADRS scores that also remained stable over time. This suggests a bi-
directional relationship, as the results also suggest that change in depression over 
time was associated with change in fatigue over time. 
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Yet, some patients experience PSF in the absence of PSD, and vice versa, suggesting 
that PSD and PSF should be considered as distinct consequences of stroke.36 Early 
PSD, together with other factors, contributes to early PSF, and vice versa. According 
to the PSF model of Wu et al.,6 potential factors that might be involved in this 
relationship include lesion location, inflammatory responses, personality traits, 
coping styles, and sleep apnea. These factors differ among individuals, which 
explains the inter-patient variability in the development of fatigue.1 Patient-tailored 
treatment is therefore important, as individual differences have to be taken into 
account when targeting PSD or PSF. With respect to treatment and rehabilitation 
programs, this suggests that an early focus on both PSD and PSF is important, as 
these conditions tend to persist. Since there are more treatment options available 
for depression, early screening for depression might have a positive effect on 
clinical outcome,37 and might also affect fatigue symptoms. Future longitudinal 
studies are needed to give more insight into the complex multifactorial origin of 
PSF. This requires large cohort studies taking into account the various factors that 
influence the complex relationship between PSD and PSF.
An important strength of the present study is the longitudinal design, which made 
it possible to study temporal associations. This is the first study that examined 
associations between fatigue and depression in both directions, and that also 
included the influence of apathy on this relationship. Well-validated instruments 
were used to measure fatigue, depression, and apathy and adequate statistical 
models for repeated measures were used to account for missing data. In addition, 
sleep apnea, neuroticism, and history of depression were included as they might 
influence the relationships between depression, apathy, and fatigue. Particularly 
the role of sleep apnea is important, as it has been shown to be a risk factor for 
incident stroke,38 and is associated with worse cognitive and functional status.39 
Also in multiple sclerosis,40,41 associations between sleep apnea and fatigue have 
been found. Treatment of sleep apnea may have a beneficial effect on PSF, though 
future studies are needed to examine this. However, some limitations of the 
study should be noted. The exclusion of patients with severe aphasia and other 
neurological or psychiatric conditions made the study sample less representative, 
and it is reasonable to assume that stroke patients with a worse clinical outcome, 
who were unable to participate, have an even higher degree of PSF, PSD, or PSA, 
resulting in an underestimation of the presence of these conditions. 
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CONCLUSIONS
PSD and PSF were strongly associated throughout time, and the association 
seemed to be bi-directional. Although apathy scores were correlated with 
level of fatigue throughout time, this appeared largely to be due to co-morbid 
depression. The present results suggest that immediate screening for both PSD 
and PSF after stroke is important, as it might help to prevent the development of 
these symptoms at an early or later stage. This will result in better participation in 
rehabilitation programs, improving clinical outcome after stroke.
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SUPPLEMENTAL DATA
Supplementary Figure 1. Flowchart of inclusion process 
Note: Twenty patients who did not participate at T1, agreed to participate at T2. 
Abbreviations: FSS, Fatigue Severity Scale; MADRS, Montgomery-Åsberg Depression Rating Scale; 
MINI, Mini International Neuropsychiatric Interview; T0, baseline measurement 3 months post stroke; 
T1, follow-up 9 months post-stroke; T2, follow-up 15 months post-stroke. 
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Supplementary Table 1. Baseline characteristics for total sample, and separate for patients who 
completed all measurements and patients who dropped out at 1 or 2 time points 
Variable
All patients T0
(n = 243)
Complete follow-up
 (n = 216) 
Dropouts
(n = 27)
Age (in years) 67.41 (11.76) 66.91 (11.65) 71.45 (12.06)
Male sex, n (%) 157 (64.6) 142 (65.7) 15 (55.6)
Low education, n (%)
Middle education, n (%)
High education, n (%)
100 (41.3)
85 (35.1)
57 (23.6)
86 (39.8)
77 (35.7)
53 (24.5)
14 (53.9)
8 (30.8)
4 (15.4)
Time since stroke (months) 2.93 (0.43) 2.92 (0.43) 2.99 (0.43)
First-ever stroke, n (%) 227 (93.4) 202 (93.5) 25 (92.6)
Barthel Index 19.44 (1.47) 19.47 (1.47) 19.22 (1.50)
Sleep apnea, n (%) 18 (7.4) 17 (7.9) 1 (3.7)
High neuroticism, n (%) 115 (48.7) 102 (48.1) 13 (54.2)
Pre-stroke depression, n (%) 55 (22.6) 47 (21.8) 8 (29.6)
Family history of depression, n (%) 34 (14.1) 33 (15.3) 1 (3.9)
MADRS 6.07 (5.84) 6.30 (5.94) 4.30 (4.68)
AES-C 26.36 (7.87) 26.46 (8.04) 25.56 (6.42)
FSS 3.78 (1.59) 3.79 (1.56) 3.68 (1.80)
MINI minor or major depression, n (%)
MDD 
MIND
28 (11.5)
13 (5.4)
15 (6.2)
26 (12.0)
12 (5.6)
14 (6.5)
2 (7.4)
1 (3.7)
1 (3.7)
PSA, n (%) 40 (16.5) 37 (17.1) 3 (11.1)
PSD, n (%) 94 (38.7) 87 (40.3) 7 (25.9)
PSF, n (%) 119 (49.0) 106 (49.1) 13 (48.2)
Abbreviations: AES-C, Apathy Evaluation Scale Clinician-rated; FSS, Fatigue Severity Scale; MADRS, 
Montgomery-Ȧsberg Depression Rating Scale; MDD, major depressive disorder; MIND, minor 
depression; MINI, Mini International Neuropsychiatric Interview; PSA, post-stroke apathy; PSD, post-
stroke depression; T0, baseline measurement 3 months post stroke. Data area mean (SD), unless 
otherwise specified.
Note: a p < 0.05 compared to complete follow-up, b p < 0.01 compared to complete follow-up.
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ABSTRACT
Objective: Post-stroke depression (PSD) and post-stroke apathy (PSA) are 
both associated with adverse outcome after stroke. This study aimed to 
examine whether pre-morbid personality traits predict the course of PSD 
and PSA over 12 months. 
Methods: In this prospective cohort study, 241 stroke patients completed the 
NEO Five Factor Inventory, Montgomery-Åsberg Depression Rating Scale, 
and Apathy Evaluation Scale at 3 months post-stroke. Neuropsychiatric 
assessment was repeated at 6- and 12-month follow-up after initial testing. 
Results: Linear mixed models showed that high neuroticism was associated 
with higher levels of PSD at baseline, which remained stable at follow-up. 
Low extraversion was associated with higher levels of PSA at baseline, 
which also remained stable throughout time. Similarly, low openness and 
conscientiousness were associated with higher levels of PSA at baseline, 
which remained high at 6-month follow-up, but decreased at 12-month 
follow-up. None of the personality traits showed a significant overall group-
by-time interaction.
Conclusion: Personality traits are associated with the development and 
sustainability of PSD and PSA. The traits associated with PSD and PSA were 
different, providing support for the independence of these constructs. The 
findings highlight the importance to take personality traits into account as a 
potential vulnerability factor for PSD and PSA. 
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INTRODUCTION
Apathy and depression are common neuropsychiatric consequences after stroke, 
both showing prevalence rates of around 30%.1,2 Post-stroke depression (PSD) is 
known to have a negative impact on the effectiveness of rehabilitation treatment,3 
whereas post-stroke apathy (PSA) is associated with poor functional recovery.4,5 
Moreover, both reduce quality of life after stroke.2,6-8 While previous research on 
determinants of PSD and PSA focused mainly on stroke-related factors, such as 
lesion characteristics,9-11 psychological factors, including personality traits, may 
play a role as well. 
Personality traits are relatively stable manners of feeling, thinking, and acting 
of individuals12 and according to the five-factor model,13 personality can be 
represented by a five-factor trait structure, comprising neuroticism, extraversion, 
openness to experience, agreeableness, and conscientiousness. Previous studies 
in the general population found personality traits, and particularly neuroticism, to 
be an important predictor of onset and course of neuropsychiatric symptoms,14-17 
but studies on personality factors in a stroke population are scarce. Some previous 
cross-sectional studies have reported an association between neuroticism and 
PSD,18,19 particularly in the acute stroke phase.19,20 A single prospective study has 
shown that high neuroticism was an important predictor of 1-year PSD,3 but no 
evidence was found for associations with any of the other five-factor personality 
traits. For PSA, the relationship with premorbid personality traits has only been 
examined in one study, but no association was found.21
Information on premorbid personality could be helpful to detect patients at 
risk for developing neuropsychiatric symptoms in patients recovering from 
stroke. Previous cross-sectional studies already indicated a strong link between 
neuroticism and PSD. However, as previously pointed out by Aben et al.,3 the 
association between personality traits and neuropsychiatric symptoms after stroke 
should preferably be studied in large longitudinal cohorts with multiple time 
points, assessing all five-factor personality traits. PSD and PSA are independent 
though overlapping syndromes,22,23 and the studies examining personality traits in 
association with PSD did not control for this overlap in symptomatology between 
the two syndromes, which could have biased the results. Therefore, the present 
study followed a cohort of 250 stroke patients to assess whether pre-morbid 
personality traits predict the course of PSD and PSA over 12 months. 
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METHODS
STUDY POPULATION
Participants of this study took part in the Cognition and Affect - a Prospective 
Evaluation of Risks (CASPER) study, a prospective clinical cohort study into 
predictors of cognitive and neuropsychiatric disorders after stroke. The study 
was approved by the Medical Ethics Committee of Maastricht University Medical 
Center (MUMC+). 
We included patients who suffered from a non-fatal ischemic or hemorrhagic 
stroke who were admitted to the Stroke Unit of MUMC+ or Zuyderland Medical 
Center in Sittard and Heerlen (the Netherlands) between June 2013 and August 
2015. Stroke was defined as a clinical stroke syndrome, with sudden neurological 
dysfunction lasting > 24 hours, with no apparent cause other than that of 
vascular origin. Ischemic strokes could be cortical or lacunar, and hemorrhagic 
strokes were non-traumatic deep, lobar, cerebellar, or brainstem hemorrhages as 
evidenced by a clinical brain scan (for details see Douven et al.24). Exclusion criteria 
include age < 40 years, pre-stroke dementia, pre-existing cognitive impairment, 
mental retardation, a Mini-Mental State Examination Score < 15,25 neurological 
or psychiatric diseases other than depression that are known to affect cognition, 
insufficient knowledge of the Dutch language, too severe aphasia to understand 
the study procedure, an Informant Questionnaire on Cognitive Decline in the 
Elderly score  3.60,26 no written informed consent, blindness, history of stroke < 3 
years or residual symptoms from previous stroke, and post-surgery stroke / post-
anoxic encephalopathy. 
PROCEDURE
Baseline measurements (T0) were scheduled approximately 3 months after stroke 
(median = 2.9 months, interquartile range = 2.0-4.3), to avoid interference with 
acute care and rehabilitation. Socio-demographic characteristics were recorded, 
and neuropsychiatric questionnaires were administered to the patient, in which the 
presence of depression and apathy was assessed. The neuropsychiatric interview 
was repeated in the chronic stroke phase (9 and 15 months post-stroke; T1 and T2, 
respectively). Pre-morbid personality was only assessed at T0, as it was assumed 
that personality traits remain stable over time. 
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CLINICAL MEASURES
Personality was assessed with the NEO Five-Factor Inventory (NEO-FFI).27,28 This 
self-report questionnaire consists of 60 statements covering the 5 personality 
traits extraversion, neuroticism, openness to new experiences, agreeableness, 
and conscientiousness. Each statement was rated by the participant on a 5-point 
scale ranging from “strongly disagree” to “strongly agree”. For each personality 
trait a total dimension score between 12 and 60 was obtained. A median split was 
applied on all personality domains to dichotomize the personality traits in low 
versus high premorbid personality domains.29
The severity of PSD symptoms was measured with the Montgomery-Åsberg 
Depression Rating Scale (MADRS), a 10-item clinician-rated scale designed to be 
especially sensitive to change in symptom severity.30 Each item was scored from 0 
to 6, resulting in a total score between 0 and 60, with higher scores reflecting more 
severe symptoms of depression. The MADRS was used as outcome measure of 
PSD symptoms as it focuses less on somatic symptoms, and is therefore evaluated 
as a valid instrument for measuring the severity of depressive symptoms after 
stroke.31 In addition, the Mini International Neuropsychiatric Inventory (MINI), 
a semi-structured interview based on DSM-IV criteria, was administered for the 
diagnosis major depressive disorder (MDD) or minor depression (MIND) by a 
trained research (neuro)psychologist.32
The Apathy Evaluation Scale (AES) was used to measure the presence and 
severity of PSA.33 It consists of 18 items rated on a 4-point scale, resulting in a 
total score between 18 and 72, with higher scores representing a higher level of 
apathy symptoms. The clinician-rated version of the AES was used, as it has been 
rated as the most valid apathy instrument.34 A cut-off score of ≥ 37 was applied to 
define clinically relevant apathy.22,35 The Barthel Index was used as a measure of 
impairment in activities of daily living.36 
STATISTICAL ANALYSIS 
All statistical analyses were performed with Stata version 13.1 for Mac OS X 
(StataCorp, USA). An alpha level of .05 (two-sided) was used for all analyses. 
Differences in demographic variables between patients who completed all 
measurements and patients who dropped out at 1 or 2 time points were tested 
using χ2 tests for qualitative variables and t-tests for quantitative variables. Separate 
linear mixed models were performed to measure the effect of personality traits on 
the course of depression (MADRS score) or apathy (AES-C score) from T0 to T2 as 
outcome measure. A group (personality trait: low, high) by time (3-levels: T0, T1, T2) 
interaction was included to study differences in the course of depression or apathy 
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between the groups. The models included a random intercept and random slope 
with an unstructured correlation matrix as this resulted in the best fit according to 
likelihood ratio testing. The analyses were corrected for age, sex, highest level of 
education, history of depression, and Barthel Index score, as based on previous 
studies these factors seem to influence the association between personality traits 
and PSD,3 and probably also PSA. Additionally, we also added apathy score to the 
model to correct for a possible confounding effect of apathy on depression, and 
vice versa, because of a possible overlap in symptomatology.
RESULTS
Of the 619 eligible patients, 250 patients agreed to participate and signed 
informed consent. Refusers were more often female (53.4% versus 35.6%; p < 
.001) and older than participants (73.2±12.3 versus 67.3±11.8 years, p < .001). 
Of the 250 participants, 241 (96%) completed the NEO-FFI. Of them, 211 (87.2%) 
completed T1 (Supplementary Figure 1) and another 12 patients dropped-out at 
T2 (10 refused, 2 deceased). Eighteen of the patients who did not participate at T1 
re-entered the study at T2, which resulted in 217 (89.7%) patients who completed 
T2. No differences were found between the 22 patients (9.1%) lost to follow-up at 
1 or 2 time points and the 219 patients (90.9%) who completed all measurements 
(Supplementary Table 1). 
Table 1 shows the baseline characteristics of the total sample. At T0, 26 patients 
(10.8%) met DSM-IV criteria for either MDD (n = 13) or MIND (n = 13). A MINI 
depression diagnosis (MDD or MIND) was found in 14.2% at T1, and in 11.1% at 
T2. The average MADRS score at T0 was 6.1 (SD = 5.8) in the total sample, 15.9 
(SD = 7.4) in patients with a MINI depression diagnosis and 4.9 (SD = 4.3) for non-
depressed patients (t(230) =  -11.02, p < .001). Mean MADRS scores in the total 
cohort remained stable at T1 (6.8, SD = 7.2) and T2 (6.6, SD = 7.5). Average AES-C 
scores were 26.4 (SD = 7.9) at T0, 28.4 (SD = 9.0) at T1 and 28.1 (SD = 9.4) at T2. 
Twenty-four patients (10.0%) scored above the cut-off on the AES-C at T0. This 
frequency increased to 19.9% at T1 and decreased to 17.1% at T2. 
PERSONALITY TRAITS AND POST-STROKE DEPRESSIVE SYMPTOMS 
Table 2 gives the results of the linear mixed models examining differences in 
the course of depression between patients with a high and a low score on each 
personality trait. Significantly higher depression scores at T0 were found in 
patients with high neuroticism (χ2 = 13.31; df = 1; p < 0.001). This group effect 
remained significant at T1 (p = .011) and T2 (p = .002; Figure 1). No significant 
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group difference in depression score was found at T0 between patients with high 
and low scores on agreeableness, openness, extraversion, or conscientiousness, 
respectively. None of the personality traits showed a significant overall group-
by-time interaction. Also, no significant change between individual time points 
(baseline to T1, or baseline to T2) was found (Table 2), implying there were no 
significant differences in the course of depressive symptoms over time.
Table 1. Baseline characteristics of patients 
Variable Total (n = 241)
Age in years (SD) 67.31 (11.78)
Male sex, n (%) 158 (65.6)
Low education, n (%)
Middle education, n (%)
High education, n (%)
97 (40.4)
84 (35.0)
59 (24.6)
First-ever stroke, n (%) 225 (93.4)
Barthel score (SD) 19.44 (1.49)
Personality score (SD)
   Neuroticism
   Agreeableness
   Openness
   Extraversion
   Conscientiousness
31.60 (4.89)
36.54 (4.60)
36.85 (4.10)
38.25 (4.19)
39.63 (3.75)
History of depression, n (%) 55 (22.8)
Family history of depression, n (%) 34 (14.2)
MADRS score (SD) 6.06 (5.84)
AES-C score (SD) 26.41 (7.86)
MINI minor / major depression, n (%)
   MDD, n (%)
   MIND, n (%)
26 (10.8)
13 (5.4)
13 (5.4)
PSA, n (%) 24 (10.0)
Abbreviations: AES-C, Apathy Evaluation Scale Clinician-rated; MADRS, Montgomery-Åsberg 
Depression Rating Scale; MDD, major depressive disorder; MIND, minor depression; MINI Mini 
International Neuropsychiatric Interview; PSA, post-stroke apathy.
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Figure 1. Course of depressive symptoms by neuroticism group
Note: Based on random-effects analysis with random intercept, random slope and unstructured 
correlation matrix, adjusted for age at baseline, sex, level of education, Barthel Index, history of 
depression, and apathy score. Predicted mean scores are estimated marginal means for neuroticism 
group by time, with all covariates fixed at their means. Higher mean scores indicate a higher level of 
depression.
Table 2. Differences in baseline depression and apathy and change in depression and apathy by 
personality trait
Parameter
Time
Baseline
6-month 
follow-up
12-month 
follow-up
Personality 
by Timec
Difference 95% CI Change 95% CI Change 95% CI χ2 (2 df)
MADRS score by
   Neuroticism 2.37b 1.10, 3.64 -0.48 -2.02, 1.06 0.25 -1.39, 1.90 0.89
   Agreeableness 0.60 -0.71, 1.91 0.66 -0.88, 2.20 1.25 -0.40, 2.89 2.22
   Openness -0.61 -1.90, 0.68 0.03 -1.51, 1.58 -0.56 -2.22, 1.10 0.64
   Extraversion 0.25 -1.08, 1.58 -0.48 -2.03, 1.07 -0.73 -2.40, 0.93 0.78
   Conscientiousness 0.44 -0.84, 1.71 0.48 -1.05, 2.02 0.20 -1.45, 1.85 0.39
AES-C score by
   Neuroticism 0.23 -1.64, 2.11 1.61 -0.17, 3.39 1.93 -0.12, 3.97 4.22
   Agreeableness 1.61 -0.24, 3.47 1.08 -0.71, 2.87 -0.29 -2.39, 1.81 2.73
   Openness -1.81 -3.62, 0.00 -0.66 -2.45, 1.14 -0.03 -2.15, 2.08 0.73
   Extraversion -4.57b -6.33, -2.80 0.32 -1.48, 2.13 0.14 -1.97, 2.25 0.13
   Conscientiousness -2.06a -3.86, -0.27 -0.21 -2.01, 1.58 0.37 -1.73, 2.47 0.39
Model: personality trait, time, personality by time, sex, age at baseline, education, Barthel score at 
baseline, and history of depression. Analyses with MADRS score as outcome were additionally 
corrected for AES-C score, and vice versa. a p < 0.05, b p < 0.01, c Overall interaction between 
personality trait (low, high) and time (baseline, 6-month follow-up, 12-month follow-up, as indicated 
by χ2, df = 2). Abbreviations: AES-C, Apathy Evaluation Scale Clinician-rated; CI, confidence interval; 
MADRS, Montgomery-Åsberg Depression Rating Scale.
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Figure 2. Course of apathy by extraversion, openness, and conscientiousness group
A, course of apathy scores by extraversion group. B, course of apathy scores by openness group. C, 
course of apathy scores by conscientiousness group. Note: Based on random-effects analysis with 
random intercept, random slope and unstructured correlation matrix, adjusted for age at baseline, 
sex, level of education, Barthel Index, history of depression, and depression score. Predicted mean 
scores are estimated marginal means for personality trait group by time, with all covariates fixed at their 
means. Higher mean scores indicate a higher level of apathy.
PERSONALITY TRAITS AND POST-STROKE APATHY SYMPTOMS
Significantly higher apathy scores were found in patients with low extraversion at 
T0 (χ2 = 25.66; df = 1; p < 0.001), which remained stable at T1 (p < 0.001; Figure 
2A) and T2 (p < 0.001). Apathy scores were almost significantly higher in patients 
with low openness at T0 (χ2 = 3.83; df = 1; p = 0.050), which became significant 
at T1 (p = 0.010, Figure 2B), but not at T2. Similarly, significantly higher apathy 
scores were found in patients with low conscientiousness at T0 (χ2 = 5.08; df = 
1; p = 0.024), which remained stable at T1 (p = 0.016), but not at T2 (Figure 2C). 
With respect to neuroticism and agreeableness, no significant group difference in 
apathy score was found at T0. None of the personality traits showed a significant 
overall group-by-time interaction. Also, no significant change between individual 
time points (baseline to T1, or baseline to T2) was found (Table 2), implying there 
were no significant differences in change of apathy over time.
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DISCUSSION
This study investigated whether pre-morbid personality traits are a predictive 
factor for the development and course of depressive or apathetic symptoms 
after stroke. The main finding of this study was a consistent positive relationship 
between PSD and neuroticism over the course of 12 months, whereas there was 
a consistent negative relationship between PSA and extraversion. Furthermore, 
a negative association between PSA and openness and conscientiousness was 
found at baseline and 6-month follow-up, but not at 12-month follow-up. None of 
the personality traits showed a significant overall group-by-time interaction.
Our finding that individuals who score high on neuroticism are more likely to 
develop depressive symptoms post-stroke is in agreement with the results of the 
1-year longitudinal study of Aben et al.3 and the cross-sectional study of Hwang et 
al.18 The present study adds that neuroticism is a prognostic factor in determining 
the course of PSD symptoms over time, i.e. from the post-acute to the chronic 
stroke phase. In contrast with earlier studies on neuroticism and depression,3,18 we 
also controlled for level of apathy, as it might influence this relationship. Research 
has shown that social inhibition37 and maladaptive forms of emotion regulation,38 
which may both be associated with apathy,39,40 mediate the relationship between 
neuroticism and depression in elderly. Emotion regulatory processes can be 
affected by stroke, which can have a negative influence on social participation.41 
Therefore, also in stroke patients it may be of importance to look at the specific 
effect of neuroticism on PSD, independent of PSA. In contrast to our findings, Van 
Mierlo et al.41 reported that extraversion was associated with PSD at 2 months 
post-stroke, too, which might be explained by the fact that they did not consider 
the role of PSA in this association. 
For PSA, individuals who scored high on extraversion were less likely to develop 
apathetic symptoms post-stroke. This finding has not been examined in a stroke 
population before, but it is consistent with a cross-sectional study including 286 
patients with neurodegenerative diseases that showed a negative association 
between apathy scores and extraversion.42 Furthermore, low conscientiousness 
and low openness were associated with high apathy levels at baseline in our study, 
which remained stable at 6-month follow-up. Also, these associations have not 
been studied before in a stroke population, though the results were consistent 
with findings in a sample with mild cognitive impairment, in which retrospective 
change in conscientiousness from 5 years prior to assessment to baseline was 
positively associated with apathy, and premorbid openness was negatively 
associated with apathy.43
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Some controversy still exists whether depression and apathy are different, yet 
overlapping, disease entities. Our finding that personality traits are differentially 
associated with PSD and PSA suggests they are independent, at least in a stroke 
population.23,44 Furthermore, our results are in agreement with the hypothesis 
that, besides an important role for biological factors,45 psychological factors also 
play a role in the development of PSD,46 and the same theory seems to be true 
for PSA. Hence, future studies should focus on how personality traits and other 
psychological factors alone and in interaction with biological factors predict the 
development and course of PSD and PSA. This is important for treatment and 
rehabilitation, as focusing on early detection of PSD and PSA might result in a 
better clinical outcome after stroke.47
Strengths of this study are the longitudinal design and the low dropout rates at 
follow-up. In addition, validated instruments were used to evaluate the presence 
and level of depression, apathy, and personality traits. The consideration of the 
role of all five-factor personality traits in the development of both depression and 
apathy provides a more complete picture of the role premorbid personality plays 
in neuropsychiatric symptoms after stroke.
There are also some limitations that should be appointed. First, personality is 
assumed to be relatively stable over time, and studies have confirmed this partly,12 
but personality traits were measured after stroke. Hence, we do not know whether 
and how the stroke event itself had an influence on the self-rating of pre-morbid 
personality, so the results may possibly be not completely representative for ‘pre-
morbid’ personality. An additional informant rating of premorbid personality could 
have been valuable, as the informant can indicate whether a trait was already high 
or low before the stroke and the informant rating is not influenced by the current 
mood state of the patient. However, due to time constraints and because not 
every participant would have an informant we only collected self-rated premorbid 
personality, which has been commonly used in previous stroke studies.3,18,20 
Nevertheless, future studies should take this critical aspect into account, 
suggesting to assess (premorbid) personality in both the stroke patient and their 
primary caregiver or informant. Second, no significant main effect of an interaction 
between personality traits and time was found. Therefore, the individual traits by 
time point analyses are of exploratory nature and should be treated very carefully 
for further interpretation. We still include them for comparison with previous 
studies that looked at individual time points only. Third, the exclusion of patients 
with aphasia, pre-stroke dementia, and co-morbid (neurological) conditions (e.g. 
Parkinson’s disease, epilepsy, substance abuse) resulted in a less representative 
stroke sample. Lastly, patients with depressive or apathetic symptoms at an 
early stage might have been less motivated to participate in the study in the first 
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place, which could have resulted in an underestimation of depression and apathy 
symptoms in our cohort, as the prevalence of PSA and PSD at baseline in our cohort 
were lower than the pooled estimated prevalences in previous meta-analyses.1,2 In 
addition, patients with a severe stroke might be underrepresented in our sample, 
as is common in these kind of studies. This might have resulted in lower levels of 
PSA and PSD in our sample as well, although a previous study showed a similar 
frequency of PSD in minor stroke.48
CONCLUSIONS
Personality traits are associated with the development and sustainability of PSD or 
PSA. The traits associated with PSD and PSA were different, providing support for 
the independence of these constructs. The findings highlight the importance to 
take personality traits into account as a potential vulnerability factor for PSD and 
PSA. 
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SUPPLEMENTAL DATA
Stroke patients	
(n = 1259)	 Not eligible	(n = 576)	
Exclusion criteria
(n = 412)
Deceased
(n = 150)
 Recurrent stroke 
before T0
(n = 2)
In poor health
(n = 12)
Considered for 
inclusion	
(n = 683)	
Eligible for 
inclusion	
(n = 619)	
No permission from 
 treating physician (n = 22)
Unreachable (n = 42)
Included (T0) 
 (n = 241)
T1
(n = 211, 87.2%)
T2
(n = 217, 89.7%)
Declined (n = 369)
No NEO-FFI (n = 9)
First-ever stroke (n = 225)
Recurrent stroke (n = 16)
Declined (n = 15)
Deceased (n = 1)
Not tested due to overlap with other 
study (n = 15)
Declined  (n = 10)
Deceased (n = 2) 
Supplementary Figure 1. Flowchart of inclusion process
Eighteen patients who did not participate at T1, agreed to participate at T2. T0 indicates baseline 
measurement 3 months post stroke; T1, follow-up 9 months post-stroke; T2, follow-up 15 months post-
stroke. 
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Supplementary Table 1. Baseline characteristics for total sample, and separate for patients who 
completed all measurements and patients who dropped out at 1 or 2 time points
Variable
All patients T0
(n = 241)
Complete follow-up 
(n = 219) 
Dropouts 
(n = 22)
Age in years (SD) 67.31 (11.78) 66.99 (11.56) 70.47 (13.71)
Male sex, n (%) 158 (65.6) 145 (66.2) 13 (59.1)
Low education, n (%)
Middle education, n (%)
High education, n (%)
97 (40.4)
84 (35.0)
59 (24.6)
86 (39.3)
78 (35.6)
55 (25.1)
11 (52.4)
6 (28.6)
4 (19.1)
Time since stroke (months) 2.93 (0.45) 2.92 (0.43) 3.07 (0.61)
First-ever stroke, n (%) 225 (93.4) 204 (93.2) 21 (95.5)
Barthel score (SD) 19.44 (1.49) 19.46 (1.48) 19.32 (1.55)
Personality score (SD)
   Neuroticism 31.60 (4.89) 31.63 (4.94) 31.27 (4.50)
   Agreeableness 36.54 (4.60) 36.56 (4.55) 36.36 (5.13)
   Openness 36.85 (4.10) 36.87 (4.14) 36.68 (3.75)
   Extraversion 38.25 (4.19) 38.29 (4.23) 37.82 (3.82)
   Conscientiousness 39.63 (3.75) 39.67 (3.80) 39.18 (3.23)
History of depression, n (%) 55 (22.8) 49 (22.4) 6 (27.3)
Family history of depression, n (%) 34 (14.2) 33 (15.1) 1 (4.8)
MADRS score T0 (SD) 6.06 (5.84) 6.26 (5.92) 4.18 (4.73)
AES-C score T0 (SD) 26.41 (7.86) 26.47 (8.02) 25.73 (6.14)
MINI minor / major depression, n (%)
   MDD, n (%)
   MIND, n (%)
26 (10.8)
13 (5.4)
13 (5.4)
25 (11.4)
12 (5.5)
13. (5.9)
1 (4.6)
1 (4.6)
0 (0.0)
PSA, n (%) 24 (10.0) 24 (10.0) 0 (0.0)
Abbreviations: AES-C, Apathy Evaluation Scale Clinician-rated; MADRS, Montgomery-Åsberg 
Depression Rating Scale; MDD, major depressive disorder; MIND, minor depression; MINI, Mini 
International Neuropsychiatric Interview; PSA, post-stroke apathy; T0, baseline measurement 3 months 
post-stroke. a p < 0.05, b p < 0.01.
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ABSTRACT
Background: It has been suggested that the development of post-stroke 
depression (PSD) and post-stroke apathy (PSA) may be more associated with 
generalized brain pathology, rather than with the stroke lesion itself. The 
present study aimed to investigate associations between imaging markers 
of lesion-related and generalized brain pathology and the development of 
PSD and PSA during a one-year follow-up.
Methods: In a prospective cohort study, 188 stroke patients received 3-Tesla 
MRI at baseline (three months post-stroke) for volumetric and visual rating 
of lesion-related, vascular, and degenerative brain pathology. Presence 
of lacunes, microbleeds, white matter hyperintensities, and enlarged 
perivascular spaces was summed to provide a measure of total cerebral 
small vessel disease (cSVD) burden. The Mini International Neuropsychiatric 
Interview and Apathy Evaluation Scale were administered at baseline and 
repeated at 6- and 12-month follow-up to define presence of PSD and PSA, 
respectively. 
Results: Population-averaged logistic regression models showed that 
global brain atrophy (ORGEE 5.33, 95% CI 1.99-14.25) and severe burden 
of cSVD (ORGEE 3.04, 95% CI 1.20-7.69) were significantly associated with 
the odds of developing PSA, independent of stroke lesion volume and 
co-morbid PSD. Medium cSVD burden (ORGEE 2.92, 95% CI 1.09-7.78) was 
significantly associated with the odds of developing PSD, independent of 
stroke lesion volume, co-morbid PSA, and pre-stroke history of depression. 
No associations were found with lesion-related imaging markers.
Conclusions: The results suggest that generalized degenerative and vascular 
brain pathology, rather than lesion-related pathology, is an important 
predictor for the development of PSA, and less strongly for PSD. 
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INTRODUCTION
Post-stroke depression (PSD) and post-stroke apathy (PSA) are frequent 
neuropsychiatric consequences of stroke, with estimated mean prevalences 
around 30% based on previous meta-analyses.1,2 Both PSD and PSA are known to 
be associated with poor clinical outcome.2,3 Though there is substantial overlap in 
symptoms,4-6 these syndromes seem to develop from different anatomical bases. 
Earlier studies suggested that PSD is associated with left anterior lesions,7,8 and 
PSA with right hemispheric subcortical lesions.9,10 However, meta-analytic studies 
did not show strong support for differential lesion locations associated with PSD 
and PSA.11-13 Recently, studies have focused on damage to neuronal networks 
being involved in the development of PSD and PSA,14-16 with evidence for different 
subcircuits associated with PSD17 and PSA.18 As damage to these networks can 
arise from both stroke lesion-related and more generalized brain damage, a broad 
range of imaging markers may be involved in the development of PSD and PSA. 
Apathy and depression are prevalent in patients with cerebral small vessel disease 
(cSVD),19-24 a condition that is radiologically characterized by extensive white matter 
hyperintensities (WMH), lacunes, enlarged perivascular spaces, and cerebral 
microbleeds (CMBs). In addition to the contribution of individual cSVD markers, 
the role of cumulative or total cSVD burden may be of interest, as a recent cross-
sectional study showed that increased total burden of cSVD markers on magnetic 
resonance imaging (MRI) was associated with PSD in lacunar stroke patients three 
months post-stroke.23 Next to cSVD imaging markers, previous studies have shown 
that atrophy might play a role in the development of PSD and PSA. PSD has been 
associated with visually rated (sub)cortical atrophy25 and frontal lobe atrophy.26 
PSA has been associated with visually rated frontal cortical atrophy27 and with 
volume reductions in the posterior cingulate cortex over the first six months post-
stroke.28 Studies using a volumetric measure of brain atrophy to study associations 
with PSD or PSA28 are relatively scarce and the role of (generalized and focal) 
brain atrophy in the development of these neuropsychiatric syndromes remains 
therefore poorly understood. 
More insight in the underlying pathophysiology of PSD and PSA is important, 
as it may help to design better treatment strategies and prevention of these 
syndromes. In the present study, we aimed to investigate the association between 
stroke-related imaging markers and more generalized degenerative and vascular 
brain pathology and the development of PSD and PSA during a one-year follow-
up period.
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METHODS
PARTICIPANTS AND PROCEDURE
This is a substudy of the Cognition and Affect after Stroke, a Prospective Evaluation 
of Risks (CASPER) study, a prospective clinical stroke cohort study that aims to 
examine predictors of cognitive impairment, apathy, and depression. The study 
was approved by the Medical Ethics Committee of Maastricht University Medical 
Center (MUMC+). Patients admitted to the Stroke Unit or out-patient clinic of 
MUMC+ or Zuyderland Hospital, the Netherlands, for a non-fatal ischemic or 
hemorrhagic stroke were approached for participation between June 2013 and 
November 2015. Patients were included after informed consent. Details of the 
study protocol have been published elsewhere.29
At baseline, neuropsychiatric questionnaires were administered by a trained 
research psychologist and socio-demographic information was recorded. A 
subset (n = 189) received 3-Tesla (3T) structural brain MRI. To avoid interference 
with acute care and rehabilitation, these baseline measurements were scheduled 
approximately three months after stroke onset (T0). At 6-month (T1) and 12-month 
(T2) follow-up, neuropsychiatric assessments were repeated. 
CLINICAL MEASURES
Patients were classified as having PSD if they fulfilled criteria for Major Depressive 
Disorder (MDD) or minor depression (MIND) on the Mini International 
Neuropsychiatric Interview30 on at least one assessment during the one-year 
follow-up period. PSA was defined as a score ≥ 376 on either the clinician-rated 
Apathy Evaluation Scale (AES-C) or informant-rated AES (AES-I)31 on at least one 
assessment during the one-year follow-up period. The Barthel Index was used as 
a global measure of impairment in activities of daily living.32
MAGNETIC RESONANCE IMAGING
Patients who were capable underwent a 3T structural brain MRI at T0 (Philips 
Achieva, Philips Medical Systems, Best, the Netherlands). The MR protocol 
consisted of axial T1-weighted, T2-weighted, fluid-attenuation inversion recovery 
(FLAIR), diffusion weighted, and susceptibility weighted sequences (for details see 
Douven et al.29).
Volumetric imaging markers. Freesurfer software33 was used to segment cortical gray 
and white matter on T1-weighted scans. WMH volume was segmented automatically 
on FLAIR images according to an automatic brain tissue segmentation method 
for WMH segmentation34 and a T1-weighted sequence was used for anatomical 
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reference. A manual correction was performed by two trained researchers (ED and 
DH), under supervision of an experienced neurologist (JS) (Supplementary Figure 
1A). WMH volume was normalized to the intracranial volume (ICV) and a natural log 
transformation was applied to normalize the data distribution.
Symptomatic and old stroke lesions and lacunes were indicated by an experienced 
neurologist (JS) and segmented manually (Supplementary Figure 1B). Stroke lesion 
volume was normalized to ICV and divided into tertiles (i.e. small, medium, and 
large lesion volumes). Stroke patients without a visible symptomatic lesion on MRI 
were classified into the small stroke volume group. The ratio of brain parenchymal 
volume to total ICV was used to measure whole brain volume. Global brain atrophy 
(GA) was calculated as 1 minus brain volume, and multiplied by 10 to ease the 
interpretation of odds ratios. Hippocampal volume (HCV) was obtained using the 
Learning Embeddings for Atlas Propagation (LEAP) method of Wolz et al.35 HCV 
was normalized by dividing the native space volume by the affine scaling factor, 
which was derived from LEAP as well.36 Scores were divided by one thousand to 
ease interpretation of odds ratios. 
Visual imaging markers. Stroke location, laterality, and lesion type (i.e. cortical/
non-lacunar, lacunar, infratentorial), presence of lacunes and other old infarcts, 
presence of CMBs, medial temporal lobe atrophy (MTA),37 presence of extensive 
WMH according to the Fazekas scale,38 and enlarged perivascular spaces in basal 
ganglia were visually rated by an experienced neurologist (JS) (for details see Data 
Supplement 1). 
A well-validated scale for total cSVD burden on MRI was used, which is based 
on counting the presence of lacunes, CMBs, perivascular spaces and extensive 
WMH.39 It should be noted that, as in contrast with the originally developed ordinal 
cSVD scale, we used susceptibility weighted imaging (SWI) for counting CMBs. 
cSVD burden scores were recoded into three categories representing low (score 
0-1), medium (score 2), and severe (score 3-4) burden.
STATISTICAL ANALYSES
All statistical analyses were performed with Stata version 13.1 (StataCorp, TX, 
USA). Statistical significance was set at 0.05 (two-sided tests). Baseline differences 
between groups were tested using χ2 tests and t-tests, as appropriate. Associations 
with imaging markers were corrected for age, sex, and highest level of education in 
logistic regression models. 
A generalized estimating equation (GEE) for the binomial family with a logit-link 
function (population-averaged logistic model) was used to evaluate the effect of 
individual baseline imaging markers on the odds of PSD and PSA at any time point. 
Chapter 6 Imaging markers of PSD and PSA 
6
146
This yielded marginal odds ratios (ORGEE) and 95% confidence intervals (95% CI). 
Each imaging marker was tested separately in model 1, which was corrected for age, 
sex, highest level of education (low, middle, high), and time (T0, T1, T2). The latter 
was included to increase model efficiency by making maximum use of all available 
data and averaging effects over all three time points. For the tests with PSD as 
outcome, history of depression was additionally added to model 1 in a second step. 
In the next model, individual imaging predictors with a p-value < .10 in the previous 
model were added to the multivariable model, which was corrected for stroke 
volume in addition to the previous covariates. Lastly, the model was repeated with 
variables with a p-value < .10, and models with PSD as outcome were additionally 
corrected for PSA, and vice versa, to control for overlap in symptomatology. 
RESULTS
Of the 250 included stroke patients, brain 3T MRI at baseline was available for 189 
patients. One patient was excluded from the analyses because responses given on 
questionnaires were considered unreliable, resulting in a total of 188 patients. Of 
them, only 168 patients had volumetric imaging data available (17 patients were 
scanned for clinical purposes according to a different scanning protocol; in three 
patients there were technical problems during image processing). CMBs were 
counted on SWI, which were only available for 147 stroke patients. Patients excluded 
for the present study (n = 62) were significantly older, more frequently female, more 
likely to be low educated, and had a lower Barthel Index score compared with 
patients who were included in the present study (n = 188) (Supplementary Table 
1). No difference was found in frequency of PSA or PSD between the groups at 
T0. Of the 188 patients at baseline, 165 (87.8%) patients completed T1 and 172 
(91.5%) patients completed T2 (Supplementary Figure 2). No difference was found 
in frequency of PSA or PSD at T0 between patients lost to follow-up at one or two 
time points (n = 14) and patients who completed all measurements (n = 174) 
(Supplementary Table 2). 
Table 1 shows the baseline characteristics of the total sample, and also separate by 
PSD and PSA status at baseline. Compared with the no-PSA group, patients with 
PSA had a higher WMH volume, more GA, and a higher frequency of severe cSVD 
burden. However, these associations were not significant anymore after correction 
for age, sex, and highest level of education. No differences were found between 
patients with and without PSD at T0. 
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Table 1. Patient characteristics of the total sample and by PSD and PSA status at baseline
Variables
Total sample 
(n = 188)
No PSD
(n = 168)
PSD
(n = 20)
No PSA
 (n = 157)
PSA
(n = 31)
Age in years, mean (SD) 65.4 (11.1) 65.5 (10.9) 64.7 (12.8) 64.2 (11.0) 71.5 (9.7)b
Male sex, n (%) 133 (70.7) 123 (73.2) 10 (50.0)b 109 (69.4) 24 (77.4)
Education, n (%)
   Low education
   Middle education
   High education
68 (36.4) 
70 (37.4)
49 (26.2)
61 (36.5)
59 (35.3)
47 (28.1)
7 (35.0)
11 (55.0)
2 (10.0)
54 (34.6)
57 (36.5)
45 (28.9)
14 (45.2)
13 (41.9)
4 (12.9)
Barthel Index, mean (SD) 19.7 (0.9) 19.7 (0.9) 19.7 (0.8) 19.7 (0.9) 19.7 (0.8)
History of depression, n (%) 40 (21.3) 30 (17.9) 10 (50.0)b 32 (20.4) 8 (25.8)
Lesion characteristics*
Ischemic stroke, n (%) 176 (93.6) 157 (93.5) 19 (95.0) 147 (93.6) 29 (93.6)
Left-sided lesion (n = 177), n (%) 80 (45.2) 74 (47.1) 6 (30.0) 66 (44.6) 14 (48.3)
Frontal lesion (n = 122), n (%) 41 (33.6) 39 (35.8) 2 (15.4) 35 (34.3) 6 (30.0)
Basal ganglia lesion (n = 138), n (%) 7 (5.1) 5 (4.1) 2 (13.3) 5 (4.3) 2 (9.1)
Stroke lesion volume (n = 168), n (%)
   Small
   Medium 
   Large
56 (33.3)
56 (33.3)
56 (33.3)
50 (33.6)
52 (34.9)
47 (31.5)
6 (31.6)
4 (21.1)
9 (47.4)
47 (33.3)
50 (35.5)
44 (31.2)
9 (33.3)
6  (22.2)
12 (44.4)
Stroke type, (n = 174), n (%)
   Cortical/non-lacunar
   Lacunar
   Infratentorial
99 (56.9)
54 (31.0)
21 (12.1)
87 (56.1)
49 (31.6)
19 (12.3)
12 (63.2)
5 (26.3)
2 (10.5)
81 (55.9)
46 (31.7)
18 (12.4)
18 (62.1)
8 (27.6)
3 (10.3)
Background damage on MRI*
Lacunes and other old infarcts, n (%) 75 (39.9) 66 (39.3) 9 (45.0) 59 (37.6) 16 (51.6)
Cerebral microbleeds, n (%) (n = 147) 86 (58.5) 77 (59.7) 9 (50.0) 70 (56.5) 16 (69.6)
ePVS in basal ganglia, n (%) n = 187) 105 (56.2) 94 (56.3) 11 (55.0) 85 (54.5) 20 (64.5)
Abnormal MTA left, n (%) (n = 170) 27 (15.9) 25 (16.6) 2 (10.5) 22 (15.5) 5 (17.9)
Abnormal MTA right, n (%) (n = 170) 36 (21.2) 32 (21.2) 4 (21.1) 29 (20.4) 7 (25.0)
WMH volume (% ICV) (n = 168) 0.65 (0.97) 0.64 (0.95) 0.74 (1.11) 0.56 (0.91) 1.09 (1.15)
GA (% ICV) (n = 168) 0.33 (0.04) 0.33 (0.04) 0.34 (0.04) 0.33 (0.04) 0.35 (0.04)a
HCV left (mm3), mean (SD) (n = 168)
2752.7 
(325.8)
2746.2 
(328.2)
2803.9 
(310.0)
2763.7 
(338.6)
2695.2 
(245.3)
HCV right (mm3), mean (SD) (n = 168)
2809.6 
(366.6)
2811.9 
(359.7)
2791.7 
(426.9)
2840.8 
(371.0) 
2647.1 
(298.4)a
cSVD burden category (n = 147)
   0-1 72 (49.0) 65 (50.4) 7 (38.9) 65 (52.4) 7 (30.4)
   2 40 (27.2) 35 (27.1) 5 (27.8) 35 (28.2) 5 (21.7)
   3-4 35 (23.8) 29 (22.5) 6 (33.3) 24 (19.4) 11 (47.8)a
*Imaging markers were corrected for age, sex, and highest level of education. 
Note: Differences were tested between no PSD and PSD, as well as between no PSA and PSA. 
ap < .10, bp < .05
Abbreviations: cSVD, cortical small vessel disease; ePVS, enlarged perivascular spaces; GA, global brain 
atrophy; HCV indicates hippocampal volume; PSA, post-stroke apathy; PSD, post- stroke depression; 
MTA, medial temporal lobe atrophy; WMH, white matter hyperintensities. 
IMAGING MARKERS ASSOCIATED WITH PSD IN THE FIRST YEAR AFTER STROKE
PSD was present in 20 patients (10.6%) at T0, 22 patients (13.3%) at T1, and 22 
patients (12.8%) at T2. Table 2 provides an overview of the results of the models with 
PSD as outcome. There was a significant association between GA and the marginal 
odds of developing PSD during the one-year follow-up period after adjusting for 
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age, sex, and highest level of education (ORGEE 2.82, 95% CI 1.07-7.44). As there 
was a significant difference in frequency of history of depression between patients 
with and without PSD, we tested whether history of depression was a significant 
covariate. History of depression was significantly associated with the marginal odds 
of developing PSD (ORGEE 4.14, 95% CI 1.98-8.66), and therefore we corrected 
for this in the second step. The results showed that the association with GA was 
no longer significant after correction (ORGEE 2.20, 95% CI 0.80-6.07). Medium, but 
not severe, total cSVD burden was significantly associated with the marginal odds 
of developing PSD during the one-year follow-up (ORGEE 2.42, 95% CI 1.01-5.80), 
also after additional correction for history of depression (ORGEE 3.11, 95% CI 1.24-
7.79). In the multivariable model, which was also corrected for stroke lesion volume, 
the association for medium total cSVD (ORGEE 3.31, 95% CI 1.16-9.46), but not GA 
(ORGEE 2.20, 95% CI 0.80-6.07), remained significantly associated with PSA. After we 
controlled in a final step for comorbid PSA, medium total cSVD burden remained 
significantly associated with the odds of developing PSD (ORGEE 2.92, 95% CI 1.09-
7.78). The inclusion of cognitive impairment and presence of old infarcts as covariates 
(Supplementary Table 3) or the exclusion of hemorrhagic strokes (Supplementary 
Table 4) in a sensitivity analysis did not substantively change the results.
IMAGING MARKERS ASSOCIATED WITH PSA IN THE FIRST YEAR AFTER STROKE
PSA was present in 31 patients (16.5%) at T0, 40 patients (24.2%) at T1, and 37 
patients (21.5%) at T2. Table 3 provides an overview of the results of the marginal 
logistic models with PSA as outcome. There was a significant association between 
GA and the odds of developing PSA during the one-year follow-up period after 
adjusting for age, sex, and highest level of education (ORGEE 5.92, 95% CI 2.36-
14.86). In addition, severe cSVD burden was significantly associated with the odds 
of developing PSA during the one-year follow-up period (ORGEE 2.92, 95% CI  1.28-
6.67). In the multivariable model, which was also corrected for stroke lesion volume, 
the association for GA (ORGEE 6.51, 95% CI 2.54-16.73), and severe cSVD burden 
(ORGEE 3.36, 95% CI 1.05-10.72), were significantly associated with PSA. After we 
controlled in a final step for comorbid PSD, both GA (ORGEE 5.33, 95% CI 1.99-14.25) 
and severe cSVD burden (ORGEE 3.61, 95% CI 1.34-9.68) remained significantly 
associated with the odds of developing PSA. The inclusion of cognitive impairment 
and presence of old infarcts as covariates (Supplementary Table 3) in a sensitivity 
analysis did not substantively change the results. When hemorrhagic strokes (n = 12) 
were excluded from the analysis the same results were found, but in addition also 
large stroke lesion volume was significantly associated with the odds of developing 
PSA (ORGEE 2.48, 95% CI 1.05-5.88) (Supplementary Table 4).
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DISCUSSION
The present study aimed to investigate the association between stroke lesion-
related, general vascular, and neurodegenerative imaging markers assessed at 
three months post-stroke and the development of PSD and PSA during a one-
year follow-up. In adjusted models, patients with more GA or higher total burden 
of cSVD at baseline had elevated odds for the presence of PSA, independent of 
stroke lesion volume and co-morbid PSD. Patients with more GA or medium cSVD 
burden showed elevated odds for the presence of PSD after adjusting for relevant 
confounders. Further analyses suggested that the association of PSD with global 
brain atrophy was however due to co-morbid PSA, as only medium cSVD burden 
remained significantly related to PSD after correction for co-morbid PSA and 
stroke lesion volume. No associations were found between PSD/PSA and lesion-
related imaging markers (i.e. location, type, or stroke lesion volume). 
Our findings suggest that GA and total cSVD burden are important predictors of 
PSA. These findings were independent from co-morbid PSD and not mediated 
by cognitive impairment or history of stroke, as the inclusion of these covariates 
in the analysis did not change the results substantively. Our findings are 
supported by different studies in stroke as well as general population studies. In 
two longitudinal stroke studies with 6-month follow-up, frontal cortical atrophy27 
and atrophic change in the dorsal posterior cingulate cortex28 were associated 
with PSA. However, these studies used a visual rating scale for atrophy27 or had 
a small sample size.28 In patients with symptomatic atherosclerotic disease, an 
association was found between greater cortical volume loss and anhedonia.40 This 
is of interest, as anhedonia is a core symptom of depression,41 which overlaps 
with the symptomatology of apathy. In a large population-based study of healthy 
older adults without dementia, apathy symptoms were associated with a reduction 
of gray and white matter volume.42 Noteworthy, these associations were found 
to be independent of depression. Previous studies have indicated that GA is 
not necessarily of degenerative origin, but is often found to be associated with 
cSVD.43 However, in contrast with the other cSVD markers included in the total 
cSVD burden score, atrophy is not specifically due to cSVD, as it may also occur in 
other conditions and is part of normal aging.39 Therefore, GA was not considered 
as a marker of cSVD burden here. 
Severe cSVD burden was associated with PSA, while medium cSVD burden was 
associated with PSD. A possible explanation for these findings could be that 
particularly in patients with severe cSVD burden PSD overlaps largely with PSA, as 
without correction for co-morbid PSA and stroke volume the association between 
PSD and severe cSVD almost reached significance. A previous cross-sectional study 
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found that greater total cSVD burden was associated with the presence of PSD at 
three months after acute lacunar stroke.23 Though associations between individual 
MRI markers of cSVD and apathy have been found before,19,22,44 this is the first 
study that found an important role of total cSVD burden in the development of 
PSA, suggesting that a global or cumulative brain burden is more important in the 
development of these neuropsychiatric syndromes than the presence or location 
of single symptomatic lesions in stroke patients. Interestingly, these findings are 
in line with the suggestion that cumulative brain pathology, rather than lesion 
location or size, plays an important role in the development of PSA and PSD,14-16 
by damaging microstructural networks that are involved in the regulation of mood 
and motivational processes. 
The present study has several important strengths. First, a broad range of imaging 
markers were assessed in relation to PSD and PSA, including both lesion-related 
markers and markers of background vascular and degenerative pathology, by 
using both visual and volumetric ratings. Other strengths are the longitudinal 
design and the minimal loss to follow-up. Presence of PSD and PSA was 
determined by validated measurement instruments and assessed at several time-
points, enabling us to evaluate predictive associations. However, some limitations 
should be addressed. In a quarter of patients, no visible symptomatic stroke lesion 
was present on MRI. This limited the possibility to look at associations with specific 
lesion locations. In addition, by including the time variable in the marginal logistic 
GEE models, the models are based on the assumption that associations remain 
stable over time, irrespective of whether PSD or PSA was measured at the first, 
second, or third measurement. Therefore, we can only conclude that we found 
associations with the development of PSD or PSA over the one-year follow-up 
period, but cannot tell whether these associations were stronger for a certain 
time point. This could have been studied by looking at the interaction with time, 
but the small incidences of PSD and PSA in our sample resulted in lack of power 
for these analyses. Also, the exclusion of patients with severe aphasia and other 
neurological or psychiatric conditions makes the sample less representative for a 
general stroke population. 
In conclusion, GA and severe cSVD burden, rather than lesion-related markers, 
were associated with the development of PSA, independent of PSD. Only medium 
cSVD burden was associated with the development of PSD, independent of PSA 
and pre-stroke history of depression. Large stroke cohort studies with long-term 
follow-up and repeated neuroimaging over time are needed to establish how 
generalized degenerative and vascular brain pathology, and changes therein, are 
involved in the development of PSD and PSA. 
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SUPPLEMENTAL DATA
Data Supplement 1. Visual rating of imaging markers.
Visual rating of symptomatic (acute) and asymptomatic (old) stroke lesions 
(laterality, type, and number) was performed on T2/FLAIR by an experienced 
neurologist (JS), who was blinded to the outcome measures. 
Lesion type classification. Lesions were classified into cortical / non-lacunar, 
lacunar and infratentorial lesion type. Cortical / non-lacunar lesions were defined 
as a lesion involving cortical ± adjacent subcortical tissue, or large striatocapsular 
or subcortical lesions > 20 mm diameter.1 Lacunar lesions were defined as 
rounded or ovoid lesions, > 3 mm but < 20 mm diameter, located in the internal 
or external capsule, nucleus lentiformis, nucleus caudatus, centrum semiovale 
/ white matter, thalamus, or brainstem and carefully distinguished from WMH.2 
Infratentorial lesions were defined as lesions in the cerebellum or lesions in the 
brain stem of non-lacunar origin. If no symptomatic lesion was visible on MRI 
that corresponded with the presenting symptoms, lesion type and laterality were 
based on the presentation of clinical stroke symptoms if possible. 
Visual rating of cerebral microbleeds (CMBs) and lacunes. Presence of CMBs was 
rated visually by two experienced neurologists (JS and RvO). CMBs were defined 
as small (< 5 mm diameter) homogeneous, round foci of low signal intensity on 
susceptibility weighted imaging, differentiated from vessel flow voids.3 Presence 
of CMBs was dichotomized in present (if at least one CMB was present) and 
absent. The interrater Kappa for presence of CMBs was 0.60. The presence of 
silent lacunes was defined as asymptomatic lacunar lesions < 20 mm.
Visual rating of medial temporal lobe atrophy (MTA). MTA4 was rated visually on 
T1-weighted images by two independent raters (E.D. and S.S.). with scores ranging 
from no atrophy (0) to maximum atrophy (4). Right and left hemispheres were 
rated separately, and the average score of the two independent raters was used. 
Based on two recent studies that studied practical cut-offs for visual rating scales 
of atrophy,5,6 the following MTA cut-off scores were applied for abnormal atrophy: 
for patients younger than 75 years an MTA score ≥1.5 and for patients aged 75 
years or older an MTA score ≥2. The inter-rater agreement for the MTA scale was 
moderate to substantial (weighted Kappa7 left MTA: 0.59, right MTA: 0.69). 
Total cerebral small vessel disease (cSVD) burden. One point was assigned for a 
periventricular WMH score of 3 and/or a deep WMH score of at least 2. One point 
was assigned for presence of enlarged perivascular spaces in the basal ganglia, 
if these were rated as moderate or extensive (≥ 10). One point was assigned for 
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presence of ≥1 silent lacunes and ≥1 CMBs). This resulted in a total cSVD burden 
score ranging from 0 to 4, which was recoded into three categories representing 
low (score 0-1), medium (score 2), and severe (score 3-4) cSVD burden.
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Supplementary Table 1. Baseline characteristics for total sample, and separate for patients who were 
included and excluded in the present study
Variables
Total sample  
(n = 250)
Included 
 (n = 188)
Excluded 
 (n = 62)
Age in years, mean (SD) 67.5 (11.8) 65.4 (11.1) 73.9 (11.7)b
Male sex, n (%) 161 (64.4) 133 (70.7) 28 (45.2)b
Education, n (%)
   Low education
   Middle education
   High education
102 (41.1)
87 (35.1)
59 (23.8)
68 (36.4)
70 (37.4)
49 (26.2)
34 (55.7)a
17 (27.9)
10 (16.4)
Time since stroke, mean (SD) 2.9 (0.5) 2.9 (0.5) 3.0 (0.4)
Barthel Index, mean (SD) 19.4 (1.5) 19.7 (0.9) 18.5 (2.4)b
History of depression, n (%) 55 (22.1) 40 (21.3) 15 (24.6)
Family history of depression, n (%) 34 (13.7) 29 (15.4) 5 (8.3)
PSD, n (%) 28 (11.3) 20 (10.6) 8 (13.3)
PSA, n (%) 42 (16.8) 31 (16.5) 11 (17.7)
Abbreviations: PSA, post-stroke apathy; PSD, post-stroke depression.
ap < .05, bp < .01
Supplementary Table 2. Baseline characteristics for total sample, and separate for patients who 
completed all measurements and patients who dropped out at 1 or 2 time points
Variables
Total sample  
(n = 188)
Complete 
follow-up  
(n = 174)
Drop-outs 
 (n = 14)
Age in years, mean (SD) 65.4 (11.1) 65.2 (11.0) 69.1 (12.0)
Male sex, n (%) 133 (70.7) 123 (70.7) 10 (71.4)
Education, n (%)
   Low education
   Middle education
   High education
68 (36.4) 
70 (37.4)
49 (26.2)
60 (34.5)
66 (37.9)
48 (27.6)
8 (61.5)
4 (30.8)
1 (7.7)
Barthel Index, mean (SD) 19.7 (0.9) 19.7 (0.9) 19.6 (0.7)
History of depression, n (%) 40 (21.3) 38 (21.8) 2 (14.3)
Family history of depression, n (%) 29 (15.4) 29 (16.7) 0 (0.0)
PSD, n (%) 20 (10.6) 19 (10.9) 1 (7.1)
PSA, n (%) 31 (16.5) 28 (16.1) 3 (21.4)
Lesion characteristics
Ischemic stroke, n (%) 176 (93.6) 163 (93.7) 13 (92.9)
Left-sided lesion, n (%) 80 (45.2) 75 (45.7) 5 (38.5)
Frontal lesion, n (%) 41 (33.6) 40 (35.4) 1 (11.1)
Basal ganglia lesion, n (%) 7 (5.1) 7 (5.5) 0 (0.0)
Stroke lesion volume, n (%)
   Small
   Medium 
   Large
56 (33.3)
56 (33.3)
56 (33.3)
50 (32.1)
51 (32.7)
55 (35.3)
6 (50.0)
5 (41.7)
1 (8.3)
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Variables
Total sample  
(n = 188)
Complete 
follow-up  
(n = 174)
Drop-outs 
 (n = 14)
Stroke type, n (%)
   Cortical / non-lacunar
   Lacunar
   Infratentorial
99 (56.9)
54 (31.0)
21 (12.1)
94 (58.4)
46 (28.6)
21 (13.0)
5 (38.5)b
8 (61.5)b
0 (0.0)
Background damage on MRI
Lacunes and other old infarcts, n (%) 75 (39.9) 65 (37.4) 10 (71.4)b
Cerebral microbleeds, n (%) 86 (58.5) 80 (58.0) 6 (66.7)
ePVS in basal ganglia, n (%) 105 (56.2) 92 (53.2) 13 (92.9)b
Abnormal MTA left, n (%) 10 (5.9) 8 (5.1) 2 (16.7)
Abnormal MTA right, n (%) 10 (5.9) 8 (5.1) 2 (16.7)
WMH volume (% ICV) 0.65 (0.97) 0.59 (0.92) 1.37 (1.31)a
GA (% ICV) 0.33 (0.04) 0.33 (0.04) 0.35 (0.03)
HCV left (mm3), mean (SD) 2752.7 (325.8) 2747.5 (321.8) 2820.6 (382.7)
HCV right (mm3), mean (SD) 2809.6 (366.6) 2802.2 (365.4) 2906.6 (383.6)a
cSVD burden category, n (%)
    0-1 72 (49.0) 71 (51.5) 1 (11.1)
    2 40 (27.2) 36 (26.1) 4 (44.4)
    3-4 35 (23.8) 31 (22.5) 4 (44.4)
Abbreviations: cSVD, cerebral small vessel disease; ePVS, enlarged perivascular spaces; GA, global 
brain atrophy; HCV, hippocampal volume; PSA, post-stroke apathy; PSD, post-stroke depression; MTA, 
medial temporal lobe atrophy; WMH, white matter hyperintensities.
Note: Differences were tested between patients with complete follow-up and patients with dropout at 
one or two time points. Imaging markers were corrected for age, sex, and highest level of education. 
ap < .10, bp < .05
Supplementary Table 2. continued
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Supplementary Table 3. Odds ratios for the association of imaging markers with post-stroke depression 
and apathy during the 1-year follow-up period in a sensitivity analysis correcting for presence of old 
infarcts and lacunes and cognitive impairment
Parameter
PSD PSA
Model 1a Model 2b
Adj. OR (95% CI) P-value Adj. OR (95% CI) P-value
Lesion characteristics
Stroke lesion volume
   Small
   Medium
   Large
1.00 (reference)
0.96 (0.34, 2.74)
0.52 (0.20, 1.36)
.945
.184
1.00 (reference)
0.59 (0.20, 1.72)
2.03 (0.89, 4.65)
.334
.093
Background damage
Lacunes and other old infarcts 1.04 (0.38, 2.79) .945 0.80 (0.37, 1.75) .578
GA (% ICV) - - 4.76 (1.64, 13.86) .004
cSVD burden category     
   0-1
   2
   3-4
1.00 (reference)
3.04 (1.19, 7.77)
1.58 (0.48, 5.16)
.020
.450
1.00 (reference)
1.08 (0.45, 2.61)
3.90 (1.38, 10.98)
.862
.010
Cognitive impairment 0.72 (0.31, 1.71) .865 1.59 (0.74, 3.37) .232
aAdjusted for age at baseline, sex, highest level of education, history of depression, stroke volume, 
old infarcts or lacunes, cognitive impairment, and post-stroke apathy. bAdjusted for age at baseline, 
sex, highest level of education, stroke volume, old infarcts or lacunes, cognitive impairment, and post-
stroke depression.
Abbreviations: cSVD, cerebral small vessel disease; CI, confidence interval; GA, global brain atrophy; 
ICV, intracranial volume; OR, odds ratio; PSA, post-stroke apathy; PSD, post-stroke depression.
Supplementary Table 4. Odds ratios for the association of imaging markers with post-stroke depression 
and apathy during the 1-year follow-up period in a sensitivity analysis excluding hemorrhagic strokes
Parameter
PSD PSA
Model 1a Model 2b
Adj. OR (95% CI) P-value Adj. OR (95% CI) P-value
Lesion characteristics
Stroke lesion volume
   Small
   Medium
   Large
1.00 (reference)
0.93 (0.33, 2.59)
0.41 (0.16, 1.05)
.884
.065
1.00 (reference)
0.83 (0.28, 2.43)
2.48 (1.05, 5.88)
.733
.039
Background damage
GA (% ICV) - - 5.68 (2.07, 15.60) .001
cSVD burden category     
   0-1
   2
   3-4
1.00 (reference)
3.16 (1.15, 8.70)
1.90 (0.56, 6.41)
.026
.302
1.00 (reference)
1.06 (0.44, 2.53)
3.41 (1.23, 9.47)
.899
.019
aAdjusted for age at baseline, sex, highest level of education, history of depression, stroke volume, and 
post-stroke apathy. bAdjusted for age at baseline, sex, highest level of education, stroke volume, and 
post-stroke depression.
Abbreviations: cSVD, cerebral small vessel disease; CI, confidence interval; GA, global brain atrophy; 
ICV, intracranial volume; OR, odds ratio; PSA, post-stroke apathy; PSD, post-stroke depression.
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Supplementary Figure 1. Fluid-attenuated inversion recovery (FLAIR) images
(A) Example of a FLAIR image showing the segmented white matter hyperintensities. (B) Example of a 
FLAIR image showing the segmented stroke lesion. 
Supplementary Figure 2. Flowchart of inclusion process
Note: Fifteen patients who did not participate at T1, agreed to participate at T2.
Abbreviations: T0 indicates baseline measurement 3 months post-stroke; T1, follow-up 9 months post-
stroke; T2, follow-up 15 months post-stroke. 
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ABSTRACT
Objective: To examine the influence of VCI on the course of post-stroke 
depression (PSD) and post-stroke apathy (PSA).
Methods: We included 250 stroke patients, who underwent 
neuropsychological and neuropsychiatric assessment 3 months after stroke 
(baseline), and at 6- and 12-month follow-up after baseline. Linear mixed 
models tested the influence of VCI in at least 1 cognitive domain (any VCI) 
or multi-domain VCI (VCI in multiple cognitive domains) at baseline, as well 
as domain-specific VCI at baseline on levels of depression and apathy over 
time, with random effects for intercept and slope.
Results: Almost half of the patients showed any VCI at baseline, and any 
VCI was associated with increasing apathy levels from baseline to 12-month 
follow-up. Patients with multi-domain VCI had higher apathy scores at 6- and 
12-month follow-up compared with patients with VCI in a single cognitive 
domain. Domain-specific analyses showed that impaired executive function 
and slowed information processing speed went together with increasing 
apathy levels from baseline to 6- and 12-month follow-up. None of the 
cognitive variables predicted the course of depressive symptoms.
Conclusion: Baseline VCI is associated with increasing apathy levels from 
baseline to the chronic stroke phase, while no association was found between 
baseline VCI and the course of depressive symptoms. Health professionals 
should be aware that apathy might be absent early after stroke, but may 
evolve over time in patients with VCI. 
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INTRODUCTION
Apathy and depression are frequent neuropsychiatric symptoms after stroke, 
with prevalences ranging from 28 to 40%,1,2 and both are associated with poor 
quality of life3,4 and long-term prognosis.5 Cross-sectional studies have indicated 
that vascular cognitive impairment (VCI) is associated with post-stroke depression 
(PSD),6 and according to longitudinal studies VCI also predicts long-term 
depressive symptoms.7-10 VCI is frequent after stroke, ranging from mild cognitive 
impairment to dementia, and is highly age-related with an overall prevalence of 
22% up to 15 years after stroke.11 
Many studies that have examined the association between VCI and PSD were cross-
sectional, and classified cognitive impairment based on a screening instrument for 
global cognition.8,12 Only few studies have assessed different cognitive domains.13,14 
According to a systematic review, including five cross-sectional studies and one 
prospective study with assessments of multiple cognitive domains, impairments in 
the domains executive function, memory, language, and processing speed were 
associated with depression three months post-stroke.15 In a six-month follow-up 
study, patients with visual memory disorders, neglect, and language impairment 
were at risk to develop depressive symptoms.7 One important limitation was that 
these studies did not consider the role of other neuropsychiatric symptoms like 
apathy. 
Post-stroke apathy (PSA) is a disorder of diminished motivation that shows large 
overlap with PSD16 and is associated with more severe cognitive impairment.17,18 
According to a meta-analysis of eight cross-sectional and two prospective studies, 
PSA was associated with lower Mini-Mental State Examination (MMSE)19 scores.1 
Few studies examined the association between PSA and cognitive functioning 
with a more extensive neuropsychological assessment.17,20 
Thus, previous studies indicate that both apathy and depression are associated 
with VCI, but prospective studies with domain-specific information on cognitive 
impairment are scarce. In addition to any VCI, insight into which specific cognitive 
domains are involved might be valuable as well, since domain-specific information 
on cognition has been shown to be a good predictor of other outcomes like long-
term cognitive and functional impairment.21,22 Therefore, the present study aimed 
to unravel the relations between VCI, domain-specific cognitive symptoms, PSD 
and PSA after stroke by examining the influence of any VCI, degree of VCI, and 
domain-specific VCI on the course of PSD and PSA over a period of 12-months.
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METHODS
PATIENT POPULATION
The Cognition and Affect after Stroke: a Prospective Evaluation of Risks (CASPER) 
study is a prospective clinical cohort study examining predictors of VCI, PSD, and 
PSA. The study was approved by the Medical Ethics Committee of Maastricht 
University Medical Center (MUMC+). Ischemic and hemorrhagic stroke patients 
who were admitted to the Stroke Unit of MUMC+ or Zuyderland Medical Center 
(the Netherlands) were approached for participation between June 2013 and 
August 2015. Stroke was defined as a clinical stroke syndrome. Exclusion criteria 
were: no written informed consent, insufficient knowledge of the Dutch language, 
age < 40, too severe aphasia to understand the study procedure, an Informant 
Questionnaire on Cognitive Decline in the Elderly (IQ-CODE) score23 ≥ 3.60, 
MMSE19 score < 15, presence of neurological or psychiatric diseases other than 
depression that are known to affect cognition, pre-stroke dementia, pre-existing 
cognitive impairment, mental retardation, blindness, history of stroke less than 
three years or residual symptoms from previous stroke, and post-surgery stroke 
/ post-anoxic encephalopathy (for details see Douven et al.24). Eligible patients 
were enrolled in the study after they signed informed consent.
At baseline (T0); approximately three months post-stroke to avoid confounding 
effects caused by the acute stroke state), neuropsychological assessment 
and neuropsychiatric questionnaires were administered by a trained research 
(neuro)psychologist to the stroke patients according to a standardized protocol, 
and were repeated at six-month (T1) and 12-month (T2) follow-up. In the 
present study, only baseline data from the neuropsychological assessment were 
considered.
NEUROPSYCHOLOGICAL AND NEUROPSYCHIATRIC ASSESSMENT
The MMSE was administered to assess global cognition. Specific neuropsycho-
logical tests were assessed covering three major cognitive domains, i.e. verbal 
memory, information processing speed, and executive function. The memory 
domain was measured with the Dutch adaptation of the Rey Verbal Learning Test 
(immediate and delayed recall).25 Information processing speed was measured 
with the Trail Making Test (TMT) part A,26 and the Digit Symbol Substitution Test 
(DSST), a subtest of the Wechsler Adult Intelligence Scale-III.27 Executive function 
was measured with the TMT part B (mental flexibility)26 and the one-minute fluency 
test (animals and professions categories).25 Test scores were converted to z-scores, 
adjusted for age, sex, and highest level of education based on available norms.27-30 
Compound scores were calculated for each domain by averaging the z-scores of 
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the tests within this domain. For each cognitive domain, patients were classified 
as no VCI (compound z-score > -1.0) or VCI (compound z-score ≤ -1.0), based on 
International Society for Vascular Behavioural and Cognitive Disorders (VASCOG) 
criteria.31 Patients with an impairment in at least one cognitive domain were 
classified as having any VCI. These patients were further divided in patients with 
an impairment in multiple cognitive domains (multi-domain VCI) and in patients 
with an impairment in only a single cognitive domain (single-domain VCI). 
The Montgomery-Åsberg Depression Rating Scale (MADRS),32 which ranges from 
0 to 60, was used as outcome measure of depressive symptoms, with a higher 
score representing a higher level of depressive symptoms. The MADRS was used 
because it is sensitive to change in symptom severity over time.32 The Apathy 
Evaluation Scale (AES-C) was administered to evaluate the presence and severity 
of apathy.33 Total scores range from 18 to 72, with a higher sum score representing 
a higher degree of apathy symptoms. The clinician-rated version was used as it has 
been rated as the most valid apathy instrument.34 The IQ-CODE was administered 
to the informant of the stroke patient to detect possible pre-stroke dementia, and 
was rated retrospectively (past 5 years prior to the index stroke).23
STATISTICAL ANALYSES
Baseline differences were tested using χ2 tests for qualitative variables and t-tests 
for quantitative variables, or Mann-Whitney U test if variables were not normally 
distributed. The influence of any VCI on the course of depression and apathy was 
assessed using linear mixed random-effects models, which account for the fact that 
repeated measurements are correlated within individuals. The models included a 
random intercept and random slope with an unstructured covariance structure 
as this resulted in the best fit according to likelihood ratio tests. A group (0 = no 
VCI, 1 = any VCI) by time (T0, T1, T2) interaction was added to study differences 
in rate of change between the groups. In a second set of random-effects models, 
we examined whether patients with multi-domain VCI differed from patients with 
single-domain VCI. Next, analyses were performed to assess the influence of 
domain-specific VCI on the course of depression and apathy, using a group (0 = 
normal cognition, 1 = impaired cognition) by time (T0, T1, T2) interaction. The null 
hypothesis of no difference in rate of change over time between the groups was 
tested with a χ2-test of homogeneity (2 degrees of freedom) to see whether there 
is a significant group-by-time interaction. All analyses were corrected for age at 
baseline, sex, and highest level of education. Baseline apathy score was added 
to the model with depression as outcome measure to correct for a possible effect 
of comorbid apathy on depression, and vice versa. All statistical analyses were 
performed with Stata version 13.1 for Mac OS X (StataCorp LP, College Station, TX, 
USA). An alpha level of .05 (two-sided) was used for all analyses. 
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RESULTS
Of the 250 stroke patients initially included at baseline, 4 patients were excluded 
from the analyses (for 3 patients compound z-scores were missing for all three 
cognitive domains and for 1 patient the performance on neuropsychological tests 
was considered unreliable because of mild aphasia). Of the 246 remaining patients, 
212 (86%) patients completed T1. At T2, 13 patients dropped-out (11 refused, two 
had died) and 19 of the patients who did not participate at T1 re-entered at T2, 
resulting in 218 (89%) patients who completed T2 (see Supplementary Figure 1). 
Patients lost to follow-up were older and had any VCI more often than patients who 
completed all measurements (see Supplementary Table 1). 
Patient characteristics of the remaining 246 patients included in the analyses are 
summarized in Table 1, separately for patients with (n = 113) and without any VCI 
(n = 133). Patients with any VCI were significantly less educated, had a lower MMSE 
score, a higher IQ-CODE score, and higher levels of depression and apathy at T0 
compared with patients without VCI (Table 1). The frequencies of patients performing 
normal or impaired on the three cognitive domains and the average z-scores on 
each domain separately are shown in Supplementary Table 2. Compound z-scores 
for memory, information processing speed, and executive function were missing for 
4, 1, and 1 patient(s) at baseline, respectively, as they were cognitively or physically 
incapable to complete the test(s). These patients were not excluded from the whole 
study, but only from the particular domain-specific analysis. 
INFLUENCE OF BASELINE COGNITIVE IMPAIRMENT ON THE COURSE OF DEPRESSION 
The results for change in depression score over time according to baseline cognition 
are shown in Table 2. The overall interaction between cognition group and time was 
not significant in any of the analyses (Table 2). Also, no differences in rate of decline 
of depressive symptoms were observed within individual time intervals (T0 to T1 or 
T0 to T2). 
Any VCI. No significant difference in depression score was found between patients 
with and without any VCI at T0 or at follow-up (Table 2, Figure 1A). Of the patients 
who had available compound z-scores on all three cognitive domains (n = 240), we 
compared patients with single-domain VCI (n = 58) with patients with multi-domain 
VCI (n = 49). No significant difference in depression score was found between the 
two groups at T0 or at follow-up (see Table 2, Supplementary Figure 2). 
Domain-specific. At T0, no significant difference in depression score was found 
between patients with or without impairment in memory (Table 2, Figure 2A), 
information processing speed (Table 2, Figure 2B), or executive function (Table 2, 
Figure 2C). 
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Table 1. Baseline characteristics of the study sample by VCI status
Characteristics
Total sample  
(n = 246)
No VCI
(n = 133)
Any VCI
(n = 113)
p
t / Mann-
Whitney U 
or χ2 (df)
Age in years, mean (SD) 67.6 (11.9) 66.3 (11.4) 69.1(12.2) 0.063 -1.869 (244)
Male sex, n (%) 158 (64.2) 91 (68.4) 67 (59.3) 0.137 2.216 (1)
Education, n (%)
Low education
Middle education
High education
102 (41.5)
86 (35.0)
58 (23.6)
42 (31.6)
52 (39.1)
39 (29.3)
60 (53.1)
34 (30.1)
19 (16.8)
<0.01 12.296 (2)
Time since stroke in months, mean (SD) 2.9 (0.5) 2.9 (0.4) 3.0 (0.5) 0.287 -1.068 (244)
First-ever stroke, n (%) 230 (93.5) 125 (94.0) 105 (92.9) 0.736 0.114 (1)
Ischemic stroke, n (%) 231 (93.9) 128 (96.2) 103 (91.2) 0.096 2.765 (1)
History of depression, n (%) 55 (22.4) 35 (26.3) 20 (17.7) 0.106 2.613 (1)
Family history of depression, n (%) 34 (13.9) 20 (15.2) 14 (12.4) 0.533 0.389 (1)
MADRS, mean (SD) 6.1 (5.8) 5.3 (5.2) 7.0 (6.4) 0.036 -2.100a
AES-C, mean (SD) 26.5 (8.0) 25.3 (7.8) 28.0 (8.0) <0.01 -2.675 (244)
IQ-CODE, mean (SD) 3.2 (0.3) 3.2 (0.2) 3.2 (0.4) 0.047 -1.984a
MMSE, mean (SD) 28.2 (1.7) 28.8 (1.3) 27.4 (1.8) <0.01 6.637a
VCI groups, n (%)
Single-domain VCI
Multi-domain VCI
Impaired memory
Impaired information processing speed
Impaired executive function
58 (24.2)
49 (20.4)
47 (19.4)
78 (31.8)
56 (22.9)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
58 (54.2)
49 (45.8)
47 (43.1)
78 (69.6)
56 (50.0)
n.a.
n.a.
n.a.
n.a.
n.a.
n.a.
n.a.
n.a.
n.a.
n.a.
Abbreviations: AES-C, Apathy Evaluation Scale clinician-rated; IQ-CODE, informant questionnaire 
on cognitive decline in the elderly; MADRS, Montgomery-Åsberg Depression Rating Scale; MMSE, 
Mini-Mental State Examination; T0, baseline assessment 3 months post-stroke; VCI, vascular cognitive 
impairment.
Notes: Missing values: 8 for MADRS, 11 for IQ-CODE, 3 for MMSE, 1 for family history of depression, 
6 for multi-domain VCI, 4 for impaired memory, 1 for impaired information processing speed, 1 for 
impaired executive function.
Univariate analyses were performed with χ2 test for categorical variables and Student’s t test (or Mann 
Whitney U test if applicable) for continuous variables.
a Z-statistic from a Mann-Whitney U Test.
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Figure 1. Effect of any vascular cognitive impairment on the course of depression and apathy 
(A) Course of depression scores by any VCI. (B) Course of apathy scores by any VCI. Based on random-
effects analysis with random intercept, random slope and unstructured correlation matrix, adjusted for 
age at T0, sex, level of education, group, and group by time interaction. Analyses with MADRS score 
as outcome were additionally corrected for AES-C score, and vice versa. Predicted mean scores are 
estimated marginal means for cognition group by time, with all covariates fixed at their means. Error 
bars represent 95% confidence intervals around the predicted means. Higher mean scores indicate a 
higher level of depression and apathy, respectively. AES-C indicates Apathy Evaluation Scale; MADRS, 
Montgomery-Åsberg Depression Rating; VCI, vascular cognitive impairment.
Figure 2. Effect of baseline cognitive performance on the course of depression
(A) Course of depression scores by memory. (B) Course of depression scores by information processing 
speed. (C) Course of depression scores by executive function. Based on random-effects analysis with 
random intercept, random slope and unstructured correlation matrix, adjusted for age at T0, sex, level 
of education, group, and group by time interaction. Analyses were additionally corrected for AES-C 
score. Predicted mean scores are estimated marginal means for cognition group by time, with all 
covariates fixed at their means. Error bars represent 95% confidence intervals around the predicted 
means. Higher mean scores indicate a higher level of depression. 
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INFLUENCE OF BASELINE COGNITIVE PERFORMANCE ON THE COURSE OF APATHY
The results for change in apathy score over time according to baseline cognition 
are shown in Table 2. The overall interaction between cognition group and time 
was not significant in any of the analyses, except for executive function (Table 2). 
In addition, group differences in rate of change between individual time-intervals 
were observed.
Any VCI. At T0, the difference in apathy scores between patients with and without 
any VCI was not significant (Table 2), but became significant at T1 (t(245) = 2.45; p 
= .015) and T2 (t(245) = 3.28; p = .001), with higher apathy levels in patients with 
any VCI (Figure 1B). In line with this, time-stratified analyses showed a significant 
increase in apathy scores from T0 to T2 in patients with any VCI (χ2 = 4.74; df = 1; p 
= .030). No significant difference in apathy score was found between patients with 
multi-domain VCI and single-domain VCI at T0 (Table 2), but this group difference 
became significant at T1 (t(239) = 1.97; p = .049), and at T2 (t(239) = 2.76; p = 
.006), though time-stratified analyses did not reach significance for differences in 
rate of change from T0 to T2 (see Table 2, Supplementary Figure 2).
Figure 3. Effect of baseline cognitive performance on the course of apathy
(A) Course of apathy scores by memory. (B) Course of apathy scores by information processing speed. 
(C) Course of apathy scores by executive function.
Note: Based on random-effects analysis with random intercept, random slope and unstructured 
correlation matrix, adjusted for age at T0, sex, level of education, group, and group by time interaction. 
Analyses were additionally corrected for MADRS score. Predicted mean scores are estimated marginal 
means for cognition group by time, with all covariates fixed at their means. Error bars represent 95% 
confidence intervals around the predicted means. Higher mean scores indicate a higher level of apathy.
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Domain-specific. At T0, no difference in apathy score was found between patients 
with and without impaired memory performance (Figure 3A), and there were 
no significant differences in rate of change over time (Table 2). In contrast, a 
significantly higher apathy score was found in patients with impaired information 
processing speed at T0 (χ2 = 4.57; df = 1; p = .033; Figure 3B, which remained 
significant at T1 (t(244) = 2.46; p = .015) and T2 (t(244) = 3.86; p < .001). Impaired 
information processing speed at baseline was not associated with increasing 
apathy scores from T0 to T2 (χ2 = 3.83; df = 1; p = .0504). No significant difference in 
apathy score was found between patients with and without impaired performance 
on executive function at T0 (Table 2), but patients with impaired performance on 
executive function showed higher apathy levels at T1 (t(244) = 2.08; p = .038) and 
at T2 (t(244) = 3.35; p = .001; Figure 3C). Indeed, the overall interaction between 
executive function and time on apathy scores was significant, and comparison 
of the time-specific slopes suggested that this effect was driven by a significant 
increase in apathy scores from T0 to T2 in patients with impaired executive function 
(Table 2).
DISCUSSION
This study examined the association between baseline VCI and the course of 
PSD and PSA symptoms over time. The results show that the association between 
VCI and course of PSA symptoms varies across time points and with number 
and type of cognitive domains that are affected. Levels of apathy increased over 
time in patients with any VCI, and even more when multiple cognitive domains 
were affected. Change was most pronounced in those with impaired executive 
functioning and impaired information processing speed. None of the cognitive 
variables predicted course of depressive symptoms. 
The observed association between impaired executive functioning and apathy is 
in line with previous findings of Almenkerk et al.,35 who showed that executive 
dysfunction was associated with apathy in the chronic stroke phase. However, the 
present study had a prospective design, showing that apathy scores increased 
from the post-acute to the chronic stroke phase. In addition, the results of the 
present study are supported by a recent study of Roussel et al.36 who reported 
that half of the stroke patients suffered from a dysexecutive syndrome, including 
apathy, according to criteria by Godefroy et al.37 Similar results were also found 
in a recent cross-sectional study with lacunar stroke patients, in which apathy, 
not depression, was associated with impaired executive function and also with 
impaired information processing speed.38 
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In the current study, baseline impairment in information processing speed 
was associated with higher levels of apathy at baseline, which remained stable 
throughout time, which is in line with results from the Sydney Stroke Study,17 who 
also found a significant association between apathy and reduced information 
processing speed after three to six months. However, they did not provide 
results on long-term follow-up. As patients with impaired information processing 
speed already showed higher levels of PSA at baseline, it might be possible that 
symptoms of PSA have a negative effect on information processing speed as well, 
or that apathy and impaired information processing speed are both the result of 
underlying brain pathology, although this had not been examined in earlier studies. 
No association was found between apathy and memory impairment. However, 
in patients with VCI memory is usually less affected compared to impairment in 
frontal functions like slowed processing speed and executive dysfunction,39 and 
apathy is also considered to be strongly related to frontal lobe dysfunction,40 
which might explain the lack of association. 
The present results suggest that (any, multiple, or domain-specific) VCI is not 
associated with the level or course of PSD in the post-acute or chronic stroke 
phase, which is in contrast with some earlier studies.7,9 This discrepancy might 
be explained by the fact that cognitive impairment was determined in the acute 
stroke phase in these studies, and also by differences in measurement instruments 
and criteria for defining cognitive impairment. However, the results of the present 
study are in agreement with a recent longitudinal study of Bour et al.41 that looked 
into the 1-year course of PSD and also indicated that cognitive deficits at baseline 
did not predict the development of PSD in the first year post-stroke, though this 
was only based on the MMSE score. The present results did not show an association 
between level or course of depression and impaired executive function at three 
months post-stroke, which was in contrast with earlier studies that indicated 
that depression and executive function are strongly linked after stroke.13,14 Yet, a 
modest association was found between the course of apathy symptoms over time 
and executive function, so lack of adjustment for comorbid apathy in these earlier 
studies could be one explanation for this discrepancy. 
The results of the present study support the hypothesis that PSA can develop 
as an independent syndrome16 and may be associated with different risk factors 
than PSD, as in the present study VCI was only related to the course of apathy. An 
explanation could be that as apathy is a common behavioral symptom in patients 
with dementia, it might be more directly related to cognitive dysfunction42 than 
depression, which may be more related to an initial psychological and emotional 
response to the stressful event of suffering from a stroke.43 Neuropsychiatric 
symptoms after stroke might develop because patients have insufficient cognitive 
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capabilities to cope with the consequences of the stroke, as a study with brain 
injury patients showed that depression and apathy were associated with different 
coping styles after brain injury.44 VCI might possibly affect coping styles after stroke, 
thereby influencing the development of neuropsychiatric symptoms. Hence, being 
aware of the consequences of VCI in the post-acute and chronic stroke phase, 
when patients are usually not engaged in rehabilitation care anymore, is important, 
because not in the early stroke phase (0-3 months post-stroke) but at a later stage 
(9-15 months), these patients are likely to develop symptoms of PSA. Professional 
caregivers should be aware of this, as PSA can have a negative impact on quality 
of life and clinical outcome after stroke. To get a better understanding of how 
cognitive deficits and neuropsychiatric symptoms affect each other, possibly in a 
bi-directional manner, the influence of apathy (and also depression) at baseline on 
long-term cognitive functioning should be studied in future studies as well. 
Strengths of our study include the longitudinal design with serial assessments 
of cognition, depression, and apathy and with relatively low dropout. We 
used an extensive neuropsychological assessment covering several cognitive 
domains, and validated instruments were used to measure levels of depression 
and apathy. A limitation of the study is the exclusion of patients with aphasia 
and other neurological or psychiatric conditions as this made the study sample 
less representative of the general stroke population. In addition, of the eligible 
patients, a substantial part refused to participate and it is possible that particularly 
these patients may have had depressive or apathetic symptoms, or cognitive 
complaints. Also, the frequency of any VCI was higher in the patients who dropped-
out compared with the patients who completed all assessments. Furthermore, it 
should be noted that there are many reasons for finding an association between 
VCI and PSA, not PSD. This could for example be due to differential reliability of 
the assessments, low prevalence of PSD, or low statistical power. Therefore, the 
results should be interpreted carefully. Lastly, in some cognitive domains the 
impaired group was small in sample size, which could have resulted in lack of 
power in the random-effects models, thereby explaining the fact that we did find 
significant differences at certain time points, but no significant interaction with 
time (except for any VCI and executive function). Thus, the present results showed 
relatively small but significant differences with respect to the course of apathy 
between patients with and without VCI after stroke. Nevertheless, these findings 
are of theoretical interest as they show that the impact of cognitive impairment 
on the development and course of PSA is likely to be different from PSD, which 
emphasizes the importance of distinguishing between symptoms of depression 
and apathy. 
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In conclusion, VCI was associated with increasing levels of apathy in the chronic 
stroke phase, which was strongest for impairments in executive function and 
information processing speed and for patients with impairments in multiple 
cognitive domains. Health professionals should be aware that neuropsychiatric 
symptoms, particularly apathy, might not be present in the early phase but evolve 
over time in patients with VCI. 
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SUPPLEMENTAL DATA
Supplementary Table 1. Baseline characteristics for total sample, and separate for patients who 
completed all measurements and patients who dropped out at 1 or 2 time points
Variables
All patients  
(n = 246)
Complete 
follow-up  
(n = 222)
Dropouts 
 (n = 24)
p
t or χ2 (df)
Age (years, SD) 67.6 (11.9) 67.0 (11.7) 73.0 (12.4) 0.02 -2.383 (244)
Male sex (%) 158 (64.2) 144 (64.9) 14 (58.3) 0.53 0.402 (1)
Education
Low education, n (%)
Middle education, n (%)
High education, n (%)
102 (41.5)
86 (35.0)
58 (23.6)
88 (39.6)
79 (35.6)
55 (24.8)
14 (58.3)
7 (29.2)
3 (12.5)
0.18 3.465 (2)
Time since stroke at T0 (months, SD) 2.9 (0.5) 2.9 (0.5) 3.0 (0.4) 0.91 -0.109 (244)
First-ever stroke, n (%) yes 230 (93.5) 207 (93.2) 23 (95.8) 0.63 0.239 (1)
Lesion type, n (% ischemic stroke) 229 (93.1) 206 (92.8) 23 (95.8) 0.68 0.173 (1)
History of depression, n (%) yes 55 (22.4) 49 (22.1) 6 (25.0) 0.74 0.107 (1)
Family depression history, n (%) yes 34 (13.9) 33 (14.9) 1 (4.4) 0.17 1.929 (1)
IQ-CODE (SD) 3.2 (0.3) 3.2 (0.3) 3.2 (0.4) 0.93 0.084 (233)
MMSE T0 (SD) 28.2 (1.7) 28.2 (1.7) 27.6 (1.6) 0.09 1.683 (241)
Any VCI, n (%) yes 113 (45.9) 97 (43.7) 16 (66.7) 0.03 4.603 (1)
MADRS T0 (SD) 6.1 (5.8) 6.3 (5.9) 4.1 (4.7) 0.09 1.729 (236)
AES-C T0 (SD) 26.5 (8.0) 26.4 (8.0) 27.2 (8.1) 0.65 -0.459 (244)
Abbreviations: AES-C, Apathy Evaluation Scale clinician-rated; IQ-CODE, informant questionnaire 
on cognitive decline in the elderly; MADRS, Montgomery-Åsberg Depression Rating Scale; MMSE, 
Mini-Mental State Examination; T0, baseline assessment 3 months post-stroke; VCI, vascular cognitive 
impairment.
Notes: Missing values: 8 for MADRS, 11 for IQ-CODE, 3 for MMSE, 1 for family history of depression.
Univariate analyses were performed with χ2 test for categorical variables and Student’s t test for 
continuous variables.
Supplementary Table 2. Cognitive functioning at baseline 
Variables Normal performance Impaired performance
Memory
N (%) 195 (80.6) 47 (19.4)
Mean z-score (SD) 0.45 (0.88) -1.66 (0.56)
Information processing speed
N (%) 189 (77.1) 56 (22.9)
Mean z-score (SD) -0.10 (0.57) -1.45 (0.40)
Executive function
N (%) 167 (68.2) 78 (31.8)
Mean z-score, SD -0.05 (0.62) -1.71 (0.55)
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Supplementary Figure 1. Flowchart of inclusion process
Note: Nineteen patients who did not participate at T1, agreed to participate at T2.
Abbreviations: T0, baseline measurement 3 months post stroke; T1, follow-up 9 months post-stroke; 
T2, follow-up 15 months post-stroke. 
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Supplementary Figure 2. Effect of degree of vascular cognitive impairment on the course of depression 
and apathy
Note: Based on random-effects analysis with random intercept, random slope and unstructured 
correlation matrix, adjusted for age at T0, sex, level of education, group, and group by time interaction. 
Analyses with MADRS score as outcome were additionally corrected for AES-C score, and vice versa. 
Predicted mean scores are estimated marginal means for cognition group by time, with all covariates 
fixed at their means. Higher mean scores indicate a higher level of depression and apathy, respectively. 
Abbreviations: AES-C, Apathy Evaluation Scale; MADRS, Montgomery-Åsberg Depression Rating; VCI, 
vascular cognitive impairment.
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ABSTRACT
Background: Post-stroke depression (PSD) is frequent after stroke, and 
heterogeneity in etiological factors is found, which results in differences 
in clinical presentation and prognosis. The co-occurrence of executive 
dysfunction (ED) and PSD might demarcate the depression-executive 
dysfunction syndrome (DES). The present study tested whether executive 
dysfunctions denote a distinct PSD subtype based on neuroimaging 
correlates and prognosis. 
Methods: The present study included 245 stroke patients, who completed 
neuropsychological and neuropsychiatric assessment at 3 months (T0) post-
stroke. A subset (n = 186) received 3-Tesla brain MRI to evaluate lesion-
related imaging markers, white matter hyperintensity (WMH) volume, global 
brain atrophy, and total cerebral small vessel disease (cSVD) burden score. 
Neuropsychological and neuropsychiatric assessments were repeated at 6- 
and 12-month follow-up after initial testing. 
Results: Patients with DES (n = 55) showed higher WMH volumes compared 
to all other groups. Patients with DES also showed more frequently old 
infarcts and higher total cSVD burden compared with PSD-only and patients 
with neither ED nor PSD, and more global brain atrophy compared with 
PSD-only. Longitudinal analyses showed that patients with DES had a more 
chronic course of depressive symptoms relative to the PSD-only group, who 
improved over time. DES patients also showed a non-improving pattern of 
worse cognitive performance, which did not differ significantly from the ED-
only group. 
Conclusions: Patients with DES showed a worse prognosis of depression and 
cognition and a higher amount of vascular and degenerative brain pathology, 
suggesting that it denotes a more severe subtype within the PSD spectrum.
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INTRODUCTION
Post-stroke depression (PSD) occurs in almost a third of stroke survivors,1 with a 
cumulative incidence of 55% over a period of 15 years after stroke.2 Cognitive 
impairment is also frequent after stroke3 and may co-occur with PSD.4 The 
relationship between cognitive impairment and depression appears to be 
complex, as the direction of the association can go both ways, and they share 
common risk factors.5 
It has been suggested that patients who present with both executive dysfunction 
(ED) and late-onset depression (first manifestation of depression after age 60 
or 65 years) show a worse course and clinical presentation, which has been 
called “depression-executive dysfunction syndrome of late life” (DES).6 DES is 
characterized by persistence of depressive symptoms7 and unstable remission.8 
In a longitudinal study with 116 first-ever stroke patients, stroke patients with 
DES showed less recovery from ED and depression after 2 years compared with 
patients with ED only or PSD only, respectively.9 Whether DES after stroke also has 
a distinct course regarding other cognitive domains is unknown. Furthermore, as 
both PSD10 and cognitive impairment11 are known to have a negative impact on 
quality of life (QoL), the co-occurrence of ED and PSD might be associated with an 
even worse course of QoL. 
With respect to underlying brain pathology, it has been suggested that DES is 
related to damage in frontal-subcortical brain circuits,6 which are known to be 
involved in mood regulation and executive function.12 This was confirmed in 
a cross-sectional study of 158 stroke patients13 which showed that frontal and 
subcortical lesions were more frequent in the DES-group. Furthermore, DES may 
be also associated with more widespread brain changes, like higher degree of 
white matter hyperintensities (WMH),14 which are a consequence of cerebral small 
vessel disease (cSVD). Total cSVD burden score15 and generalized brain atrophy16 
both have been shown to be predictors of decline in executive function. However, 
whether these imaging markers also play a role in the demarcation of the DES 
subtype remains to be studied. 
The aim of the present 1-year follow-up study was to examine whether ED denotes 
a distinct subtype of depression after stroke. Our primary aim was to study 
differences regarding lesion-related and general vascular imaging markers as well 
as prognostic markers (i.e. course of depression and executive function) between 
DES, PSD-only, and ED-only groups relative to a comparison group (patients 
without PSD and ED). Secondary, we examined whether DES was associated with 
a different course on other cognitive domains (global cognition, memory, and 
information processing speed) and QoL. 
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METHODS
PATIENT POPULATION
The present study is a sub-study of the Cognition and Affect after Stroke, a 
Prospective Evaluation of Risks (CASPER) study, a prospective clinical stroke cohort 
study, which aims to examine predictors of cognitive impairment, depression, 
and apathy after stroke.17 Patients admitted to the Stroke Unit or out-patient clinic 
of Maastricht University Medical Center (MUMC+), or Zuyderland Hospital, the 
Netherlands for a non-fatal ischemic or hemorrhagic stroke between June 2013 
and November 2015 were approached for participation. The study was approved 
by the Medical Ethics Committee of MUMC+ and patients signed informed consent 
before participation. Exclusion criteria are described in detail elsewhere.17 
PROCEDURE
Appointments for baseline measurements (T0) were scheduled around 3 months 
post-stroke, to avoid interference with acute care and rehabilitation. At T0, patients 
completed neuropsychological assessment and neuropsychiatric questionnaires. 
Socio-demographic information was recorded and patients received 3-Tesla 
(3T) brain Magnetic Resonance Imaging (MRI) if they had no contra-indications 
and were able to visit the hospital. The neuropsychological assessment and 
neuropsychiatric questionnaires were repeated at 6-month (T1) and 12-month 
(T2) follow-up. 
MAGNETIC RESONANCE IMAGING 
At baseline, a 3T structural brain MRI was conducted (Philips Achieva, Philips 
Medical Systems, Best, the Netherlands) The MR protocol consisted of axial T1-
weighted, T2-weighted, fluid-attenuation inversion recovery (FLAIR), diffusion 
weighted, and susceptibility weighted sequences (for details see Douven et al.17). 
Images were anonymized and analyzed blinded for the patient’s neuropsychiatric 
and cognitive status. 
Freesurfer software18 was used to segment cortical gray and white matter on 
T1-weighted scans. WMH volume was segmented on FLAIR images with a semi-
automated segmentation tool for WMH,19 using a T1-weighted sequence for 
anatomical reference and was corrected manually and normalized to intracranial 
volume (ICV). The ratio of brain parenchymal volume to total ICV was used to 
measure global brain atrophy and was calculated as 1 minus brain volume. Stroke 
location, laterality, and presence of old infarcts or lacunes were visually rated 
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by an experienced neurologist (JS). The stroke lesion was segmented manually. 
This volume was normalized to ICV and divided into tertiles (i.e. small, medium, 
large). Total cSVD burden on MRI was based on a well-validated ordinal scale,20 
which is based on the counting of presence of WMH, microbleeds, lacunes, and 
perivascular spaces in the basal ganglia resulting in a total score ranging from 0 to 
4 (details can be found in Data Supplement 1). 
NEUROPSYCHOLOGICAL ASSESSMENT
Executive function was measured with the Trail Making Test (TMT) part B (mental 
flexibility),21 the one-minute fluency test (animals and professions categories),22 and 
the Behavioral Assessment of the Dysexecutive Syndrome (BADS) Zoo Map and 
Key search subtasks.23 The MMSE24 was used to assess global cognition, episodic 
verbal memory (immediate and delayed recall) was measured with the Dutch 
adaptation of the Rey Verbal Learning Test,22 and information processing speed 
was measured with the TMT part A21 and Digit Symbol Substitution Test (DSST).25 
Test scores of the TMT, DSST, verbal fluency test, and Rey Verbal Learning Test 
were converted to z-scores, adjusted for age, sex, and highest level of education 
based on available norms.25-28 Raw scores on the BADS subtasks were converted 
to profile scores ranging from 0 to 4. ED was defined as a z-score on the TMT-B, 
verbal fluency animals, or verbal fluency professions < -1.0, or a BADS Zoo Map or 
Key Search profile score < 1. For each cognitive domain, compound scores were 
created by averaging the available z-scores of the tests within this domain.
QUESTIONNAIRES
Patients fulfilling criteria for major or minor depression on the Mini International 
Neuropsychiatric Interview (M.I.N.I),29 or scoring above the cut-off score ≥ 7 on the 
Montgomery-Åsberg Depression Rating Scale (MADRS),30 were defined as having 
PSD. In addition, the Barthel Index,31 was administered to measure impairment in 
activities of daily living, and the Stroke Specific Quality of Life (SS-QoL) scale was 
used to measure health-related QoL.32
STATISTICAL ANALYSIS
Statistical analyses were performed with Stata version 13.1 for Mac OS X 
(StataCorp, USA). A p-value < 0.05 (two-sided) was defined as statistically 
significant. Patients fulfilling criteria for both ED and PSD were grouped in the 
DES-group. Patients with only ED were grouped in the ED-only group, patients 
with only PSD were grouped in the PSD-only group, and patients with neither ED 
nor PSD were grouped in the None-group, which was the reference group in all 
Chapter 8 Depression-executive dysfunction syndrome post stroke
8
188
analyses. Baseline differences between subgroups were tested using logistic and 
linear regression analyses. For the imaging variables, the regression models were 
corrected for age, sex, and highest level of education. The MADRS score (square 
root transformation), QoL scores, and MMSE scores (logarithmic transformation) 
required data transformations to normalize skewed distributions. Linear mixed 
models were performed to examine whether the course of executive function and 
depression differed over time from baseline to 12-month follow-up between the 
subgroups. A group (4 levels: None, ED-only, PSD-only, DES) by time (3 levels: T0, 
T1, T2) interaction was included to study differences in the course of depression, 
executive function, other cognitive domains, and QoL between the groups. All 
models included a random intercept and a random slope with an unstructured 
correlation matrix was added if this gave the best fit according to likelihood ratio 
tests. The linear mixed models were corrected for age at baseline, sex, and highest 
level of education. 
RESULTS
Of the 250 participants, 246 completed the MADRS or M.I.N.I and the 
neuropsychological assessment, and one patient was excluded because of 
unreliable test results. Of the 245 remaining patients, 211 (86.1%) patients 
completed assessments at T1, and 217 (88.6%) patients completed assessments 
at T2 (Supplementary Figure 1). Patients lost to follow-up at one or two time points 
(n = 25) did not differ from patients who completed all measurements (n = 220) 
(Supplementary Table 1). 
Table 1 shows the baseline characteristics separately for the four groups at T0. 
Of the 245 patients, 55 (22.5%) fulfilled criteria for DES, 38 (15.5%) patients had 
depressive symptoms but no ED (PSD-only), 88 (35.9%) patients showed ED but 
no depressive symptoms (ED-only), and the remaining 64 (26.1%) patients showed 
neither depressive symptoms nor ED (None). 
Differences between the DES group and the other groups with respect to the 
imaging markers are shown in Table 2. Patients with DES had a higher WMH 
volume compared with the None group (F(1,158) = 5.37, p = .022), ED-only group 
(F(1,158) = 5.71, p = .018), and PSD-only group (F(1,158) = 8.67, p =  .004). Also, 
DES patients showed more global brain atrophy compared with the PSD-only 
group (F(1,158) = 6.15, p = .014) and had more frequently old infarcts or lacunes 
compared with the None group (χ2 = 4.22; df = 1 p = .040) and PSD-only group (χ2 
= 5.15; df = 2; p = .040). A higher total cerebral small vessel disease burden score 
was found in the DES group compared with the None group (F(1,137) = 5.57, p = 
.020) and PSD-only group (F(1,137) = 5.80, p = .017).
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Table 1. Baseline characteristics separate for DES subgroup 
Characteristic
None
(n = 64)
ED only 
(n = 88)
PSD only 
(n = 38)
DES 
(n = 55)
Age (in years), mean (SD) 65.9 (11.0) 69.9 (11.4)AC 64.7 (11.3) 67.7 (13.5)
Sex, n (%) male 48 (75.0) 67 (76.1) 15 (39.5)AB 27 (49.1)AB
Low education, n (%)
Middle education, n (%)
High education, n (%)
25 (39.1)
23 (35.9)
16 (25.0)
37 (42.1)
29 (33.0) 
22 (25.0)
13 (34.2)
16 (42.1)
9 (23.7)
26 (47.3) 
18 (32.7)
11 (20.0)
Barthel Index, mean (SD) 19.8 (1.1) 19.4 (1.7) 19.6 (0.9) 18.9 (1.7)ABC
Pre-stroke depression, n (%) yes 12 (18.8) 9 (10.2) 19 (50.0)AB 15 (27.3)BC
Family history of depression, n (%) yes 5 (7.9) 10 (11.4) 10 (26.3)AB 9 (16.4)
Quality of life (SS-QoL) mean (SD) 4.4 (0.6) 4.3 (0.6) 3.8 (0.7)AB 3.4 (0.7)ABC
MMSE score, mean (SD) 28.8 (1.4) 27.8 (1.8)AC 28.8 (1.0) 27.5 (1.8)AC
MADRS, mean (SD) 2.0 (2.0) 2.8 (2.0) 11.6 (5.0)AB 11.7 (5.5)AB
Note:  A p < 0.05 compared with the None group a, B p < 0.05 compared with the ED-only group, C p < 
0.05 compared with the PSD-only group, D p < 0.05 compared with the DES group. 
Abbreviations: DES, depression executive dysfunction syndrome; ED, executive dysfunction; MADRS, 
Montgomery-Åsberg Depression Rating Scale; MMSE, mini-mental state examination; PSD, post-stroke 
depression.
Table 2. Imaging characteristics separate for DES subgroup 
Characteristic
None
(n = 54)
ED only 
(n = 68)
PSD only 
(n = 27)
DES 
(n = 37)
Lesion characteristics
Ischemic stroke, (n (%) 50 (92.6) 63 (92.7) 26 (96.3) 35 (94.6)
Left hemispheric stroke, (n = 175), n (%) 33 (54.1) 48 (57.8) 21 (65.6) 24 (43.6)
Frontal or basal ganglia lesion, (n = 136), n (%) 14 (31.8) 24 (47.1) 4 (28.6) 10 (37.0)
Stroke lesion volume, (n = 166), n (%)
   Small
   Medium
   Large
12 (25.5) 
23 (48.9) 
12 (25.5)
 
19 (32.2) 
19 (32.2) 
21 (35.6)
 
12 (50.0) 
4 (16.7) 
8 (33.3)
 
12 (33.3) 
10 (27.8) 
14 (38.9)
Background damage on MRI
Lacunes and other old infarcts, n (%) 18 (33.3) 29 (42.7) 7 (25.9) 20 (54.1)AC
Cerebral microbleeds, (n = 145), n (%) 24 (58.4) 34 (65.4) 12 (57.1) 15 (48.4)
WMH volume (% ICV) (n = 166), mean (SD) 0.53 (1.03) 0.61 (0.79) 0.31 (0.43) 0.97 (1.17)ABC
Global atrophy (% ICV) (n = 166), mean (SD) 0.33 (0.04) 0.33 (0.04) 0.31 (0.03) 0.34 (0.05)C
cSVD burden ordinal score (0-4), (n = 145), mean (SD) 1.41 (0.97) 1.71 (1.30) 1.33 (0.91) 1.97 (1.45)AC
Note: A p < 0.05 compared with the None group a, B p < 0.05 compared with the ED-only group, C p 
< 0.05 compared with the PSD-only group, D p < 0.05 compared with the DES group. The regression 
models were corrected for age, sex, and highest level of education. 
Abbreviations: cSVD, cerebral small vessel disease; DES, depression executive dysfunction syndrome; 
ED, executive dysfunction; ICV, intracranial volume; PSD, post-stroke depression; WMH, white matter 
hyperintensities.
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Table 3 gives the results for the analyses comparing patients on executive function, 
depression, memory, information processing speed, and QoL.
Table 3. Mean differences (and 95% confidence interval) in baseline depression, cognition, and quality 
of life and in change in depression, cognition, and quality of life (slopes) from baseline between those 
with Depression Executive Dysfunction Syndrome (DES, n = 55), executive dysfunction only (ED-only, 
n = 88), post-stroke depression only (PSD-only, n = 38), and those without depression and executive 
dysfunction at baseline as reference group (n = 64)
Time
Baseline difference
Change baseline to  
6-month FU
Change baseline to  
12-month FU
Parameter Estimate 95% CI Estimate 95% CI Estimate 95% CI Group xTime1
Depression 
   ED-only 0.40** 0.12, 0.68 -0.00 -0.44, 0.44 -0.01 -0.54, 0.52 0.00
   PSD-only 2.17** 1.82, 2.52 -0.80** -1.33, -0.25 -0.56 -1.20, 0.08 8.33*
   DES 2.20** 1.91, 2.53 -0.47 -0.95, 0.01 -0.36 -0.94, 0.22 3.70
Executive function
   ED-only -0.82** -1.02, -0.61 0.10 -0.07, 0.26 0.10 -0.07, 0.26 1.75
   PSD-only 0.12 -0.14, 0.37 -0.04 -0.24, 0.16 -0.12 -0.32, 0.09 1.28
   DES -0.97** -1.20, -0.74 0.14 -0.03, 0.32 0.20* 0.01, 0.38 4.63
Global Cognition 
   ED-only 0.14** 0.05, 0.23 -0.02 -0.12, 0.08 0.03 -0.07, 0.13 0.85
   PSD-only 0.03 -0.08, 0.14 0.00 -0.12, 0.13 -0.01 -0.13, 0.11 0.03
   DES 0.18** 0.08, 0.28 0.02 -0.09, 0.13 0.02 -0.09, 0.13 0.25
Memory 
   ED-only -0.50** -0.86, -0.12 0.09 -0.37, 0.37 -0.14 -0.44, 0.16 2.11
   PSD-only 0.14 -0.33, 0.61 -0.00 -0.37, 0.37 0.02 -0.34, 0.38 0.02
   DES -0.88** -1.30, -0.46 -0.06 -0.39, 0.28 -0.21 -0.54, 0.12 1.57
Processing speed
   ED-only -0.49** -0.76, -0.22 -0.02 -0.22, 0.19 -0.15 -0.36, 0.05 2.55
   PSD-only -0.01 -0.35, 0.34 0.18 -0.08, 0.43 0.17 -0.08, 0.42 2.50
   DES -0.84** -1.15, -0.53 -0.04 -0.27, 0.19 -0.03 -0.26, 0.19 0.13
Quality of life 
   ED-only 0.07 -0.07, 0.21 0.11 -0.02, 0.24 0.07 -0.07, 0.21 2.90
   PSD-only 0.45** 0.28, 0.63 0.10 -0.06, 0.26 0.03 -0.14, 0.20 1.62
   DES 0.64** 0.48, 0.79 0.02 -0.13, 0.16 0.05 -0.11, 0.20 0.35
Note: 1χ2-test (2 degrees of freedom) of overall interaction between subgroup and time (baseline, 
6-month-up, 12-month follow-up) omnibus test of the null hypothesis of no difference in rate of change 
over time between subgroups. *P<0.05, **P<0.01.
Abbreviations: FU, follow-up; CI, confidence interval; DES, depression executive dysfunction syndrome; 
ED, executive dysfunction; MADRS, Montgomery-Åsberg Depression Rating Scale; MMSE, Mini Mental 
State Examination; PSD, post-stroke depression; SS-QoL, stroke-specific quality of life; 
Depression-executive dysfunction syndrome post stroke
8
191190
COURSE OF DEPRESSION BY SUBGROUP
Overall, a significant difference in the course of depressive symptoms was found 
between the four groups (χ2 = 12.96; df = 6; p = .044). The PSD-only group showed 
a significant decrease in depressive symptoms over time compared with the None 
group (χ2 = 8.33; df =2; p = .016). In contrast, depressive symptom levels in the 
DES group remained stable over time compared to the None group (χ2 = 3.70; 
df = 2; p = .157, Figure 1A). 
Figure 1. Change over time in executive function and depression scores by subgroup 
(A) Course of depressive symptoms measured with the MADRS by DES subgroup. (B) Course of 
executive function performance by DES subgroup. 
Note: Based on random-effects analysis adjusted for age at T0, sex, level of education, group, and 
group by time interaction. Predicted mean scores are estimated marginal means for DES subgroup by 
time, with all covariates fixed at their means. Higher mean scores indicate a higher level of depression 
and better performance on executive function, respectively.
COURSE OF EXECUTIVE FUNCTION BY SUBGROUP
There was a significant difference in performance from T0 to T2 between the four 
groups (χ2 = 9.63; df = 3; p = .022). Overall, performance on executive function 
in the DES group tended to improve over time relative to the None group (χ2 
= 4.63; df = 2; p = .099, Figure 1B), and time-stratified analyses showed that 
this improvement was most notable from T0 to T2 (χ2 = 4.20; df = 1; p = .040). 
Furthermore the PSD-only group showed a significant decrease in performance 
over time from T0 to T2 relative to the DES group (χ2 = 8.35; df = 1; p = .004) 
and ED-only group (χ2 = 4.54; df = 1; p = .033). There were no differences in 
cognitive trajectories between ED-only and DES, suggesting that these groups 
had a more or less similar course of performance on executive function over time 
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(Figure 1B). Results with respect to differences in performance on the individual 
test instruments measuring executive function between the subgroups showed 
that the ED-only group was more likely to show improvement over time compared 
to the DES group (see TMT-B and TMT-index in Supplementary Table 2).
COURSE OF OTHER COGNITIVE OUTCOMES AND QUALITY OF LIFE BY SUBGROUP
Global cognition. At T0, patients with DES and ED-only showed lower MMSE 
scores compared with patients in the None group (Table 2). Overall, no significant 
difference in the course of MMSE scores was found between the four groups (χ2 = 
1.77; df = 6; p = .939), indicating that DES and ED-only scored consistently lower 
on the MMSE over the course of 12 months (Figure 2A).
Memory. The DES group and ED-only performed significantly worse on memory 
compared with the None group at T0 (Table 2). Overall, no significant difference 
in the course of memory performance was found between the four groups (χ2 = 
4.09; df = 6; p = .664), indicating that DES and ED-only scored lower on memory 
over the course of 12 months (Figure 2B). 
Information processing speed. The DES group and ED-only performed worse on 
information processing speed compared with the None group at T0 (Table 2). 
Overall, no significant difference was found between the four groups in the course 
of performance (χ2 = 8.69; df = 6; p = .192), while time-stratified analyses showed 
a trend for significant differences in the course of performance between the four 
groups from T0 to T2 (χ2 = 7.40; df = 3; p = .060). Further analyses showed that 
this difference was due to the comparison of trajectories between PSD-only and 
ED-only, with the former showing a relative improvement in performance from T0 
to T2 compared with the ED-only group (χ2 = 7.19; df = 1; p = .007). There was no 
significant difference in cognitive trajectory between the DES group and the None 
group (χ2 = 0.13; df = 2; p = .939), suggesting stable low performance over time 
in the DES group (Figure 2C).
QoL. The SS-QoL score of the DES-group and PSD-only group was significantly 
lower compared with the None group at T0 (Table 2). Overall, no significant 
difference was found in the course of QoL between the four groups, (χ2 = 4.67; 
df = 6; p = .587), suggesting that QoL scores remained relatively stable in all four 
groups, with the DES and ED-only groups scoring lower over the course of 12 
months (Figure 2D). 
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Figure 2. Change over time in performance on global cognition, memory, and processing speed and 
quality of life scores by subgroup 
(A) Course of performance on global cognition measured with the MMSE by DES subgroup. (B) Course 
of memory performance by DES subgroup. (C) Course of performance on information processing 
speed by DES subgroup. (D) Course of quality of life scores by DES subgroup. 
Note: Based on random-effects analysis adjusted for age at T0, sex, level of education, group, and 
group by time interaction. Predicted mean scores are estimated marginal means for DES subgroup 
by time, with all covariates fixed at their means. Higher mean scores indicate better performance on 
memory, and processing speed. For global cognition and quality of life, higher scores indicate worse 
performance and worse quality of life, respectively.
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DISCUSSION
The aim of the present study was to examine whether ED denotes a distinct 
PSD subtype based on neuroimaging correlates and prognosis. The results 
of the present study showed that DES is associated with higher WMH volume, 
more global brain atrophy, higher frequency of old infarcts, and a higher total 
cSVD burden on MRI. Furthermore, patients with DES showed more functional 
impairment at baseline, and had a chronic course of depressive symptoms relative 
to patients with PSD only. DES patients showed a non-improving pattern of worse 
cognitive performance, which did not differ significantly from the ED-only group. 
Depressive symptoms improved in the PSD-only group, whereas they remained 
stable in the DES-group, suggesting a more chronic course of depression. This 
is in agreement with earlier findings in patients with late-life depression,8 in 
which ED was associated with relapse and recurrence of depression and residual 
depressive symptoms. A smaller study by Bour et al,9 who studied the relation 
between depression and ED in 116 first-ever stroke patients also found that DES 
patients showed a chronic course of depressive symptoms after 2 years. 
The DES-group generally showed a stable course of executive function over 
time, which did not differ significantly from ED-only group. However, results of 
the individual test instruments showed that the ED-only group was more likely to 
show improvement over time compared to the DES group. These findings seem 
to imply, that in general executive function remained impaired in the DES-group. 
This is consistent with the study by Bour et al.,9 in which about 50% of patients with 
ED-only or DES were still impaired in executive functions after 2 years. However, 
only presence of ED was evaluated at follow-up, not change in severity over time. 
On global cognition, information processing speed, and memory, the DES group 
performed worst, and performance remained stable low over time. QoL scores 
were lowest in the DES group and remained stable over time as well.
Patients with DES had a significant higher WMH volume compared to all other 
groups. This is in contrast to the results of the study of Vataja et al.,13 who could 
not find an association with white matter changes. Our results seem consistent 
with findings in depressed geriatric patients, particularly late-onset depression, 
who tend to show white matter changes in frontal-subcortical circuits.6,33 Indeed, it 
has been shown that WMH in older adults with major depressive disorders relate 
to more severe impairment in executive functions and memory.34 Next to higher 
WMH volume, patients with DES also had significantly more frequent old infarcts, 
a higher total cSVD burden score, and more global brain atrophy, compared 
to patients with PSD-only. These findings suggest that DES is associated with 
increased generalized (vascular) brain pathology. This provides support for a 
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strong biological origin of depression in the DES group compared with the PSD-
only group, for which psychosocial factors like a psychological response to the 
stroke itself might be more involved.35 DES therefore seems to denote a subtype 
of depressed stroke patients with a distinct etiology and poor prognosis, and may 
need a different treatment approach as some studies found worse response to 
antidepressant treatment in depressed older adults with executive impairment,36 
though the evidence base is still weak,37 and lacking for DES after stroke.
Important strengths of the present study include the relatively large sample with 
minimal dropout, the longitudinal design with serial assessments of cognitive and 
neuropsychiatric functioning, and the use of linear mixed models, which provide 
the opportunity to look at differences in functioning over time between groups. 
Yet, some limitations need to be addressed. Patients with pre-stroke cognitive 
impairment, severe aphasia, and comorbid neurological conditions that are 
known to affect cognition were excluded from the present study, which may limit 
the generalizability of our results. Next, imaging markers were only available for 
a subset of patients, which hampered the possibility to study associations with 
specific lesion locations. Lastly, the follow-up period was 12 months after initial 
testing. Although some differences in course over time were found in this medium-
term follow-up, longer follow-up periods might show clearer demarcation of 
trajectories in cognition and depression. Furthermore, it would allow examining 
additional outcome parameters such as incident dementia and mortality, as 
a 12-year follow-up stroke population study indicated that DES was associated 
with poor long-term survival,38 and a population-based cohort study with non-
demented elderly found an increased risk for developing dementia in patients 
with DES over a 9-year follow-up period.39
In conclusion, DES seems to denote a subtype of depressed stroke patients with 
a distinct etiology and poor prognosis. DES might then also ask for a different 
treatment approach than patients with only PSD. 
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SUPPLEMENTAL DATA
Data Supplement 1. Total cerebral small vessel disease (cSVD) burden score 
The total cSVD burden score is based on counting the presence of microbleeds, 
lacunes, perivascular spaces in the basal ganglia, and extensive white matter 
hyperintensities (WMH) on MRI.1 One point was assigned for visual rating of 
extensive WMH (JS), which was defined as a periventricular WMH Fazekas score 
of 3 and/or a deep WMH Fazekas score of at least 2.2 Presence of microbleeds 
was rated visually on susceptibility weighted imaging by two experienced 
neurologists (JS and RvO). Microbleeds were defined as small (< 5 mm diameter) 
homogeneous, round foci of low signal intensity, differentiated from vessel flow 
voids.3 One point was assigned for the presence of ≥1 microbleed(s). The presence 
of silent lacunes was defined as asymptomatic lacunar lesions < 20 mm3 and one 
point was assigned for presence of ≥1 silent lacune(s). For perivascular spaces, 
one point was assigned if these were visually rated (JS) as moderate or extensive 
(≥ 10) in the basal ganglia. Summing of the scores for each cSVD marker resulted 
in a total cSVD burden score ranging from 0 to 4. The original cSVD burden scale 
was slightly adapted here, as in contrast with the original cSVD scale, we used 
susceptibility weighted imaging (SWI) for counting microbleeds. 
REFERENCES
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Supplementary Table 1. Baseline characteristics for total sample, and separate for patients who 
completed all measurements and patients who dropped out at 1 or 2 time points
Variables
All patients
(n = 245)
Complete 
follow-up 
(n = 220)
Dropouts 
(n = 25)
Age (in years), mean (SD) 67.5 (11.9) 66.9 (11.6) 73.6 (12.5)b
Male sex, n (%) 157 (64.1) 143 (65.0) 14 (56.0)
Low education, n (%)
Middle education, n (%)
High education, n (%)
101 (41.2)
86 (35.1)
58 (23.7)
86 (39.1)
79 (35.9) 
55 (25.0)
15 (60.0)
7 (28.0)
3 (12.0)
Barthel Index, mean (SD) 19.4 (1.5) 19.5 (1.4) 19.0 (1.7)
Pre-stroke depression, n (%) 55 (22.5) 49 (22.3) 6 (24.0)
Family history of depression, n (%) 34 (13.9) 33 (15.0) 1 (4.2)
Quality of life (SS-QoL) mean (SD) 4.1 (0.7) 4.1 (0.7) 4.0 (0.9)
MMSE score, mean (SD) 28.1 (1.7) 28.2 (1.7) 27.6 (1.6)
MADRS, mean (SD) 6.1 (5.8) 6.3 (5.9) 4.4 (4.8)
Note: a p < .05, b p < .01.
Abbreviations: MADRS, Montgomery-Åsberg Depression Rating Scale; MMSE, Mini-Mental State 
Examination; SS-QoL, Stroke-Specific Quality of Life. 
Supplementary Table 2. Mean differences (and 95% confidence interval) in executive function and 
in change in executive function (slopes) from baseline between those with Depression Executive 
Dysfunction Syndrome (DES, n = 55), executive dysfunction only (ED-only, n = 88), post-stroke 
depression only (PSD-only, n = 38), and those without depression and executive dysfunction at baseline 
as reference group (n = 64) on individual tests 
Time
Baseline difference
Change baseline to  
6-month FU
Change baseline to  
12-month FU
Parameter Estimate 95% CI Estimate 95% CI Estimate 95% CI Group xTime1
Executive function
Verbal fluency - animals
   ED-only -0.77** -1.01, -0.53 -0.16 -0.39, 0.07 0.03 -0.23, 0.29 3.02
   PSD-only 0.02 -0.29, 0.33 -0.16 -0.44, 0.12 -0.07 -0.38, 0.24 1.30
   DES -1.02** -1.30, -0.75 0.21 -0.05, 0.46 0.34* 0.05, 0.62 5.54
TMT-B
   ED-only -0.94** -1.26, -0.63 0.41** 0.11, 0.70 0.25 -0.05, 0.56 7.49*
   PSD-only 0.13 -0.27, 0.53 -0.00 -0.36, 0.35 -0.13 -0.49, 0.23 0.65
   DES -0.98** -1.33, -0.62 -0.02 -0.34, 0.31 0.13 -0.20, 0.46 0.84
TMT-index
   ED-only 0.64** 0.32, 0.96 -0.50** -0.87, -0.13 -0.51** -0.88, -0.14 9.96**
   PSD-only -0.07 -0.47, 0.34 0.12 -0.33, 0.57 0.37 -0.07, 0.81 2.86
   DES 0.21 -0.16, 0.58 -0.05 -0.45, 0.36 -0.02 -0.42, 0.39 0.06
Note: 1 χ2-test (2 degrees of freedom) of overall interaction between subgroup and time (baseline, 
6-month-up, 12-month follow-up) omnibus test of the null hypothesis of no difference in rate of change 
over time between subgroups. 
Abbreviations: FU, follow-up; CI, confidence interval; DES, depression executive dysfunction syndrome; 
ED, executive dysfunction; PSD, post-stroke depression; TMT-B, trail making test part B; TMT-index, trail 
making test index part. *P<0.05, **P<0.01.
Chapter 8 Depression-executive dysfunction syndrome post stroke
8
200
Supplementary Figure 1. Flowchart of inclusion process
Note: Nineteen patients who did not participate at T1, agreed to participate at T2.
Abbreviations: T0 indicates baseline measurement 3 months post stroke; T1, follow-up 9 months post-
stroke; T2, follow-up 15 months post-stroke. 
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GENERAL DISCUSSION
Post-stroke depression (PSD) and post-stroke apathy (PSA) are frequently 
occurring neuropsychiatric syndromes after stroke, with estimated mean 
prevalences of 31%1 and 35%,2 respectively. Over the past years, many studies 
have been conducted to study the underlying factors involved in the etiology of 
PSD, while only few studies have been conducted to unravel the etiological factors 
involved in the development of PSA. Despite a large overlap in clinical symptoms 
between PSD and PSA, some studies found evidence for differences in associated 
biological and psychosocial factors, suggesting that these two concepts might, 
at least to some extent, represent independent syndromes. However, few studies 
looked at the development, course, and associated factors of both syndromes at 
the same time in a longitudinal study. Therefore, we investigated the association 
between several biological and psychosocial risk factors and the development 
and course of PSD and PSA. In particular, we focused on potential similarities and 
differences between these two syndromes. A better understanding of how these 
risk factors differentially influence the development and course of PSD and PSA is 
not only important from a conceptual point of view, but may also result in better 
recognition, and earlier detection of these conditions. Of particular interest, a 
better understanding may lead to a better diagnostic distinction between PSD 
and PSA. Consequently, this may lead to better treatment and a better clinical 
prognosis after stroke.
The Cognition and Affect after Stroke: a Prospective Evaluation of Risks (CASPER) 
study, a one-year prospective clinical stroke cohort follow-up study (n = 250) was 
performed (Chapter 3) to answer the following research questions. We examined 
whether there is evidence for a bi-directional relationship between post-stroke 
fatigue (PSF) and PSD, and PSF and PSA (Chapter 4). In addition, we studied 
the influence of premorbid personality traits (Chapter 5) and vascular cognitive 
impairment (VCI) (Chapter 7) on the development and course of PSD and PSA. 
A systematic review and meta-analysis was conducted (Chapter 2) to examine 
associations between imaging markers and PSD and PSA and we studied the 
role of stroke lesion-related and more generalized brain imaging markers in the 
development of PSD and PSA in the CASPER cohort (Chapter 6). Furthermore, 
we examined whether the co-occurrence of executive dysfunction and PSD, the 
so-called “Depression-Executive Dysfunction Syndrome” (DES), denotes a distinct 
PSD subtype based on neuroimaging correlates and prognosis (Chapter 8).
First, in this chapter the main findings and conclusions of this thesis are presented 
and methodological considerations are addressed. Furthermore, conceptual and 
clinical implications and recommendations for future research are discussed. 
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MAIN FINDINGS 
Imaging markers 
The neurobiology of PSD has received much attention in the past decades, and 
focused mainly on associations with lesion laterality (i.e. the ‘lesion location 
hypothesis’ of PSD, stating that PSD is associated with left frontal lesions). 
Neurobiological markers of PSA have been studied less frequently compared with 
PSD. In Chapter 2, we performed a systematic literature review and meta-analysis 
to examine the association between PSD or PSA and stroke lesion laterality, 
type, and location, also stratified by study phase (i.e. acute, post-acute, chronic). 
Associations with other imaging markers (e.g. white matter hyperintensities 
(WMH), atrophy, lesion volume, number of lesions, cerebral microbleeds) were 
reviewed qualitatively to provide an up-to-date overview. We found that lesions in 
the frontal lobe or basal ganglia were associated with increased odds of PSD in the 
post-acute (0.5 – 6 months) stroke phase. PSA was associated with hemorrhagic 
stroke in the acute phase (< 15 days), whereas in the post-acute phase it was 
associated with ischemic stroke. However, as the number of included PSA studies 
was limited, no firm conclusions could be drawn. Therefore, large cohort studies 
using sophisticated imaging techniques and considering a broad range of imaging 
markers in association with both PSD and PSA are needed.
With respect to the underlying neurobiology of PSD and PSA, focus has shifted 
from individual lesion locations to extent of damage to neuronal networks being 
involved in the development of PSD and PSA, with evidence for different sub-
circuits associated with PSD3 and PSA.4 This damage can arise from single stroke 
lesions, but also as a consequence of more generalized brain damage such as 
WMH, lacunes, and microbleeds. These are markers that occur as a consequence of 
cerebral small vessel disease (cSVD) and can be identified on magnetic resonance 
imaging (MRI). In Chapter 6 the association between lesion-related imaging 
markers and background markers of vascular and degenerative pathology and 
the development of PSD and PSA was examined in the CASPER cohort including 
250 patients with recent stroke. The results showed that after correction for stroke 
lesion volume, global brain atrophy and severe cSVD burden, but not stroke 
lesion-related markers, were associated with the development of PSA in the 
first year post-stroke, independent of co-morbid PSD. After correction for stroke 
lesion volume and history of depression, global brain atrophy and medium cSVD 
burden were associated with the development of PSD. After correction for co-
morbid PSA, only medium cSVD remained significantly associated with PSA. This 
suggests that atrophy and increased cSVD burden are important predictors for the 
development of PSA, and, less strongly, for PSD. In general, these findings indicate 
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that particularly cumulative background brain damage is involved in developing 
neuropsychiatric symptoms after stroke, and not the location or volume of the 
stroke lesion itself, with a stronger involvement in PSA than for PSD. A possible 
underlying mechanism could be that the cumulative brain pathology results in 
damage to microstructural networks, which are involved in the regulation of mood 
and motivational processes.
Fatigue 
Post-stroke fatigue (PSF) is a frequent complaint after stroke and several cross-
sectional studies found an association between PSF and PSD.5 However, few 
longitudinal studies have examined this association, therefore little is known about 
the directionality of this relationship. As there is large overlap in symptoms between 
PSA and PSD,6 and both frequently co-occur,7,8 PSA might be related to PSF as 
well, though this relationship has not been studied yet. A better understanding of 
the inter-relationships between PSD, PSA, and PSF is important, as incorporation 
of this information may eventually lead to better treatment strategies for these 
syndromes. 
In Chapter 4 we examined the temporal relationships between PSF and PSD and 
between PSF and PSA, by measuring the effect of PSF at three months post-stroke 
on the course of depressive and apathetic symptoms over a period of 12-month 
follow-up. In addition, we studied the reverse direction by examining the effect 
of PSD (or PSA) at three months post-stroke on the course of fatigue symptoms. 
Since the relationship between PSF and PSD is likely to be influenced by multiple 
other factors,9 we controlled for sleep apnea, high neuroticism, and history 
of depression in our analyses. The results showed a bi-directional association 
between PSF and PSD, whereas PSA was not associated with PSF. Levels of PSF and 
PSD remained stable over time. Therefore, a timely detection of these conditions 
in stroke patients is important, as they tend to persist. As there are currently few 
treatment options available to treat or relieve PSF per se,10 a potential treatment 
strategy is to focus on treating PSD, which might also have a beneficial effect on 
(the prevention of) PSF. 
Premorbid personality traits 
Previous studies in the general population found personality traits, and 
particularly high neuroticism, to be an important predictor of onset and course 
of neuropsychiatric symptoms.11,12 However, associations with personality have 
been less frequently studied in a stroke population. In Chapter 5 we found an 
association between high neuroticism and high levels of depression in 245 stroke 
patients at baseline (three months post-stroke), and this figure remained stable 
during the 12-month follow-up. In contrast, low extraversion was associated with 
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high levels of apathy at baseline, and this association remained stable over time 
as well. Since different personality traits were associated with PSD and PSA, the 
results are in line with the suggestion that PSA can develop as an independent 
syndrome from PSD, having its own associated risk factors. 
Although previous studies already showed that high neuroticism is associated 
with PSD,13,14 the present study adds to this that high neuroticism is a prognostic 
factor in determining the course of PSD symptoms over time. We controlled for 
level of apathy, as apathy might mediate the relationship between neuroticism 
and PSD by influencing emotion regulation15 and causing social inhibition.16 
The results implicate that pre-stroke factors, like premorbid personality, may act 
as potential vulnerability factors to develop PSD or PSA and are associated with 
the sustainability of PSD and PSA. Possibly, personality traits may influence the 
way patients cope with the stressful event of suffering from a stroke,17 which is 
important to take into account during treatment and rehabilitation. 
Vascular cognitive impairment
Vascular Cognitive Impairment (VCI) is frequent after stroke, with an overall 
prevalence of 22% up to 15 years after stroke.18 VCI can be due to (strategic) 
infarcts, but is often mixed with AD pathology.19 According to VASCOG criteria,20 
VCI can be defined as an impairment in one or more cognitive domains, with a 
clear temporal relationship between a vascular event (e.g. acute stroke) and 
the cognitive impairment, preferably with neuroimaging evidence of stroke or 
other vascular pathology. Therefore, to ensure the vascular etiology of cognitive 
impairment, stroke patients with pre-stroke cognitive impairment or dementia 
were excluded in the CASPER study. 
Although many studies found an association between VCI and PSD21,22 or PSA,23 
these often defined cognitive impairment based on a global cognitive screening 
instrument, rather than studying associations with different cognitive domains. 
Also, prospective studies studying the influence of VCI on the course of PSD and 
PSA are scarce. In Chapter 7 we performed longitudinal analyses to examine the 
influence of “any VCI” (impairment in at least one cognitive domain) and degree 
of VCI (impairment in multiple cognitive domains versus impairment in a single 
domain) on the course of depression and apathy symptoms over time. Any VCI 
predicted an increase in apathy levels from three to 15 months post-stroke, 
which was most pronounced in patients with VCI in multiple cognitive domains 
(particularly executive dysfunction and slowed information processing speed). 
None of the cognitive variables predicted the course of depressive symptoms. 
These results implicate that although apathy symptoms may be absent in the first 
months after stroke, these symptoms can develop over time in patients with VCI. 
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Health professionals should be aware of this risk, as apathy is associated with a 
worse clinical prognosis.2 
Depression-executive dysfunction syndrome as a subtype of PSD 
Heterogeneity in clinical presentation and prognosis of PSD might be due to 
differences in etiological factors and subtypes of PSD may exist. In Chapter 8 we 
examined whether executive dysfunctions (ED) denote a distinct PSD subtype by 
studying whether the co-occurrence of ED and PSD in a depression-executive 
dysfunction depression subtype (DES) is associated with different clinical correlates 
and a worse prognosis. In a subset (n = 186) that received 3 Tesla structural brain 
MRI, we found that the DES-subtype was associated with higher WMH volume, a 
higher frequency of old infarcts, more global brain atrophy, and higher total cSVD 
burden on MRI at three months post-stroke. Longitudinal analyses in 245 stroke 
patients showed that DES was associated with a less benign course, including a 
non-improving pattern of worse cognitive performance compared with ED-only 
and higher, and chronic high levels of depression compared with PSD-only. Our 
findings suggest that DES is associated with increased generalized (vascular) brain 
pathology, which provides support for a strong biological origin of depression in 
the DES group compared with the PSD-only group, for which psychosocial factors 
like a psychological response to the stroke itself might be more involved.24,25 Thus, 
DES might denote a subtype of depressed stroke patients with a distinct etiology 
and poor prognosis compared with patients with PSD only, and may therefore ask 
for a different treatment approach. 
EVIDENCE FOR INDEPENDENCE OF PSD AND PSA
Factors associated with PSD and PSA in this thesis are summarized in 
Figure 1. Global atrophy, low extraversion, and VCI in multiple cognitive domains, 
particularly executive dysfunction and slowed information processing speed, 
were all associated with the development of PSA. Patients with VCI in multiple 
domains also showed an increase in apathy levels, but not depressive levels, over 
time during the one-year follow-up. Lesions in the frontal lobe or basal ganglia, 
high levels of fatigue, and high neuroticism were specifically associated with 
the development of PSD. Levels of depression remained stable from baseline 
to follow-up. As we controlled for the overlap in symptomatology between PSD 
and PSA in our analyses, the factors in Figure 1 are specifically associated with 
PSD and PSA, respectively and enable us to differentiate between these two 
syndromes. However, a phenotypical overlap exists between these syndromes, as 
some patients presented with both PSD and PSA. Figure 2 shows the independent 
occurrence of PSD and PSA and its overlap in the CASPER cohort for each time 
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point after stroke. The number of patients with independent PSA is rather small, 
though these numbers are dependent on how we defined PSD and PSA, which 
also differs greatly in previous literature, as there is no consensus. 
Figure 1. Factors specifically involved in the development of post-stroke apathy and depression
Abbreviations: cSVD, cerebral small vessel disease; VCI, vascular cognitive impairment.
DEFINING PSD AND PSA
In Figure 2 and in Chapters 4 and 6, we defined PSA as a score ≥ 37 on either the 
clinician-rated Apathy Evaluation Scale (AES)26 or informant-rated AES. The AES is 
a frequently used measure for apathy in the stroke population, and is evaluated 
to be a psychometrically robust measure for apathy.27 It has a good discriminant 
validity as it correlates low with measures of depression and anxiety.26,28 At three 
months post-stroke, a PSA frequency of almost 17% was found in our cohort, 
increasing to almost 27% at six-month follow-up, and 23% at 12-month follow-up. 
The frequency for PSA in CASPER is somewhat lower than the estimated mean 
prevalence of 34.6% reported in the meta-analysis by van Dalen and colleagues.2 
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This may be due to the fact that the patients in our cohort were relatively mild 
to moderately affected by the stroke, as patients with severe stroke were more 
severely impaired and therefore not eligible to participate or it was too burdensome 
for them. Also, patients with severe aphasia and pre-stroke cognitive impairment 
were excluded, which may have affected the frequency of PSA as well. 
Figure 2. Overlap and independence of PSD and PSA at 3, 9, and 15 months post-stroke
Abbreviations: PSA, post-stroke apathy; PSD, post-stroke depression; T0, 3 months post-stroke; T1, 9 
months post-stroke; T2, 15 months post-stroke.
PSD was defined as a score ≥ 7 on the Montgomery-Åsberg Depression Rating 
Scale (MADRS)29 or a diagnosis of major depressive disorder or minor depression 
on the Mini International Neuropsychiatric Interview (M.I.N.I.)30 (Figure 2 and 
Chapter 4). Although both the Hospital Anxiety and Depression Scale (HADS-D) 
Depression subscale,34 and MADRS are valid screening instruments for PSD as they 
focus less on somatic symptoms,31 we chose to use the MADRS over the HADS-D 
as outcome measure for depressive symptoms, as the MADRS is a clinician-rated 
questionnaire, which is especially designed to be sensitive to change.29
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In the CASPER cohort, a PSD frequency of 38% was found at three months post-
stroke, which remained stable over time (39% at six-month and 12-month follow-up). 
This frequency is somewhat higher compared with the estimated mean prevalence 
of 31% reported in the meta-analysis by Hackett and Pickles.1 Studies included in 
the meta-analysis either applied diagnostic criteria according to Diagnostic and 
Statistical Manual of Mental Disorders DSM third-edition revised (DSM-III-R), DSM-
IV, or DSM-5 using a (semi-)structured interview (e.g. M.I.N.I,32 Structured Clinical 
Interview for DSM disorders (SCID)33), or they defined PSD as a score above a cut-
point on a self-rated or clinician-rated depression scale (e.g. MADRS,29 HADS-D,34 
Beck Depression Inventory,35 Geriatric Depression Scale36), with different cut-offs 
applied for the same instrument between studies. The diversity in instruments 
and cut-off scores and also the time of measurement is likely to have affected the 
frequencies found in each study. In CASPER, we applied relatively mild criteria for 
PSD (Chapter 4) with respect to the MADRS score, resulting in a heterogeneous 
group of PSD patients with mild to severe depression. 
We examined the influence of risk factors (e.g. severe fatigue, personality traits, 
VCI, DES) on the level and course of depressive symptoms by looking at change 
in the continuous MADRS scores (Chapter 4, 5, 7, and 8), rather than whether it 
influenced the categorization of patients as either depressed or non-depressed, so 
the difficulty of applying correct criteria to define PSD did not influence our results. 
For PSA, we looked at the influence of risk factors (i.e. severe fatigue, personality 
traits, VCI) on the level and course of apathy symptoms by examining change in 
the continuous AES scores on the clinician-rated AES (Chapter 4, 5, and 7). We 
chose to use the clinician-rated AES over the informant-rated AES, as the former 
was shown to have the highest reliability.27 However, an important disadvantage 
of using continuous scales is that it is unclear whether a significant increase or 
decrease on the scale is also clinically relevant. Particularly for patients who cannot 
be defined as being depressed or apathetic, it is questionable whether it matters 
if these patients show higher or lower scores on a scale compared to a previous 
assessment. Nevertheless, for our understanding of the complex relationship 
between biological and psychosocial risk factors and PSD and PSA, our findings 
provide relevant indications. 
As we studied a broad range of imaging markers in association with PSD and PSA 
(Chapter 6), we chose to look at the development of PSD and PSA at any time 
point in the one-year follow-up period, since the sample size was too small to 
look at interactions with time. In this study, we used stricter criteria for PSD, by 
defining it as a diagnosis of either major depressive disorder or minor depression 
on the M.I.N.I. on at least one assessment during the one-year follow-up period, to 
ensure that the depression was clinically relevant.
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METHODOLOGICAL CONSIDERATIONS
The most important strengths and limitations of the studies in this thesis will be 
discussed below.
Strengths and limitations of the systematic review and meta-analysis
A systematic review and meta-analysis (Chapter 2) was conducted to provide a 
comprehensive and up-to-date evaluation of imaging markers associated with 
PSD and PSA. A large amount of PSD studies was included (n = 132), which made 
it possible to conduct meta-analyses on lesion laterality, lesion type, and also on 
lesion location associated with PSD. In addition, an extensive qualitative overview 
was provided of a broad range of imaging markers associated with PSD and PSA. 
The systematic review and meta-analysis (Chapter 2) also had limitations. The most 
important limitation was the small amount of studies on PSA, which compromised 
the generalizability of the results. Moreover, the heterogeneity between PSA 
studies was small, so the results need to be interpreted with caution. Nevertheless, 
we believe they are still of importance, but also emphasize the need for more 
PSA studies to be able to draw firm conclusions. Furthermore, moderate to high 
(unexplained) heterogeneity in some meta-analyses indicated large differences 
in methodology between studies. Meta-regression analyses were performed 
to identify potential sources of heterogeneity, but only study phase for PSD 
studies and imaging method for PSA studies could be identified. Probably also 
other potential variables (e.g. years of education, cognitive status) that were not 
included as covariates in the meta-regression analyses might explain some of the 
heterogeneity, but due to the large variability in methods and availability of data 
between studies we were not able to examine this. 
Strengths and limitations of the CASPER study
Strengths of the CASPER study (Chapter 4 - 8) include the direct comparison 
of associated risk factors of PSD and PSA in the same cohort. Furthermore, the 
longitudinal design enabled us to examine differences in trajectories between 
patients with and without PSD or PSA in a relatively large sample. Also, the design 
allowed us to study temporal relationships between the development of different 
syndromes. The dropout of participants was rather low at follow-up, resulting in 213 
(85%) study completers at six-month follow-up and 219 study completers (88%) 
at 12-month follow-up. Another strength was the extensive neuropsychological 
assessment that was conducted at all time points, which covered a screening 
instrument to assess global cognition, and several test instruments to measure 
(verbal) episodic memory, working memory, information processing speed, and 
executive function. Also, a number of validated instruments (e.g. AES,26 MADRS,29 
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M.I.N.I.30) was administered to evaluate presence and severity of PSD and PSA at 
all time points. This is one of the few studies that studied factors associated with 
both PSD or PSA in a prospective cohort, as the majority of studies focused only 
on one of the two, or only on cross-sectional associations. Another strength is that 
analyses with PSD as outcome were corrected for PSA and vice versa. This was 
done to be able to study the effect of a certain factor on PSD independently of PSA 
and vice versa. Lastly, the majority received a 3-Tesla MRI at baseline (three months 
post-stroke), which provided a range of imaging data, consisting of advanced 
volumetric and visually rated imaging markers. 
The CASPER study had the following limitations. First, the exclusion of patients 
with severe aphasia, pre-existing cognitive impairment, and other neurological 
conditions that are known to affect cognition may limit the generalizability of 
our results to the general population of stroke survivors. However, patients with 
severe aphasia had to be excluded as participants needed to understand the 
study procedure fully to be able to give informed consent. Also, patients with pre-
existing cognitive impairment were excluded to ensure that cognitive impairment 
was due to vascular pathology, and not due to other origins. Second, the number 
of patients with PSA was rather small in the CASPER cohort. In literature, there is no 
consensus on how to define PSA, although many previous stroke studies defined 
PSA according to the same criteria as we did.37-39 A possible explanation for the 
low frequency could be that our cohort included largely mild to moderately severe 
stroke, as participation was too burdensome for a large group of eligible patients 
(60%). Patients who refused participation were older and more frequently female 
compared with patients who agreed to participate. Thus, these factors could have 
contributed to a selection bias in our cohort. Therefore, all analyses were at least 
corrected for age, sex, and level of education. Third, not all patients included 
at baseline managed to complete all follow-up assessments, which resulted in 
missing data. However, the frequency of PSD and PSA did not differ between 
patients who dropped-out at one or two time points compared with patients who 
completed all measurements. By applying random-effects linear mixed models or 
generalized estimating equation (GEE) logistic models we accounted for missing 
data, as these methods can also model trajectories over time for participants who 
did not complete all measurements and does not require imputation of missing 
data. Fourth, patients were followed in the first 15-months post-stroke, which is 
generally assumed to be the period of most recovery. Although this medium-
term follow-up provides the opportunity to look at differences in trajectories over 
time, an even longer follow-up period (2-5 years) would allow to also examine 
associations between PSD and PSA and other outcomes, like dementia and 
mortality, as PSD has been associated with an increased risk for mortality,40,41 and 
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this has not been examined in PSA yet. Lastly, imaging data were only collected at 
baseline as due to logistical and financial reasons it was not possible to repeat MRI 
at follow-up. However, these data would have been interesting, as changes in MRI 
markers could then have been related to changes in PSD or PSA as well. 
CONCEPTUAL AND CLINICAL IMPLICATIONS 
The present findings provide evidence that, at least in the stroke population, 
different risk factors are associated with apathy and depression. However, this 
does not necessarily mean that they are strictly different entities, as apathy can also 
be a symptom of depression, which complicates the conceptualization of these 
constructs. With respect to symptoms, a depressive disorder can differ greatly 
between individuals, with for example some patients particularly feeling sadness 
and lowered mood, while in others anhedonia (i.e. lack of feeling pleasure and 
loss of interest) dominates. The latter greatly overlaps with the diagnostic criteria 
for apathy.42 This means that in some depressed patients, there is much overlap 
with apathy symptoms, whereas in others this overlap may be minimal or absent. 
Also, some patients may experience apathy in absence of depressed mood. With 
respect to the differentiation between syndrome and symptom, this indicates that 
apathy can be a symptom of depression, but can also develop as an independent 
syndrome in absence of depression. To distinguish apathy from depression, it is 
suggested that apathy is more likely a behavioral disorder, characterized by lack 
of primary motivation and affective blunting,43 while depression can be defined 
as a disorder of mood.44 Particularly the absence of negative moods (i.e. sadness, 
feelings of guilt, helplessness, hopelessness) can help to distinguish apathy from 
depression.44 However, a depressive disorder can also be defined in absence of 
negative mood, if the core symptom anhedonia is present. Therefore, instead of 
following a categorical approach, which classifies disorders on the basis of fulfilling 
symptoms and characteristics that are typical of the disorder, it may be better 
to conceptualize apathy and depression following a dimensional or continuous 
approach.45 This has the advantage that it overcomes the problem of applying 
diagnostic criteria or (arbitrary) cut-offs to define clinically relevant depression or 
apathy. Also, in statistical analyses, continuous measures result in greater statistical 
power. Thus, the findings presented in this thesis should also be interpreted from 
a dimensional perspective, meaning that differential risk factors are associated 
with increased levels of apathetic and depressive symptoms after stroke. 
Nevertheless, an important difficulty remains with respect to the measurement of 
depression and apathy, since no objective measurement instrument is available. 
Therefore, assessments are always dependent on the way patients respond to 
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questions asked by the clinician and the clinicians’ interpretation of this. Since 
particularly patients with apathy show lack of insight44 and may not be able to 
provide a good picture of how they are feeling, this hampers the reliability of 
evaluating the presence of mood disorders in this patient group. Apathy is 
characterized by a reduction in motivationally driven behavior and poor reward 
sensitivity. Therefore, apathy can also be measured with a behavioural task, like 
a reward sensitivity task. Studies using this task showed that stroke patients46 and 
patients with Parkinson’s disease47 with apathy showed impaired reward sensitivity. 
This reward insensitivity appeared to be related to reduced pupillary dilation,47 
and may therefore provide a novel and useful objective clinical marker of apathy. 
The indications for differences in risk factors involved in the development of 
symptoms of PSD and PSA that are described in this thesis are helpful to denote 
patients particularly vulnerable for developing these neuropsychiatric disorders. 
It supports the idea that there are important differences between them and 
contributes to the understanding of their pathophysiology and showed that 
both biological and psychosocial factors play a role. So far, little knowledge was 
available with respect to risk factors of PSA. Therefore, our findings are particularly 
important for the comprehension of the underlying etiology of PSA, which seems 
to be different, in some extent, from PSD. Thus, the studies described in this thesis 
provided more insight into the differential role of biopsychosocial factors on the 
course of PSD and PSA. However, more research is needed to understand the 
whole picture as not all potentially involved factors could have been studied here. 
Our findings indicate that PSD and PSA are prevalent after stroke, with almost 45% 
of the patients showing PSD, PSA, or a combination of the two in the post-acute 
stroke phase. This has important clinical implications, since both PSD and PSA are 
associated with worse clinical outcome.2,21 Therefore, it is important that clinicians 
are aware of both syndromes and that they are recognized correctly. Also, they 
should be taken into consideration during rehabilitation, as PSD and PSA are 
known to have a negative impact on functional recovery,48 and are associated with 
poor involvement in rehabilitation.49 
The findings in this thesis provide evidence for the suggestion that PSD and PSA 
are independent syndromes, with differences in symptomatology, risk factors, and 
course. Health professionals should be aware that PSA can develop independently 
from PSD. Therefore screening for PSA is important, and a standardized protocol 
for health professionals is recommended. Apathy symptoms are usually noticed 
by caregivers or close relatives of the patients, but are often not reported as 
complaints by the patients themselves, as they may not feel affected by these 
symptoms. Even though apathetic symptoms may be observed by caregivers 
or close relatives, they are usually not aware that these are somehow associated 
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with the stroke and are mainly bothered or irritated by the passiveness and lack 
of interest of the patient. Therefore, also special attention should be given to 
caregivers, as living with someone with apathy can be particularly burdensome,50 
and they are often not capable to deal with it. Psychoeducation programs for 
caregivers and stroke survivors focusing on awareness of PSD and PSA and on 
how to cope with these syndromes would therefore be helpful.
In some patients, neuropsychiatric complaints develop only after a long period 
of time, in the chronic stroke phase, in which the patients usually no longer have 
regular check-ups in the hospital or rehabilitation center.51 This implicates that the 
general practitioner (GP) should be aware of this. PSD in the chronic stroke phase 
has been shown to be related to worse outcome with respect to instrumental 
activities of daily living and quality of life.52 Furthermore, one study showed that 
depressive symptoms were found to be a risk factor for the presence of unmet 
demands three years after stroke, with a third of stroke patients not receiving the 
appropriate care.53 In a prospective cohort study with five year follow-up, PSA 
became more prevalent with time, and risk factors were dementia, functional 
impairment, high levels of depression, and cerebrovascular events.6 The presence 
of PSD and PSA in the post-acute and chronic stroke phase has a negative impact 
on clinical outcome. Therefore, it is important that there is sufficient attention for 
these conditions, also at a later time point post-stroke. Hence, it is recommended 
that GPs are attentive to neuropsychiatric symptoms and cognitive impairment in 
stroke patients. Also attention should be paid to patients who do not report any 
complaints, because stroke can affect disease insight, also called anosognosia.54 
In a study by Aben and colleagues,55 GPs recognized PSD in less than 40% of the 
depressed patients, which stresses that education with respect to neuropsychiatric 
symptoms after stroke may be helpful for GPs, but undoubtedly also for other 
clinicians working in the field of stroke care. The current development of specialized 
stroke after-care clinics, in which there is specific expertise with respect to late-
onset and ‘invisible’ complaints after stroke, like neuropsychiatric and cognitive 
complaints, is a good and promising development in this sense. 
Taken together, there should be more awareness for the possible development of 
PSD and PSA after stroke in health care, so that these syndromes can be detected 
in time. Special attention should be paid to correct recognition of PSA, which 
could be reached by implicating standardized diagnostic criteria or standard 
use of a screening instrument like the AES, which can be applied by health care 
professionals. Regular visits to a GP in the first years post-stroke would be helpful 
for early recognition of symptoms, which may result in more adequate treatment 
or prevention of developing neuropsychiatric symptoms. Also, psychoeducation 
for stroke survivors and their caregivers with respect to neuropsychiatric symptoms 
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after stroke would be recommended, to increase awareness that in addition to 
physical complaints, speech difficulties, and other ‘more visible’ consequences of 
stroke, also neuropsychiatric symptoms may develop. Correct recognition of these 
syndromes will result in better understanding and also better handling of these 
symptoms, but it is the question whether this will also help in finding treatment 
possibilities. It is plausible that early identification is beneficial for clinical prognosis, 
if there are appropriate treatment strategies available. However, this was not 
examined in the present thesis and remains an important topic for future research. 
RECOMMENDATIONS FOR FUTURE RESEARCH
Previous research on neuropsychiatric symptoms after stroke focused mainly on 
the prevalence and biological and psychosocial factors associated with PSD. Over 
the last fifteen years there has been an increase in attention for PSA. However, only 
few longitudinal studies are available that looked at differences in associated risk 
factors of PSD and PSA in the same stroke cohort. Therefore, the present thesis 
provided important insight into the differential factors that play a role in the 
development of PSD and PSA. Based on our findings, some recommendations can 
be given for future research. 
First of all, the lack of a consensus with respect to instruments and cut-offs for 
assessing PSD and PSA is a major difficulty, as it leads to under-recognition of these 
syndromes and large heterogeneity between studies. Consensus on the application 
of rating scales and cut-offs in future studies would be helpful to overcome this, which 
makes it easier to assemble and compare study findings. The results of this thesis 
indicate that different factors play a role in the development of PSD and PSA. Though 
a broad range of factors was covered, this only comprised a small part of factors 
that are potentially involved. Therefore, additional large cohort studies focusing 
on both syndromes that cover a broad range of both biological and psychosocial 
factors are needed to provide more insight into the complex multifactorial origins 
of PSD and PSA. For example, the role of inflammatory cytokines that are released 
after ischemia, and genetic polymorphisms that could predispose stroke patients 
to develop neuropsychiatric symptoms are studied to a much lesser extent. In 
CASPER, data on several inflammatory markers and epigenetics are available and 
will be investigated. So, research on biological determinants of neuropsychiatric 
symptoms needs to incorporate all these potential factors, and study their inter-
relationships and interactions with psychosocial factors, to be able to shed light on 
the complex multifactorial origin of PSD and PSA. The study of multiple predictors 
to find subtle associations with PSD and PSA requires large sample sizes to reach 
sufficient power. Therefore, CASPER was designed to allow harmonization with 
other (comparable) stroke cohorts. This harmonization provides the opportunity to 
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conduct large individual patient data meta-analyses, which have several advantages 
over standard meta-analyses that only use published results.56 Therefore, CASPER 
joined the STROKOG consortium (https://cheba.unsw.edu.au/group/strokog),57 
which has built a database with more than 12,000 stroke patients already and will 
likely yield important results concerning factors associated with PSD and PSA. 
This will hopefully result in potential targets for treatment and prevention of these 
syndromes, which is another urgent area for future research. 
More research into optimal pharmacological and psychological treatment for 
PSD is necessary. There are currently no guidelines with respect to effective 
approaches,58 and a large amount of patients remains currently untreated or 
inadequately treated.58 A meta-analysis on treatment for PSD found a moderate 
effect of antidepressants, whereas no effect was found for psychotherapy.59 Both 
European60 and American61 guidelines recommend using antidepressants as 
pharmaceutical treatment for PSD, although they require that effectiveness should 
be clearly monitored. However, there is debate around the safety of prescribing 
selective serotonin reuptake inhibitor (SSRI) antidepressants in stroke patients, 
as they appeared to be associated with increased risk of mortality.41 This is 
probably related to an increased risk for hemorrhage62 due to an interaction with 
anticoagulants (blood thinners).63 Therefore, further investigation into successful 
treatment options is clearly needed. Also, routinely screening for PSD in the first 
year(s) post-stroke would be helpful to treat and prevent PSD adequately, and 
more research is needed to examine whether this also has a beneficial effect on 
clinical prognosis in these patients. 
For treatment of apathy there are currently no recommended treatment options.8 
There is insufficient evidence showing the effectiveness of pharmacological 
treatments,64,65 and most research on apathy treatment has been performed in other 
disease populations, like Alzheimer’s66 and Parkinson’s Disease.67 The use of SSRIs 
may have a negative influence on apathy,68 therefore it is particularly important that 
apathy is distinguished from depression, and that alternative treatment options 
will be available for depressed patients with co-morbid apathy. Hence, large 
randomized controlled trials are needed to investigate potential treatment targets 
for PSA. The results of the CASPER study described in this thesis provided important 
information on which patients may be vulnerable to develop apathy after stroke 
(i.e. cognitive impairment, low extraversion, global brain atrophy and high cSVD 
burden). These findings are important for a better understanding of the biological 
and psychosocial processes involved in the development of this syndrome, and how 
this differs from the underlying factors involved in PSD. Eventually, this information 
will be helpful in finding potential treatment targets for PSA. 
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CONCLUSIONS
The findings presented in this thesis provide evidence that different factors 
are involved in the development of PSD and PSA, which are of biological and 
psychosocial origin. This improves our understanding of the pathophysiology 
of these entities and supports the idea that PSA can occur as an independent 
syndrome, in absence of PSD. Information on cognitive functioning, level of fatigue, 
(premorbid) personality traits, and degenerative and vascular brain pathology 
should be considered by health professionals. Differences in these vulnerability 
factors between patients are important to incorporate, by means of providing 
patient-tailored treatment. Also, during the acute stroke phase, clinicians should 
be aware of patients with high vulnerability to develop PSD and PSA, and patients 
and their caregivers should be informed that these neuropsychiatric symptoms 
can develop, also at a later post-stroke stage. Earlier detection of these conditions, 
and better distinction between PSD and PSA treatment may hopefully lead to 
development of treatment strategies and a better clinical prognosis after stroke.
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SUMMARY
Post-stroke depression (PSD) and apathy (PSA) are two of the most common 
neuropsychiatric outcomes after stroke, and have substantial overlap in symptoms. 
Both are associated with poor prognosis, as they have a negative influence on 
functional recovery and quality of life after stroke. Despite a significant overlap in 
associated factors, several studies found indications for differences in associated 
risk factors between PSD and PSA, suggesting that these might represent 
independent syndromes. However, findings were largely based on cross-sectional 
data and studies on PSA are relatively scarce. Furthermore, only few studies have 
looked at the development, course, and associated factors of both syndromes 
at the same time in a longitudinal study. In this thesis, we aimed to examine the 
influence of biological and psychosocial risk factors on the development and 
course of PSD and PSA, and whether differences could be found between the 
associations with these two syndromes. 
In Chapter 2 we provided a systematic review and meta-analysis on imaging 
markers associated with PSD and PSA. We examined the association between PSD 
or PSA and stroke lesion laterality, type, and location, also stratified by study phase 
(i.e. acute, post-acute, chronic phase after stroke) in a meta-analysis. Associations 
with other imaging markers (e.g. white matter hyperintensities (WMH), atrophy, 
lesion volume, number of lesions, cerebral microbleeds) were reviewed 
qualitatively to provide an up-to-date overview. In the post-acute stroke phase 
(0.5 – 6 months post-stroke), PSD was associated with frontal lesions and lesions in 
the basal ganglia. No associations were found with lesion laterality (i.e. left or right 
hemisphere) or lesion type (i.e. ischemic or hemorrhagic stroke). PSA was more 
frequent after hemorrhagic stroke in the acute stroke phase (< 15 days), whereas 
it was more frequent after ischemic stroke in the post-acute phase. Furthermore, 
PSA did not depend on lesion laterality or location, but the amount of available 
PSA studies was limited. The present findings suggest that lesion location rather 
than lesion laterality or type is an important risk factor for PSD in the post-acute 
stroke phase. In contrast, lesion type rather than location or laterality might be an 
important risk factor for PSA, though additional PSA studies are needed to confirm 
this. 
In Chapter 3 the rationale and design of The Cognition and Affect after Stroke: a 
Prospective Evaluation of Risks (CASPER) study is presented. The CASPER study is a 
one-year prospective clinical stroke cohort follow-up study, which was performed 
to study predictors of vascular cognitive impairment, depression and apathy after 
stroke. For this study, 250 patients who suffered from ischemic or hemorrhagic 
stroke were included. A baseline measurement was scheduled at three months 
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post stroke and consisted of a venepuncture, recording of socio-demographic 
information, a neuropsychological assessment and neuropsychiatric interview, 
and a structural 3-Tesla Magnetic Resonance Imaging (MRI) of the brain. The 
neuropsychological assessment and neuropsychiatric interview was repeated at 
6-month and 12-month follow-up. 
In Chapter 4 we studied the temporal relationships between post-stroke fatigue 
(PSF) and PSD and between PSF and PSA. The effect of PSF at three months post-
stroke on the course of depressive and apathetic symptoms over a period of 
12-month follow-up was measured. In addition, we studied the reverse direction 
by examining the effect of PSD (or PSA) at three months post-stroke on the course 
of fatigue symptoms. The results showed a bi-directional association between 
PSF and PSD, whereas PSA was not associated with PSF. Levels of PSF and PSD 
remained stable over time. Therefore, a timely detection of PSF and PSD conditions 
in stroke patients is important, as they tend to persist.
In Chapter 5 we examined the role of premorbid personality traits in the 
development and course of symptoms of depression and apathy after stroke. We 
found an association between high neuroticism and high levels of depression at 
baseline (three months post-stroke), and this figure remained stable during the 
12-month follow-up. In contrast, low extraversion was associated with high levels 
of apathy at baseline, and this association remained stable over time as well. 
These findings show the importance of taking personality traits into account as a 
potential vulnerability factor for PSD and PSA. 
In Chapter 6 we studied the association between lesion-related imaging markers 
and background markers of vascular and degenerative pathology and the 
development of PSD and PSA. The results showed that global brain atrophy and 
severe cerebral small vessel disease (cSVD) burden, but not stroke lesion-related 
markers, were associated with the development of PSA in the first year post-stroke, 
independent of co-morbid PSD and stroke lesion volume. Global brain atrophy 
and medium cSVD burden were associated with the development of PSD, after 
correction for stroke lesion volume and history of depression. After correction for 
co-morbid PSA, only medium cSVD remained significantly associated with PSA. 
This suggests that atrophy and increased cSVD burden are important predictors 
for the development of PSA, and, less strongly, for PSD.
In Chapter 7 we performed longitudinal analyses to examine the influence of 
“any Vascular Cognitive Impairment (VCI)” (impairment in at least one cognitive 
domain due to vascular brain pathology) and degree of VCI (impairment in 
multiple cognitive domains versus impairment in a single domain) on the course 
of depression and apathy symptoms over time. Any VCI predicted an increase in 
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apathy levels from three to 15 months post-stroke, which was most pronounced in 
patients with VCI in multiple cognitive domains. Domain-specific analyses showed 
that particularly impairment in executive dysfunction and slowed information 
processing speed was associated with an increase in apathy symptoms over time. 
None of the cognitive variables predicted the course of depressive symptoms. 
These results implicate that although apathy symptoms may be absent in the first 
months after stroke, these symptoms can develop over time in patients with VCI.
In Chapter 8 we examined whether executive dysfunctions (ED) denote a distinct 
PSD subtype by studying whether the co-occurrence of ED and PSD in a depression-
executive dysfunction depression subtype (DES) is associated with different 
clinical and neuroimaging correlates and a worse prognosis. The DES-subtype 
was associated with higher WMH volume, a higher frequency of old infarcts, more 
global brain atrophy, and higher total cSVD burden on MRI at three months post-
stroke. Longitudinal analyses showed that DES was associated with a less benign 
course, including a non-improving pattern of worse cognitive performance 
compared with ED-only and chronic high levels of depression compared with 
PSD-only. Our findings suggest that DES is associated with increased generalized 
(vascular) brain pathology, which provides support for a strong biological origin of 
depression in the DES group compared with the PSD-only group.
Chapter 9 provided a general discussion of the findings presented in this thesis. 
Also, methodological considerations and conceptual and clinical implications 
were addressed and recommendations for future research were discussed. 
Furthermore, this last chapter includes a summary of the findings, a knowledge 
valorisation, acknowledgements, a list of publications, and information about the 
author. 
Overall, the studies in this thesis provide evidence that different factors are involved 
in the development of PSD and PSA, which are of biological and psychosocial 
origin. This improves our understanding of the pathophysiology of these entities 
and supports the hypothesis that PSA can occur as an independent syndrome, in 
absence of PSD. Differences in vulnerability factors between patients are important 
to incorporate, by means of providing patient-tailored treatment. Earlier detection 
of these conditions, and better distinction between PSD and PSA may hopefully 
lead to development of treatment strategies and a better clinical prognosis after 
stroke.
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NEDERLANDSE SAMENVATTING 
Depressie na een beroerte (oftewel post-stroke-depressie, PSD) en post-stroke 
apathie (PSA) zijn twee van de vaakst voorkomende neuropsychiatrische syndromen 
na een beroerte, en er is een substantiële overlap in symptomen tussen deze 
syndromen. Beide zijn geassocieerd met een slechte prognose, omdat ze een 
negatieve invloed hebben op functioneel herstel en kwaliteit van leven na een 
beroerte. Ondanks een significante overlap in geassocieerde factoren hebben 
verschillende studies aanwijzingen gevonden voor verschillen in geassocieerde 
risicofactoren tussen PSD en PSA, wat suggereert dat ze wellicht onafhankelijke 
syndromen representeren. Echter, bevindingen zijn grotendeels gebaseerd op 
cross-sectionele data en studies naar PSA zijn relatief schaars. Bovendien, hebben 
slechts enkele studies gekeken naar de ontwikkeling, het beloop, en geassocieerde 
factoren van beide syndromen tegelijkertijd binnen een longitudinale studie. Het 
doel van dit proefschrift was om de invloed te onderzoeken van biologische en 
psychosociale risicofactoren op de ontwikkeling en het beloop van PSD en PSA, 
en of er verschillen kunnen worden gevonden tussen de associaties met deze twee 
syndromen. 
In Hoofdstuk 2 hebben we een systematisch literatuuronderzoek en een meta-
analyse gedaan naar kenmerken op beeldvorming (oftewel imaging markers) 
geassocieerd met PSD en PSA. We includeerden in totaal 149 studies die aan de 
criteria voldeden. In een meta-analyse onderzochten we de associatie tussen PSD 
of PSA en de zijde, het type en de locatie van de laesie, ook gestratificeerd per 
studie fase (acute, post-acute, chronische fase na de beroerte). Associaties met 
andere imaging markers (zoals witte stof hyperintensiteiten (WMH), atrofie, laesie 
volume, aantal laesies, cerebrale microbloedingen) werden kwalitatief onderzocht 
om zo een volledig overzicht te geven. In de post-acute fase (0.5 – 6 maanden na de 
beroerte) was PSD geassocieerd met frontale laesies en laesies in de basale ganglia. 
Er werden geen associaties gevonden met de zijde van de laesie (links of rechts), of 
het type van de laesie (ischemisch of hemorrhagisch). PSA was frequenter na een 
hersenbloeding in de acute fase (< 15 dagen), terwijl het frequenter was na een 
herseninfarct in de post-acute fase na de beroerte. PSA was niet afhankelijk van de 
zijde of de locatie van de laesie maar de hoeveelheid beschikbare PSA studies was 
beperkt. De huidige bevindingen suggereren dat locatie van de laesie, in plaats van 
zijde of type, een belangrijke risicofactor is voor PSD in de post-acute fase na de 
beroerte. Daarentegen was laesie type in plaats van locatie of zijde een belangrijke 
risicofactor voor PSA, maar meer PSA studies zijn nodig om dit te kunnen bevestigen. 
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In Hoofdstuk 3 worden de rationale en het design van de Cognitie en Affect 
na Stroke (beroerte) een Prospectieve Evaluatie van Risicofactoren (CASPER) 
gepresenteerd. De CASPER studie is een eenjarige prospectieve follow-up studie 
van een cohort dat een beroerte heeft doorgemaakt. Deze studie is uitgevoerd 
om voorspellers van vasculaire cognitieve beperking, depressie en apathie na een 
beroerte te bestuderen. Voor deze studie werden 250 patiënten geïncludeerd die 
een ischemische of hemorrhagische beroerte hebben gehad. De baseline meting 
werd drie maanden na de beroerte ingepland en bestond uit een bloedafname, 
registratie van socio-demografische informatie, een neuropsychologisch 
onderzoek en een neuropsychiatrisch interview. Ook werd er een structurele 
3-Tesla Magnetische Resonantie Imaging (MRI) van het brein gemaakt. Het 
neuropsychologisch onderzoek en neuropsychiatrisch interview werden herhaald 
tijdens de 6-maand en 12-maand follow-up meting.  
In Hoofdstuk 4 hebben we de temporele relaties tussen vermoeidheid na een 
beroerte (post-stroke fatigue, PSF) en PSD en tussen PSF en PSA bestudeerd. Het 
effect van PSF drie maanden na de beroerte op het beloop van depressieve en 
apathische symptomen werd gemeten over een periode van twaalf maanden. 
Daarnaast hebben we de omgekeerde richting bestudeerd door het effect van PSD 
(of PSA) drie maanden na de beroerte op het beloop van vermoeidheidssymptomen 
te onderzoeken. De resultaten toonden een wederzijdse associatie tussen PSF en 
PSD, maar PSA was niet geassocieerd met PSF. Niveaus van PSF en PSD bleven 
stabiel over tijd. Het tijdig opsporen van deze aandoeningen is dan ook belangrijk 
in patiënten met een beroerte, omdat PSF en PSD de neiging hebben om te 
persisteren. 
In Hoofdstuk 5 hebben we de rol van premorbide persoonlijkheidskenmerken 
in de ontwikkeling en het beloop van symptomen van depressie en apathie na 
een beroerte onderzocht. Op baseline (drie maanden na de beroerte) vonden 
we een associatie tussen hoog neuroticisme en hoge niveaus van depressieve 
symptomen en dit bleef stabiel over een periode van 12 maanden. Laag in 
extraversie (introversie) was geassocieerd met hoge niveaus van apathie op 
baseline en deze associatie bleef ook stabiel over tijd.  Deze bevindingen tonen het 
belang aan van het inachtnemen van persoonlijkheidskenmerken als potentiële 
kwetsbaarheidsfactoren voor PSD en PSA. 
In Hoofdstuk 6 hebben we de associatie bestudeerd tussen laesie-gerelateerde 
imaging markers en markers van vasculaire en degeneratieve achtergrondschade 
en de ontwikkeling van PSD en PSA. Deze resultaten toonden aan dat globale 
hersenatrofie en ernstige cerebral small vessel disease (cSVD) pathologie op 
MRI (ziekte van de kleine hersenvaten), maar niet laesie-gerelateerde markers, 
geassocieerd waren met het ontwikkelen van PSA in het eerste jaar na de beroerte, 
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onafhankelijk van co-morbide PSD en het volume van de beroerte. Globale 
brein atrofie en medium cSVD pathologie op MRI waren geassocieerd met het 
ontwikkelen van PSD, na correctie voor het laesie volume en depressie in de 
voorgeschiedenis. Na correctie voor co-morbide PSA bleef alleen medium cSVD 
pathologie op MRI significant geassocieerd met PSA. Dit suggereert dat atrofie en 
ernst van cSVD pathologie belangrijke voorspellers zijn voor het ontwikkelen van 
PSA, en in mindere mate voor PSD. 
In Hoofdstuk 7 hebben we longitudinale analyses uitgevoerd om de invloed 
van “any Vascular Cognitive Impairment (VCI)” (een cognitieve beperking ten 
gevolge van vasculaire hersenpathologie in tenminste één cognitief domein) en 
ernst van VCI (cognitieve beperking in meerdere cognitieve domeinen versus 
een beperking in een enkel cognitief domein) op het beloop van depressie en 
apathie symptomen over tijd te onderzoeken. “Any VCI” voorspelde een toename 
in niveaus van apathie over de periode van drie tot vijftien maanden na de 
beroerte en deze was het meest uitgesproken voor patiënten met VCI in meerdere 
cognitieve domeinen. Domein-specifieke analyses toonden aan dat voornamelijk 
executief dysfunctioneren en vertraagde informatie verwerkingssnelheid 
geassocieerd waren met een toename in apathie symptomen over tijd. Geen van 
de cognitieve variabelen voorspelden het beloop van depressieve symptomen. 
Deze resultaten impliceren dat hoewel apathie symptomen wellicht afwezig zijn 
in de eerste maanden na de beroerte, deze symptomen wel kunnen ontwikkelen 
over tijd in patiënten met VCI. 
In Hoofdstuk 8 hebben we onderzocht of executief dysfunctioneren (ED) een 
subtype van PSD onderscheidt door te bestuderen of het samen voorkomen van 
ED en PSD in een depressie-executieve dysfunctie subtype (DES) geassocieerd is 
met verschillende klinische en imaging correlaten van het brein en een slechtere 
prognose. De resultaten lieten zien dat het DES-subtype geassocieerd is met 
een groter witte stof laesie volume, een hogere frequentie van oude infarcten, 
meer globale brein atrofie, en een hogere totale cSVD brein pathologie score 
op MRI drie maanden na de beroerte. Longitudinale analyses lieten zien dat DES 
geassocieerd was met een minder voorspoedig beloop, met een niet-verbeterend 
patroon van slechtere cognitieve prestaties in vergelijking met patiënten met 
enkel ED en chronisch hoge niveaus van depressie in vergeljking met patiënten 
met alleen PSD. Onze bevindingen suggereren dat DES geassocieerd is met 
meer gegeneraliseerde (vasculaire) hersenpathologie, wat bewijs is voor een 
sterke biologische oorsprong voor depressie in de DES groep in vergelijking met 
patiënten met alleen PSD. 
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Hoofdstuk 9 bevat een algemene discussie van onze bevindingen gepresenteerd 
in dit proefschrift. Daarnaast werden er methodologische overwegingen 
en conceptuele en klinische implicaties besproken en aanbevelingen voor 
toekomstig onderzoek werden gegeven. Daarnaast bevat dit laatste hoofdstuk 
een Engelse en Nederlandse samenvatting van de belangrijkste bevindingen, een 
kennisvalorisatie, een dankwoord, een publicatielijst en informatie over de auteur. 
In het algemeen hebben de studies in deze dissertatie bewijs geleverd dat er 
verschillende factoren betrokken zijn bij de ontwikkeling van PSD en PSA en deze 
zijn van biologische en psychosociale aard. Deze kennis verbetert ons begrip 
van de pathofysiologie van deze entiteiten en ondersteunt het idee dat PSA kan 
voorkomen als een onafhankelijk syndroom, in afwezigheid van PSD. Verschillen 
in kwetsbaarheidsfactoren tussen patiënten zijn belangrijk om in overweging 
te nemen, door het aanbieden van behandeling op maat (patiënt-specifiek). 
Vroegere detectie van deze condities en beter onderscheid tussen PSD en PSA 
leidt hopelijk tot de ontwikkeling van behandelingsstrategieën en een betere 
klinische prognose na een beroerte. 
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KNOWLEDGE VALORIZATION
The aim of this thesis was to examine the association of biological and psychosocial 
risk factors on the development and course of post-stroke depression (PSD) and 
post-stroke apathy (PSA), and whether differences could be found between the 
associations with these two syndromes. This valorization paragraph describes how 
the results of this thesis are of societal relevance and economic application. 
Mrs. K is a 69-year-old married woman who suffered from a stroke in her right 
hemisphere. Shortly after the stroke, her clinical symptoms were nausea and 
vomiting, sensations in the left corner of her mouth and in the fingers of her left 
hand. These symptoms were present for two weeks and then disappeared slowly. 
After ten weeks Mrs. K has an appointment with her neurologist. She tells him that 
she feels fine, and experiences no residual complaints anymore from the stroke. 
When the neurologist asks her husband how he experiences the situation, he 
answers: “My wife changed a lot since she suffered from the stroke. Since the stroke 
she is sleeping a lot during the day. She does not perform in any household chores 
and is also relatively inactive in comparison to her activities before the stroke, when 
she used to swim very often, which she no longer cares to do. Also, her social life 
is very limited at the moment. She is not interested in meeting with other people, 
except for our sons.”
This case describes an example of a stroke patient suffering from apathy. However, 
she does not report this as a complaint to her neurologist, though her husband 
is worried about her passive behavior and lack of interest. Will the neurologist 
recognize the behavior of this patient as apathy? 
SOCIETAL RELEVANCE
Stroke is a leading cause of disability in the world. In the Netherlands, each year 
around 41,000 individuals suffer from a stroke, and currently more than 240,000 
individuals are estimated to live with the consequences of stroke every day. As 
a result of the aging population, the prevalence of stroke will increase steadily, 
from 186,000 in 2011 to 343,000 in 2040. Currently, the costs associated with 
care for stroke patients are approximately 2.5% of the total health care costs. As 
the life expectancy after stroke has been increasing due to better acute stroke 
treatment, the number of stroke survivors dealing with the consequences of stroke 
is increasing as well. 
The residual consequences of stroke vary between patients, but can include 
physical impairments (i.e. paresis), speech difficulties, visual impairment, cognitive 
impairment, changes in personality, and the occurrence of neuropsychiatric 
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symptoms. These factors all have a huge impact on stroke survivors and their 
caregivers, family, and other close relatives. Neuropsychiatric symptoms, like 
depression and apathy, occur in around a third of stroke survivors and have 
a negative influence on functional outcome and quality of life. As health-care 
professionals often do not recognize these neuropsychiatric consequences timely, 
several stroke survivors have unmet treatment needs. 
As loss of motivation plays an important role in both apathy and depression, there 
is large overlap in clinical symptomatology and several studies found also overlap 
in risk factors between these syndromes. Despite this overlap, there is also some 
evidence suggesting that different risk factors may be involved in the development 
of PSD and PSA.  However, risk factors associated with PSA are studied less 
frequently compared with PSD and only few longitudinal studies are available. 
Also, studies examining and comparing risk factors involved in the development 
of both PSD and PSA are scarce. Therefore, it is currently poorly understood if and 
how both biological and psychosocial factors have a differential influence on the 
development and course of PSD and PSA over time. A better understanding of 
the role of these risk factors is important, as for developing treatment strategies 
for PSD and PSA, a better understanding of the underlying pathophysiological 
mechanisms is required. Also, a better understanding of the etiological factors 
involved in these syndromes may result in better recognition, distinction, and 
earlier detection of PSD and PSA. Eventually, this could have a positive effect on 
quality of life and clinical outcome of stroke survivors, as this knowledge may 
help improving treatment possibilities. By providing patient-tailored care options 
for patients at risk for developing PSD and PSA, the prevalence of PSD and PSA 
will hopefully reduce, which will eventually also lower the health care costs and 
societal burden associated with it.
TARGET AUDIENCE
The findings presented in this thesis are relevant for several target groups, including 
stroke survivors and their relatives, health care professionals, and researchers.
The results are relevant for stroke survivors and their relatives, as the studies 
presented in this thesis provide more information about risk factors that are 
involved in the development of PSD and PSA, and also how these influence the 
course of PSD and PSA over time. A better explanation and psycho-education 
with respect to the risk of developing PSD and PSA to stroke survivors and their 
relatives is important, as currently a lot of them are not aware that these syndromes 
can develop as a consequence of their brain damage, also at a later stage during 
the chronic stroke phase. The current development of specialized stroke after-care 
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clinics, which have specific expertise regarding neuropsychiatric symptoms after 
stroke, like PSD and PSA, are therefore a good and promising development, as 
these clinics can provide this psycho-education. Therefore, we deem the findings 
of this thesis of particular relevance to these specialized stroke after-care clinics.
All health care professionals (neurologists, rehabilitation physicians, psychiatrists, 
general practitioners, and (neuro)psychologists) treating stroke survivors are 
important stakeholders as well, as they are the ones who need to inform stroke 
survivors about the risk of developing symptoms of depression and apathy after 
stroke, and which risk factors are involved in the development of these syndromes. 
The results of this thesis have shed more light on the risk factors that play an 
important role in the development and course of apathy and depression and 
shows that the risk factors being involved are different to some extent for PSD and 
PSA. More knowledge about the etiology of PSD and PSA will help to recognize 
these conditions by health care professionals and identify patients (timely) who 
are at risk to develop PSD or PSA. Better diagnostic distinction between PSD and 
PSA is important, as these conditions seem to benefit from different treatment 
strategies.
The findings resulting from this thesis are also relevant for researchers in the stroke 
field, as they shed more light on the biological and psychosocial factors that are 
involved in the etiology of PSD and PSA, which improves the understanding of the 
pathophysiology of these syndromes. This information is particularly important 
for researchers who examine possible pharmacological and psychotherapeutical 
treatment strategies for PSD and PSA, as the results indicate that PSA can occur as 
an independent syndrome, independent of PSD, and has its own associated risk 
factors that influence the development and course of this syndrome. In addition, 
the results may also be of use for researchers who work with other patient 
populations in which both apathy and depression are frequent (like Parkinson’s 
disease, Alzheimer’s disease and other types of dementia, or traumatic brain 
injury), as some of the associations found in this thesis might also hold for these 
other disease populations. 
INNOVATION AND PRODUCTS
The CASPER study measured a range of 3-Tesla structural brain MRI markers, 
both volumetric and visual. The semi-automatic volumetric assessment of white 
matter hyperintensities and manual segmentation of stroke lesion tissue provided 
a precise measure, which made it possible to study subtle differences and also 
to study the role of both lesion-related markers (location, volume, laterality) and 
generalized background brain pathology (total cerebral small vessel disease 
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burden, global brain atrophy, white matter hyperintensity volume, number of old 
infarcts or lacunes, and number of cerebral microbleeds). This made it possible 
to compare the influence of certain MRI markers on the development of PSD 
and PSA. The main product of this thesis is the implications that the findings 
have for the understanding of the pathophysiology of PSD and PSA. The findings 
provide evidence that both biological and psychosocial factors are involved in the 
development of PSD and PSA. Also, differences in associated risk factors between 
PSD and PSA suggest that PSA can also occur as an independent syndrome, in 
absence of depressive symptoms. These findings are important for researchers 
developing treatment strategies for PSD and PSA, as a better understanding of 
the complex multifactorial origin of these conditions is needed for successful 
treatment. 
Participants of the study were updated about the study progress through 
newsletters. Also, the results in this thesis were presented at several international 
and national congresses. 
IMPLEMENTATION
The clinical importance of this thesis involves the differentiation between risk 
factors being involved in the development of PSD and PSA, which were of both 
biological and psychosocial origin. The knowledge derived from the studies 
presented in this thesis will be the base for research into the role of biological and 
psychosocial predictors of PSD, PSA, and VCI. The results presented in this thesis 
show that it is important to consider the role of both biological and psychosocial 
factors, and studying their inter-relationships and interactions is another future 
goal, as this is needed to unravel the complex multifactorial origin of PSD and 
PSA. Also other biomarker data were collected for CASPER (inflammatory markers 
and epigenetics), which were not part of the present thesis but will be used for 
future studies, as these are also likely to be important factors influencing the 
development and course of PSD and PSA. In addition, the CASPER study joined 
the STROKOG consortium (https://cheba.unsw.edu.au/group/strokog), which has 
built a database with more than 12,000 stroke patients. This large dataset yields 
new opportunities for studying subtle changes, which require large datasets and 
will likely yield important results concerning factors associated with PSD and PSA. 
Also, participants of CASPER were approached for participation in our long-term 
follow-up study, for which we are currently collecting data. For this study, we are 
collecting data at 3 years post-stroke. These long-term data can provide interesting 
findings with respect to PSD and PSA as potential risk factors for mortality and the 
development of vascular dementia.
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HOW COULD MRS. K BENEFIT FROM THE RESULTS OF THIS THESIS?
The neurologist of Mrs. K has read some articles on apathy after stroke and realizes 
that this is a frequent complaint after stroke, which is often confused with depression. 
He administers a semi-structured questionnaire based on DSM-5 criteria to find out 
if Mrs. K has depressed feelings, but that was not the case. The neurologist explains 
to Mrs. K and her husband that apathy is a frequent complaint after stroke and that 
it is sometimes part of a depressive disorder, but not necessarily. He tells them that 
there are currently no pharmacological treatment options for apathy available. He 
advises the husband to keep motivating Mrs. K to stay active and to help her setting 
goals, because that is difficult for her. The neurologist also decides to refer them 
to a neuropsychologist, who can help the couple dealing with this new situation. 
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DANKWOORD (ACKNOWLEDGEMENTS)
De afgelopen drie jaar zijn voorbij gevlogen en met veel plezier heb ik gewerkt aan 
de totstandkoming van dit proefschrift. Het was een bijzondere ervaring, waarin ik 
veel heb geleerd. Dit mooie resultaat heb ik niet in mijn eentje bereikt en daarom 
wil ik ik graag alle mensen bedanken die hieraan een bijdrage hebben geleverd.
Allereerst wil ik mijn promotieteam bedanken voor de expertise en begeleiding. 
Mijn promotor, Prof. Dr. Frans Verhey, beste Frans. Bedankt dat je me de kans 
hebt geboden om de afgelopen jaren aan dit onderzoek te mogen werken en 
om mezelf te ontwikkelen tot de wetenschapper die ik nu ben. Zowel je klinische 
als wetenschappelijke kennis waren van onschatbare waarde voor het project. 
Bedankt voor de fijne samenwerking.
Mijn co-promotoren, dr. Pauline Aalten en dr. Julie Staals. 
Beste Pauline, vanaf het begin van mijn promotietraject gaf je me het gevoel 
dat jij er alle vertrouwen in had dat ik aan het eind van mijn promotietraject een 
proefschrift zou afleveren waar we trots op konden zijn; en ik heb het gevoel dat 
het gelukt is! Jouw enthousiasme en support speelden hierin een belangrijke rol. 
Het is bewonderenswaardig hoe je je werk als onderzoeker en studieadviseur 
combineert en vaak in de (late) avonduren bezig was om mijn stukken na te kijken, 
of bijna 6000 abstracts te screenen. Ik wil je bedanken voor je begeleiding, het 
vetrouwen, de fijne overleggen waarin we ook andere dingen dan het onderzoek 
konden bespreken, en voor de prettige samenwerking. 
Beste Julie, wat heb ik veel van je geleerd. In ruil voor wat zakjes drop was je bereid 
om voor de CASPER studie bijna 200 MRI scans samen te bekijken (de meeste 
zelfs twee keer) en het was voor mij erg leerzaam. Je hielp bij het vinden van de 
deelnemers en dacht mee op alle fronten van het onderzoek. Als ik een nieuw 
manuscript rondstuurde was je bijna altijd de eerste die er naar had gekeken. 
Hier stond dan vaak in dat het wat aan de lange kant was (omdat psychologen in 
tegenstelling tot neurologen soms wat lang van stof kunnen zijn). Je expertise was 
van onschatbare waarde. Bedankt voor de prettige samenwerking.
Dank aan alle leden van de beoordelingscommissie, Prof. dr. Hofman, Prof. dr. 
Visser-Meily, Prof. dr. de Leeuw, Dr. Duits en Dr. Leentjens, voor het lezen en 
beoordelen van mijn proefschrift.
Een bijzonder woord van dank aan de andere leden van het CASPER-team.
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Dr. Köhler, beste Seb, jij was de spil van het onderzoek en jouw kennis en 
vaardigheden tilden onze artikelen naar een hoger level. Bedankt voor alles wat ik 
van je heb mogen leren in de afgelopen jaren, voor je statistische kennis en hulp, 
de interessante gesprekken over de bevindingen die we deden, en voor je support 
als ik een praatje moest geven op een congres. Jouw passie, gedrevenheid en 
enthousiasme werken aanstekelijk, bedankt voor de fijne samenwerking!
Prof. dr. Robert J. van Oostenbrugge, beste Robert. Bedankt voor je expertise 
en kritische blik op alle artikelen. Je hielp ons om de soms ingewikkelde 
neuropsychologische resultaten begrijpelijk te houden voor clinici. Ondanks 
je drukke agenda had je toch tijd om samen met mij zo’n 100 MRI scans te 
beoordelen. Bedankt!
Syenna, lieve roomie, en mijn partner op het project. Dankzij jouw harde werken 
aan het opzetten van de CASPER studie, een enorme klus waarbij aan ieder detail 
gedacht is, kon ik als stagiaire en daarna als AIO direct van start om samen met jou 
deelnemers te vinden en de data te verzamelen. Dit ging niet altijd zonder slag of 
stoot, maar we bleven positief en vierden iedere geïncludeerde deelnemer. Met 
jou kon ik als geen ander sparren over studie-gerelateerde kwesties en over nog 
zoveel meer! Veel lief en leed hebben we de afgelopen jaren met elkaar gedeeld, 
maar vooral ontzettend gelachen! Bedànk meadje! 
Hartelijk dank aan alle deelnemers en naasten die hebben meegewerkt aan de 
CASPER studie. Zonder jullie bereidheid en enthousiasme om een bijdrage te 
leveren aan deze studie was het totstandkomen van dit proefschrift nooit mogelijk 
geweest. Ook dank ik alle stagiaires en onderzoeksassistenten die zich hebben 
ingezet voor de studie: Dynah, Danique (op jou kom ik later nog even terug!), 
Lieke, Loes, Esmee, Sascha, Janneke, Tessa, Lise, Ileana, Anne en Wies. Tanja, 
bedankt voor alle telefonische naaste-interviews die je voor ons hebt gedaan. 
Joost, bedankt voor je hulp bij de dubbele datainvoer.  
Bedankt aan alle medewerkers van de afdeling neurologie van het MUMC+, in het 
bijzonder de baliemedewerkers van verpleegafdeling C5 en CVA-verpleegkundige 
Anouk van der Kwaak, voor de hulp bij het benaderen van de deelnemers. 
Ook hartelijk dank aan Zuyderland Medisch Centrum te Sittard en Heerlen, in het 
bijzonder Roger Nieling en Tiny Simons-Sporken, voor jullie hulp bij de inclusie 
voor de CASPER studie. 
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De medewerkers van de afdeling radiologie, in het bijzonder Martijn Wolters, May 
Wong, Harm van de Haar, Marc Geerlings en Jos Slenter, bedankt voor al jullie 
expertise en hulp bij het verkrijgen, anonimiseren, bewerken en analyseren van 
onze MRI data. 
Many thanks to Mercedes for her contribution to the systematic review and meta-
analysis. It resulted in a great publication! Robin Wolz, thank you for the acquisition 
of the hippocampal volume data.
Een speciaal woord van dank aan Iliana Boshoven van AgileColor.com voor de 
cover en lay-out van het boekje. Dankzij jou ziet het proefschrift er prachtig uit!
Dymphie in de Braek, Chantal Geusgens en Marjolein de Vugt. Door jullie is bij 
mij het enthousiasme voor de klinische praktijk altijd gebleven. Bedankt voor alles 
wat ik van jullie “neuropsychologen” heb mogen leren in de afgelopen jaren. 
Alle (oud-)collega’s van de afdeling Psychiatrie en Neuropsychologie wil ik 
bedanken voor de fijne samenwerking, gezellige sfeer op de afdeling en de leuke 
uitjes en congressen. 
Mijn paranimfies Danique en Liselot! Wat ben ik trots dat jullie tijdens de 
verdediging achter mij staan!
Lieve Danique, bijna 4 jaar geleden leerde ik je kennen als mijn stagiaire-partner 
op de CASPER studie. Daarna heb je ook als onderzoeksassistent mij op alle 
fronten geholpen bij de studie en was je af en toe mijn redder in nood! Ook 
hebben we samen vele uren doorgebracht in het MRI computerhok waar we de 
hele dag zaten te “kleuren” onder het genot van Sky radio christmas! Inmiddels 
ben je alweer ruim een jaar bezig met je eigen PhD en zijn we zelfs roomies. Lieve 
Danique, bedankt voor alle mentale support, je hulp, je gezelligheid. Voor alles. 
Zonder jou was het lang niet zo leuk geweest! 
Lieve Liselot, in september 2014 begonnen we beide aan onze PhD, als roomies! 
Samen verkenden we het AIO wereldje, gingen we naar alle cursussen. Jij 
overtuigde me dat ik best even pauze kon nemen als ik weer eens (te) druk bezig 
was, samen even een rondje wandelen, een koffietje doen. Bedankt voor alle 
gezelligheid, voor de leuke logeerpartijtjes, chocola-uitwisselingen, bioscoop 
bezoekjes, en met als hoogtepunt toch wel de leuke trip naar Florence dit jaar, 
samen met Anne, Leonie, en Angélique. Wat hebben we gelachen, lekkere 
cheesecake gehad (en ook vieze), een ruime hoeveelheid zon, lekker eten, veel 
wijn…. Dankjewel lieve Liselot, je bent een topper!
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Mijn buurvrouwen van de UNS40: Alieske, Isabelle, Whitney en Lotte. Jullie zijn 
geweldig! Wat is het fijn om de laatste loodjes van je PhD te kunnen delen met zulke 
supportgevende collega’s! Het maakte het allemaal een stuk draaglijker. Alieske, 
samen met jou naar Berlijn en Florence was een feestje, wat een gezellige tijd, 
konden we het nog maar eens overdoen! Isabelle, je vrolijkheid en enthousiasme 
en altijd goede raad maken je een topcollega. Whitney, super leuk dat je als co-
auteur op een van de artikelen staat! Jouw radiologische kennis kwam goed van 
pas. Bedankt voor alle gezellige momenten! Lotte, jij staat altijd voor iedereen 
klaar! Bedankt dat je nog een blik op mijn discussie hebt willen werpen voor de 
laatste grammaticale punten op de i. 
Angélique, ruim een jaar geleden begon je als AIO maar het voelt alsof ik je al veel 
langer ken. Uren hebben we al samen in de trein gezeten op het traject Weert-
Maastricht, maar we zijn nóóit uitgepraat. Je bent altijd geïnteresseerd, wist altijd 
de status van mijn artikelen, je bent een topper! 
Leonie, altijd fijn om met jou even onze ervaringen uit te wisselen, omdat je net als 
ik een 1+3 constructie doet. Dankjewel voor je support en gezelligheid!
Mijn ex-roomies, Kay, Inge en Babette. Wat een gezellige drukte was het soms hè 
op onze kamer! Het was fijn om ervaringen uit te wisselen en ondanks dat we aan 
verschillende projecten werkten konden we bij elkaar terecht voor advies. Kay, 
bedankt voor je hulp en raad bij het uitvoeren van mijn systematische review en 
bij allerlei andere zaken. Leuk dat je me in een sneltreinvaart wat van Londen kon 
laten zien! Inge, je staat altijd voor iedereen klaar en hebt ook geholpen bij het 
includeren van onze deelnemers. Babette, bedankt voor de gezellige tijd, veel 
succes met de laatste loodjes van je proefschrift. 
Rosalie, Lizzy, Willemijn en Joany. Jullie waren de senior AIOs bij wie ik altijd 
terecht kon met vragen. Super fijn als iemand met je meedenkt en hulp biedt 
bij de laatste loodjes van het promoveren! Bedankt voor alle gezelligheid op het 
werk, in de trein en op congres. 
Nico, zonder jouw hulp was het uitvoeren van het onderzoek praktisch onmogelijk. 
Wat een verademing was het toen we ons excel bestand konden vervangen door 
filemaker, dit scheelde een hoop werk en vooral stress! Bedankt voor al je hulp 
bij computerproblemen, je stond altijd voor me klaar. Daniëlle en Els, jullie waren 
altijd bereid om te helpen, bedankt!
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Renske en Eleana, collega AIOs van de neurologie. Renske, het was altijd fijn 
en gezellig om onze PhD ervaringen te delen en om elkaar tegen te komen bij 
cursussen. We waren tegelijkertijd bezig met onze laatste loodjes en nu gaan 
we vlak na elkaar verdedigen. Fijn dat ik nog even bij jou kan afkijken voordat ik 
zelf aan de beurt ben ;-)! Samen op congres in Amsterdam en Praag was onwijs 
gezellig! 
Eleana, als collega binnen het stroke onderzoek was het fijn om met je samen te 
werken, om ervaringen te delen en om bij te kletsen over vanalles en nog wat. 
Sanne, Anne, Niky en Danique (coffeelovers). Wij waren de harde kern die 
overbleef in Maastricht na onze stage periode als MUMC chicks. Wat een toppers 
zijn jullie! Bedankt voor de lunches, koffiedates, en etentjes de afgelopen tijd. Met 
jullie is het altijd een berg gezelligheid. Hopelijk volgen er nog vele afspraakjes!
Lieve vriendinnen, vrienden en schoonfamilie, het was wellicht een raadsel voor 
jullie wat dat promoveren nou precies inhield, maar hopelijk is het met het zien 
van dit boekje nu wat duidelijker! Bedankt voor jullie interesse in de voortgang 
van mijn onderzoek en voor jullie gezelligheid en afleiding wanneer dat soms 
nodig was. Hopelijk volgen er nog vele leuke en gezellige feestjes, etentjes, 
borrels, uitjes en andere momenten samen! 
Lieve Inge, mijn grote zus, en schoonbroer Martijn. Bedankt voor jullie interesse 
en voor de leuke dingen die we samen doen. Dat ik dit jaar getuige mocht zijn op 
jullie bruiloft was een hele eer! 
Lieve pap en mam. Door jullie ben ik geworden wie ik nu ben. Bedankt voor alles 
wat jullie me hebben meegegeven en voor alle steun en interesse die jullie altijd 
lieten en laten blijken. Door jullie heb ik geleerd om te genieten van alles wat ik 
mee mag maken. Ik weet dat jullie trots op mij zijn! Het is fijn om zo’n fijn “thuis” 
te hebben. 
Tot slot, liefste Patrick. Jij bent zonder twijfel de allerbelangrijkste reden dat het 
mij gelukt is om dit proefschrift af te ronden. Jij wist altijd precies wat ik nodig 
had als ik even gestresst was. Jouw nuchtere kijk op dingen werkt verhelderend. 
Bedankt voor je steun en hulp, maar vooral bedankt voor wat wij samen hebben. 
Op nog vele mooie jaren!
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THESIS DEFENSES FROM MHENS (SCHOOL FOR MENTAL 
HEALTH AND NEUROSCIENCE)
2013
Rob Havermans: Bipolar disorder in daily life; Mood and cortisol responses to naturally occurring 
events. Supervisor: Prof.dr. M. de Vries; Co-Supervisor: Dr. N. Nicolson. 
Véronique Moers-Hornikx: Deep brain stimulation and the cerebellum. Supervisors: Prof.dr. J. Vles / 
Prof.dr. Y. Temel; Co-Supervisor: Dr. G. Hoogland. 
Nicole Veldhorst-Janssen: Intranasal delivery of rapid acting drugs. Supervisors: Prof.dr. M. Marcus / 
Prof.dr. C. Neef; Co-Supervisor: Dr. P.H. van der Kuy. 
Stéphanie Knippenberg: Vitamin D and Multiple Sclerosis: immunological and clinical outcome. 
Supervisor: Prof.dr. J. Cohen-Tervaert; Co-Supervisors: Dr. J. Damoiseaux / Dr. Y. Bols. 
Erik D. Gommer: Dynamic Cerebral Autoregulation: from methodology towards clinical application. 
Supervisors: Prof.dr. W.H. Mess / Prof.dr. R.B. Panerai, UK; Co-Supervisor: Dr.ir. J.P.H. Reulen. 
Olga A.H. Reneerkens: Can PDE inhibition improve cognition ? Translational insights. Supervisor: Prof.
dr. H.W.M. Steinbusch; Co-Supervisor: Dr. J. Prickaerts. 
Lyzel S. Elias-Sonnenschein: Clinical and biomarker correlates of genetic risk factors for Alzheimer’s 
disease. Supervisor: Prof.dr. F.R.J. Verhey; Co-Supervisor: Dr. P.J. Visser. 
Diego F. Mastroeni: Epigenetic Dysregulation and the Pathophysiology of of Alzheimer’s Disease. 
Supervisors: Prof.dr. H.W.M. Steinbusch / Prof.dr. P.D. Coleman, Sun City, Arizona; Co-Supervisors: 
Dr. B.P.F. Rutten / Dr. D.L.A. van den Hove. 
Leonidas Chouliaras: Epigenetic Regulation in Aging and Alzheimer’s disease: A translational 
perspective. Supervisor: Prof.dr. H.W.M. Steinbusch; Co-Supervisors: Dr. B.P.F. Rutten / Dr. D.L.A. 
van den Hove. 
Liesbeth Knaepen: Perinatal events and altered pain sensitivity in later life. Supervisors: Prof.dr. E.A.J. 
Joosten / Prof.dr. D. Tibboel, EUR; Co-Supervisor: Dr. J. Patijn. 
Marisela Martinez-Claros: Hippocampal plasticity and corticosterone: From dendrites to behaviour. 
Supervisor: Prof.dr. H.W.M. Steinbusch; Co-Supervisors: Dr. J.L. Pawluski / Dr. J. Prickaerts. 
Marcus D. Lancé: A circle of improvement in bleeding management: from laboratory to clinic and 
back. Supervisors: Prof.dr. M.A.E. Marcu / Prof.dr. J.W.M. Heemskerk; Co-Supervisor: Dr. Y.M.C. 
Henskens. 
Hilde Braakman: Imaging the brain; neuronal correlates of cognitive impairment in children with 
frontal lobe epilepsy. Supervisors: Prof.dr. A.P. Aldenkamp /Prof.dr. J.S.H. Vles; Co-Supervisors: 
Dr.ir. W.H. Backes / Dr. P.A.M. Hofman. 
Willem H. van Zwam: Aneurysmal subarachnoid hemorrhage: imaging strategies and cost-
effectiveness aspects in diagnostic work-up and post-therapeutic follow-up. Supervisors: Prof.
dr. J.T. Wilmink / Prof.dr. J.E. Wildberger; Co-Supervisor: Dr. P.A.M. Hofman. 
Klara De Cort: The Pathogenesis of Panic Disorder. Supervisors: Prof.dr. I. Myin-Germeys / Prof.dr. E.J.L. 
Griez; Co-Supervisors: Dr. K.R.J. Schruers / Dr. I. Van Diest, Leuven. 
Kim van Wijck: Mind the Gap; experimental studies on splanchnic hyperfusion and gastrointestinal 
integrity loss in man. Supervisors: Prof.dr. W.A. Buurman / Prof.dr. C.H.C. Dejong; Co-Supervisor: 
Dr. K. Lenaerts. 
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Yvette Roke: Antipsychotic-induced hyperprolactinemia in children and adolescents with mainly 
autism spectrum disorders. Prevalence, symptoms, clinical consequences and genetic risk 
factors. Supervisors: Prof.dr. P.N. van Harten / Prof.dr. J.K. Buitelaar (RUN); Co-Supervisor: Dr. A. 
Boot (UMCG). 
Fleur Goezinne: Retinal detachment surgery: pre and postoperative prognostic factors. Supervisors: 
Prof.dr. F. Hendrikse / Prof.dr. C.A.B. Webers; Co-Supervisor: Dr. E.C. La Heij (Amsterdam). 
Ralph L.J.G. Maassen: The Merits of Videolaryngoscopy during Glottic Visualisation for Endotracheal 
Intubation. Supervisors: Prof.dr. M. Marcus / Prof.dr. A. van Zundert (University of Queensland). 
Maria J. de Sousa Guerreiro: The role of sensory modality in age-related distraction Supervisor: Prof.
dr. C.M. van Heugten; Co-Supervisor: Dr. P.W.M. van Gerven. 
Ine Rayen: Effects of developmental fluoxetine exposure on neurobehavioral outcomes. Supervisor: 
Prof.dr. H.W.M. Steinbusch; Co-Supervisors: Dr. J.L. Pawluski / Dr. T.D. Charlier (Ohio University, 
USA). 
Nynke M.G. Bodde: Psychogenic non-epileptic seizures; a separate disorder or part of a continuum? 
Supervisors: Prof.dr. R. van Oostenbrugge / Prof.dr. K. Vonck (UZ Gent); Co-Supervisors: Dr. R. 
Lazeron / Dr. A. de Louw (Epilepsiecentrum Kempenhaeghe, Heeze). 
Alejandro M. Gomez: Novel strategies for making myasthenia less gravis: targeting plasma cells and 
the neuromuscular junction. Supervisor: Prof.dr. M.H. De Baets; Co-Supervisors: Dr. M. Losen / 
Dr. P. Martinez-Martinez. 
Mohammad S. Rahnama’i: Prostaglandins and Phosphodiesterases in the Urinary Bladder Wall. 
Supervisors: Prof.dr. Ph. Van Kerrebroeck / Prof.dr. S. de Wachter (Universiteit Antwerpen); Co-
Supervisor: Dr. G. van Koeveringe. 
Mariken B. de Koning: Studying biomarkers in populations at genetic and clinical high risk for 
psychosis. Supervisors: Prof.dr. T. Amelsvoort / Prof.dr. J. Booij (AMC). 
Fabien Boulle: Epigenetic regulation of BDNF/TrkB signaling in the pathophysiology and treatment 
of mood disorders. Supervisors: Prof.dr. H.W.M. Steinbusch / Prof.dr. L. Lanfumey (Universiteit 
Parijs); Co-Supervisors: Dr. D. van den Hove / Dr. G. Kenis. 
2014
Iris Nowak-Maes: Tinnitus; assessment of quality of life & cost-effectiveness. Supervisors: Prof.dr. M. 
Peters / Prof.dr. B. Kremer; Co-Supervisors: Dr. M. Joore / Dr. L. Anteunis. 
Marjolein Huijts: Cognitive function in patients with cerebral small vessel disease. Supervisor: Prof.dr. 
R.J. van Oostenbrugge; Co-Supervisors: Dr. A.A. Duits / Dr. J. Staals. 
Markus Gantert: Fetal inflammatory injury as origin of long term disease: Lessons from animal models. 
Supervisors: Prof.dr. B. Kramer / Prof.dr. L. Zimmermann; Co-Supervisor: Dr. A. Gavilanes. 
Elke Kuypers: Fetal development after antenatal exposures: Chorioamnionitis and maternal 
glucocorticoids. Supervisors: Prof.dr. B.W. Kramer / Prof.dr. H.W. Steinbusch / Prof.dr. Suhas G. 
Kallapur (University of Cincinnati, Ohio, USA). 
Pieter Kubben: Ultra low-field strength intraoperative MRI for Glioblastoma Surgery. Supervisor: Prof.
dr. J.J. van Overbeeke; Co-Supervisor: Dr. H. van Santbrink. 
Laura Baijens: Surface electrical stimulation of the neck for oropharyngeal dysphagia in Parkinson’s 
disease: therapeutic aspects and reliability of measurement. Supervisor: Prof.dr. B. Kremer; Co-
Supervisor: Dr. R. Speyer, Townsville. 
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Janneke Hoeijmakers: Small fiber neuropathy and sodium channels; a paradigm shift. Supervisor: 
Prof.dr. R.J. van Oostenbrugge; Co-Supervisors: Dr. C.G. Faber / Dr. I.S.J. Merkies. 
Stephanie Vos: The Role of biomarkers in preclinical and prodromal Alzheimer’s disease. Supervisor: 
Prof.dr. F.R. Verhey; Co-Supervisor: Dr. P.J. Visser. 
Muriël Doors: The Value of Optical Coherence Tomography in Anterior Segment Surgery. Supervisors: 
Prof.dr. R.M. Nuijts / Prof.dr. C.A. Webers; Co-Supervisor: Dr. T.T.J.M. Berendschot. 
Anneke Maas: Sleep problems in individuals with genetic disorders associated with intellectual 
disability. Supervisors: Prof.dr. I. Curfs / Prof.dr. R. Didden. 
Sebastiaan van Gorp: Translational research on spinal cord injury and cell-based therapies; a focus on 
pain and sensorimotor disturbances. Supervisors: Prof.dr. B. Joosten / Prof.dr. M. van Kleef; Co-
Supervisors: Dr. J. Patijn /Dr. R. Deumens, KU Leuven. 
Andrea Sannia: High risk newborns and brain biochemical monitoring. Supervisor: Prof.dr. J.S.H. Vles; 
Co-Supervisors: Dr. D. Gazzolo, Alessandria, Italy / Dr. A.W.D. Gavilanes. 
Julie A.D.A. Dela Cruz: Dopamine mechanisms in learning and memory: Evidence from rodent 
studies. Supervisors: Prof.dr. H.W.M. Steinbusch / Prof.dr. R.J. Bodnar, New York; Co-Supervisor: 
Dr. B.P.F. Rutten. 
René Besseling: Brain wiring and neuronal dynamics; advances in MR imaging of focal epilepsy. 
Supervisors: Prof.dr. A.P. Aldenkamp / Prof.dr.ir. W.H. Backes; Co-Supervisor: dr. J.F.A. Jansen. 
Maria Quint-Fens: Long-term care after stroke; development and evaluation of a long-term 
intervention in primary care. Supervisors: Prof.dr. J.F.M. Metsemakers / Prof.dr. C.M. van Heugten 
/ Prof.dr. M. Limburg, Almere; Co-Supervisor: dr. G.H.M.I. Beusmans. 
Veronique Moulaert: Life after survival of a cardiac arrest; the heart of the matter. Supervisors: Prof.dr. 
J.A. Verbunt / Prof.dr. C.M. van Heugten / Prof.dr. D.T. Wade, Oxford, UK. 
Feikje Smeets: The hallucinatory-delusional state: a crucial connection in the psychosis symptom 
network. Supervisor: Prof.dr. J. van Os; Co-Supervisor: Dr. T. Lataster. 
Lies Clerx: Alzheimer’s disease through the MR-eye; novel diagnostic markers and the road to clinical 
implementation. Supervisor: Prof.dr. F. Verhey; Co-Supervisors: Dr. P.J. Visser / P. Aalten. 
Sonny Tan: The subthalamic nucleus in Parkinson’s disease. Supervisors: Prof.dr. Y. Temel / Prof.dr. 
H.W.M. Steinbusch / Prof.dr. T. Sharp, Oxford, UK / Prof.dr. V. Visser-Vandewalle, Koln. 
Koen van Boxem: The use of pulsed radiofrequency in the management of chronic lumbosacral 
radicular pain. Supervisors: Prof.dr. M. van Kleef / Prof.dr. E.A.J. Joosten; Co-Supervisor: Assoc. 
Prof.dr. J. van Zundert. 
Jérôme Waterval: Hyperostosis cranialis interna. Supervisors: Prof.dr. J.J. Manni / Prof.dr. R.J. Stokroos. 
Sylvie Kolfschoten-van der Kruijs: Psychogenic non-epileptic seizures; the identification of 
neurophysiological correlates. Supervisors: Prof.dr. A.P. Aldenkamp / Prof.dr. K.E.J. Vonck, 
Universiteit Gent; Co-Supervisors: Dr. J.F.A. Jansen / Dr. R.H.C. Lazeron, Kempenhaeghe. 
Wouter Pluijms: Spinal cord stimulation and pain relief in painful diabetic: polyneuropathy, a 
translational approach. Supervisors: Prof.dr. M. van Kleef / Prof.dr. E.A. Joosten; Co-supervisor: 
Dr. C.G. Faber. 
Ron Handels: Health technology assessment of diagnostic strategies for Alzheimer’s disease. 
Supervisors: Prof.dr. F.R.J. Verhey / Prof.dr. J.L. Severens (EUR); Co-Supervisor: Dr. M.A. Joore / 
Dr. C.A.G. Wolfs. 
Evelyn Peelen: Regulatory T cells in the pathogenesis of Multiple Sclerosis: potential targets for 
vitamin D therapy. Supervisors: Prof.dr. R.M.M. Hupperts / Prof.dr. J.W. Cohen Tervaert; Co-
Supervisor: Dr. J.G.M.C. Damoiseaux / Dr. M.M.G.L.Thewissen, Diepenbeek. 
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Reint Jellema: Cell-based therapy for hypoxic-ischemic injury in the preterm brain. Supervisors: Prof.
dr. B.W.W. Kramer / Prof.dr. H.W.M. Steinbusch; Co-Supervisor: Dr. W.T.V. Germeraad / Dr. P. 
Andriessen, Veldhoven. 
Maria Wertli: Prognosis of Chronic Clinical Pain Conditions: The Example of Complex Regional Pain 
Syndrome 1 and Low Back Pain. Supervisors: Prof.dr. M. van Kleef; Co-Supervisor: Dr. F. Brunner, 
Zürich / Dr. R. Perez, VUmc. 
Dagmar Zeef: An experimental model of Huntington’s disease: Validation & Stimulation. Supervisors: 
Prof.dr. Y. Temel / Prof.dr. H.W.M. Steinbusch; Co-supervisor: Dr. A. Jahanshahi. 
Jeroen Decoster: Breaking Down Schizophrenia into phenes, genes and environment. Supervisors: 
Prof.dr. I. Myin-Germeys / Prof.dr. M. De Hert, KU Leuven; Co-Supervisor: Dr. R. van Winkel. 
Eaja Anindya Sekhar Mukherjee: Fetal Alcohol Spectrum Disorders: exploring prevention 
and management. Supervisor: Prof.dr. L.M.G. Curfs; Co-Supervisor: Prof. S. Hollins, 
St. George’s University of London, UK. 
Catherine van Zelst: Inside out; On stereotype awareness, childhood trauma and stigma in psychosis. 
Supervisors: Prof.dr. Ph. Delespaul / Prof.dr. J. van Os. 
Ibrahim Tolga Binbay: Extended Psychosis Phenotype in the Wider Social Environment. Supervisor: 
Prof.dr. J. van Os; Co-Supervisor: Dr. M. Drukker. 
Frank Van Dael: OCD matters in psychosis. Supervisors: Prof.dr. J. van Os / Prof.dr. I. Myin-Germeys. 
Pamela Kleikers: NOXious oxidative stress: from head toe too and back. Supervisors: Prof.dr. H.H.H.W. 
Schmidt / Prof.dr. H.W.M. Steinbusch; Co-Supervisor: Dr. B. Janssen. 
José Luis Gerardo Nava: In vitro assay systems in the development of therapeutic interventions 
strategies for neuroprotection and repair. Supervisors: Prof.dr.med. J. Weis / Prof.dr. H.W.M. 
Steinbusch; Co-Supervisor: Dr. G.A. Brook, RWTH Aachen. 
Eva Bollen: Cyclic nucleotide signaling and plasticity. Supervisors: Prof.dr. H.W.M. Steinbusch / Prof.dr. 
R. D’Hooge, KU Leuven; Co-Supervisor: Dr. J. Prickaerts. 
2015
Jessica A. Hartmann: A good laugh and a long sleep; Insights from prospective and ambulatory 
assessments about the importance of positive affect and sleep in mental health. Supervisor: 
Prof.dr. J. van Os; Co-Supervisors: C.J.P. Simons / Dr. M. Wichers. 
Bart Ament: Frailty in old age; conceptualization and care innovations. Supervisors: Prof.dr. G.I.J.M. 
Kempen / Prof.dr. F.R.J. Verhey; Co-Supervisor: Dr. M.E. de Vugt. 
Mayke Janssens: Exploring course and outcome across the psychosis-continuum. Supervisor: Prof.dr. 
I. Myin-Germeys; Co-Supervisor: Dr. T. Lataster. 
Dennis M.J. Hernau: Dopayours is not dopamine: genetic, environmental and pathological variations 
in dopaminergic stress processing. Supervisor: Prof.dr. I. Myin- Germeys; Co-Supervisors: Prof.dr. 
F.M. Mottaghy / Dr. D. Collip. 
Ingrid M.H. Brands: The adaptation process after acquired brain injury Pieces of the puzzle. 
Supervisors: Prof.dr. C.M. van Heugten / Prof.dr. D.T. Wade, Oxford UK; Co-Supervisors: Dr. S.Z. 
Stapert / Dr. S. Köhler. 
Francesco Risso: Urinary and salivary S100B monitoring in high risk infants. Supervisor: Prof.dr. J.S.H. 
Vles; Co-Supervisors: Dr. D. Gazzolo, Genoa,Italy / Dr. A.W.D. Gavilanes. 
Alessandro Borghesi: Stem and Progenitor Cells in Preterm Infants: Role in the Pathogenesis and 
Potential for Therapy. Supervisor: Prof.dr. L. Zimmermann; Prof.dr. B. Kramer; Co-Supervisors: Dr. 
D. Gazzolo, Genoa,Italy / Dr. A.W.D. Gavilanes. 
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Claudia Menne-Lothmann: Affect dynamics; A focus on genes, stress, and an opportunity for change. 
Supervisor: Prof.dr. J. van Os; Co-Supervisors: Dr. M. Wichers / Dr. N. Jacobs. 
Martine van Nierop: Surviving childhood new perspectives on the link between childhood trauma 
and psychosis. Supervisors: Prof.dr. I. Myin-Germeys / Prof.dr. J. van Os; Co-Supervisor: Dr. R. 
van Winkel. 
Sylvia Klinkenberg: VNS in children; more than just seizure reduction. Supervisors: Prof.dr. J. Vles / 
Prof.dr. A. Aldenkamp; Co-Supervisor: Dr. H. Majoie. 
Anouk Linssen: Considerations in designing an adult hearing screening programme. Supervisor: Prof.
dr. B. Kremer; Co-Supervisors: Dr. L. Anteunis / Dr. M. Joore. 
Janny Hof: Hearing loss in young children; challenges in assessment and intervention. Supervisors: 
Prof.dr. B. Kremer / Prof.dr. R. Stokroos / Prof.dr. P. van Dijk, RUG; Co-Supervisor: Dr. L. Antheunis. 
Kimberly Cox-Limpens: Mechanisms of endogenous brain protection; Clues from the transcriptome. 
Supervisors: Prof.dr. J. Vles / Prof.dr. L. Zimmermann; Co-Supervisor: Dr. A. Gavilanes. 
Els Vanhoutte: Peripheral Neuropathy outcome measures; Standardisation (PeriNomS) study part 2: 
Getting consensus. Supervisors: Prof.dr. C. Faber / Prof.dr. P. van Doorn; Co-Supervisor: Dr. I. 
Merkies, Spaarne ziekenhuis Hoofddorp. 
Mayienne Bakkers: Small fibers, big troubles; diagnosis and implications of small fiber neuropathy. 
Supervisors: Prof.dr. C. Faber / Prof.dr. M. de Baets; Co-Supervisor: Dr. I. Merkies, Spaarne 
ziekenhuis Hoofddorp. 
Ingrid Kramer: Zooming into the micro-level of experience: An approach for understanding and 
treating psychopathology. Supervisor: Prof.dr. J. van Os; Co-Supervisors: Dr. M. Wichers, UMC 
Groningen / Dr. C. Simons. 
Esther Bouman: Risks and Benefits of Regional Anesthesia in the Perioperative Setting. Supervisors: 
Prof.dr. M. van Kleef / Prof.dr. M. Marcus, HMC, Qatar / Prof.dr. E. Joosten; Co-Supervisor: Dr. H. 
Gramke. 
Mark Janssen: Selective stimulation of the subthalamic nucleus in Parkinson’s disease; dream or near 
future. Supervisors: Prof.dr. Y. Temel / Prof.dr. V. Visser-Vandewalle, Keulen / Prof.dr. A. Benazzouz, 
Bordeax, France. 
Reina de Kinderen: Health Technology Assessment in Epilepsy; economic evaluations and preference 
studies. Supervisors: Prof.dr. S. Evers / Prof.dr. A. Aldenkamp; Co-Supervisor: Dr. H. Majoie / Dr. 
D. Postulart, GGZ O-Brabant. 
Saskia Ebus: Interictal epileptiform activity as a marker for clinical outcome. Supervisors: Prof.dr. A. 
Aldenkamp / Prof.dr. J. Arends, TUE / Prof.dr. P. Boon, Universiteit Gent, België. 
Inge Knuts: Experimental and clinical studies into determinants of panic severity. Supervisor: Prof.dr. 
I. Myin-Germeys; Co-Supervisor: Dr. K. Schruers; Influencing panic. 
Nienke Tielemans: Proactive coping post stroke: The Restored4Stroke Self-Management study. 
Supervisors: Prof.dr. C. van Heugten / Prof.dr. J. Visser-Meily, UMC Utrecht; Co-Supervisor: Dr. V. 
Schepers, UMC Utrecht. 
Tom van Zundert: Improvements Towards Safer Extraglottic Airway Devices. Supervisors: Prof.dr. 
A.E.M. Marcus / Prof.dr. W. Buhre / Prof.dr. J.R. Brimacombe, Queensland, Australia / Prof.dr. C.A. 
Hagberg. 
Tijmen van Assen: Anterior Cutaneous Nerve Entrapment Syndrome Epidemiology and surgical 
management. Supervisors: Prof.dr. G.L. Beets / Prof.dr. M. van Kleef / Dr. R.M.H. Roumen / Dr. 
M.R.M. Scheltinga, MMC Veldhoven. 
Rohit Shetty: Understanding the Clinical, Immunological and Genetic Molecular Mechanisms of 
Keratoconus. Supervisors: Prof.dr. R.M.M.A. Nuijts / Prof.dr. C.A.B. Webers. 
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Christine van der Leeuw: Blood, bones and brains; peripheral biological endophenotypes and their 
structural cerebral correlates in psychotic disorder. Supervisor: Prof.dr. J. van Os; Co-supervisor: 
Dr. M. Marcelis. 
Sanne Peeters: The Idle Mind Never Rests; functional brain connectivity across the psychosis 
continuum. Supervisor: Prof.dr. J. van Os; Co-supervisor: dr. M. Marcelis. 
Nick van Goethem: α7 nicotinic acetylcholine receptors and memory processes: mechanistic and 
behavioral studies. Supervisor: Prof.dr. H.W.M. Steinbusch; Co- supervisor: Dr. J. Prickaerts. 
Nicole Leibold: A Breath of fear; a translational approach into the mechanisms of panic. Supervisor: 
Prof.dr. H.W.M. Steinbusch; Co-supervisors: Dr. K.R.J. Schruers / Dr. D.L.A. van den Hove. 
Renske Hamel: The course of mild cognitive impairment and the role of comorbidity. Supervisor: Prof.
dr. F.R.J. Verhey; Co-supervisors: Dr. I.H.G.B. Ramakers / Dr. P.J. Visser. 
Lucia Speth: Effects of botulinum toxin A injections and bimanual task-oriented therapy on hand 
functions and bimanual activities in unilateral Cerebral Palsy. Supervisors: Prof.dr. J. Vles; Prof.dr. 
R. Smeets; Co-supervisor: Dr. Y. Janssen-Potten, Adelante Hoensbroek. 
Yuan Tian: The effects of Lutein on the inflammatory pathways in age-related macular degeneration 
(AMD). Supervisors: Prof.dr. C. Webers; Prof.dr. A. Kijlstra, WUR; Co- supervisor: Dr. M. 
Spreeuwenberg; Dr. H. Tange. 
Peggy Spauwen: Cognition and Type 2 diabetes; the interplay of risk factors. Supervisors: Prof.dr. F. 
Verhey; Prof.dr. C. Stehouwer; Co-supervisor: Dr. M. van Boxtel 
Marc Hilhorst: Crescentic glomerulonephritis in ANCA associated vasculitis. Supervisors: Prof.dr. J. 
Cohen-Tervaert; Co-supervisor: Dr. P. van Paassen 
Martin Gevonden: The odd one out: exploring the nature of the association between minority status 
and psychosis. Supervisors: Prof.dr. J-P. Selten; Prof.dr. J. Booij, Uva; Prof.dr. I. Myin-Germeys 
Bart Biallosterski: Structural and functional aspects of sensory-motor Interaction in the urinary bladder. 
Supervisors: Prof.dr. Ph. Van Kerrebroeck; Prof.dr. S. De Wachter, UvAntwerpen; Co-supervisors: 
Dr. G. van Koeveringe; Dr. M. Rahnama’i. 
Alexandra König: The use of information and communication technologies (ICT) for the assessment 
of patients with Alzheimer’s Disease and related disorders. Supervisors: prof.dr. F. Verhey; prof.
dr. Ph. Robert, Nice, Fr; Co-supervisors: dr. P. Aalten; dr. R. David, Nice. Fr. 
Michelene Chenault: Assessing Readiness for Hearing Rehabilitation. Supervisors: prof.dr. M.P.F. 
Berger; prof.dr. B. Kremer; Co-supervisor: dr. L.J.C. Anteunis. 
Anand Vinekar: Retinopathy of Prematurity. Recent advances in tele-medicine screening, risk factors 
and spectral domain optical coherence tomography imaging. Supervisor: prof.dr. C.A.B. 
Webers; Co-supervisor: dr. N.J. Bauer 
Fleur van Dooren: Diabetes and Depression: exploring the Interface between Pathophysiological and 
Psychological factors. Supervisors: prof.dr. F.R.J. Verhey; prof.dr. J.K.L. Denollet, UvT; prof.dr. F. 
Pouwer, UvT; Co-supervisor: dr. M.T. Schram. 
Gabriëlla Pons van Dijk: Taekwondo and physical fitness components in middle-aged healthy 
volunteers; the Sekwondo study. Supervisors: prof.dr. J. Lodder; prof.dr. H. Kingma; Co-
supervisor: dr. A.F. Lenssen. 
Yara Pujol López: Development and psychoneuroimmunological mechanisms in depression. 
Supervisor: prof.dr. H.W.M. Steinbusch; Co-supervisors: Dr. G. Kenis; Dr. D. van den Hove; Dr. Aye 
Mu Myint, München. 
Romina Gentier: UBB+1; an important switch in the onset of Alzheimer’s disease. Supervisors: Prof. H. 
Steinbusch; Prof. D. Hopkins; Co-supervisor: Dr. F. van Leeuwen. 
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Sanne Smeets: Insights into insight: studies on awareness of deficits after acquired brain injury. 
Supervisor: Prof. C. van Heugten; Prof. R. Ponds; Co-supervisor: Dr. I. Winkens 
Kim Beerhorst: Bone disease in chronic epilepsy: fit for a fracture. Supervisor: Prof. A. Aldenkamp; 
Prof. R. van Oostenbrugge; Co-supervisor: Dr. P. Verschuure. 
Alex Zwanenburg: Cerebral and cardiac signal monitoring in fetal sheep with hypoxic- ischemic 
encephalopathy. Supervisor: Prof. T. Delhaas; Prof. B. Kramer; Co-supervisors: Dr. T. Wolfs; Dr. P. 
Andriessen, MMC. 
Ismail Sinan Guloksuz: Biological mechanisms of environmental stressors in psychiatry. Supervisor: 
Prof. J. van Os; Co-supervisors: Dr. B. Rutten; Dr. M. Drukker. 
Seyed Ehsan Pishva MD: Environmental Epigenetics in mental health and illness. Supervisor: Prof.dr. 
J. van Os; Co-supervisors: Dr. B.P.F. Rutten; Dr. G. Kenis. 
Ankie Hamaekers: Rescue ventilation using expiratory ventilation assistance; innovating while 
clutching at straws. Supervisors: Prof.dr. W.F. Buhre; Prof.dr. M. van Kleef. 
Rens Evers: 22q11.2 deletion syndrome: intelligence, psychopathology and neurochemistry at adult 
age. Supervisors: Prof.dr. L.M.G. Curfs; Prof.dr. T. v. Amelsvoort. 
Sarah-Anna Hescham: Novel insights towards memory restoration. Supervisor: Prof.dr. Y. Temel; Co-
supervisor: Dr. A. Blokland; Dr. A. Jahanshahi. 
João P. da Costa Alvares Viegas Nunes: Insulin receptor sensitization improves affective pathology in 
various mouse models. Supervisor: Prof.dr. H.W.M. Steinbusch; Co- supervisors: Dr. K-P. Lesch; 
Dr. T. Strekalova; Dr.B.H. Cline, Oxford. 
Yanny Ying-Yee Cheng: Clinical Outcomes After Innovative Lamellar Corneal Transplantation Surgery. 
Supervisor: Prof.dr. R.M.M.A. Nuijts; Co-supervisor: Dr. J.S.A.G. Schouten. 
2016
Oliver Gerlach: Parkinson’s disease, deterioration during hospitalization. Supervisor: Prof.dr. R. van 
Oostenbrugge; Co-supervisor: Dr. W. Weber. 
Remo Arts: Intracochlear electrical stimulation to suppress tinnitus. Supervisor: Prof.dr. R.J. Stokroos; 
Co-supervisor: Dr. E.L.J. Georg. 
Mitchel van Eeden: The €- Restore4stroke study: Economic evaluation of stroke care in the 
Netherlands. Supervisors: Prof.dr.mr. S.M.A.A. Evers; Prof.dr. C.M. v. Heugten; Co-supervisor: dr. 
G.A.P. van Mastrigt. 
Pim Klarenbeek: Blood pressure and cerebral small vessel disease. Supervisor: Prof.dr. R.J. van 
Oostenbrugge; Co-supervisor: Dr. J. Staals. 
Ramona Hohnen: Peripheral pharmacological targets to modify bladder contractility. Supervisor: Prof.
dr. Ph.E.V. van Kerrebroeck; Co-supervisors: Dr. G.A. van Koeveringe; Dr. M.A. Sahnama’i; Dr. C. 
Meriaux. 
Ersoy Kocabicak: Deep brain stimulation of the subthalamic nucleus: Clinical and scientific aspects. 
Supervisors: Prof.dr. Y. Temel; Prof.dr. K. van Overbeeke; Co-supervisor: Dr. A. Jahanshahi. 
Sven Akkerman: Temporal aspects of cyclic messenger signaling in object recognition memory; a 
pharmalogical approach. Supervisor: Prof.dr. H.W.M. Steinbusch; Co-supervisors: dr. J. Prickaerts; 
dr. A. Blokland. 
Anja Moonen: Emotion and Cognition in Parkinson’s disease; etiology and neurobiological 
mechanisms. Supervisor: Prof.dr. F.R.J. Verhey; Co-supervisor: dr. A.F.G. Leentjens. 
Anna Schüth: Three-dimensional bladder tissue morphology. Supervisors: Prof.dr. G.A. van 
Koeveringe; Prof.dr. M. v. Zandvoort, Aachen; Prof.dr. Ph. V. Kerrebroeck. 
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Elisabeth van der Ven: Ethnic minority position as risk indicator for autism- Spectrum and psychotic 
disorders. Supervisors: Prof.dr. J.P. Selten; Prof.dr. J. van Os. 
Zuzana Kasanova: Environmental reactivity for better or worse; The impact of stress and reward on 
neurochemistry, affect and behavior across the psychosis continuum. Supervisor: Prof.dr. I. Myin-
Germeys, KU Leuven/UM; Co-supervisor: dr. D. Collip. 
Danielle Lambrechts: Ketogenic diet therapies; treatment for children and adults with refractory 
epilepsy. Supervisors: Prof.dr. H.J.M. Majoie; Prof.dr. J.S.H. Vles; Prof.dr. A.P. Aldenkamp; Co-
supervisor: dr. A.J.A. de Louw, Kempenhaghe, Heeze. 
Frank van Bussel: Advanced MRI in diabetes; cerebral biomarkers of cognitive decrements. 
Supervisors: Prof.dr.ir. W.H. Backes; Prof.dr. P.A.M. Hofman; Co-supervisor: dr. J.F.A. Jansen. 
Lisa Schönfeldt: Neurostimulation to treat brain injury? Supervisors: Prof.dr. Y. Temel; Prof.dr. S. 
Hendrikx, Hasselt; Co-supervisor: dr. A. Jahanshahi. 
Rianne Geerlings: Transition in patients with childhood-onset epilepsy; a long way to adulthood. 
Supervisor: Prof.dr. A.P. Aldenkamp; Co-supervisors:dr. A.J.A. de Louw, dr. L.M.C. Gottmer, 
Kempenhaeghe. 
Nele Claes: B cells as multifactorial players in multiple sclerosis pathogenesis: insights from 
therapeutics. Supervisors: Prof.dr. V. Somers, Hasselt; Prof.dr. R. Hupperts Co-supervisors: Prof.
dr. P. Stinissen, dr. J. Fraussen, Hasselt. 
Olaf Schijns: Epilepsy surgery and biomarkers from history to molecular imaging. Supervisors: Prof.dr. 
J.J. van Overbeeke; Prof.dr. H. Clustermann, Aachen; Co-supervisors: dr. G. Hoogland; dr. M.J.P. 
v. Kroonenburgh. 
Lizzy Boots: Balanced and Prepared; development and evaluation of a supportive e-health intervention 
for caregivers of people with early-stage dementia. Supervisors: Prof.dr. F.R.J. Verhey; Prof.dr. 
G.I.J.M. Kempen; Co-supervisor: dr. M.E. de Vugt. 
Wouter Donders: Towards patient-specific (cerebro-) vascular model applications. Supervisors: Prof.
dr. T. Delhaas; Prof.dr.ir. F.N. van de Vosse, TUE; Co-supervisor: dr.ir. W. Huberts. 
Sizzle Vanterpool: The implications of intrauterine invasion by microbes for placental Pathology and 
the occurrence of adverse pregnancy outcomes. Supervisor: Prof.dr. B.W. Kramer. Co-supervisors: 
dr. J.V. Been, Erasmus MC Rotterdam, dr. U von Rango. 
Manuela Heins: The Relationship between Social Adversity, Psychosis, and Depression across an 
Individual’s Life Span. Supervisor: Prof.dr. I. Myin-Germeys. 
Christianus van Ganzewinkel: NEONATAL PAIN; Out of Sight, Out of Mind? Supervisor: Prof.dr. B.W.W. 
Kramer; Co-supervisor: dr. P. Andriessen, MMC Veldhoven. 
Anne-Hilde Muris: Hype or hope? Vitamin D in multiple sclerosis; A clinical and immunological 
perspective. Supervisor: Prof.dr. R.M.M. Hupperts; Co-supervisor: dr. J.G.M.C. Damoiseaux. 
Gerard Bode: The link between ceramide transporters, innate Immunity and Alzheimer’s disease. 
Supervisor: Prof.dr. M.H.V. de Baets; Co-supervisors: dr. P. Martinez, dr. M. Losen. 
Jo Stevens: Advanced diagnostics and therapeutics for Alzheimer’s disease. Supervisor: Prof.dr. M. de 
Baets; Co-supervisors: dr. M. Losen, dr. P. Martinez-Martinez. 
Rosan Luijcks: Stress and pain in muscles and brain; developing psychophysiological paradigms to 
examine stress and pain interactions. Supervisors: Prof.dr. J.J. van Os; Prof.dr.ir. H.J. Hermens, 
UT; Co-supervisor: dr. R. Lousberg. 
M.C. Haanschoten: Towards efficient cardiac surgery – the integrating role of anesthesiology 
and intensive care. Supervisors: Prof. dr. W. Buhre; Prof. dr. A. van Zundert (Queensland); Co-
supervisors: Dr. M.A. Soliman Hamad; Dr. A. van Straten (Catharina zkhs.) 
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Harmen Jan van de Haar: Microvascular and blood-brain barrier dysfunction in Alzheimer’s disease. 
Supervisor: Prof.dr.ir. W. Backes; Prof.dr. F. Verhey; Co-supervisor: Dr. J. Jansen; Dr.ir. M. v. Osch, 
LUMC. 
Coenraad Itz: Chronic low back pain, considerations about: Natural Course, Diagnosis, Interventional 
Treatment and Costs. Supervisor: Prof.dr. M. van Kleef; Prof.dr. F. Huygen, EUR; Co- supervisor: 
Dr. B. Ramaekers. 
Willemijn Jansen: The Path of Alzheimer’s disease: from neuropathology to clinic. Supervisor: Prof.dr. 
F. Verhey; Co-supervisors: Dr. P.J. Visser; Dr. I. Ramakers. 
Ligia dos Santos Mendes Lemes Soares: Phosphodiesterase inhibitors: a potential therapeutic 
approach for ischemic cerebral injury. Supervisor: Prof.dr. H.W.M. Steinbusch; Co-supervisors: 
Dr. R.M. Weffort de Oliveira, Brazil; Dr. J. Prickaerts 
Martijn Broen: Anxiety and depression in Parkinson’s disease. Supervisor: Prof.dr. R.J. van 
Oostenbrugge; Co-supervisors: Dr. A.F.G. Leentjens; Dr. M.L. Kuijf. 
Sandra Schipper: Extrasynaptic receptors as a treatment target in epilepsy. Supervisor: Prof.dr. J.H.S. 
Vles; Co-supervisors: Dr. G. Hoogland; Dr. S. Klinkenberg; Dr. M.W. Aalbers, RUG. 
João Casaca Carreira: Making sense of Antisense Oligonucleotides Therapy in Experimental 
Huntington’s disease. Supervisor: Prof.dr. Y. Temel; Co-supervisors: Dr. A. Jahanshahi; Dr. W. van 
Roon-Mom, LUMC. 
Dominique IJff: Trick or Treat? Cognitive side-effects of antiepileptic treatment. Supervisors: Prof.dr. 
A.P. Aldenkamp; Prof.dr. M. Majoie; Co-supervisors: Dr. J. Jansen; Dr. R. Lazeron, Kempenhaeghe. 
Alfredo Ramirez: Neurogenetic approach in neurodegenerative disorders. Supervisors: Prof.dr. B.P.F. 
Rutten; Prof.dr. H.W.M. Steinbusch; Prof.dr. M.M. Nöthen, University of Bonn. 
Nienke Visser: Toric Intraocular lenses in cataract surgery. Supervisor: Prof.dr. R.M.M.A. Nuijts; Co-
supervisor: Dr. N.J.C. Bauer. 
Jakob Burgstaller: Prognostic indicators for patients with degenerative lumbar spinal stenosis. 
Supervisor: Prof.dr. M. van Kleef; Co-supervisors: Dr. M.M. Wertli, University of Zurich; Dr. H.F. 
Gramke. 
Mark van den Hurk: Neuronal Identity and Maturation: Insights from the Single-Cell Transcriptome. 
Supervisors: Prof.dr. H.W.M. Steinbusch; Prof.dr. B.P.F. Rutten; Co- supervisors: Dr. G. Kenis; Dr. C. 
Bardy, Adelaide. 
Maria Nikiforou: Prenatal stress and the fetal gut. Potential interventions to prevent adverse outcomes. 
Supervisors: Prof.dr. B.W. Kramer; Prof.dr. H.W. Steinbusch; Co- supervisor: Dr. T.G. Wolfs. 
Janneke Peijnenborgh: Assessment of cognition, time perception, and motivation in children. 
Supervisors: Prof.dr. J.S.H. Vles; Prof.dr. A.P. Aldenkamp; Co-supervisors: Dr. J. Hendriksen; Dr. 
P. Hurks. 
Joany Millenaar: Young onset dementia; towards a better understanding of care needs and 
experiences. Supervisors: Prof.dr. F. Verhey; Prof.dr. R. Koopmans, RUN; Co- supervisors: Dr. M. 
de Vugt; Dr. C. Bakker, RUN. 
2017 
Adriana Smits: Perinatal factors and hearing outcome. Supervisors: Prof.dr. R.J. Stokroos; Prof.dr. B.W. 
Kramer; Prof.dr. B. Kremer. 
Angela Bouwmans: Transcranial sonography in parkinsonian disorders: clear window or blurred 
vision. Supervisor: Prof.dr. W.H. Mess; Co-promotores: Dr. W.E.J. Weber; Dr. A.F.G. Leentjens. 
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Björn K. Stessel: Patient centred care after day surgery: scope for improvement. Supervisors: Prof.dr. 
W. Buhre; Prof.dr. B. Joosten. Co-supervisor: Dr. A.H. Gramke. 
Jan Guy Bogaarts: Quantitative EEG and machine learning methods for the detection of epileptic 
seizures and cerebral asymmetry. Supervisor: Prof.dr. W.M. Mess; Co-supervisor: Dr.ir. J.P.H. 
Reulen; Dr.ir. E.D. Gommer. 
Martin M. Müller: Pregnancy derived products for treatment of perinatal brain injuries. Supervisors: 
Prof.dr. B.W.W. Kramer; Prof.dr. D. Surbek, Bern; Co-supervisors: Dr. T. Wolfs; Dr. G. Gavilanes. 
Daan Ophelders: Novel treatment strategies for the protection of the preterm brain; Re- balancing 
inflammation and regeneration. Supervisor: Prof.dr. B. Kramer; Co-supervisor: Dr. T. Wolfs; Dr. R. 
Jellema. 
Rosalie van Knippenberg: Experience sampling in dementia care; an innovative intervention to 
support caregivers in daily life. Supervisors: Prof.dr. F. Verhey; Prof.dr. R. Ponds; Prof.dr. I. Myin-
Germeys, KU Leuven; Co-supervisor: Dr. M. de Vugt. 
Claudia Vingerhoets: Investigating neurobiological mechanisms underlying comorbid cognitive 
symptoms in psychosis and substance use. Supervisors: Prof.dr. T. van Amelsvoort; Prof.dr. J. 
Booij, UvA; Co-supervisor: Dr. O. Bloemen 
Dennis Oerlemans: Evolution of Neuromodulation for Lower Urinary Tract Dysfunction; Past, Present 
and Future. Supervisors: Prof.dr. Ph. van Kerrebroeck; Prof.dr. G. van Koeveringe. Co-supervisors: 
Dr. E. Weil; Dr. T. Marcelissen. 
Marion Levy: Evaluation of BDNF/TrkB signaling as a common target in the treatment of major 
depression and Alzheimer’s disease. Supervisors: Prof.dr. H. Steinbusch; Prof. L. Lanfumey, 
Université Paris Descartes, France. Co-supervisors: Dr. G. Kenis; Dr. D. van den Hove. 
Patrick Domen: Stay connected: a family-based diffusion imaging study in psychotic disorder. 
Supervisor: Prof.dr. J. van Os. Co-supervisor: Dr. M. Marcelis 
Geor Bakker: Innovative Approaches to Understanding the Neurobiology of Psychosis. Supervisors: 
Prof.dr. T. van Amelsfoort; Prof.dr. J. Booij, UvA. Co-supervisor: dr. M. Caan, UvA; dr. O. Bloemen. 
Wilma Boevink: HEE! Over Herstel, Empowerment en Ervaringsdeskundigheid in de psychiatrie. 
Supervisors: Prof.dr. J. van Os; Prof.dr. Ph. Delespaul. Co-supervisor: dr. H. Kroon. 
Nataliia Markova: Modified swim test as a mouse depression paradigm of enhanced cognitive 
processing: the role of GSK3β. Supervisor: Prof.dr. H. Steinbusch; Prof.dr. K-P. Lesch, University of 
Wuerzburg. Co-supervisor: Dr. T. Strekalova. 
Merijn van de Laar: Individual differences in insomnia; implications of psychological factors for 
diagnosis and treatment. Supervisor: Prof.dr. A. Aldenkamp; Prof.dr. D. Pevernagie, Universiteit 
Gent. Co-supervisor: Dr. S. Overeem, TUE. 
Willem Buskermolen: If only I could tell ...; Measuring predictors for challenging behaviour in people 
with both intellectual disability and hearing impairment. Supervisor: Prof.dr. A. Aldenkamp. Co-
supervisor: Dr. J. Hoekman, UL. 
Kay Deckers: The role of lifestyle factors in primary prevention of dementia; an epidemiological 
perspective. Supervisor: Prof.dr. F. Verhey. Co-supervisor: Dr. M. van Boxtel; Dr. S. Köhler. 
Brechje Dandachi-FitzGerald: Symptom validity in clinical assessments. Supervisors: Prof.dr. R. Ponds; 
Prof.dr. F. Verhey. 
Maurice Theunissen: Understanding factors affecting postoperative Quality of Life. Supervisors: Prof.
dr. M. Peters, Prof.dr. M. Marcus. Co-supervisor: Dr. H. Gramke. 
Anna Cleutjens: COgnitive-Pulmonary Disease? Neuropsychological functioning in patients with 
COPD. Supervisors: Prof.dr. E. Wouters, Prof.dr. R. Ponds. Co-supervisors: Dr. D. Janssen, Horn, 
Dr. J. Dijkstra. 
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Laura Serpero: Next Generaton Biomarkers in Perinatal Medicine: S100B Protein. Supervisors: Prof.dr. 
D. Gazzalo, Alessandria, Italy; Prof.dr. B..W.W. Kramer. Co-supervisor: Dr. A.W.D. Gavilanes. 
Alessandro Varrica: S100B Protein and Congential Heart Diseases: Brain Aspects. Supervisors: Prof.
dr. D. Gazzalo, Alessandria, Italy; Prof.dr. J.S.H. Vles; Prof.dr. L.J.I. Zimmermann. Co-supervisor: 
Dr. A.W.D. Gavilanes. 
Pim R.A. Heckman: Targeting phosphodiesterase type 4 for improving cognitive fronto- striatal 
function: a translational approach. Supervisor: Prof.dr. J.G. Ramaekers. Co- supervisors: Dr. 
J.H.H.J.. Prickaerts; Dr. A. Blokland. 
Sven van Poucke: Platelets, form sample to big data; exploring granularity in platelet research. 
Supervisors: Prof.dr. M.A.E. Marcus; Prof.dr. W. Buhre. Co-supervisor: Dr. M. Lancé. 
Désirée M.J. Vrijens: Dysfunctions of the Lower Urinary Tract and Affective Symptoms. Supervisors: 
Prof.dr. Ph.E.V. van Kerrebroeck; Prof.dr. G.A. van Koeveringe. Co- supervisors: Dr. C. Leue. 
Tamar van Veenendaal: Neurotransmitters & Networks. An MR view on epilepsy and antiepileptic 
drugs. Supervisors: Prof.dr.ir. W.H. Backes; Prof.dr. A.P. Aldenkamp. Co- supervisor: Dr. J.F.A. 
Jansen. 
Evelien M. Barendse: Autism Spectrum Disorders in High functioning Adolescents; Diagnostic 
considerations (AHA). Supervisors: Prof.dr. A.P. Aldenkamp; Prof.dr. R.P.C. Kessels, Radboud 
University. 
Roy Lardenoije: A venture into the epigenetics of aging and Alzheimer’s Disease. Supervisors: Prof.dr. 
B.P.F. Rutten; Prof.dr. H.W.M. Steinbusch. Co-supervisors: Dr. D. van den Hove; Dr. C.A. Lemere, 
USA. 
Charlotte L. Mentzel: The course recognition and treatment of movement disorders in severe mental 
illness. Supervisors: Prof.dr. P.N. van Harten; Prof.dr. M.A.J. de Koning- Tijssen, UMCG. Co-
supervisor: Dr. P.R. Bakker. 
Tim Batink: Third Wave Behaviour Therapy: Process Measures and Contextual Interventions. 
Supervisors: Prof.dr. F.P.M.L. Peeters; Prof.dr. J.J. van Os; Prof.dr. M.C. Wichers, UMC Groningen. 
Kevin L.J. Rademakers: Detrusor Underactivity: From Theory To Clinical Assessment. Supervisors: Prof.
dr. G.A. van Koeveringe; Prof.dr. Ph.E.V. van Kerrebroeck. Co-supervisor: Dr. M. Oelke. 
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Elles Douven was born on February 19 1991 in Nederweert-
Eind, the Netherlands. After graduating from high school 
(Philips van Horne, Weert) in 2009, she started to study 
Psychology at Maastricht University and graduated cum 
laude in 2012. During her bachelor she also completed 
the Honours program of the Faculty of Psychology and 
Neuroscience. In the same year, Elles started the two-year 
Research Master Neuropsychology at Maastricht University. 
She performed a research internship on the CASPER study 
at the department of Psychiatry and Neuropsychology of Maastricht University. She 
also performed a clinical internship at the Memory Clinic of Maastricht University 
Medical Center in Maastricht and acquired her psychodiagnostics registration 
(BAPD). In 2014 she graduated and started working as a PhD candidate on 
the CASPER study at the Department of Psychiatry and Neuropsychology of 
Maastricht University under supervision of Prof. dr. Frans Verhey, Dr. Pauline 
Aalten, and Dr. Julie Staals. Currently, Elles is working as a postdoctoral researcher 
at the department of Psychiatry and Neuropsychology at Maastricht University and 
Alzheimer Center Limburg.
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zij haar studie Psychologie aan de Universiteit van Maastricht. In 2012 werd haar 
bachelor diploma cum laude behaald. Tijdens haar bachelor rondde zij ook het 
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onderzoeksstage gedaan bij de afdeling Psychiatrie en Neuropsychologie van 
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zij haar psychodiagnostiek registratie behaalde (BAPD). In 2014 studeerde ze af 
en begon als promovenda op de CASPER studie bij de afdeling Psychiatrie en 
Neuropsychologie van de Universiteit Maastricht  onder supervisie van Prof. dr. 
Frans Verhey, Dr. Pauline Aalten en Dr. Julie Staals. Momenteel is Elles werkzaam 
als postdoc onderzoeker op de afdeling Psychiatrie en Neuropsychologie van 
Maastricht University en Alzheimer Centrum Limburg. 

